<SEC-DOCUMENT>0001047469-18-002770.txt : 20180413
<SEC-HEADER>0001047469-18-002770.hdr.sgml : 20180413
<ACCEPTANCE-DATETIME>20180413060908
ACCESSION NUMBER:		0001047469-18-002770
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20180607
FILED AS OF DATE:		20180413
DATE AS OF CHANGE:		20180413

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		18753098

	BUSINESS ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		(609) 662-2000

	MAIL ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>a2235295zpre14a.htm
<DESCRIPTION>PRE 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZAG13701_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Amicus Therapeutics,&nbsp;Inc.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=587612,FOLIO='blank',FILE='DISK109:[18ZAG1.18ZAG13701]BA13701A.;3',USER='JTAYLORA',CD='12-APR-2018;15:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g429299.jpg" ALT="LOGO" WIDTH="291" HEIGHT="97">
  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>April&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
2018 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Dear
Stockholder: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are pleased to invite you to attend our 2018 Annual Meeting of Stockholders to be held at the offices of Amicus Therapeutics,&nbsp;Inc., located at 1 Cedar Brook Drive, Cranbury,
New Jersey 08512 on Thursday, June&nbsp;7, 2018, at 9:00&nbsp;a.m. Eastern Daylight Time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enclosed
are the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Our Notice of Annual Meeting of Stockholders and Proxy Statement for 2018; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Our Annual Report on Form&nbsp;10-K for 2017; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> A proxy card with a return envelope to record your vote. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
accompanying notice of the 2018 Annual Meeting and Proxy Statement describe the business we will conduct at the meeting and provide information about Amicus Therapeutics,&nbsp;Inc.
that you should consider when you vote your shares. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
vote is important. When you have finished reading the Proxy Statement, please promptly vote your shares by marking, signing, dating and returning the proxy card in the enclosed
envelope or vote via telephone or Internet according to the instructions in the Proxy Statement. If you attend the Annual Meeting, you may vote your shares in person even though you have previously
voted by proxy if you follow the instructions in the Proxy Statement. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting, whether or not you can attend
in person. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Sincerely,
</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>
<IMG SRC="g650180.jpg" ALT="GRAPHIC" WIDTH="237" HEIGHT="96">
  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR>
John F. Crowley<BR></FONT> <FONT SIZE=2><I>Chairman and Chief Executive Officer</I></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=477286,FOLIO='blank',FILE='DISK109:[18ZAG1.18ZAG13701]BC13701A.;8',USER='JTAYLORA',CD='12-APR-2018;15:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g429299.jpg" ALT="LOGO" WIDTH="291" HEIGHT="97">
  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>April&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
2018 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="be13701_notice_of_2018_annual_meeting_of_stockholders"> </A>
<A NAME="toc_be13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  NOTICE OF&nbsp;2018 ANNUAL MEETING OF STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>To
our Stockholders: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2018 Annual Meeting of Stockholders of Amicus Therapeutics,&nbsp;Inc. will be held at the offices of Amicus Therapeutics,&nbsp;Inc., located at 1 Cedar Brook Drive, Cranbury, New
Jersey 08512 on Thursday, June&nbsp;7, 2018 at 9:00&nbsp;a.m. Eastern Daylight Time. The purpose of this meeting is to vote on the following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Elect
two Class&nbsp;II directors as nominated by the Board of Directors each to serve a three</FONT><FONT SIZE=2><B>-</B></FONT><FONT SIZE=2>year term expiring at
the 2021 Annual Meeting or until their respective successors have been elected;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Approve
an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01 per share, that we are authorized
to issue from 250,000,000 shares to 500,000,000 shares
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Approve
the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Ratify
the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as the Company's independent registered public accounting firm for the fiscal year ending
December&nbsp;31, 2018;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Approve,
on an advisory basis, the Company's executive compensation; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>6.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consider
and act upon any other business that is properly presented at the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
items of business are more fully described in the Proxy Statement accompanying this Notice. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
record date for the 2018 Annual Meeting is [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018]. Only stockholders of record at the close of business on that date are entitled to notice
of and to vote at the meeting or any adjournment thereof. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>BY ORDER OF THE BOARD OF DIRECTORS:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g245976.jpg" ALT="GRAPHIC" WIDTH="211" HEIGHT="72">
 </B></FONT><FONT SIZE=2><BR>
<BR>
Ellen Rosenberg<BR></FONT> <FONT SIZE=2><I>General Counsel and Corporate Secretary</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>Cranbury,
New Jersey<BR>
April&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2018 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are cordially invited to attend the meeting in person. Whether or not you expect to attend the meeting, please complete, date, sign and return the proxy card or vote by telephone or
the Internet as instructed in the accompanying materials as promptly as possible in order to ensure your representation at the meeting. You can revoke a proxy at any time prior to its exercise by
following the instructions in the Proxy Statement. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must provide
a valid proxy issued in your name from that record holder. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=829173,FOLIO='blank',FILE='DISK109:[18ZAG1.18ZAG13701]BE13701A.;8',USER='JTAYLORA',CD='12-APR-2018;15:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dc13701_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>AMICUS THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>1 Cedar Brook Drive, Cranbury, New Jersey 08512<BR>
(609)&nbsp;662-2000  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROXY STATEMENT FOR THE AMICUS THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>2018 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON<BR>
JUNE 7, 2018  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> GENERAL INFORMATION ABOUT THE ANNUAL MEETING  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Why Did You Send Me this Proxy Statement?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We sent you this Proxy Statement and the enclosed proxy card because the Board of Directors (the "Board") of Amicus Therapeutics,&nbsp;Inc.
(sometimes referred to as "we," "us," "our," "Amicus" or the "Company") is soliciting your proxy to vote at the 2018 Annual Meeting of
Stockholders (the "Annual Meeting") and any adjournments of the meeting to be held at the offices of Amicus Therapeutics,&nbsp;Inc., located at 1 Cedar Brook Drive, Cranbury, New Jersey 08512 on
Thursday, June&nbsp;7, 2018 at 9:00&nbsp;a.m. Eastern Daylight Time. This Proxy Statement, along with the accompanying Notice of Annual Meeting of Stockholders, summarizes the purposes of the
meeting and the information you need to know to vote at the Annual Meeting. You are invited to attend the Annual Meeting to vote on the proposals described in this Proxy Statement. You do not need to
attend the Annual Meeting to vote your shares. Instead you may simply complete, date, sign and return the enclosed proxy card, or follow the instructions on the enclosed proxy card to submit your
proxy by telephone or on the Internet. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to mail this Proxy Statement, our 2017 Annual Report on Form&nbsp;10-K, the attached Notice of Annual Meeting and the enclosed proxy card to all stockholders entitled to vote
at the Annual Meeting on or about April&nbsp;27, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc13701_important_notice_regarding_the__imp04167"> </A>
<A NAME="toc_dc13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS<BR>  FOR THE ANNUAL MEETING TO BE HELD ON JUNE 7, 2018.    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc13701_the_proxy_statement_and_form_o__the00927"> </A>
<A NAME="toc_dc13701_2"> </A></FONT> <FONT SIZE=2><B>  THE PROXY STATEMENT AND FORM OF PROXY FOR OUR 2018 ANNUAL MEETING<BR>  OF STOCKHOLDERS AND OUR ANNUAL REPORT ON FORM 10-K FOR THE<BR>  YEAR ENDED DECEMBER 31, 2017 ARE AVAILABLE AT:<BR>
</B></FONT><FONT SIZE=2><I>www.sec.gov</I></FONT><FONT SIZE=2>, through the Investor Relations section of our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com</I></FONT><FONT SIZE=2> or at<BR>  http://www.astproxyportal.com/ast/15417/
<BR></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who Can Vote?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018] are entitled to vote at
the Annual
Meeting. On this record date, there were [187,995,994] shares of our common stock ("Common Stock")
outstanding and entitled to vote. Each share of Common Stock is entitled to one vote. The Common Stock is our only outstanding class of voting stock. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder of Record: Shares Registered in Your Name  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018], your shares were registered directly in your name with our transfer agent, American
Stock Transfer&nbsp;&amp; Trust Company, then you are a stockholder of record. As a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy. Whether or not you attend the
Annual Meeting, we urge you to fill out and return the enclosed proxy card or follow the instructions on the proxy card to submit your vote by telephone or Internet to ensure your vote is counted. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=727038,FOLIO='1',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;9',USER='JTAYLORA',CD='12-APR-2018;15:43' -->
<A NAME="page_dc13701_1_2"> </A>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Beneficial Owner: Shares Registered in the Name of a Broker or Bank  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018], your shares were held, not in your name, but rather in an account at a brokerage firm,
bank, dealer, or other similar organization, then you are the beneficial owner of shares held in "street name" and these proxy materials are being forwarded to you by that organization. The
organization holding your account is considered the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent
on how to vote the shares in your account. A number of brokers and banks enable beneficial owners to give voting instructions&nbsp;via telephone or the Internet. Please refer to the voting
instructions provided by your bank or broker. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are also invited to attend the Annual Meeting. However, since you are not the stockholder of record, you may not vote your shares in person at the meeting unless you provide a valid
proxy from your broker, bank or other custodian. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What am I voting on?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are five matters scheduled for a vote:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Elect two Class&nbsp;II directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Approve an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01 per share,
that we are authorized to issue from 250,000,000 shares to 500,000,000 shares </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Approve the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Ratify the selection of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for our fiscal year ending
December&nbsp;31, 2018; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Approval, on an advisory basis, of the Company's executive compensation. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How Do I Vote?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether you plan to attend the Annual Meeting or not, we urge you to vote by proxy. Voting by proxy will not affect your right to attend the
Annual Meeting. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If your shares are registered directly in your name, you may vote: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> By mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Complete and mail the enclosed proxy card in the enclosed postage
prepaid envelope. Your proxy will be voted in accordance with your instructions. If you sign the proxy card but do not specify how you want your shares voted, they will be voted as recommended by our
Board.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> In person at the meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you attend the meeting, you may deliver your
completed proxy card in person or you may vote by completing a ballot, which will be available at the meeting.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> By telephone.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may vote over the telephone by calling toll-free
1-800-PROXIES (1-800-776-9437) in the United States or 1-718-921-8500 from outside the United States and follow the recorded instructions. Please have your proxy card available when you call. Your
vote must be received by 11:59&nbsp;p.m. Eastern Daylight Time on June&nbsp;6, 2018 to be counted.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> Internet.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may vote via the Internet by going to </FONT> <FONT SIZE=2><I>www.voteproxy.com</I></FONT><FONT SIZE=2> and follow the
on-screen instructions. Please have your proxy card available when you access the web page. Your vote must be received
by 11:59&nbsp;p.m. Eastern Daylight Time on June&nbsp;6, 2018 to be counted. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=442726,FOLIO='2',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;9',USER='JTAYLORA',CD='12-APR-2018;15:43' -->
<A NAME="page_dc13701_1_3"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If your shares are held in "street name" (held in the name of a bank, broker or other nominee), you must provide the
bank, broker
or other nominee with instructions on how to vote your shares and can do so as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> By mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You will receive instructions from your broker or other nominee
explaining how to vote your shares.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> In person at the meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Contact the broker or other nominee who holds
your shares to obtain a broker's proxy card and bring it with you to the meeting. You will not be able to vote at the meeting unless you have a proxy card from your broker. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How Many Votes do I have?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of Common Stock that you own as of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018], entitles you to one vote on each matter to be
voted on at the Annual Meeting. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Will My Shares be Voted if I Do Not Return My Proxy Card?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If your shares are registered in your name, they will not be voted if you do not return your proxy card by mail or vote at the meeting as
described above under "How Do I Vote?" If your shares are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your shares as described above
under "How Do I Vote?," the bank, broker or other nominee has the authority to vote your unvoted shares only for Proposal 2. The broker, bank or other nominee will not be permitted to vote on the
other Proposals without your voting instructions. We encourage you to provide voting instructions. This ensures your shares will be voted at the meeting in the manner you desire. If your broker cannot
vote your shares on a particular matter because it has not received instructions from you and does not have discretionary voting authority on that matter or because your broker chooses not to vote on
a matter for which it does have discretionary voting authority, this is referred to as a "broker non-vote". </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


May I Revoke My Proxy?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you give a proxy, you may revoke it at any time before the Annual Meeting. You may revoke your proxy in any one of the following
ways:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> signing a new proxy card and submitting it as instructed above; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> notifying the Company's Secretary in writing before the Annual Meeting that you have revoked your proxy; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> attending the meeting in person and voting in person if you are a stockholder of record. Attending the meeting in person will not in and of
itself revoke a previously submitted proxy unless you specifically request it. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What if I Receive More Than One Proxy Card?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may receive more than one proxy card or voting instruction form if you hold shares of our Common Stock in more than one account, which may
be in registered form or held in street name. Please vote in the manner described under "How Do I Vote?" for each account to ensure that all of your shares are voted. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How Does the Board of Directors Recommend That I Vote on the Proposals?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board recommends that you vote as follows: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>"FOR"</B></FONT><FONT SIZE=2> the election of the nominees for director; </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=348638,FOLIO='3',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;9',USER='JTAYLORA',CD='12-APR-2018;15:43' -->
<A NAME="page_dc13701_1_4"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>"FOR"</B></FONT><FONT SIZE=2> the approval of an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par
value $0.01 per share, that we are authorized to issue from 250,000,000 shares to 500,000,000 shares; </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" the approval of the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool; </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>"FOR"</B></FONT><FONT SIZE=2> ratification of the selection of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for our fiscal
year ending December&nbsp;31, 2018; and </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>"FOR"</B></FONT><FONT SIZE=2> the approval of the compensation of our named executive officers. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any other matter is properly presented, the proxy card provides that your shares will be voted by the proxy holder listed on the proxy card in accordance with his best judgment. At
the time this Proxy Statement was printed, we knew of no matters that needed to be acted on at the Annual Meeting other than those discussed in this Proxy Statement. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What Vote is Required to Approve Each Proposal and How are Votes Counted?  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 1: Elect Directors</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The nominees for director who receive the most votes (also known as a "plurality" of the votes) will be elected. Abstentions are not counted as voting on the matter for purposes of electing directors. You may vote FOR all of the nominees, WITHHOLD
 your vote from all of the nominees or WITHHOLD your vote from any one or more of the nominees. Votes that are withheld will not be included in the vote tally for the election of directors. Brokerage firms do not have authority to vote customers'
 unvoted shares held by the firms in street name for the election of directors. These broker non-votes will have no effect on the results of this vote.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 2: Approve the Amendment to our Restated Certificate of Incorporation</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to approve the amendment to our Restated Certificate of Incorporation. Abstentions will
 have the effect of a vote against this proposal. Brokerage firms do not have the authority to vote customers' unvoted shares held by the firms in street name on this proposal. These broker non-votes will have no effect on the results of this vote.
 Our Board has approved the amendment to our Restated Certificate of Incorporation and believes it is in the best interest of the stockholders to approve it.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=432353,FOLIO='4',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;9',USER='JTAYLORA',CD='12-APR-2018;15:43' -->
<A NAME="page_dc13701_1_5"> </A>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 3: Approve the Amended and Restated 2007 Equity Incentive Plan</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to approve the Amended and Restated 2007 Equity Incentive Plan. Abstentions will have
 the effect of a vote against this proposal. Brokerage firms do not have the authority to vote customers' unvoted shares held by the firms in street name on this proposal. These broker non-votes will have no effect on the results of this vote. Our
 Board has approved the Amended and Restated 2007 Equity Incentive Plan and believes it is in the best interest of the stockholders to approve it.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 4: Ratify Selection of Independent Registered Public Accounting Firm</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to ratify the selection of our independent registered public accounting firm.
 Abstentions will have the effect of a vote against this proposal. Brokerage firms have authority to vote customers' unvoted shares held by the firms in street name on this proposal. We are not required to obtain the approval of our stockholders to
 select our independent registered public accounting firm. However, our Board believes it is advisable to give stockholders the opportunity to ratify this selection. If our stockholders do not ratify the selection of Ernst&nbsp;&amp; Young&nbsp;LLP as
 our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2018, the Audit and Compliance Committee of our Board will reconsider its selection.</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 5: Approval, on an Advisory Basis, of Executive Compensation</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to adopt this resolution. Abstentions will have the effect of a vote against this
 proposal. Brokerage firms do not have authority to vote customers' unvoted shares held by the firms in street name for this proposal. If a broker does not exercise this authority, such broker non-votes will have no effect on the results of this vote.
 This advisory vote on executive compensation is not binding on our Board. However, the Board will take into account the result of the vote when determining future executive compensation arrangements.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How are votes counted?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes will be counted by the inspector of election appointed for the Annual Meeting, who will separately count "For" and "Withhold" and (with
respect to proposals other than the election of directors) "Against" votes, abstentions and broker non-votes. Shares represented by
abstentions and broker non-votes will be counted in determining whether there is a quorum for the Annual Meeting. Abstentions </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=8,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=492292,FOLIO='5',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;9',USER='JTAYLORA',CD='12-APR-2018;15:43' -->
<A NAME="page_dc13701_1_6"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>will
have no effect on Proposal 1 but will have the effect of a vote against Proposal 2, 3, 4 and 5. Broker non-votes will not be counted towards the vote total for any proposal. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who Will Pay the Costs of Soliciting these Proxies and How Are They Being Solicited?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will pay all of the costs of soliciting these proxies. Our directors and employees may solicit proxies in person or by telephone, fax or
email. We will pay these employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy
materials to their principals and to obtain authority to execute proxies. We will then reimburse them for their expenses. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What Constitutes a Quorum for the Meeting?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The presence, in person or by proxy, of the holders of a majority of the issued and outstanding shares of our Common Stock is necessary to
constitute a quorum at the meeting. Votes of stockholders of record who are present at the meeting in person or by proxy, abstentions and broker non-votes are counted for purposes of determining
whether a quorum exists. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How can I find out the results of the voting at the Annual Meeting?  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preliminary voting results will be announced at the Annual Meeting. Final voting results will be published in a Current Report on
Form&nbsp;8-K within four business days after the Annual Meeting. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


When are stockholder proposals due for next year's Annual Meeting?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you wish to submit a proposal to be considered for inclusion in next year's proxy materials or nominate a director, your proposal must be in
proper form according to Securities and Exchange Commission ("SEC") Regulation&nbsp;14A, Rule&nbsp;14a8 and received by the Secretary of the Company no later than December&nbsp;28, 2018.
Proposals received after that date will not be included in the proxy materials we send out in connection with the 2019 Annual Meeting of Stockholders. If a proposal is received before that date, the
proxies that management solicits for the meeting may still exercise discretionary voting authority on the proposal under circumstances consistent with the proxy rules of the SEC. To be timely in
accordance with our Restated By-laws, stockholder notice of any such proposal must be received by us not earlier than November&nbsp;28, 2018 and not later than December&nbsp;28, 2018; provided,
however, that in the event that the date of the 2019 Annual Meeting of Stockholders is more than 30&nbsp;days before or more than 60&nbsp;days after the anniversary date of the 2018 Annual Meeting
of Stockholders, notice by the stockholder to be timely must be delivered not earlier than the close of business on the 90th&nbsp;day prior to the 2019 Annual Meeting of Stockholders and not later
than the close of business on the later of the 60th&nbsp;day prior to the 2019 Annual Meeting of Stockholders or the 10th&nbsp;day following the day on which we make a public announcement of the
2019 Annual Meeting of Stockholders. All stockholder proposals should be marked for the attention of General Counsel and Corporate Secretary, c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive,
Cranbury, New Jersey 08512. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Attending the Annual Meeting  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Annual Meeting will be held at the offices of Amicus Therapeutics,&nbsp;Inc., located at 1 Cedar Brook Drive, Cranbury, New Jersey 08512
on Thursday, June&nbsp;7, 2018 at 9:00&nbsp;a.m. Eastern Daylight Time. When you arrive at Amicus, signs will direct you to the appropriate meeting rooms. You are not required to attend the Annual
Meeting in order to vote. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=9,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=506561,FOLIO='6',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;9',USER='JTAYLORA',CD='12-APR-2018;15:43' -->
<A NAME="page_dc13701_1_7"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc13701_proposal_no._1_#151;election_of_directors"> </A>
<A NAME="toc_dc13701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 1&#151;ELECTION OF DIRECTORS    <BR>    </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation</I></B></FONT><FONT SIZE=2><B>:  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>The Board recommends the vote "FOR" the election of each of </B></FONT><FONT SIZE=2><B><I>Donald Hayden, Jr.  </I></B></FONT><FONT SIZE=2>and </FONT><FONT
SIZE=2><B><I>Craig Wheeler</I></B></FONT><FONT SIZE=2><B> as a director, and proxies solicited by the Board will be voted in favor thereof unless a stockholder has
indicated otherwise on the proxy.</B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board has voted to nominate Donald Hayden, Jr. and Craig Wheeler for election at the Annual Meeting for a term of three years to serve as Class&nbsp;II directors until the 2021
Annual Meeting of Stockholders, and until their respective successors are duly elected and qualified. The Class&nbsp;I directors&#151;Dr.&nbsp;Ted Love and Robert Essner&#151;and the
Class&nbsp;III directors&#151;John F. Crowley, Margaret McGlynn, Michael Raab, and Glenn Sblendorio&#151;will serve until the Annual Meetings of Stockholders to be held in 2020 and
2019, respectively, and until their respective successors have been elected and qualified. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
authority to vote for any of these nominees is withheld, the shares represented by the signed and dated proxy cards will be voted </FONT> <FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the election as directors of Donald Hayden, Jr. and Craig Wheeler.
In the event that any nominee becomes unable or unwilling to serve, the shares
represented by the enclosed proxy will be voted at the discretion of the individuals designated as proxies on the proxy cards. We have no reason to believe that any nominee will be unable or unwilling
to serve as a director. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
plurality of the shares voted at the Annual Meeting is required to elect each nominee as a director. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Board of Directors  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Restated Certificate of Incorporation and Restated By-laws provide that our business is to be managed by or under the direction of our
Board. Our Board is divided into three classes and one class is elected at each Annual Meeting of Stockholders to serve for a three-year term. Our Board consisted of eight members. Our Board is
divided amongst three classes as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Class&nbsp;I directors are Dr.&nbsp;Love and Mr.&nbsp;Essner and their term will expire at the 2020 Annual Meeting of Stockholders; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Class&nbsp;II directors are Mr.&nbsp;Hayden and Mr.&nbsp;Wheeler and their term will expire at the 2018 Annual Meeting of
Stockholders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Class&nbsp;III directors are Messrs.&nbsp;Crowley, Raab, and Sblendorio and Ms.&nbsp;McGlynn, and their term will expire at the 2019
Annual Meeting of Stockholders. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Restated Certificate of Incorporation and Restated By-laws provide that the authorized number of directors may be changed only by resolution of the Board. Our Board has authorized
that the size of the Board be set at ten members. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
February&nbsp;23, 2018, our Board, upon the recommendation of the Nominating and Corporate Governance Committee, voted to nominate Mr.&nbsp;Hayden and Mr.&nbsp;Wheeler for
re-election as Class&nbsp;II directors at the 2018 Annual Meeting for a term of three years to serve until the 2021 Annual Meeting of stockholders until their respective successors have been duly
elected and qualified. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board has determined that each of the director nominees possesses the requisite skills, personal integrity, business judgment, industry experience and willingness to devote adequate
time and effort necessary to serve as an effective member of the Board. A description of the background of each, along with other specific experiences, qualifications, attributes or skills that
contributed to the Board's
decision to nominate the nominees, is set forth below, followed immediately by like disclosure for our existing directors whose terms of office extend beyond the Annual Meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=10,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=172649,FOLIO='7',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;9',USER='JTAYLORA',CD='12-APR-2018;15:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_de13701_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->



<!-- PARA=JUSTIFY -->
</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominees for Election at the Annual Meeting  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald Hayden(1)(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler(3)(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chair
of Nominating/Corporate Governance Committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Lead
Independent Director
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Compensation Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Science and Technology Committee  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Donald J. Hayden, Jr.</I></FONT><FONT SIZE=2> has served as a member of our Board since March 2006 and as Lead Independent Director since February 2010.
Mr.&nbsp;Hayden served as Chairman from March 2006 until February 2010 and from September 2006 until March 2007 as Interim President and Chief Executive Officer. From 1981 to 2006, he held several
executive positions with Bristol-Myers Squibb Company, most recently serving as Executive Vice President and President, Americas. Mr.&nbsp;Hayden is Chair of the Boards of Directors of Insmed
Incorporated (NASDAQ: INSM) and REGENXBIO&nbsp;Inc. (NASDAQ: RGNX). Mr.&nbsp;Hayden holds a B.A. from Harvard University and an M.B.A. from Indiana University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Hayden has more than 30&nbsp;years of experience in the pharmaceutical industry, including
leadership roles
in commercialization, drug launch, executive management, financial and strategic planning and business development. He also has significant Board experience through his service on the Board of
Directors of other publicly-held biopharmaceutical companies and his service as our Interim Chief Executive Officer all of which contribute to our conclusion that he should continue to serve as a
director of the Company and is particularly well suited to serve as Lead Independent Director and Chair of the Nominating and Corporate Governance Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Craig Wheeler</I></FONT><FONT SIZE=2> has served as a member of our Board since June 2016. Since September 2006, Mr.&nbsp;Wheeler has served as President and
Chief Executive Officer of Momenta Pharmaceuticals,&nbsp;Inc. (NASDAQ: MNTA). At Momenta, Mr.&nbsp;Wheeler led the company through the launch of its first complex drug products. He has overseen
the company's growth into the diversified business it is today. In 2011, he was an E&amp;Y Entrepreneur of the Year Regional Award winner. In May 2012, the Boston Globe named Momenta the number one
company in their annual Globe 100 survey of top performing companies. Prior to joining Momenta, Mr.&nbsp;Wheeler was President of Chiron Biopharmaceuticals where, during his five-year tenure, he led
US and European commercial organizations and the pharmaceutical division's global sales more than doubled. Before that, he was a senior member of The Boston Consulting Group's health care practice and
worked extensively in the health care sector with focus on pharma and biotech, particularly in regard to corporate and R&amp;D strategy. He began his career at Merck&nbsp;&amp; Company,&nbsp;Inc.'s (NYSE:
MRK) MSDRL research unit. He also previously served as the Chairman of the Board of Avanir Pharmaceuticals,&nbsp;Inc. where he helped oversee the transition of the company from a research-based
platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5&nbsp;billion. Mr.&nbsp;Wheeler received his BS and MS in chemical
engineering from Cornell University and his MBA from the Wharton School of the University of Pennsylvania. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Wheeler has extensive pharmaceutical industry knowledge and leadership experience, including his
demonstrated
expertise in drug development, manufacturing and the technical issues facing growing biopharmaceutical companies. Mr.&nbsp;Wheeler's deep understanding of the management and growth of pharmaceutical
companies contribute to our conclusion that he should continue to serve as a director of the Company and as a member of the Science and Technology and Compensation Committees. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=11,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=672953,FOLIO='8',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_de13701_1_9"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directors Whose Terms Do Not Expire This Year  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chairman</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret McGlynn(3)(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Raab(1)(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn Sblendorio(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ted Love, MD(3)(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Compensation Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chair,
Science and Technology Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Nominating/Corporate Governance Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Audit and Compliance Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Lead
Independent Director
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chair,
Compensation Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chair,
Audit and Compliance Committee  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>John F. Crowley</I></FONT><FONT SIZE=2> has served as a Director, Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since
January 2005, except for the period from April 2011 through August 2011 during which time he served as Executive Chairman. Mr.&nbsp;Crowley has also served as a director of Amicus since August 2004,
with the exception of the period from September 2006 to March 2007 when he was in active duty service in the United States Navy (Reserve). Mr.&nbsp;Crowley was President and Chief Executive Officer
of Orexigen Therapeutics,&nbsp;Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals,&nbsp;Inc., from March 2000 until that company
was acquired by Genzyme Corporation ("Genzyme") in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002. Mr.&nbsp;Crowley received a B.S.
degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Crowley possesses strong leadership qualities, demonstrated through his service as an executive in
the
pharmaceutical industry, including his prior roles as Chief Executive Officer of development stage biopharmaceutical companies, and has extensive and intimate knowledge of the rare disease community
and the needs of people living with rare diseases. He also provides our Board with in-depth knowledge of our company through the day-to-day leadership of our executives, all of which contributed to
our conclusion that he should continue to serve as a Director and Chairman of the Company. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Ted W. Love</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>M.D.</I></FONT><FONT SIZE=2>, has served as a member of the Board since June 2012. Dr.&nbsp;Love is
currently the CEO of Global Blood Therapeutics,&nbsp;Inc. (NASDAQ: GBT). From February 2010 to August 2012, Dr.&nbsp;Love served as Executive Vice President and Head of Research and Development of
Onyx Pharmaceuticals,&nbsp;Inc. From 2001 to 2009, Dr.&nbsp;Love was the President, Chief Executive Officer and Chairman of the Board of Directors of Nuvelo&nbsp;Inc. Before joining Nuvelo in
2001, he served as Senior Vice President of Development at Theravance,&nbsp;Inc. Prior to that, Dr.&nbsp;Love spent six years at Genentech,&nbsp;Inc. in a number of senior management positions
in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr.&nbsp;Love oversaw all drugs in development including Herceptin, Rituxan,
and TNKase. He also served as chairman of Genentech's Product Development Committee. In addition to Amicus, Dr.&nbsp;Love currently serves on the Board of Directors of Global Blood </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=12,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=935206,FOLIO='9',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_de13701_1_10"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>and
was previously a board member of Cascadian Therapeutics. Dr.&nbsp;Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Love's significant medical, scientific and drug development experience, in addition to his executive
leadership
experience in the pharmaceutical industry, experience as Chief Executive Officer and Chairman of a biopharmaceutical company and service on the Boards of Directors of other publicly-held
biopharmaceutical companies, contributed to our conclusion that he should be re-elected to serve as a director of the Company and lead the Science and Technology Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Robert Essner</I></FONT><FONT SIZE=2> has served as a member of the Board since June 2012. Mr.&nbsp;Essner is Senior Advisor to the global healthcare group at
The Carlyle Group, a global private equity firm. Mr.&nbsp;Essner retired as Chairman and Chief Executive Officer of Wyeth Pharmaceuticals,&nbsp;Inc., now part of Pfizer&nbsp;Inc., in 2008.
During his 32-year career in the pharmaceutical industry, he held several prominent leadership positions, including Chairman of the Pharmaceutical Research and Manufacturers Association. Prior to
Wyeth, Mr.&nbsp;Essner spent more than a decade in various management positions at Sandoz Pharmaceuticals Corporation and as President of Sandoz Consumer Healthcare Group. Mr.&nbsp;Essner is
currently a Director at MassMutual Financial Group. He received a Bachelor's degree from Miami University and a Master's degree from the University of Chicago. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Essner's significant executive leadership experience in the pharmaceutical industry, including
building and
leading pharmaceutical businesses, launching products and managing corporate risks, including as Chairman and Chief Executive Officer of a pharmaceutical company, as well as his service on the Board
of Directors of another publicly-held company in the pharmaceutical industry, contributed to our conclusion that he should be re-elected to serve as a director of the Company and continue to serve on
the Audit and Compliance Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Margaret G. McGlynn</I></FONT><FONT SIZE=2> has served as a member of our Board since October 2009. Following a 26&nbsp;year career at Merck, Ms.&nbsp;McGlynn
served as CEO and President of The International AIDS Vaccine Initiative from July 2011 through September 2015. She previously served as President, Vaccines and Infectious Diseases of Merck from 2005
until her retirement in 2009, where she led a global organization of 2000&nbsp;employees with over $7B in sales. Ms.&nbsp;McGlynn joined Merck in 1983, and served in a variety of executive
leadership roles in marketing, sales and managed care. Currently, Ms.&nbsp;McGlynn serves as a member of the Boards of Directors of Air Products and Chemicals,&nbsp;Inc. (NYSE: APD) and Vertex
Pharmaceuticals,&nbsp;Inc. (NASDAQ: VRTX). She is also Chair of the Board of HCU Network America, a non-profit which provides advocacy and support for patients affected by the rare disease
homocystinuria. Ms.&nbsp;McGlynn holds a B.S. in Pharmacy and a MBA in Marketing from the State University of New York at Buffalo. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Ms.&nbsp;McGlynn has significant leadership experience in the pharmaceutical industry, including her service
as a senior
executive of Merck where she led commercialization across several therapeutic areas and geographies and managed large organizations. This experience, combined with her service on biopharmaceutical
company boards and a rare disease patient advocacy organization, which gives her important insights into Amicus's business and a comprehensive understanding of compensation management and the
relationship of compensation practices to the organization and its development, contributed to our conclusion that she should continue to serve as a director of the Company, Chair of the Compensation
Committee and member of the Nominating and Corporate Governance Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Michael G. Raab</I></FONT><FONT SIZE=2> has served as a member of our Board of Directors since its founding. Mr.&nbsp;Raab has served as President and Chief
Executive Officer of Ardelyx,&nbsp;Inc. (NASDAQ: ARDX) since March 2009.
Mr.&nbsp;Raab previously served as a partner of New Enterprise Associates ("NEA") from June 2002 until December 2008, with a focus on healthcare investing. From 1999 to 2002, he was Senior Vice
President, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=13,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=838365,FOLIO='10',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_de13701_1_11"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Therapeutics
and General Manager, Renagel&reg; at Genzyme Corporation. Mr.&nbsp;Raab currently serves as a member of the Board of Directors of Ardelyx,&nbsp;Inc. Mr.&nbsp;Raab holds a
B.A. from DePauw University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Raab has significant experience in drug development and commercialization of products in the rare
diseases,
cardio renal and GI diseases. He also has extensive management experience in the biopharmaceutical industry serving as Chief Executive Officer of a late-stage biopharmaceutical company and from his
prior time overseeing NEA investments in pharmaceuticals and biotechnology, all of which contributed to our conclusion that he should continue to serve as a director of the Company and a member of the
Audit and Compensation Committees. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Glenn P. Sblendorio</I></FONT><FONT SIZE=2> has served as a member of our Board since June 2006. On April&nbsp;24, 2017, Mr.&nbsp;Sblendorio is currently
Chief Executive Officer of Ophthotech Corporation ((NASDAQ: OPHT) and is a Director on the Board of Directors of Ophthotech. Prior to Ophthotech, Mr.&nbsp;Sblendorio was President and Chief
Financial Officer of The Medicines Company (NASDAQ: MDCO) from March, 2006 through March, 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through
December&nbsp;31, 2015. Before joining The Medicines Company, Mr.&nbsp;Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals,&nbsp;Inc. from February
2002 until it was acquired by OSI Pharmaceuticals,&nbsp;Inc. in November 2005. Mr.&nbsp;Sblendorio also serves as a member of the Boards of Directors of Intercept Pharmaceuticals,&nbsp;Inc.
(NASDAQ: ICPT) (Chair, Audit). Mr.&nbsp;Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Sblendorio has significant corporate leadership experience, industry knowledge and demonstrated
knowledge of
financial and financing matters through his prior experience in leading pharmaceutical companies. He brings substantial expertise in the management of financial and compliance risks associated with
global pharmaceutical operations and financial management strategies. Mr.&nbsp;Sblendorio's specific expertise includes his service on other boards and he devotes significant time to Amicus matters.
He is the "audit committee financial expert" as defined in the SEC regulations, with particular expertise in the matters faced by the audit committee of a company with its commercial revenue guidance,
geographic expansion and related expenses, all of which contributed to our conclusion that he should continue to serve as a director of the Company and Chair of the Audit and Compliance Committee. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de13701_amicus_corporate_govenance"> </A>
<A NAME="toc_de13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  AMICUS CORPORATE GOVENANCE    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes key corporate governance policies and practices that we believe ensure that Amicus is managed for the long term benefit
of all our stakeholders. We continuously review these policies and practices and compare them to those of our peer group and those suggested by various authorities in corporate governance to ensure we
adopt best industry practices. Policies and practices that we have adopted include criteria for selecting director nominees, board leadership structure, and responsibilities of the Board of Directors
and its committees, among others. Complete copies of our Corporate Governance Guidelines, Board Committee charters, and Code of Conduct are available on the "Investors&#151;Corporate
Governance" section of our website, www.amicusrx.com. You may also request a copy of these documents in writing to: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amicus
Therapeutics&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, N.J. 08512, Attn: Ellen Rosenberg, Secretary </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Governance Guidelines  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has adopted corporate governance guidelines to assist our directors in the exercise of their duties and responsibilities
and to serve the best interests of Amicus and its stakeholders. These guidelines provide, among other things, that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The responsibility of the Board is to oversee the business and operations of Amicus; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=14,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=727371,FOLIO='11',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_de13701_1_12"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The majority of the Board must be independent directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The directors have full access to management and to outside independent consultants as needed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Board conducts an annual self-evaluation; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Board establishes appropriate limitations for service as directors on other company boards. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Independence  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board has reviewed the materiality of any relationship that each of our directors has with Amicus, either directly or indirectly as well as
other factors that may impact the independence determination for each of our directors. Based on this review, our Board has determined that the following directors are "independent directors" as
defined by the rules and regulations of The Nasdaq Stock Market&nbsp;LLC ("NASDAQ"): Messrs.&nbsp;Essner, Hayden, Raab, Sblendorio and Wheeler, Dr.&nbsp;Love, and Ms.&nbsp;McGlynn. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Leadership Structure  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2010, the Board elected Mr.&nbsp;Crowley as chairman of the Board in addition to his role as chief executive officer to succeed
Donald J. Hayden, Jr. Simultaneous with Mr.&nbsp;Crowley's election to chairman, the Board appointed Mr.&nbsp;Hayden as Lead Independent Director. As Lead Independent Director, Mr.&nbsp;Hayden
is responsible for, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> leading executive sessions of the Board's independent directors, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> advising the independent Board Committee chairs in fulfilling their responsibilities to the Board, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> assisting the Board and the Company's officers in complying with the Company's governance guidelines, and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing the process of evaluating, developing and compensating the chief executive officer. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company combines the chairman and chief executive officer positions because it believes that, at this critical juncture in the Company's development, Mr.&nbsp;Crowley is best
suited to oversee the development and implementation of the Company's strategic vision including our ongoing transition from a development stage entity into a commercial biotechnology company.
Mr.&nbsp;Crowley's tenure as chairman also reflects the Board's confidence in his leadership and vision for the Company and recognizes his accomplishments since joining the Company. However, the
Company wished to maintain the strong independent leadership provided by Mr.&nbsp;Hayden during his tenure as chairman. The Company believes that by creating a Lead Independent Director position
held by Mr.&nbsp;Hayden, it has designed a governance structure that best advances the objectives of the Company while maintaining proper checks and balances on senior management, and providing the
independent members of the Board with open and transparent communication regarding the Company's strategic planning activities. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risk Oversight Management  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board provides risk oversight for the Company primarily through the Audit and Compliance Committee. Under our Risk Management Action Plan,
the Company identifies risks utilizing various methodologies, including interviews with senior employees and members of the Board. We then evaluate the identified risks and implement procedures and
activities, as necessary, which are designed to manage and mitigate such risks. We present reports on this risk identification, management and mitigation process along with regular updates on
compliance issues generally to the Audit and Compliance Committee, who provides guidance and feedback to senior management. The Audit and Compliance Committee apprises the Board of any developments
under this plan throughout the year. The Chief Compliance Officer has a dotted line reporting to the Audit and Compliance Committee and provides quarterly updates on the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=15,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=403405,FOLIO='12',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_de13701_1_13"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>development
of the Compliance Program and any reports of violations of the Code of Conduct or other policies. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CODE OF CONDUCT AND ETHICS  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a code of conduct and ethics that applies to all of our employees, including our principal executive officer and principal
financial and accounting officer, and our directors. The text of the code of conduct and ethics is posted on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com</I></FONT><FONT SIZE=2> and will
be made available to stockholders without charge, upon request, in writing to Secretary, c/o Amicus Therapeutics,&nbsp;Inc. at 1&nbsp;Cedar Brook Drive, Cranbury, New Jersey 08512. Disclosure
regarding any amendments to, or waivers from, provisions of the code of conduct and ethics that apply to our directors, principal executive and financial and accounting officers will be included in a
Current Report on Form&nbsp;8-K within four business days following the date of the amendment or waiver, unless web site posting of such amendments or waivers is then permitted by the rules of
NASDAQ. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Attendance  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended December&nbsp;31, 2017, there were thirteen meetings of our Board, and the various committees of the Board met a total
of twenty times. No director attended fewer than 86% of the total number of meetings of the Board and of Committees of the Board on which he or she served during 2017. The Board has adopted a policy
under which each member of the Board is strongly encouraged to attend each Annual Meeting of our Stockholders. All of the directors, with the exception of Mr.&nbsp;Essner, attended our 2017 Annual
Meeting of Stockholders. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Committees of the Board and Meetings  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board has an Audit and Compliance Committee, a Compensation Committee, a Nominating and Corporate Governance Committee and a Science and
Technology Committee, each of which has the composition and responsibilities described below. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit and Compliance Committee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Audit and Compliance Committee ("ACC") met six times during 2017. The current members of our ACC are
Messrs.&nbsp;Sblendorio, Essner and Raab. Mr.&nbsp;Sblendorio is the Chair of the ACC. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board has determined that Mr.&nbsp;Sblendorio is an Audit and Compliance Committee financial expert within the meaning of Item&nbsp;407(d)(5) of Regulation&nbsp;S-K and has
"accounting or related financial management expertise" within the meaning of the rules and regulations of NASDAQ. Our Audit and Compliance Committee was established in accordance with
Section&nbsp;3(a)(58) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Our ACC assists our Board in its oversight of the integrity of our financial statements, our
independent registered public accounting firm's qualifications and independence and the performance of our independent registered public accounting firm. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ACC's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of certain reports
from our independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements
and related disclosures; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=16,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=414534,FOLIO='13',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_de13701_1_14"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> monitoring our Compliance Program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> establishing policies regarding hiring employees from our independent registered public accounting firm and procedures for the receipt and
retention of accounting related complaints and concerns; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> meeting independently with our independent registered public accounting firm and management; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> meeting independently with our Chief Compliance Officer; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> preparing the Audit Committee report required by SEC rules. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
audit and non-audit services to be provided to us by our independent registered public accounting firm must be approved in advance by our Audit and Compliance Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NASDAQ
rules require that all members of the Audit and Compliance Committee be independent directors, as defined by the rules of NASDAQ and the SEC. Our Board has determined that all the
members of the Audit and Compliance Committee satisfy the independence requirements for service on the Audit and Compliance Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
copy of the ACC written charter is publicly available on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com.</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation Committee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee met five times during 2017. Ms.&nbsp;McGlynn, Mr.&nbsp;Raab and Mr.&nbsp;Wheeler are
the
members of our Compensation Committee. Ms.&nbsp;McGlynn is the chair of the Compensation Committee. Our Compensation Committee assists our Board in the discharge of its responsibilities relating to
the compensation of our executive officers. The Compensation Committee has retained Pay Governance,&nbsp;LLC ("Pay Governance") as its independent executive compensation consultant. Pay Governance
reports directly to the Compensation Committee and provides guidance on matters including trends in executive and non-employee director compensation, the development of certain executive compensation
programs, determination of the Company peer group and other matters as directed by the Compensation Committee. Pay Governance does not provide any other services to the Company. Based on the
consideration of the various factors as set forth in the rules of the SEC, the Compensation Committee has determined that its relationship with Pay Governance and the work of Pay Governance on behalf
of the Compensation Committee has not raised any conflict of interest. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and approving executive officer compensation including the compensation of our Chief Executive Officer; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing the evaluation of performance of our senior executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing and administering, and making recommendations to our Board with respect to our cash and equity incentive plans; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and approving potential executive and senior management succession plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and approving non-routine employment agreements, severance agreements and change in control agreements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and recommending to the Board for approval the annual corporate goals and objectives; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing the Company's performance against the annual corporate goals and objectives and recommending to the Board a corporate multiplier
which represents the percentage of achievement against the corporate goals and objectives. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board has determined that the members of our Compensation Committee qualify as independent directors under the rules and regulations of NASDAQ and the SEC. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=17,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=983284,FOLIO='14',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_de13701_1_15"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
copy of the Compensation Committee's written charter is publicly available on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com.</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further
discussion of the process and procedures for considering and determining executive compensation, including the role that our executive officers play in determining compensation
for other executive officers, is included below in the section entitled "Compensation Discussion and Analysis." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
also see the report of the Compensation Committee set forth elsewhere in this Proxy Statement. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nominating and Corporate Governance Committee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Nominating and Corporate Governance Committee met five times during 2017.
Mr.&nbsp;Hayden,
Dr.&nbsp;Love and Ms.&nbsp;McGlynn are the members of our Nominating and Corporate Governance Committee. Mr.&nbsp;Hayden chairs the Nominating and Corporate Governance Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Nominating and Corporate Governance Committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> recommending to our Board the persons to be nominated for election as directors and to each of the Board's Committees; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> conducting searches for appropriate directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing the size, composition and structure of our Board; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> developing and recommending to our Board corporate governance principles; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing a periodic self-evaluation of our Board and any Board Committees; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing compensation and benefits for directors and Board Committee members. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board has determined that the members of our Nominating and Corporate Governance Committee qualify as independent directors under the rules and regulations of NASDAQ and the SEC. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
copy of the Nominating and Corporate Governance Committee's written charter is publicly available on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com.</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Science and Technology Committee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Science and Technology Committee met four times in 2017. Dr.&nbsp;Love and Mr.&nbsp;Wheeler are
currently
members of our Science and Technology Committee. Dr.&nbsp;Love serves as Chair of the committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Science and Technology Committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> identifying and discussing new and emerging trends in pharmaceutical science, technology and regulation to ensure that the Company makes well
informed choices in the investment of its Research and Development resources; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing, evaluating and advising the Board regarding the quality, direction and competitiveness of the Company's Research and Development
programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing, evaluating and advising the Board regarding the Company's overall manufacturing strategy to ensure that the Company makes well
informed choices in the investment in manufacturing capabilities and secures appropriate levels of drug supply and drug product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing, evaluating and advising the Board regarding the Company's clinical and regulatory strategy, goals and objectives, and progress in
achieving the clinical and regulatory strategy, goals and objectives; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and making recommendations to the Board on the Company's internal and external investments in science and technology. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=18,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=2155,FOLIO='15',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_de13701_1_16"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board has determined that the members of the Science and Technology Committee qualify as independent directors under the rules and regulations of NASDAQ and the SEC. A copy of the
Science and Technology Committee's written charter is publicly available on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com.</I></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policies Governing Director Nominations  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director Qualifications.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Nominating and Corporate Governance Committee is responsible for reviewing with the directors from time to
time the
appropriate qualities, skills and characteristics desired of members of the Board in the context of the needs of the business and the composition of the Board. This assessment includes consideration
of the following minimum qualifications that the Nominating and Corporate Governance Committee believes must be met by all directors:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> a reputation for integrity, honesty and adherence to high ethical standards; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the ability to exercise sound business judgment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> substantial business or professional experience and the ability to offer meaningful advice and guidance to the Company's management based on
that experience; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the ability to devote the time and effort necessary to fulfill their responsibilities to the Company. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Nominating and Corporate Governance Committee also considers numerous other qualities, skills and characteristics when evaluating director nominees, including whether the nominee has
specific strengths that would augment existing skills and experience of the Board, such as an understanding of and experience in technology, drug development, accounting, governance, finance or
commercialization and whether the nominee has leadership experience with public companies or other sophisticated and complex organizations. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Process for Identifying and Evaluating Director Nominees.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Nominating and Corporate Governance
Committee has established a process for identifying and evaluating nominees for director. Although the Nominating and Corporate Governance Committee will consider nominees recommended by stockholders,
it believes that the process it uses to identify and evaluate nominees for director is designed to produce nominees that possess the educational, professional, business and personal attributes that
are best suited to further the Company's mission. Our Nominating and Governance Committee may identify nominees through the use of professional search firms that may utilize proprietary screening
techniques to match candidates to the Nominating and Governance Committee's specified qualifications. The Nominating and Governance Committee may also receive recommendations from existing directors,
executive officers, key business partners, and trade or industry affiliations. Our Nominating and Corporate Governance Committee will evaluate nominations at regular or special meetings, and in
evaluating nominations, will seek to achieve a balance of knowledge, experience and capability on the Board and to address the membership criteria set forth above under "Director Qualifications." The
Board itself is ultimately responsible for recommending candidates for election to the stockholders or for appointing individuals to fulfill a vacancy. Although the Board does not have a policy with
regard to the consideration of diversity in identifying director nominees, among the various factors the Nominating and Corporate Governance Committee considers in selecting candidates for nomination
to the Board are the benefits to the Company of national origin, gender, race, scientific and pharmaceutical experience and cultural diversity in board composition. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Procedures for Recommendation of Director Nominees by Stockholders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Nominating and Corporate Governance Committee will consider
director
candidates recommended by our stockholders. In evaluating candidates recommended by our stockholders, the Nominating and Corporate Governance Committee applies the same criteria set forth above under
"Director Qualifications." Any stockholder recommendations of director nominees proposed for consideration by the Nominating and Corporate Governance Committee should include the nominee's name and
qualifications for Board membership and should be addressed in writing to the Nominating and Corporate Governance Committee, care of: Amicus </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=19,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=234760,FOLIO='16',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_de13701_1_17"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Therapeutics&nbsp;Inc.,
1 Cedar Brook Drive, Cranbury, New Jersey 08512, Attention: Secretary. In addition, our Restated By-laws permit stockholders to nominate directors for consideration at an
annual stockholder meeting in accordance with certain procedures described in this Proxy Statement under the heading "Stockholder Proposals and Nominations for Director." </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation Committee Interlocks and Insider Participation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Ms.&nbsp;McGlynn, Mr.&nbsp;Raab and Mr.&nbsp;Wheeler are the members of our
Compensation Committee. None of the members of our Compensation Committee has ever been an officer or employee of the Company. None of our executive officers serves as a member of the Board of
Directors or Compensation Committee, or other committee serving an
equivalent function, of any entity that has one or more of its executive officers serving as a member of our Board or our Compensation Committee. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Communications to the Board  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board provides a process for stockholders to send communications to the Board. Any stockholders who wish to address questions regarding our
business directly with our Board, or any individual director, should direct his or her questions in writing to the Chairman of the Board or the Secretary of the Board, c/o Amicus
Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512. Communications will be distributed to the Board, or to any individual director or directors as appropriate, depending on the
facts and circumstances outlined in the communications. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Officers  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a brief summary of the background of each of our executive officers: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>John F. Crowley, 50,</I></FONT><FONT SIZE=2> has served as Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since January
2005, except for the period during April 2011 through August 2011 during which time he served as Executive Chairman. Mr.&nbsp;Crowley has also served as a director of Amicus since August 2004, with
the exception of the period from September 2006 to March 2007 when he was not an officer or director of Amicus while he was in active duty service in the United States Navy (Reserve).
Mr.&nbsp;Crowley was President and Chief Executive Officer of Orexigen Therapeutics,&nbsp;Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme
Pharmaceuticals,&nbsp;Inc., from March 2000 until that company was acquired by Genzyme Corporation in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until
December 2002. Mr.&nbsp;Crowley received a B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A.
from Harvard Business School. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Bradley L. Campbell, 42,</I></FONT><FONT SIZE=2> has served as President and Chief Operating Officer since January 2015. Mr.&nbsp;Campbell served as Chief
Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012, Mr.&nbsp;Campbell served as Senior Vice President,
Business Operations; from May 2007 to January 2010, as Vice President, Business Planning and from April 2006 until May 2007, as Senior Director, Business Development. Mr.&nbsp;Campbell served as
Senior Product Manager of Myozyme&copy; for Pompe Disease and
later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr.&nbsp;Campbell has also worked in sales&nbsp;&amp; marketing for Bristol-Myers Squibb and as a business
strategy consultant for Marakon Associates. Mr.&nbsp;Campbell is also a director for Progenics (NASDAQ: PGNX) and a board member of BioNJ. Mr.&nbsp;Campbell received his B.A. from Duke University
and his M.B.A. from Harvard Business School. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>William D. "Chip" Baird III, 46,</I></FONT><FONT SIZE=2> has served as Chief Financial Officer since April 2012. Prior to joining Amicus, Mr.&nbsp;Baird served
as Chief Financial Officer of PTC Therapeutics,&nbsp;Inc. ("PTC") from April 2005 until April 2012. Before that, Mr.&nbsp;Baird held various positions of increasing responsibility with PTC from
2002 to 2005. Mr.&nbsp;Baird previously worked at L.E.K. Consulting, a strategy consulting firm, from 1999 to 2002 and at First Union National Bank as a corporate underwriter from 1994 to 1997.
Mr.&nbsp;Baird received a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=20,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=13096,FOLIO='17',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_de13701_1_18"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>B.S.
from Georgetown University's Edmund A. Walsh School of Foreign Service and an M.B.A. from The Wharton School of the University of Pennsylvania. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Jay Barth, M.D., 54,</I></FONT><FONT SIZE=2> has served as Chief Medical Officer since March 2014. Prior to joining Amicus, Dr.&nbsp;Barth held roles of
increasing responsibility at PTC from 2009 to 2014. He most recently served as PTC's Senior Vice President, Clinical Development. Previously Dr.&nbsp;Barth served as Executive Director of Clinical
Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US,&nbsp;Inc.; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical
Research&nbsp;Inc. Dr.&nbsp;Barth received a B.A. from Columbia University and an M.D. from the University of Pennsylvania School Of Medicine. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Hung Do, Ph.D., 50</I></FONT><FONT SIZE=2>, has served as Chief Science Officer since July 2015. Previously, he served as Senior Vice President, Discovery Biology
since December 2013. Prior to joining Amicus, Dr.&nbsp;Do was a co-founder and Chief Scientific Officer of Callidus Biopharma,&nbsp;Inc. ("Callidus") a privately held biologics company that was
acquired by Amicus. Prior to founding Callidus, he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at Amicus. He previously helped to
demonstrate proof of concept for ERTs, and served as the project leader for a second generation Pompe ERT at Genzyme. Dr.&nbsp;Do also led molecular biology, cell culture and purification work and
helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at Novazyme Pharmaceuticals,&nbsp;Inc., which was acquired by Genzyme. Dr.&nbsp;Do
holds a Ph.D. in medical biochemistry and genetics from Texas A&amp;M University and was a post-doctoral fellow in Hematology/Oncology at Emory University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Ellen S. Rosenberg, 55</I></FONT><FONT SIZE=2>, has served as our General Counsel and Corporate Secretary since February 2016. Prior to joining Amicus, she served
as Senior Vice President, Associate General Counsel of Shire
Pharmaceuticals. Prior to Shire, Ms.&nbsp;Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono&nbsp;Inc., the U.S. affiliate of Merck KGaA.
Ms.&nbsp;Rosenberg brings extensive and broad ranging legal experience in the biopharmaceutical and medical device industry including mergers and acquisitions, licensing, corporate governance,
product launches, risk management, and compliance matters. Ms.&nbsp;Rosenbereg also has significant experience building and developing legal teams and the in-house legal function.
Ms.&nbsp;Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Law School. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Daphne Quimi, 52</I></FONT><FONT SIZE=2>, currently serves as our Senior Vice President, Finance and has been employed with Amicus since September 2007. Prior to
Amicus, Ms.&nbsp;Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department at
Johnson&nbsp;&amp; Johnson. Ms.&nbsp;Quimi brings extensive experience in public accounting and financial reporting. Ms.&nbsp;Quimi received a B.S. in Accountancy from Monmouth University and an
M.B.A. from the Stern School of Business of New York University. She is a certified public accountant in New Jersey and a member of the American Institute of Certified Public Accountants and the
Institute of Management Accountants. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Kurt J.W. Andrews, 48,</I></FONT><FONT SIZE=2> has served as our Senior Vice President, Human Resources since February 2016. Prior to joining Amicus,
Mr.&nbsp;Andrews served as Vice President, Human Resources at Valeritas,&nbsp;Inc. Previously Mr.&nbsp;Andrews was Vice President, Human Resources and Administration at PTC
Therapeutics,&nbsp;Inc. Mr.&nbsp;Andrews brings experience working in leadership roles at biotechnology and technology companies including business and commercial strategy, implementation of
organization-wide goals and strategies, performance management, and compensation planning. Mr.&nbsp;Andrews earned a B.A. and M.A. from The University of Illinois at Urbana-Champaign. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=21,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=769173,FOLIO='18',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dg13701_1_19"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg13701_compensation_discussion_and_analysis_#151;2017"> </A>
<A NAME="toc_dg13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  COMPENSATION DISCUSSION AND ANALYSIS&#151;2017    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Summary  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee, in consultation with the Board, is responsible for establishing, implementing and overseeing our overall
compensation strategy and policies, including our executive compensation program, in a manner that supports our business objectives. Based on the events described below, our Compensation Committee
determined that in 2017, the Company made significant progress towards the goal of becoming a leading orphan and rare disease company with global commercial operations and a diversified product
pipeline. Specific milestones achieved in 2017 in support of the Company's business strategy include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> In 2017, we made significant progress in the advancement of the International commercial launch of Galafold (migalastat) for the treatment of
Fabry patients with amenable mutations. We exceeded the corporate goal of 300 patients and achieved more than 310 patients taking reimbursed Galafold at year end. We secured access and reimbursement
for Galafold in 15&nbsp;countries and recognized $36.9&nbsp;million of net product revenue in 2017. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> In July 2017, we announced that, based on feedback from the FDA, data from completed studies were deemed sufficient to support a New Drug
Application ("NDA") for migalastat under the accelerated approval pathway. This reversed prior FDA guidance received in 4Q16 which stated that the Company would need to conduct a new Phase&nbsp;3
study focused on collecting gastrointestinal symptoms data prior to submitting an NDA. The updated FDA guidance announced in July 2017 accelerated the potential approval of migalastat by several
years. In December 2017, the Company completed the submission of the NDA for migalastat. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> During 2017, we provided several updates from our ongoing Phase&nbsp;1/2 study of our novel Enzyme Replacement Therapy ("ERT") combined with
chaperone, ATB200/AT2221, in patients with Pompe disease. The final update was presented at the World Muscle Society meeting in October 2017. The data showed that both previously-treated patients and
na&iuml;ve patients experienced meaningful improvements in their six-minute walk tests, an accepted measure of clinical benefit in Pompe disease. Patients showed consistent and durable
improvements in other measures of muscle function, as well as improvements in key biomarkers of disease. Patients experienced very low rates (&#60;1%) of infusion associated reactions,
which are a common side effect of existing ERTs. Taken together, these results exceeded our expectations and suggest that the effect of ATB200/AT2221 may be very clinically meaningful for people
living with Pompe disease. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> We substantially strengthened our financial position in 2017. In July 2017, we completed a $258.8&nbsp;million follow on equity offering.
Through careful expense management, our net cash spend for 2017 was $216.5&nbsp;million, which was within the full-year guidance range of $200&nbsp;million to $225&nbsp;million. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee adheres to a long-standing pay-for-performance philosophy. The Compensation Committee continually evaluates our compensation program, taking into consideration
best practices and emerging trends, stockholder input as well as data and feedback provided by our independent executive compensation consultant, Pay Governance. In the past year, we have continued
to take measures to align our compensation program with stockholder interests including the following actions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Base salaries comprise approximately 18% of our named executive officers' total compensation on an aggregate basis, with Mr.&nbsp;Crowley's
2017 salary representing approximately 11% of his total compensation and, for our other named executive officers, representing between 20% and 28% of their total compensation. For 2017, the
Compensation Committee determined that Mr.&nbsp;Crowley would receive an increase in his base salary of 3.0%. Approximately 16% of Mr.&nbsp;Crowley's total compensation in 2017 was represented by
payments we make to him for medical expenses and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=22,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=776814,FOLIO='19',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dg13701_1_20"> </A>
<UL>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>associated
tax liabilities incurred for the treatment of a rare medical condition afflicting two members of Mr.&nbsp;Crowley's immediate family. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> A large portion of our named executive officers compensation was represented by long-term incentives, including the grant date fair value of
equity awards, which are inherently performance based. Approximately 61% of Mr.&nbsp;Crowley's total compensation was in the form of long-term incentives. For our named executive officers other than
Mr.&nbsp;Crowley, 54% to 60% of their total compensation for 2017 was represented by long-term incentives. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> For 2017, the Compensation Committee determined that Mr.&nbsp;Crowley, along with the Senior Leadership team, including all of our named
executive officers, would receive one-third of the value of their equity grant in Performance Restricted Stock Units ("PRSUs"). This was part of an overall strategic shift which encompassed using 1/3
the value of annual grants in Stock Options, 1/3 of the value in Restricted Stock Units and 1/3 in PRSUs. The PRSUs utilized performance measures of relative total shareholder return and strategic
pipeline metrics. Utilizing PRSUs aligns the management team with shareholders and strengthens our pay-for-performance philosophy because these awards only deliver value to our named executive
officers if the Company achieves the performance goals selected. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Consistent with our pay-for-performance philosophy, and in recognition of our strong performance against stated corporate objectives, with most
corporate objectives fully accomplished or exceeded and additional achievements beyond the stated objectives, the Compensation Committee determined that the corporate multiplier used in determining
cash bonuses for our named executive officers for 2017 should be set at 158.5%, resulting in bonuses above target levels. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results of our compensation program in 2017 show a clear heavy weighting on Performance Based Compensation for not only the CEO, but all named executive officers. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g677153.jpg" ALT="GRAPHIC" WIDTH="523" HEIGHT="285">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=23,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=108295,FOLIO='20',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dg13701_1_21"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g144310.jpg" ALT="GRAPHIC" WIDTH="523" HEIGHT="285">
  </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Ownership Guidelines  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of January&nbsp;1, 2018, we implemented a stock ownership and retention guidelines for our directors and executive officers to ensure that
each of them has a long term equity stake in Amicus, in order to both closely align the interests of directors and executive officers to those of our shareholders and to further our commitment to
corporate governance. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the stock ownership guidelines, directors and executive officers must maintain a multiple of their annual retainer or salary, as applicable, as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="39%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="39%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Retention Amount </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CEO</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>4 times executive's base salary</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>President</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>2 times executive's base salary</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Executive Officers</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>1 time executive's base salary</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Directors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>3 times director's annual retainer</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
executive officer or director has five years to attain the required stock ownership. Stock ownership includes shares of common stock, vested RSUs, and vested RSUs in a deferred
equity plan. All executive officers and directors have met or are on track to meet the stock ownership guidelines. . The Compensation Committee of the Board monitors compliance with this policy and
will take any actions necessary to ensure compliance. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clawback Policy  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also have established a policy for recoupment of performance based compensation in the event of a financial restatement. Our policy provides
that in the event of a financial restatement, the Board will seek to recover any incentive based compensation and equity awards made to an executive officer during the three-year period preceding a
restatement. In determining whether a recoupment is necessary, the Board may consider (1)&nbsp;the executive officer's intentional misconduct or gross negligence that was a contributing factor to
the restatement; (2)&nbsp;the amount of incentive compensation or equity award predicated on achieving financial results that were part of the restatement and (3)&nbsp;the difference in the amount
of incentive compensation or equity award that would have been awarded based upon the restatement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=24,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=821548,FOLIO='21',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dg13701_1_22"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
factors that the Board can consider include (1)&nbsp;whether the recoupment would violate law or prejudice a claim; (2)&nbsp;other penalties or repercussions, instead of
recoupment; and/or; (3)&nbsp;the nature of events leading to a restatement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board retains the discretion to amend the policy as appropriate. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Compensation  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We describe our executive compensation program below and provide an analysis of the compensation paid and earned in 2017 by our "named executive
officers"&#151;our chief executive officer, chief financial officer, and three other most highly compensated executive officers. In 2017, our named executive officers
were:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Chairman and Chief Executive Officer, John F. Crowley; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Chief Financial Officer, William D. Baird, III; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> President and Chief Operating Officer, Bradley L. Campbell; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Chief Medical Officer, Jay Barth, M.D.; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> General Counsel, Ellen S. Rosenberg. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Compensation Good Governance Practices  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below we summarize certain executive compensation-related good governance practices that we follow and that we believe serve our stockholders'
long-term interests. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What
We Do:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Maintain an Executive Compensation Program Designed to Align Pay with Performance </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Conduct an Annual Say-on-Pay Vote </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Seek Input from, Listen to and Respond to Stockholders </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Have Double-Trigger on Executive Severance Arrangements and Executive Stock Option Grants </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Prohibit Hedging and Pledging of Company Stock </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Retain an Independent Compensation Consultant </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Maintain Stock Ownership Guidelines </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Maintain a Claw-Back Policy </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What
We Do Not Do:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provide Executives with Tax Gross-ups other than for Company required relocations </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provide Guaranteed Bonuses </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


"Say-on-Pay" Consideration  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At our 2017 annual meeting of stockholders, approximately 99% of the shares voted at the meeting approved, on an advisory basis, the
compensation of the named executive officers. In addition to the voting at the annual meeting, we proactively engaged with major stockholders representing approximately 78% of shares outstanding on
the Company's pay practices. The great majority of the shares voted approved the 'say-on-pay' advisory proposal and the Compensation Committee continues to focus on pay practices that align
compensation with performance. The Compensation Committee placed a continued emphasis on performance-based pay, in tying one third of the targeted equity compensation value to the performance of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=25,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=68967,FOLIO='22',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dg13701_1_23"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Amicus
in Total Shareholder Return and pipeline goals over three years. The Compensation Committee monitors and considers the results of the annual advisory 'say-on-pay' proposal and feedback received
from stockholders. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Objectives and Philosophy of Executive Compensation  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a global, commercial stage, patient-focused biotechnology company engaged in the discovery and development of a diverse set of novel
treatments for patients living with devastating rare and orphan diseases. We operate in an extremely competitive, rapidly changing and heavily regulated industry, and the long-term success of our
business requires a high degree of innovation and adaptability. We believe that the skill, talent and dedication of our executive officers are critical factors affecting our long-term success,
especially at this critical time in our history as we execute our business strategy. Therefore, our compensation program for our executive officers, including our named executive officers, is designed
to attract, retain and motivate the best possible executive talent. Utilizing a pay-for-performance compensation philosophy, we have designed a program that provides the ability to differentiate the
total compensation mix of our named executive officers based on their demonstrated performance and their potential to contribute to our long-term success. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
compensation philosophy is to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> provide our executives a competitive total compensation opportunity relative to the organizations with which we compete for executive talent; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> attract and retain individuals of superior ability and managerial talent who can successfully perform and succeed in our environment; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> increase the incentive to achieve key strategic and financial performance measures by linking compensation opportunities and actual
compensation earned through our pay for performance compensation program to the achievement of corporate goals; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> deliver pay in a cost efficient manner that aligns employees' compensation with stockholders' long-term interests. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
compensation program is designed to reward the accomplishment of our corporate goals in a manner consistent with the Company's values, which stresses not only results but also how
those results are attained. In order to meet the objectives of our compensation philosophy, we maintain a robust goal setting and performance management program. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
chief executive officer established general individual goals for the named executive officers other than himself at the beginning of 2017 that were specific to such executive
officer's area of expertise and supported our corporate goals for the year. For 2017, annual cash incentive bonuses for our named executive officers other than Mr.&nbsp;Crowley were determined by
the combination of both the corporate and an individual multiplier. For Messrs.&nbsp;Baird, Campbell, Dr.&nbsp;Barth and Ms.&nbsp;Rosenberg the attainment of individual goals was assessed with a
0-150% multiplier for each individual; this multiplier was applied to the final corporate multiplier to determine final annual incentive bonus payouts. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee believes that the corporate multiplier should continue to be the dominant factor in determining bonus payouts because it closely aligns our named executive
officers' compensation with the interests of our stockholders, and that some portion of an executive's compensation should be linked to individual performance, which we believe is consistent with our
peers. The Compensation Committee believes that including the individual multiplier as a component of named executive officers' bonus payouts is important to incentivize our officers during this
crucial time in Amicus' history as we continue our transformation into a global commercial biotechnology company. However, because of Mr.&nbsp;Crowley's influence on the overall performance of
Amicus, the Compensation Committee believes it is appropriate and in the best interests of our stockholders to continue to base Mr.&nbsp;Crowley's </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=26,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=523458,FOLIO='23',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dg13701_1_24"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>cash
bonus solely on the Compensation Committee's determination regarding the achievement of corporate objectives. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risk Analysis of Compensation Policies and Practices  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee is aware that compensation arrangements, if not properly designed, could encourage inappropriate or excessive risk
taking. We believe that our overall compensation program encourages our named executive officers and other employees to focus on both short-term and long-term objectives and does not encourage
excessive risk taking. While the value of stock options is inherently tied to the performance of the Company, and an important part of our current and future performance based compensation, our stock
options vest over multiple years and the value is not directly linked to the achievement of short term defined metrics. To enhance this posture, the Committee made the decision in 2017 to award
performance-based restricted stock grants in addition to market priced options and restricted stock units. In addition, cash incentive bonuses tied to the achievement of Company and individual goals
have historically made up a small percentage of our executive officers' total compensation package. For example, in 2017, payouts under our cash incentive bonus plan represented approximately 14% of
the total compensation, or 16% of direct compensation awarded to our named executive officers. Further, we operate as a single business unit and therefore are not exposed to the risks that may be
associated with operating through several segments, such as one business unit being significantly more profitable than another or having a compensation structure that is significantly different than
that of other units. The Compensation Committee will continue to review risk as one of the elements it considers in the planning process for executive compensation in the future. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Program Elements and Pay Level Determination  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each year, the Compensation Committee reviews and determines base salaries, annual cash incentive and long-term incentive awards for all
executive officers. In setting our executive compensation programs, the Compensation Committee reviews market data at the 25<SUP>th</SUP>, 50<SUP>th</SUP>, and
75<SUP>th</SUP>&nbsp;percentile and generally targets aggregate total direct compensation for the named executive officers as a group to approximately the 50<SUP>th</SUP>&nbsp;percentile of
our peer group (as discussed below). Actual compensation levels for each named executive officer depend on factors such as individual performance, Company performance, skills/capabilities, overall
impact/contribution, experience in
position, criticality of position and internal equity. For 2016, the base salaries, annual cash incentives and long-term incentive awards determination for all named executive officers, including our
chief executive officer, were approved by our Compensation Committee, which is comprised solely of independent directors. The Compensation Committee considered all the information presented (including
external competitiveness, the individual's performance, Company performance and internal equity) and applied its collective knowledge and discretion to determine the compensation for each named
executive officer. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of the compensation evaluation process, the chief executive officer presents to the Compensation Committee an individual assessment of each named executive officer's performance,
excluding the chief executive officer's performance, over the prior year, as well as the recommended compensation action for each such named executive officer. Based on corporate and individual
performance, the chief executive officer makes a compensation recommendation for each such named executive officer which includes actions on base salary, bonus and long-term incentive grant target
value. Individual goals and objectives are established at the beginning of each year and are designed to support the achievement of the corporate goals. All employees, including the named executive
officers, participate in annual individual goal setting as well as mid-year and year-end performance reviews. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results of the named executive officer's performance (other than the performance of the chief executive officer) are a determination by each such named executive officer's
supervisor, the chief executive officer, with input from other peers, and direct reports, as appropriate, but the final determination is made by the Compensation Committee. The chief executive
officer's performance is </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=27,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=284607,FOLIO='24',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dg13701_1_25"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>assessed
by all independent directors under the leadership of our Lead Independent Director while the chief executive officer compensation recommendation to the Board is made by the Compensation
Committee based upon this assessment. Long-term incentive grants are based on an executive's level within the organization, and in the case of our named executive officers, several other factors which
are more fully described below under "Long-Term Incentive Programs". Long-term incentive grants are designed to motivate the executive team to best achieve the Company's goals and implement our
business strategy, thereby increasing stockholder value. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Developments in Company Leadership in 2017  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We had no material changes to our leadership structure in 2017. In August 2017, Bradley Campbell, President and COO, completed the one year
assignment working from the
Company's United Kingdom office to oversee and ensure the successful commercialization of Galafold and returned to continue his duties in the United States. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Role of Independent Compensation Consultant  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee has engaged Pay Governance to assist the Compensation Committee by providing ongoing executive compensation
consulting. The Compensation Committee has concluded that Pay Governance's work does not raise any conflict of interest. The Compensation Committee has also considered the independence of Pay
Governance. Because of policies and procedures that Pay Governance and the Compensation Committee have in place, the Compensation Committee is confident that the advice it receives from executive
compensation consultants at Pay Governance is objective and not influenced by Pay Governance's or its affiliates' relationships with the Company or its officers. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Peer Group  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee, with the help of its independent executive compensation consultant, Pay Governance, established the peer group set
forth below as a reference point for assessing named executive officer target compensation against market competitive data. The Compensation Committee, upon advice of Pay Governance, selected the
companies that comprise our peer group through a robust screening process that considered publicly traded U.S. biopharmaceutical companies that were similar to Amicus in size, market capitalization
and business operating model and operate in geographic locations that generally have similar pay levels. Four companies (CellDex Therapeutics, Raptor Pharmaceuticals, Rigel Pharmaceuticals and Sangamo
Biosciences) were removed from the peer group established last year due primarily to acquisition or changes in structure or size, including market capitalization. The Compensation Committee replaced
these entities with four companies (</FONT><FONT SIZE=2><I>Intercept Pharmaceuticals, Ionis Pharmaceuticals, Spark Therapeutics and Theravance Biopharma</I></FONT><FONT SIZE=2>) upon the
recommendation of Pay Governance due to each company's similarity based on the criteria set forth above. The Compensation Committee intends to continue reviewing and revising the peer group
periodically to ensure that it continues to reflect publicly traded companies of similar size and business model. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="153pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="147pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>ACADIA Pharmaceuticals</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Insmed</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Sarepta Therapeutics</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Acceleron Pharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Intercept Pharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Spark Therapeutics</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Agios Pharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Ionis Pharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Theravance Biopharma</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Bluebird Bio</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>PTC Therapeutics</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Ultragenyx Pharmaceutical</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Cytokinetics</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sage Therapeutics</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Ziopharm Oncology</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Elements of Compensation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive compensation consists of base salary, annual cash incentive plan, and long-term incentive program, each of which plays an
important role in our pay-for-performance philosophy and in achieving our compensation program objectives. For each element of compensation, we target an overall executive compensation program that is
competitive with market data. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=28,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=769514,FOLIO='25',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;10',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_di13701_1_26"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Base Salaries  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base salaries are paid to our named executive officers to provide a level of compensation that is both competitive with the external market and
is commensurate with each executive officer's scope of responsibilities, past performance, experience and skills. The base salary for each of our named executive officers was as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Base salary at<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>601,037</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>619,068</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>396,550</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>408,447</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>427,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>450,105</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>431,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>444,548</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>400,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>412,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2017, Messrs.&nbsp;Crowley, Baird and Campbell, Dr.&nbsp;Barth and Ms.&nbsp;Rosenberg each received a base salary market increase of 3%. Mr.&nbsp;Campbell received an
additional base salary increase of 2.3%, reflecting additional global operational responsibilities. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Cash Incentive Plan  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain an annual cash incentive program to motivate and reward the attainment of annual strategic, operational, financial and individual
goals. For all program participants, annual target cash incentive opportunities are expressed as a percentage of base salary, which we believe is consistent with market practice. The target bonus
percentages of base salary were generally determined by level in the organization in accordance with market-based considerations and contractual entitlements. The target bonus percentages for 2017 are
as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 Target<BR>
Bonus % of<BR>
Base Salary </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief executive officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>President</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other chief officers</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Senior vice presidents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vice presidents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2017, bonuses awarded under the plan to our named executive officers, other than Mr.&nbsp;Crowley, were determined based on both the corporate multiplier and an individual
multiplier. The corporate multiplier generally ranges from 50% to 150%, with the Compensation Committee having final discretion to adjust the upper or lower limits as appropriate. For bonuses related
to 2017 performance, the corporate multiplier was determined to be 158.5% based on the Company's performance for the reasons discussed below. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to determine bonus calculations under the plan, the target bonus for each eligible named executive officer, other than Mr.&nbsp;Crowley, was determined by first multiplying
the officer's target bonus by the 158.5% corporate multiplier and then applying his or her individual multiplier. Mr.&nbsp;Crowley's bonus was determined by multiplying the 158.5% corporate
multiplier by his target bonus percentage of 60% of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=29,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=290095,FOLIO='26',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;13',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_di13701_1_27"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>base
salary, which results in a 2017 bonus of approximately 95% of Mr.&nbsp;Crowley's base salary. The table below titled "Calculation of Annual Cash Incentive Bonuses" illustrates further how 2017
awards under the plan were calculated for our named executive officers. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


</I></FONT><FONT SIZE=2><U>The Corporate Multiplier</U> </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
an annual basis, the Board works with management to set Company goals and objectives that are challenging and reflect an ambitious timetable for the execution of the
Company's strategies commensurate with our short and long-term business plan. The Company's internal goals and objectives reflect complex assumptions based on internal analyses and projections, and
are intended to encourage the Company to pursue its business plan in an expedited, aggressive manner. Once the Company's goals and objectives have been developed, they are reviewed by the Compensation
Committee and finally approved by the full Board. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the time the goals and objectives are set, the Compensation Committee believes that their full attainment will be appropriately challenging and may not be reached, despite great
effort, due in part to internal and external factors, many of which may be out of the Company's control. However, while total achievement of all goals and objectives set at the beginning of the year
may not be expected, the Compensation Committee considers the achievement of the corporate objectives in its sole discretion in setting the corporate multiplier and holds management accountable to
significantly advance the Company's business objectives throughout the year in order to achieve a 100% corporate multiplier. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2017, our corporate objectives were as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Complete
successful launch of Galafold in additional International geographies and finish 2017 with at least 300 Fabry patients on reimbursed Galafold
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Advance
registration-directed activities for migalastat in key geographies
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Complete
successful Phase&nbsp;3 study of our development candidate SD-101
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Complete
successful Phase <SUP>1</SUP>/<SMALL>2</SMALL> study and define clinical development strategy for ATB200 for the treatment of Pompe
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Evaluate
research opportunities to develop clinical candidates for 2019 and beyond
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>6.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Finish
2017 with 18&nbsp;months of cash necessary to operate our business </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee then reviews corporate performance against each of the pre-established targets and weighting to determine the extent to which such goals were attained. The
Compensation Committee's rationale behind its determination of both the attainment of corporate goals and the percentage completed for each such goal is described below. In reaching its determination
on the corporate multiplier for 2017, the Compensation Committee applied the percentage that the Compensation Committee determined was completed against the pre-established weighting of the corporate
objectives as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Objective


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighting </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage<BR>
Completed </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Score </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Complete successful launch of Galafold in additional International geographies and finish 2017 with at least 300 Fabry patients on reimbursed
Galafold</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advance registration-directed activies for migalastat in key geographies</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Complete successful Phase&nbsp;3 study of our development candidate SD 101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Complete successful Phase <SUP>1</SUP>/<SMALL>2</SMALL> study and define clinical development strategy for ATB200 for the treatment of Pompe</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Evaluate research opportunities to develop clinical candidates for 2019 and beyond</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>95</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Finish 2017 with a minimum of 18&nbsp;months of cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Plus: Overall Performance Adjustment for exceptional results</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>TOTAL SCORE</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>158.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=30,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=971367,FOLIO='27',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;13',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_di13701_1_28"> </A>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


</I></FONT><FONT SIZE=2><U>2017 Corporate Objectives Measurement</U> </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
establishing the 2017 corporate objectives at the end of 2016, the Company and the Compensation Committee believed that the three most important goals for Amicus in
2017 were related to the International Galafold commercial launch, advancing migalastat regulatory approvals in other geographies, and achieving definitive proof-of-concept for ATB200/AT2221 and
finding the best and fastest path to approval. Collectively, these three goals accounting for 70% of the overall weightings. The commercial objective for Galafold was focused on the successful launch
of Galafold in European and select other countries. "Target 300"&#151;the goal of having 300 patients on reimbursed commercial product by the end of the year was communicated externally in
January 2017. With more than 310 patients on reimbursed product at the end of the year and with $36.9&nbsp;million of revenue for 2017, the Compensation Committee determined that this objective was
105% completed and determined a score of 21.0% by multiplying the 20% weighting of this goal by the 105% achievement percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
regions where Galafold (migalastat) was not yet approved, the goal was to advance registration-directed activities towards eventual regulatory approval. In Japan, the goal was to
complete a J-NDA submission for regulatory approval. The J-NDA was successfully submitted in June 2017. In the U.S., we began 2017 with guidance from FDA which required the Company to successfully
complete a third Phase&nbsp;3 study prior to submitting an NDA which would have delayed an NDA submission by three or more years. Through a series of meetings and correspondences with the FDA, we
were successful in gaining agreement with the FDA that existing data were sufficient to support an NDA submission. We completed the successful submission of the migalastat NDA in December 2017. Given
the progress in Japan and the unexpected and extremely positive developments with the FDA, the Compensation Committee determined that this objective was 200% completed and determined a score of 50.0%
by multiplying the 25% weighting of this goal by the 200% achievement percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company began 2017 with the SD-101 program for Epidermolysis Bullosa close to completion of Phase&nbsp;3 enrollment. The Company and the Compensation Committee established the goal
for 2017 to successfully complete the Phase&nbsp;3 trial for SD-101. Through diligent efforts, the Company overenrolled the study and made favorable changes to the statistical analysis plan (SAP)
which were approved by the FDA and the EMA. Unfortunately, in September 2017 the Company announced that the Phase&nbsp;3 study did not meet its two primary endpoints. Given the study results, we
made the difficult decision to discontinue future investment in the program. Given the Phase&nbsp;3 outcome, the Compensation Committee determined a score of 4% by multiplying the 10% weighting by a
40% achievement percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given
the significant level of unmet need in Pompe disease and our belief that we have a differentiated product candidate (ATB200 plus chaperone AT2221) that could offer meaningful
improvements over the current standard of care, we have identified Pompe disease as an area of long-term strategic importance to the Company. The Pompe goal for 2017 was to successfully complete our
Phase <SUP>1</SUP>/<SMALL>2</SMALL> study and define the clinical development strategy. In 2017, we provided several updates from our ongoing Phase <SUP>1</SUP>/<SMALL>2</SMALL> study which showed that both
previously-treated patients as well as na&iuml;ve patients experienced meaningful improvements in their six-minute walk tests, an accepted measure of clinical benefit in Pompe disease.
Patients showed consistent and durable improvements in other measures of muscle function as well as improvements in key biomarkers of disease. Patients experienced very low rates (&#60;1%)
of infusion associated reactions, which are a common side effect of existing ERTs. Taken together, these results exceeded our expectations and suggest that the effect of ATB200/AT2221 may be very
clinically meaningful for people living with Pompe disease. The Compensation Committee weighed these factors and determined that this objective was 200% completed and determined a score of 50.0% by
multiplying the 25% weighting by a 200% achievement percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given
the Company's stated objective of being at the forefront of rare and orphan disease, we believe that development of the earlier-stage pipeline is an important objective. In setting
pipeline development goals for 2017, the Compensation Committee felt the goal of evaluating research opportunities to develop </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=31,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=254592,FOLIO='28',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;13',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_di13701_1_29"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>clinical
candidates for 2019 and beyond balanced the Company's strategic needs with its financial resources. Based upon the progress achieved with the CDKL5 program and the Fabry ERT program, but in
also taking into account the status of a comprehensive pipeline development strategy, the Compensation Committee subjectively determined that 95% of the goal was complete and determined a score of
4.8% by multiplying the 5% weighting by a 95% achievement percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
cash position directly affects our ability to establish commercial infrastructure, conduct our clinical and preclinical activities, hire and retain qualified and talented employees
and pursue business development opportunities. Even though we have commercial sales, careful management of our cash is critical to our operations. Due to our careful expense management and a
successful $258&nbsp;million equity financing in July 2017, we achieved our goal of ending the year with enough cash to fund our operations for a period of 18&nbsp;months. Given the achievement of
the cash goal and the strength and quality execution of the equity financing, the Compensation Committee determined a score of 18.8% by multiplying the 15% weighting by a 125% subjectively determined
completion percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally,
in evaluating the overall corporate performance for 2017, the Compensation Committee felt that the Company had significantly outperformed its peers and industry benchmarks as
evidenced by the 190% increase in the share price during 2017, had demonstrated high quality execution across the
business, and had positioned the Company for continued success in 2018 and beyond , particularly with the commercial and regulatory progress of migalastat and the strong momentum established in the
clinical program for ATB200/AT2221 for Pompe Disease. As such, the Compensation Committee awarded an additional 10% performance adjustment to the overall corporate modifier to arrive at a 158.5%
corporate modifier for 2018. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


</I></FONT><FONT SIZE=2><U>The Individual Multiplier</U> </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Design  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While we believe that the corporate multiplier should remain the dominant factor in the bonus calculation, the Compensation Committee believes
it is important to recognize and incentivize individual performance of our non-CEO Executive Officers as we advance towards our goal of becoming a fully integrated pharmaceutical company. We therefore
determined that the individual multiplier for Messrs.&nbsp;Baird and Campbell Dr.&nbsp;Barth, and Ms.&nbsp;Rosenberg would range from 0-150% based on performance described below. As noted above,
the Compensation Committee continues to believe that Mr.&nbsp;Crowley's bonus should be determined solely by reference to the corporate multiplier. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
individual multiplier for each executive is determined after considering several factors including achievement of individual objectives, departmental or organizational performance,
and other significant accomplishments. Individual objectives are necessarily tied to the particular area of expertise of the executive and are designed to support the Company's achievement of its
corporate goals. Individual goals are evaluated based on leadership and performance on specific functional goals that are tied to the corporate goals. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
objectives are set with the belief that full achievement will be difficult and challenging, but attainable, so long as the officer is fully committed to the accomplishment of such
objectives through significant effort and dedication to the Company's strategies, and an ability to quickly adapt to a constantly evolving business environment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Individual
performance objectives of our named executive officers, other than Mr.&nbsp;Crowley, are set by the executive officer to whom each such named executive officer reports,
which for 2017 was Mr.&nbsp;Crowley for all of our named executive officers. These objectives are neither reviewed nor approved by the Compensation Committee. Rather, these objectives serve as a
measuring tool for our chief
executive officer in formulating his recommendation to the Compensation Committee as to the appropriate individual multiplier for each named executive officer. During the annual review process, the
Company's </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=32,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=921614,FOLIO='29',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;13',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_di13701_1_30"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>chief
executive officer discusses with the Compensation Committee his overall evaluation for each executive which includes each such executive's performance and accomplishments as they relate to the
Company's corporate goals, departmental performance, and other significant accomplishments. While the Compensation Committee relies in part on the chief executive officer's evaluation of the other
named executive officers, it also considers the degree of difficulty in attaining the Company's goals and such executive's accomplishments. In considering the degree of difficulty, the Compensation
Committee considers factors such as the influence of external events, including unanticipated clinical events and regulatory timelines, and the effort expanded by executives. The Compensation
Committee reviews and discusses their evaluation of the Company's chief executive officer's performance and accomplishments in executive session along with the Lead Independent Director of the Board
and without the presence of the chief executive officer. Upon the completion of such process the Compensation Committee subjectively determines the individual multiplier for each named executive
officer, other than the chief executive officer, based on the Compensation Committee's subjective determination of such officer's satisfaction of the applicable goals. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Determinations  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In determining the individual multiplier for our named executive officers, the Compensation Committee noted each executive officer's individual
and departmental performance throughout the year, and how those performances supported the Company's achievement of its corporate goals. The specific individual factors that the Compensation Committee
noted in subjectively determining each named executive officer's individual multiplier were as follows: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Bradley L. Campbell, President and Chief Operating Officer (120% Individual Multiplier)  </I></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provided overall leadership of the continued build out of the international commercial organization and successful launch of Galafold Ex-US,
with high level of patient uptake in areas with reimbursement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Oversaw the program management function including the successful integration of development activities across migalastat, SD 101, and ATB200
programs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Oversaw the successful manufacturing scale up efforts for ATB200, including successful engineering batches at 1,000 liter commercial scale. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


William D. Baird, III, Chief Financial Officer (95% Individual Multiplier)  </I></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Significantly strengthened the balance sheet through the leadership and execution of a $258&nbsp;million equity financing; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Led company-wide project to redesign decision making and governance to support future growth, increased entrepreneurship throughout the
company, and empowered functional leaders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provided strategic and financial leadership to the Board, the Senior Leadership Team, Business Development, and the program steering teams
throughout the year. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Jay Barth, Chief Medical Officer (95% Individual Multiplier)  </I></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Oversaw regulatory discussions with FDA to obtain agreement that existing clinical results were sufficient to support NDA submission for
migalastat and that a third Phase&nbsp;3 study would no longer be required; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Led efforts among the clinical and regulatory teams to obtain regulatory approval for migalastat in Canada, Israel, and Switzerland and oversaw
successful regulatory submissions for migalastat in Japan and the U.S.; and; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=33,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=57002,FOLIO='30',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;13',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_di13701_1_31"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Designed and oversaw implementation of clinical strategy for ATB200/AT2221 for Pompe disease, including the communication of ongoing Phase
<SUP>1</SUP>/<SMALL>2</SMALL> results and the discussions with regulators on the best and fastest path to approval for ATB200/AT2221. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ellen S. Rosenberg, General Counsel (110% Individual Multiplier)  </I></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Led due diligence and legal negotiations for successful $258&nbsp;million equity financing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Streamlined global legal operations to support rapid global commercial expansion, clinical development and manufacturing activities; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provided strategic legal counsel, corporate governance and risk mitigation advice to the Board and Board Committees, the CEO and Executive
Officers. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


</I></FONT><FONT SIZE=2><U>Calculation of Annual Cash Incentive Bonuses</U> </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
calculation of the named executive officers' individual cash incentive payments for service in 2017 is summarized in the table below. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Corporate<BR>
Multiplier<BR>
(%) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Individual<BR>
Multiplier<BR>
(%) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Target<BR>
Bonus<BR>
(%) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Base<BR>
Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Payout<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>158.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>619,068</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>588,734</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>158.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>95</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>408,447</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>246,007</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>158.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>450,105</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>428,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>158.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>95</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>444,548</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>267,751</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>158.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>110</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>412,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>287,329</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Long Term Incentive Programs  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that long-term performance will be achieved through an ownership culture that rewards our executives for maximizing stockholder value
over time and that aligns the interests of our employees and management with those of stockholders. Our Amended and Restated 2007 Equity Incentive Plan, or the 2007 Plan, authorizes us to grant stock
options, restricted stock, RSUs and other equity-based awards. We have historically elected to use stock options as the primary long-term equity incentive vehicle. We typically grant an initial stock
option award to new employees and annual long-term incentive awards as part of our overall compensation program as well as option grants to reflect promotions, as necessary. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2017, we continued our strategy for equity compensation that was implemented in 2016 of using a mix of Stock Options and time based Restricted Stock Units (RSUs), however we added
Performance Restricted Stock Units (PRSUs) to this mix for the first time. We utilize a value based approach to allocating equity, with one third of the assigned value to each named executive officers
assigned to each type of equity vehicle. Under our current equity plan, for the named executive officers, our stock option awards vest over a four-year period with 25% vesting one year after the
vesting commencement date and the remainder vesting ratably each month thereafter in equal installments over a three-year period subject to continued employment or service with us. The stock options
expire ten years after the date of grant. RSU awards vest over a four-year period with 25% vesting each year upon the anniversary of the grant. PRSU awards vest over a three year period based on the
attainment of the applicable goals at the end of such period. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=34,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=516822,FOLIO='31',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;13',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_di13701_1_32"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
use a mix of stock options, RSUs, and PRSUs as long-term incentive vehicles because we believe that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Committee believes that stock options, RSUs, and PRSUs, along with their vesting periods, provide a balanced mix to attract, motivate and
retain executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Stock options are inherently performance based. Because all of the value received by the recipient of a stock option is based on the growth of
the stock price, stock options enhance the executives' incentive to increase our stock price and maximize stockholder value; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> RSUs help enhance executive actual stock ownership while helping to retain executives. Final value depends on the change in stock price over
the vesting period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> PRSUs align executives with the goals of the company and its shareholders, while still assisting in the retention of our executives. Final
value depends on company performance over the vesting period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Stock options, RSUs and PRSUs help to provide a balance to the overall executive compensation program as base salary and our annual performance
bonus program focus on short-term compensation, while stock options and RSUs reward executives for increases in stockholder value over the longer term. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Initial Equity Grants  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executives who join us are typically awarded initial equity grants. Amicus is utilizing a mix of Stock Options and RSUs to all employees,
including executives, as part of new hire grants. The options portion of the grants have an exercise price equal to the closing price of our Common Stock on the date of grant. Our goal is to create a
total compensation package for new employees that is competitive with other biotechnology companies and that will enable us to attract high quality people. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Option, Restricted Stock Unit Awards, Performance Restricted Stock Unit Awards  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee believes that providing annual equity awards beyond the initial equity awards provides management with a strong link
to long-term corporate performance and the creation of stockholder value, as well as providing continued retention via long-term vesting. Starting in 2017, the Compensation Committee decided that
Amicus should move to an annual grant cycle along with the new mix of equity vehicles consisting of fair market value stock options, RSUs and PRSUs as part of a performance share program. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee determines the value and corresponding number of shares subject to options or RSUs that are granted to our named executive officers in its sole discretion. In
applying that discretion, the Compensation Committee takes into account a number of factors including the current price of our Common Stock, peer group data, each individual's role and performance and
recent Company developments. All of the stock option and RSU awards are subject to four-year vesting schedules. The 2017 stock option and RSU grants are described in the section entitled "Grants of
Plan-Based Awards." With the introduction of RSUs, the committee moved to approving 2017 and future LTI grants based on a fixed dollar value instead of its historical approach of granting on a fixed
number of shares basis. The Compensation Committee determined that this methodology provides a greater level of sophistication in ensuring the value of LT1 grants is aligned to market. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2017, Amicus granted PRSU Awards for the first time. These grants were 33% of the value assigned to each executive officer. Goals were established by management and the Compensation
Committee for Total Shareholder return versus NASDAQ Biotechnology Index and a strategic pipeline goal. 50% of the PRSUs granted were assigned to "Relative Total Shareholder return" with 0-200%
achievement of the number of target PRSU's. 50% of the PRSUs granted were based on achievement of a "Pipeline Goal" that was focused on the Pompe Program Milestone of having the first patient dosed in
a registration directed study. Both TSR and Pipeline Goal have 3-year cliff vesting period. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=35,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1025201,FOLIO='32',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;13',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dk13701_1_33"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>The
Compensation Committee believes that these goal are difficult and challenging to attain and appropriately align incentives with performance. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have typically awarded the largest equity grant in each grant cycle to our chief executive officer in recognition of his role as our principal executive officer, Chairman of the Board
and primary decision maker for the Company. For these reasons, and the factors noted below for other executive officers, the Compensation Committee awarded Mr.&nbsp;Crowley options to purchase
282,485 shares of Common Stock, 203,252 Restricted Stock Units and 203,252 Performance Restricted Stock Units in our company-wide grant award in January 2017. The 2017 equity grants for all other NEOs
are described in the section entitled "Grants of Plan-Based Awards." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Factors
that the Compensation Committee and our chief executive officer considered in making these stock option grants for other Executive Officers included (i)&nbsp;relative
contribution toward achievement of current year corporate objectives, (ii)&nbsp;breadth of internal and external responsibilities, (iii)&nbsp;management responsibilities including managing direct
reports, (iv)&nbsp;external benchmarking and (v)&nbsp;tenure with Amicus. The specific individual factors that the Compensation Committee relied on for granting each award are substantially
similar to those factors that contributed to a determination of the individual multiplier for each named executive officer discussed above under "2017 Determinations." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Qualified Deferred Compensation Plans  </I></B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amicus Therapeutics,&nbsp;Inc. Restricted Stock Unit Deferral Plan  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains the Amicus Therapeutics,&nbsp;Inc. Restricted Stock Unit Deferral Plan as amended (the "Stock Deferral Plan"). The Stock
Deferral Plan provides eligible non-employee directors and executives, including each of the named executive officers, with the voluntary opportunity to defer the receipt of RSUs otherwise payable to
such eligible executives. The Stock Deferral Plan was updated in fiscal year 2017 to allow directors to participate. After a deferral election is made, an individual's account is credited with the
deferred RSUs. All RSUs deferred under the Stock Deferral Plan are fully vested. The Company does not otherwise contribute to the Stock Deferral Plan and the amount a participant receives at the end
of a deferral period is based solely on the value of the Company's stock at the end of the deferral period. Generally a participant may voluntarily elect to re-defer any previously deferred RSUs for
an additional period of not less than five years if, as required under the Code, such an election is made at least 12&nbsp;months before the year in which the RSUs would otherwise be delivered. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
only does the Stock Deferral Plan allow our participants, including the named executive officers to defer the Federal income taxes otherwise payable upon the delivery of RSUs, but
the Compensation Committee believes that with respect to non-employee directors and executives who avail themselves of the deferral features of the Stock Deferral Plan, such person will necessarily
hold Company stock for a longer period of time. Accordingly, any RSUs deferred under the Stock Deferral Plan will continue to align such portion of our non-employee directors and named executive
officers' compensation with the interests of our stockholders for a longer period of time than would be provided by typical vesting periods. Regardless of a participant's election, any deferred RSUs
will be distributed following the non-employee director or executive's death, disability or separation of service from the Company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
amounts deferred under the Stock Deferral Plan will continue for all purposes to be a part of the general funds of the Company and the non-employee director's or executive's deferral
will be subject to the general creditors of the Company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amicus Therapeutics,&nbsp;Inc. Cash Deferral Plan  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains the Amicus Therapeutics,&nbsp;Inc. Cash Deferral Plan, as amended (the "Cash Deferral Plan"). The Cash Deferral Plan
provides eligible executives, including each of the named executive officers and non-employee directors, with the voluntary opportunity to defer receipt of such </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=36,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=730133,FOLIO='33',FILE='DISK109:[18ZAG1.18ZAG13701]DK13701A.;22',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dk13701_1_34"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>participant's
base salary, bonus and/or director's fees, as applicable. Any such deferrals are credited to a bookkeeping account maintained for the participant. The participant may make periodic
hypothetical investments of the account and gains and losses on such hypothetical investments will be credited to the participant's account. A participant is fully vested in all amounts, including
earnings deferred under the Cash Deferral Plan. Distribution of the deferred amounts will generally be made on the distribution date elected by the participant. Generally, a participant may
voluntarily elect to re-defer any previously deferred amount for an additional period of not less than five years if, as required under the Code, such an election is made at least 12&nbsp;months
before the year in which the amount would otherwise be delivered. Regardless of a participant's election, any deferred amount will be distributed following a change in control of the Company or upon
the participant's death, disability or separation of service from the Company. The Company does not match when a participant defers any amounts in the Cash Deferral Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
amounts deferred under the Cash Deferral Plan will continue for all purposes to be a part of the general funds of the Company and the amounts deferred by the participants, including
all deemed gains and losses attributable thereto, and will be subject to the general creditors of the Company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Compensation  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent with our compensation philosophy, we intend to continue to maintain our current benefits for our named executive officers, including
medical, dental, vision and life insurance coverage. All employees receive Company paid term life insurance equal to two times annual base salary, up to a maximum benefit of $1,000,000. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we provide a Company match for our 401(k) Plan, subject to Federal guidelines and plan maximums. We match $1 for each $1 a participant, including each named executive
officer, defers into the plan up to 5% of each participant's salary and bonus paid during the year. The match vests 100% on the participant's one-year anniversary of employment at Amicus. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Additional Chief Executive Officer Benefits  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Company is engaged in a highly competitive industry developing medicines for unique and complicated genetic disorders. As chief executive
officer, Mr.&nbsp;Crowley has significant responsibility for leading our Company and managing its progress toward achieving our corporate goals. Mr.&nbsp;Crowley's compensation reflects this
responsibility and takes into account his unique circumstances. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of his overall compensation, Mr.&nbsp;Crowley receives significant payments and benefits from the Company related to the healthcare and other associated costs incurred by his
family. These amounts reflect substantial costs incurred for the treatment of a rare medical condition afflicting two members of Mr.&nbsp;Crowley's immediate family. We continued to make monthly
compensation payments of $66,667 to Mr.&nbsp;Crowley to help defray the substantial out-of-pocket medical expenses incurred by Mr.&nbsp;Crowley and his family which we refer to as the Monthly
Medical Payments. We agreed to make the Monthly Medical Payments to Mr.&nbsp;Crowley when we amended his employment agreement in December 2010 in order to compensate him for the loss of certain
medical benefits previously afforded to Mr.&nbsp;Crowley resulting from the passing of federal legislation in 2010, as well as to limit the Company's exposure to Mr.&nbsp;Crowley's expected growth
in future medical expenses. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Secondment Agreement with Mr.&nbsp;Campbell  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2016, the Company requested that Mr.&nbsp;Campbell temporarily relocate himself and his family to the United Kingdom to oversee and
ensure the successful launch of Galafold in the pivotal first year of its international launch. Accordingly, on August&nbsp;22, 2016, the Company entered into a secondment letter with Bradley
Campbell outlining the relocation and tax equalization benefits for such assignment over the expected twelve month term of the agreement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=37,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=909100,FOLIO='34',FILE='DISK109:[18ZAG1.18ZAG13701]DK13701A.;22',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dk13701_1_35"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to such agreement, the Company paid Mr.&nbsp;Campbell a lump sum relocation payment of $15,000 to assist with miscellaneous transition expenses, as well as providing him with
tuition reimbursement for his children and a per diem as a cost of living adjustment. In addition, the Company has reimbursed Mr.&nbsp;Campbell for, or directly paid, certain other expenses incurred
in connection with such relocation. Pursuant to the Agreement, Mr.&nbsp;Campbell was also entitled to certain tax equalization payments, including a gross-up, and other payments and/or
reimbursements upon his relocation back to the United States, which were intended to defray the costs he would otherwise incur in connection with this Company-requested relocation. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2017, Bradley Campbell, President and COO, completed the one year assignment working from the Company's United Kingdom office to oversee and ensure the successful
commercialization of Galafold. Upon his relocation to the United States, as stated above, he received a lump sum relocation payment of $15,936. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Termination-Based Compensation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon termination of employment under certain circumstances, our named executive officers are entitled to receive varying types of compensation.
Elements of this compensation may include payments based upon a number of months of base salary, bonus amounts, acceleration of vesting of equity, health care coverage and other similar benefits. We
believe that our termination-based compensation and acceleration of vesting of equity arrangements are in line with severance packages offered to named executive officers of other similar companies
based upon market information, and are otherwise appropriate given the executive's role and service to the Company. We also have granted severance and acceleration of vesting of equity benefits to our
named executive officers in the event of a change of control if the executive is terminated within a certain period of time following the change of control. We believe that change of control-related
benefits are necessary in order for our named executive officers to direct their full attention to the successful consummation of a transaction without distraction, and that this "double trigger"
requirement maximizes stockholder value because it prevents an unintended windfall to management in the event of a friendly or non-hostile change of control. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=38,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=418079,FOLIO='35',FILE='DISK109:[18ZAG1.18ZAG13701]DK13701A.;22',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dk13701_1_36"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Compensation  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk13701_summary_compensation_table"> </A>
<A NAME="toc_dk13701_1"> </A></FONT> <FONT SIZE=2><B>  Summary Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information regarding the compensation that we paid to each person serving as our principal chief executive
officer, our principal financial officer and each of our other three most highly compensated executive officers during the years indicated below (collectively, the "named executive officers"). </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fiscal<BR>
Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus(1)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock<BR>
Awards(2)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards(2)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change in<BR>
Pension<BR>
Value&nbsp;&amp; Non-<BR>
Qualified<BR>
Deferred<BR>
Compensation<BR>
Earnings </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>619,068</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>588,734</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,385,162</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,044,082</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>94,189</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>881,845</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,613,080</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>601,037</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>299,316</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>254,169</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,198,129</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>31,539</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>815,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,199,368</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>582,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>314,496</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,013,039</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>815,166</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,725,101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>William D. Baird III</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>408,447</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>246,007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>715,535</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>313,253</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,310</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,698,552</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>396,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>131,655</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>91,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>832,036</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,316</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,467,056</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>385,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>141,680</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,264,576</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,805,906</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>450,105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>428,050</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>874,544</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>382,867</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>71,816</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,207,382</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>427,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>177,392</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>152,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>960,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>53,146</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,770,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Operating Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>415,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>152,720</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,346,302</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,166</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,929,188</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Jay Barth, M.D.,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>444,548</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>267,751</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>596,284</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>261,045</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,560</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,584,188</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Medical Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>431,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>336,127</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>91,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>832,036</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,566</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,505,828</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>415,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>154,380</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,205,793</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,789,823</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>412,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>287,329</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>596,284</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>261,045</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,560</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,571,218</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
2017 amount represents bonuses earned in 2017 and paid in 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
grant date fair value of time based restricted stock unit awards (RSUs), performance based restricted stock unit awards (PRSUs) and option awards granted to our
named executive officers was computed in accordance with FASB ASC Topic 718, Compensation&#151;Stock Compensation. Assumptions made in this valuation are discussed in our annual report for the
year ended December&nbsp;31, 2017, filed with the SEC on Form&nbsp;10-K on March&nbsp;1, 2018 at Item&nbsp;7&#151;Management's Discussion and Analysis of Financial Condition and Results
of Operations&#151;Stock Option Grants and Restricted Stock Units ("RSUs") and Performance-Based Restricted Stock Units. These amounts reflect the stock price at the time of the grant. In
accordance with SEC rules, the amounts reported in the Stock Awards column for 2017 include the grant date fair value of the RSUs and PRSUs granted during 2017. The grant date fair value for this
purpose is required to be shown even where the PRSUs were not ultimately earned. The following table provides information regarding the 2017 PRSUs based on the expected performance outcomes (and is
the grant date fair value of the award, as reflected in the Summary Compensation Table) and maximum performance outcomes:
<BR></FONT></DD></DL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 </DIV>
<DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant Date<BR>
Fair<BR>
Value for<BR>
2017 PRSUs<BR>
(i.e.,&nbsp;Based<BR>
on Expected<BR>
Performance)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value at<BR>
Grant Date<BR>
Assuming<BR>
Maximum<BR>
Performance<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual<BR>
Realizable<BR>
Value at<BR>
Grant<BR>
Date<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,342,479</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2,684,958</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>William D. Baird III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>402,733</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>805,466</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>492,231</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>984,462</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Jay Barth, M.D.,</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>335,613</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>671,226</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Ellen S. Rosenberg</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>335,613</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>671,226</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Consists
of gains on investments in Mr.&nbsp;Crowley's deferred compensation plan account; please see the "Nonqualified Deferred Compensation" table below.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
$13,000 of 401(k) employer match, $866,667 of Monthly Medical Payments pursuant to Mr.&nbsp;Crowley's current employment agreement (see page&nbsp;30),
$750 for health care savings account and $1,428 in life insurance premiums.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
$13,000 of 401(k) employer match, $1,500 for health care savings account and $810 in life insurance premiums.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
$13,000 of 401(k) employer match, $750 for health care savings account and $1,428 in life insurance premiums. In addition, the following items were related
to Mr.&nbsp;Campbell's secondment agreement: $15,936 for relocation, $17,746 for tuition reimbursement for his children and $23,324 for per diem payments for cost of living adjustment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
$13,000 of 401(k) employer match, $750 for health care savings account and $810 in life insurance premiums.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>As
described more fully below, Mr.&nbsp;Crowley participates in our Non-Qualified Cash Deferral Plan and for 2017, the deferral amounts were: $309,534 of salary
and $441,550 of bonus. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=39,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=216304,FOLIO='36',FILE='DISK109:[18ZAG1.18ZAG13701]DK13701A.;22',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dm13701_1_37"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Grants of Plan-Based Awards  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents information concerning grants of equity awards to each of the named executive officers during 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Stock<BR>
Awards:<BR>
Number of<BR>
Shares of<BR>
RSUs<BR>
Units(1)<BR>
(#) </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Option<BR>
Awards:<BR>
Number of<BR>
Securities<BR>
Underlying<BR>
Options(2)<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated Future Payouts<BR>
Under Equity Incentive<BR>
PRSU Awards </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercise or<BR>
Base<BR>
Price of<BR>
Option<BR>
Awards<BR>
($/Sh)(3) </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant<BR>
Date Fair<BR>
Value of<BR>
Stock and<BR>
Option<BR>
Awards(4)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Threshold<BR>
# </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Target<BR>
# </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Maximum<BR>
# </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>282,485</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,044,182</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>203,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,042,683</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101,626</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>203,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>521,341</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101,626</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>203,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>821,138</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
84,745</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
313,253</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,975</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>312,802</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,243</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,487</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,974</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>156,398</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,243</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,487</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,974</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>246,335</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
103,578</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
382,867</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>382,313</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,631</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>37,262</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74,524</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>191,154</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,631</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>37,262</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74,524</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>301,077</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
70,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
261,045</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>260,671</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>205,280</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen Rosenberg</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
70,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
261,045</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>260,671</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Corporate Secretary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>205,280</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Amounts
represent PRSUs granted to NEOs during the 2017 fiscal year. The criteria used to determine the number of PRSUs earned by each NEO are described above under
"Performance-Based Restricted Stock Units" The service-vesting schedule associated with the annual PRSUs granted to all NEOs on January&nbsp;3, 2017 is three-year graded vesting.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Vesting
of the RSU is subject to the participant's continuous service with the Company through the applicable vesting date with the following schedule: 25% of the
total number of shares vest on the first anniversary of the Grant Date, with 25% on each successive Grant Date anniversary.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Each
option has a term of ten years and vests in accordance with the following schedule: 25% of the total number of shares vest on the first anniversary of the Grant
Date and 1/48<SUP>th</SUP>&nbsp;of the total number of shares vest on the first day of the following 36&nbsp;months.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Amounts
represent the grant date fair value calculated in accordance with FASB ASC 718, as stated in footnote&nbsp;#2 to the Summary Compensation Table. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=40,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=107288,FOLIO='37',FILE='DISK109:[18ZAG1.18ZAG13701]DM13701A.;15',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dm13701_1_38"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at Year-End  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents the outstanding equity awards held by each of the named executive officers as of December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="77pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Unexercisable(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Units of<BR>
Stock That<BR>
Have Not<BR>
Vested<BR>
(#)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Market<BR>
Value of<BR>
Units of<BR>
Stock That<BR>
Have Not<BR>
Vested<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Unearned<BR>
Units of<BR>
Stock That<BR>
Have Not<BR>
Vested<BR>
(#)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Market<BR>
Value of<BR>
Unearned<BR>
Units of<BR>
Stock That<BR>
Have Not<BR>
Vested<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>103,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10.36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>41,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>207,085</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>103,975</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/19/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>203,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2,924,796</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>131,024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/15/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>101,626</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,462,398</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>136,378</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/4/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>203,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2,924,796</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,538</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/28/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11,686</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>201,230</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>28,770</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/26/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>167,693</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>62,307</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11.19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/2/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>143,738</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>86,262</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>15.96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>119,788</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>130,212</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11.74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/4/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>31,249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>52,084</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>31,249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>52,084</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>7.93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>282,245</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>William D. Baird III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>175,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4.66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4/16/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>161,888</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/4/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>60,975</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>877,430</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>38,259</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/28/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>30,487</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>438,708</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6,224</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/18/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>60,974</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>877,416</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>62,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>78,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.94</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/26/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>65,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>24,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>8.61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/2/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>56,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>33,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>43,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>46,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/4/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>37,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>84,745</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>32,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/5/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>18,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>269,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>36,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10.36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>74,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,072,415</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>30,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/19/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>37,262</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>536,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>60,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.06</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/16/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>74,524</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,072,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>70,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/15/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>80,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/4/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>78,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/28/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>85,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/18/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>88,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>78,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.94</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/26/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>65,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>24,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>8.61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/2/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>62,494</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>37,506</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>47,913</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>52,087</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/4/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>28,122</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>46,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>103,578</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>124,035</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10,965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3/7/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>161,888</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>43,730</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6,270</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.94</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/26/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>50,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>731,199</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>58,318</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>21,682</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>8.61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/2/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>25,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>365,592</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>56,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>33,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>50,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>731,185</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>43,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>46,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/4/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>37,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>70,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>57,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>67,710</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/8/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4,687</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>67,446</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>9,370</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>15,630</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>50,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>731,199</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Corporate Secretary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>70,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>25,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>365,592</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>50,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>731,185</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>25%
of the total number of shares subject to the option vest on the first anniversary of the date of grant; the remainder vest 1/36<SUP>th</SUP>&nbsp;per month
thereafter. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=41,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=382550,FOLIO='38',FILE='DISK109:[18ZAG1.18ZAG13701]DM13701A.;15',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dm13701_1_39"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Vesting
of the RSU is subject to the participant's continuous service with the Company through the applicable vesting date with the following schedule: 25% of the
total number of shares vest on the first anniversary of the grant date, with 25% on each successive grant date anniversary for the next three years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Vesting
of PRSUs are based on the goals were established by management and the Compensation Committee; the units noted for the total shareholder return goal and the
strategic pipeline goal related to the Pompe program are at target and maximum payout, respectively.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
market value is based on the closing stock price of $14.39 on December&nbsp;31, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was January&nbsp;3, 2014.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of grant was March&nbsp;7, 2014.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was June&nbsp;26, 2014.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was January&nbsp;2, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(9)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was June&nbsp;1, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(10)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of grant was January&nbsp;4, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(11)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of grant was February&nbsp;8, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(12)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of grant was June&nbsp;15, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(13)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of grant was January&nbsp;3, 2017. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Option Exercises and Stock Vested at Year End  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive officers must use pre-established trading plans to sell shares of Amicus Therapeutics,&nbsp;Inc. stock. Trading plans may only
be entered into when the executive is not in possession of material non-public information about the Company, and we require a waiting period following the establishment of a trading plan before any
trades may be executed. Our policy is designed to provide safeguards that will allow our executives an opportunity to realize the value intended by the Company in granting equity-based awards. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows information regarding option exercises and stock vested for each named executive officer during the year ended December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Acquired on<BR>
Exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value<BR>
Realized<BR>
upon<BR>
Exercise(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Acquired on<BR>
Vesting </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value<BR>
Realized<BR>
upon<BR>
Vesting(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>666,395</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,505,043</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,417</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>91,565</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird III</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>469,332</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,963</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>106,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>567,938</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>347,605</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,963</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,563</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,739</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
value realized is the difference between the fair market value of a share of our common stock at the time of exercise and the option exercise price, multiplied
by the number of shares acquired on each exercise.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
value realized on vesting on stock awards is based on the closing price on the date of vesting.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=42,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=986565,FOLIO='39',FILE='DISK109:[18ZAG1.18ZAG13701]DM13701A.;15',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_do13701_1_40"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Qualified Deferred Compensation  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As described more fully above, our Non-Qualified Cash Deferral Plan (and Stock Deferral Plan (collectively, the "Deferral Plans") covers our
executive officers and our non-employee directors. Earnings are determined solely by an executive's hypothetical investment of any amount deferred in any pre-selected investment permitted under the
Cash Deferral Plan or in the value of our stock, with respect to the Stock Deferral Plan. All amounts in the Deferral Plans are fully vested at all times. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Executive<BR>
Contributions in<BR>
Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Earnings in<BR>
Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Distributions in<BR>
Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Balance at<BR>
Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>751,085</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>94,188</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,041,030</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>513,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>$309,534
of this amount is included in the salary column and $441,550 of this amount is included in the bonus column, respectively, in the summary compensation
table.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
investments gains determined by the hypothetical investments elected by Mr.&nbsp;Crowley in the last fiscal year as permitted under the Deferral Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
column includes $1,195,757 compensation earned and deferred in prior years, which was disclosed in prior year Proxy statements.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
amount in this column represents the value of the vested RSUs that Mr.&nbsp;Campbell deferred and distributed on January&nbsp;3, 2017.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Severance Benefits and Change of Control Arrangements  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have agreed to provide severance benefits and change of control arrangements to our current executives as described below. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John F. Crowley.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We employ Mr.&nbsp;Crowley as our Chief Executive Officer pursuant to an employment agreement. The agreement will
continue for
successive one-year terms until either Mr.&nbsp;Crowley or the company provide written notice of termination to the other in accordance with the terms of the agreement. Upon the termination of his
employment by the company other than for cause, or if the company decides not to extend Mr.&nbsp;Crowley's agreement at the end of any term, or if Mr.&nbsp;Crowley resigns for good reason,
Mr.&nbsp;Crowley has the right to receive (i)&nbsp;a severance payment in an amount equal to his then current base salary payable over 18&nbsp;months in accordance with the company's regular
payroll practices, (ii)&nbsp;an additional payment equal to 150% of the target bonus for the year in which the
termination occurs, (iii)&nbsp;continued Monthly Medical Payments for a period of 18&nbsp;months, and (iv)&nbsp;continuation of health care coverage under COBRA with premiums to be paid by the
Company for up to 29&nbsp;months. Further, the vesting of all options then held by Mr.&nbsp;Crowley shall accelerate by one year. Mr.&nbsp;Crowley is not entitled to severance payments if the
company terminates him for cause or if he resigns without good reason. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
if upon the termination of Mr.&nbsp;Crowley's employment by the company other than for cause, or if the company decides not to extend his employment agreement at the end of
any term, or if Mr.&nbsp;Crowley resigns for good reason, in each case within twelve months following a change of control in the Company, then Mr.&nbsp;Crowley has the right to receive
(i)&nbsp;a severance payment in an amount equal to two times his then current base salary payable over 24&nbsp;months in accordance with our regular payroll practices, (ii)&nbsp;an additional
payment equal to 200% of the target bonus for the year in which the termination occurs, (iii)&nbsp;continued Monthly Medical Payments for a period of 24&nbsp;months, and (iv)&nbsp;continuation
of health care coverage under COBRA with premiums to be paid by the Company for up to 29&nbsp;months. Further, the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=43,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=695907,FOLIO='40',FILE='DISK109:[18ZAG1.18ZAG13701]DO13701A.;11',USER='JLAWRENA',CD='12-APR-2018;15:46' -->
<A NAME="page_do13701_1_41"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>vesting
of all remaining unvested options and restricted stock grants then held by Mr.&nbsp;Crowley would accelerate in full. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally,
if Mr.&nbsp;Crowley's employment ceases due to his death or disability, he (or his estate, as applicable) will be entitled to (i)&nbsp;continuation of the Monthly Medical
Payments for 12&nbsp;months, and (ii)&nbsp;continuation of health care coverage under COBRA with premiums to be subsidized by the Company for up to 12&nbsp;months. We believe that the severance
package for our chief executive officer is appropriate considering his role, responsibilities and his excellent historical service to the Company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Named Executive Officers.  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Messrs.&nbsp;Baird and Campbell, Dr.&nbsp;Barth and Ms.&nbsp;Rosenberg.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We employ Mr.&nbsp;Baird as our Chief Financial Officer,
Mr.&nbsp;Campbell as our President and Chief Operating Officer, Dr.&nbsp;Barth as our Chief Medical Officer, and Ms.&nbsp;Rosenberg as our General Counsel and Corporate Secretary, pursuant to
their
respective employment agreements. If any of these executive officers is terminated without cause, then the executive officer has the right to receive:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continuation of such executive's base salary for 12&nbsp;months; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an amount equal to the target bonus for such executive officer pro-rated for the number of months actually worked in the year of termination; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> vesting of option awards then held by them will automatically accelerate by twelve months; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continuation of health care coverage under COBRA with premiums to be paid by the Company for a period of 12&nbsp;months. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, if any of these executive officers is terminated other than for cause within 12&nbsp;months following change of control or, if following those changes, the executive
officer resigns for good reason, then the executive officer has the right to receive:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continuation of such executive's base salary for 18&nbsp;months; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an amount equal to such executive officer's target annual bonus; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any outstanding unvested stock options and restricted stock grants held by the executive officer will fully vest; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continuation of health care coverage under COBRA with premiums to be paid by the Company for a period of 18&nbsp;months. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally,
if the executive's employment ceases due to death or disability, such executive will be entitled to continuation of health care coverage under COBRA with premiums to be
subsidized by the Company for up to 12&nbsp;months. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a condition to the payment of the foregoing severance benefits, a departing executive officer is required to execute a general release of claims against the Company and its
affiliates. Each named executive officer is bound by non-disclosure, inventions transfer, non-solicitation and non-competition covenants that prohibit the executive officer from competing with the
Company during the term of his or her employment and for twelve months after termination of employment. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Potential Payments upon Termination without Cause or Resignation for Good Reason  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For each named executive officer the following table sets forth quantitative estimates of the benefits that would have accrued if such
executive's employment had been terminated without cause or, in the case of Mr.&nbsp;Crowley, he resigned for good reason, on December&nbsp;31, 2017 other than in connection with a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=44,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=707709,FOLIO='41',FILE='DISK109:[18ZAG1.18ZAG13701]DO13701A.;11',USER='JLAWRENA',CD='12-APR-2018;15:46' -->
<A NAME="page_do13701_1_42"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>change
of control. Amounts below reflect potential payments pursuant to the severance agreements for such named executive officers. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="15pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="15pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
Continuation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Benefit<BR>
Continuation<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
RSU<BR>
Vesting<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Stock<BR>
Option<BR>
Vesting<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>928,602</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>557,161</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,204,263</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>881,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,264,700</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,835,827</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>408,447</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>246,007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,747</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>273,309</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>949,640</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,905,151</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>450,105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>428,050</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,820</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>358,038</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,082,848</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,343,861</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>444,548</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>267,751</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26,997</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>236,759</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>925,768</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,901,823</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>412,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>287,329</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,508</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>205,288</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>653,470</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,579,595</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Bonus
component paid in lump sum.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Other
than with respect to Mr.&nbsp;Crowley, benefits to be continued consist of COBRA premiums paid by the Company for 12&nbsp;months.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Value
of the options that would accelerate upon such event is calculated using the closing stock price of $14.39 on December&nbsp;31, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over an 18&nbsp;month period following such termination of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Benefits
to be continued consist of estimated healthcare costs and health insurance premiums for Mr.&nbsp;Crowley's family, which primarily consists of the Monthly
Medical Payments paid over 18&nbsp;months and up to 29&nbsp;months of COBRA coverage.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over a 6&nbsp;month period following such termination of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over a 12&nbsp;month period following such termination of employment. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Potential Payments upon Termination Due to Change of Control  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth quantitative estimates of the benefits that would have accrued to each of our named executive officers, if his or
her employment had been terminated due to a termination without cause or a resignation with good reason on December&nbsp;31, 2017, assuming that such termination occurs </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=45,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=848245,FOLIO='42',FILE='DISK109:[18ZAG1.18ZAG13701]DO13701A.;11',USER='JLAWRENA',CD='12-APR-2018;15:46' -->
<A NAME="page_do13701_1_43"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>within
twelve months following a change of control or, in the case of Mr.&nbsp;Crowley, within three months prior to or twelve months following the date on which the change of control occurs. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="15pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="15pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
Continuation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Benefit<BR>
Continuation<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
RSU<BR>
Vesting<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Stock<BR>
Option<BR>
Vesting<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,238,137</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>721,244</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,604,265</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,299,280</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,282,937</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,167,501</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>612,670</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>246,007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41,621</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,916,734</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,710,164</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,527,195</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>675,158</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>428,050</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>37,230</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,414,628</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,998,162</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,553,228</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>666,822</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>267,751</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,496</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,624,271</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,617,078</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,216,419</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>618,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>287,329</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,262</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,529,830</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,408,486</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,975,907</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Bonus
component paid in lump sum.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Other
than with respect to Mr.&nbsp;Crowley, benefits to be continued consist of COBRA premiums paid by the Company for 18&nbsp;months.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Value
of the options that would accelerate upon such event is calculated using the closing stock price of $14.39 on December&nbsp;31, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over a 24&nbsp;month period following such termination of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Benefits
to be continued consist of estimated healthcare costs and health insurance premiums for Mr.&nbsp;Crowley's family, which primarily consists of the Monthly
Medical Payments paid over 24&nbsp;months and up to 29&nbsp;months of COBRA coverage.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over an 18&nbsp;month period following such termination of employment. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=46,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=195741,FOLIO='43',FILE='DISK109:[18ZAG1.18ZAG13701]DO13701A.;11',USER='JLAWRENA',CD='12-APR-2018;15:46' -->
<A NAME="page_do13701_1_44"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Potential Payments upon Termination Due to Death or Disability  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following sets forth quantitative estimates of the benefits that would have accrued to each of our named executive officers, if his or her
employment had been terminated due to death or disability on December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Benefit<BR>
Continuation<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>801,766</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>801,766</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,747</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,747</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,820</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,820</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,508</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,508</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Benefits
to be continued consist of COBRA and HSA premiums paid by the Company for 12&nbsp;months following such termination. For Mr.&nbsp;Crowley, this also
includes the Monthly Medical Payments.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CEO Pay Ratio  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under Section&nbsp;953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item&nbsp;402(u) of Regulation&nbsp;S-K, we
are required to provide the following disclosure regarding the ratio of the annual total compensation of our Chief Executive Officer to the annual total compensation of our median employee (the "Pay
Ratio"). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the Pay Ratio calculation, we identified our median employee by determining the 2017 total annualized target cash compensation for all of our global employees (excluding
our Chief Executive Officer), whether employed on a full-time, part-time or seasonal basis, who were employed by us on October&nbsp;1, 2017 as our consistently applied compensation measure. Total
annualized target cash compensation for these purposes consists of annualized base salary and annual target bonus. Once we identified our median employee, we calculated such employee's annual total
compensation for 2017 in the same manner that we determined the total compensation of our Chief Executive Officer for purposes of the Summary Compensation Table disclosed above. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2017, (i)&nbsp;the annual total compensation of our Chief Executive Officer was $5,613,080; (ii)&nbsp;the annual total compensation of our
median employee was $184,514; and (iii)&nbsp;based
on this information, we reasonably estimate our Pay Ratio to be 30:1. Because the SEC rules for identifying the median employee and calculating the Pay Ratio allow companies to use different
methodologies, to apply certain exemptions, and to make reasonable estimates and assumptions, the Pay Ratio calculation presented above is a reasonable estimate and may not be comparable to the pay
ratio reported by other companies. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Compensation  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to our Director Compensation Policy, each non-employee member of our Board received the following cash compensation for Board services
during 2017, as applicable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $30,000 per year for service as lead independent director; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=47,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=665302,FOLIO='44',FILE='DISK109:[18ZAG1.18ZAG13701]DO13701A.;11',USER='JLAWRENA',CD='12-APR-2018;15:46' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dq13701_1_45"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $40,000 per year for service as a Board member; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $30,000 per year for service as chairperson of the Audit and Compliance Committee (inclusive of committee membership fees described below); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $20,000 per year for service as chairperson of the Compensation Committee (inclusive of committee membership fees described below); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $12,500 per year for service as chairperson of the Nominating/Corporate Governance Committee or the Science and Technology Committee (inclusive
of committee membership fees described below); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $10,000 per year for service as a member of the Audit and Compliance Committee and $7,500 per year for service as a member of the Compensation
Committee, the Nominating and Corporate Governance Committee or the Science and Technology Committee. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2017, after a market study completed by Pay Governance, the Board of Directors approved a new methodology to determine equity grants to members of the Board of Directors, using a
value based approach benchmarked vs peers to be aligned with executives. As of June 2017, each director received an annual grant of options and RSUs worth $150,000, with 2/3 of the value assigned to
Non-Qualified Stock options, and 1/3 of the value assigned to Restricted Stock Units. The grant date is the date of our Annual Meeting of Stockholders and each grant will vest in full at the following
Annual Meeting of Stockholders. The exercise price of each option granted to a non-employee director will be equal to 100% of the fair market value of a share on the date of grant. Options will have a
maximum term of 10&nbsp;years measured from the grant date, subject to termination in the event of the director's cessation of Board service. All of our directors are also eligible to participate in
our 2007 Equity Incentive Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of the new methodology, each of our new, independent Board members will receive non-qualified options and RSU's with the value of $225,000 in connection with their election to
the Board. The exercise price of each option granted will be equal to 100% of the fair market value of a share on the date of the grant. Unlike the annual grant to our directors, but consistent with
our grants to our named executive officers, these initial grant awards vest over a four year period with 25% vesting one year after the vesting commencement date and the remainder vesting ratably each
month thereafter in equal installments over a three year period subject to continued service as a director. We expect to make additional initial grants of stock options and RSU's to any new Board
members in the future. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary of Non-Employee Director Compensation Table  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information regarding the compensation that each of our non-employee directors earned during the year ended
December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees<BR>
Earned<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>RSU<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>218,763</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>198,763</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael G. Raab</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>55,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>205,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ted W. Love, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>210,638</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald J. Hayden, Jr.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>232,513</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret G. McGlynn.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>216,263</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>201,263</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
fees earned by non-employee director pursuant to Director Compensation Policy. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=48,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=49086,FOLIO='45',FILE='DISK109:[18ZAG1.18ZAG13701]DQ13701A.;13',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dq13701_1_46"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
the aggregate grant date fair value computed in accordance with FASB ASC Topic 718, Compensation&#151;Stock Compensation. Assumptions made in this
valuation are discussed in our annual report for the year ended December&nbsp;31, 2017, filed with the SEC on Form&nbsp;10-K on March&nbsp;1, 2018, at Item&nbsp;7&#151;Management's
Discussion and Analysis of Financial Condition and Results of Operations&#151;Stock Option Grants and Restricted Stock Units ("RSUs") and Performance-Based Restricted Stock Units ("PRSUs").
Subject generally to continued service, annual director grant options vest one year from date of grant while the initial director grant options vest over four years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>As
described more fully below, Mr.&nbsp;Sblendorio participates in our Non-Qualified Cash Deferral Plan and for 2017, the fees deferred were $40,500. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017, our non-employee directors had the following number of stock options outstanding: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="83pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Options<BR>
Outstanding </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Vested/Unvested </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael G. Raab</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>141,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>125,000/16,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>85,000/16,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald J. Hayden, Jr.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>156,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>140,000/16,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret G. McGlynn</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>151,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135,000/16,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ted W. Love, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>116,246</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000/16,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>116,246</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000/16,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,250/34,986</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-employee
directors are also eligible to defer board fees pursuant to the terms of the Cash Deferral Plan, described more fully above. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017, our non-employee directors had the following number of restricted stock units outstanding: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Restricted<BR>
Stock Units<BR>
Outstanding </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael G. Raab</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald J. Hayden, Jr.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret G. McGlynn</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ted W. Love, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Qualified Deferred Compensation for Non-Employee Directors  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Deferral Plans cover our executive officers and members of our Board. The Company does not match participants' voluntary contributions to
the deferral plan. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Director<BR>
Contributions<BR>
in Last Fiscal<BR>
Year(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Earnings<BR>
in Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Distributions<BR>
in Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Balance at<BR>
Last Fiscal<BR>
Year(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,844</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>37,051</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,895</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Amount
deferred is reflected in the "Fees Earned" column above in the Summary Director Compensation Table.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
column includes director fees earned and deferred in prior years.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=49,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=286936,FOLIO='46',FILE='DISK109:[18ZAG1.18ZAG13701]DQ13701A.;13',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dq13701_1_47"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq13701_compensation_committee_report"> </A>
<A NAME="toc_dq13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  COMPENSATION COMMITTEE REPORT    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee is comprised entirely of independent directors. The Compensation Committee of our Board has reviewed and discussed
the Compensation Discussion and Analysis required by Item&nbsp;402(b) of Regulation&nbsp;S-K, which appears in this Proxy Statement, with our management. Based on this review and discussion, the
Compensation Committee has recommended to the Board that the Compensation Discussion and Analysis be included in this Proxy Statement and our 2017 Annual Report on Form&nbsp;10-K. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Members
of the Amicus Therapeutics,&nbsp;Inc. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Compensation
Committee: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Margaret
G. McGlynn, Chair<BR>
Michael G. Raab<BR>
Craig Wheeler </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended (the "Securities Act") or the Exchange
Act that might incorporate this proxy statement or future filings with the SEC, in whole or in part, the above report shall not be deemed to
be "soliciting material" or "filed" with the SEC and shall not be deemed to be incorporated by reference into any such filing.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=50,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=686765,FOLIO='47',FILE='DISK109:[18ZAG1.18ZAG13701]DQ13701A.;13',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dq13701_1_48"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq13701_section_16(a)_benefici__dq102032"> </A>
<A NAME="toc_dq13701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Exchange Act requires our directors, executive officers and persons who own more than 10% of a registered class of
our equity securities to file reports of holdings and transactions in our Common Stock with the SEC. To our knowledge, based solely on our review of copies of the reports received by us and written
representations by these individuals that no other reports were required, all such Section&nbsp;16(a) filing requirements were met. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq13701_security_ownership_of_certain___sec02525"> </A>
<A NAME="toc_dq13701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information with respect to the beneficial ownership of our Common Stock as of March&nbsp;31, 2018 for
(a)&nbsp;the executive officers named in the Summary Compensation Table contained in this Proxy Statement, (b)&nbsp;each of our directors and director nominees, (c)&nbsp;all of our current
directors and executive officers as a group and (d)&nbsp;each stockholder known by us to own beneficially more than 5% of our Common Stock. Beneficial ownership is determined in accordance with the
rules of the SEC and includes voting or investment power with respect to the securities. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
deem shares of Common Stock that may be acquired by an individual or group within 60&nbsp;days of March&nbsp;31, 2018 pursuant to the exercise of options or warrants to be
outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other
person shown in the table. Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of
Common Stock shown to be beneficially owned by them based on information provided to us by these stockholders. Percentage of ownership is based on 187,972,218 shares of Common Stock outstanding on
March&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise indicated below, the address of each of the individuals named below is: c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, NJ 08512. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Address of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage<BR>
Of Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>5% Stockholders</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Perceptive Advisors&nbsp;LLC(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,424,424</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>499 Park Avenue, 25<SUP>th</SUP>&nbsp;Floor</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New York, NY 10022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Entities affiliated with FMR&nbsp;LLC(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,983,566</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 245 Summer Street</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Boston, MA 02210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Black Rock&nbsp;Inc.(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,712,097</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>55 East 52nd&nbsp;Street</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New York, NY 10055</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Entities affiliated with Vanguard Group(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,634,785</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 100 Vanguard Blvd.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Malvern, PA 19355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Redmile Group,&nbsp;LLC(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,085,770</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>One Letterman Drive, Bldg. D, Suite D3-700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>San Francisco, CA 94129</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Entities affiliated with Prudential Financial,&nbsp;Inc.(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,301,723</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 466 Lexington Avenue</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 New York, NY 10017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=51,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=677004,FOLIO='48',FILE='DISK109:[18ZAG1.18ZAG13701]DQ13701A.;13',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dq13701_1_49"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage<BR>
Of Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Named Executive Officers and Directors</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John F. Crowley(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,610,967</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird III(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>692,566</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bradley L. Campbell(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>934,299</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>399,660</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ellen S. Rosenberg(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130,536</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald J. Hayden, Jr.(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>120,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>96,933</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael G. Raab(14)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>105,634</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret G. McGlynn(15)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>145,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ted W. Love, M.D.(16)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>242,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner(17)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler(18)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,375</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All directors and executive officers as a group (15 persons)(19)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,530,678</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
beneficial ownership of less than one percent of our outstanding Common Stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided solely in reliance upon information included in a Schedule&nbsp;13G/A filed with the SEC on February&nbsp;14, 2018 by Perceptive
Advisors&nbsp;LLC ("Perceptive"), and supplemented by a Form&nbsp;4 filed with the SEC on March&nbsp;7, 2018. As of December&nbsp;31, 2017, Perceptive reported shared voting and investment
power of 17,888,597 shares of common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided solely in reliance upon information included in a Schedule&nbsp;13G/A filed with the SEC on February&nbsp;13, 2018 by FMR&nbsp;LLC
("FMR"). As of December&nbsp;31, 2017, FRM reported sole voting power of 2,807,665 shares of common stock and sole investment power of 17,983,566 shares of common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided solely in reliance upon information included in a Schedule&nbsp;13G/A filed with the SEC on February&nbsp;8, 2018 by
Blackrock&nbsp;Inc. ("Blackrock"). As of December&nbsp;31, 2017, Blackrock reported sole voting power of 13,343,785 shares of common stock and sole investment power of 13,712,097 shares of common
stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided solely in reliance upon information included in a Schedule&nbsp;13G filed with the SEC on February&nbsp;12, 2018 by Vanguard Group
("Vanguard"). As of December&nbsp;31, 2017, Vanguard reported sole voting power of 322,380 shares of common stock, shared voting power of 22,462 shares of common stock, sole investment power of
13,301,881 shares of common stock and shared investment power of 332,904 shares of common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided solely in reliance upon information included in a Schedule&nbsp;13G filed with the SEC on February&nbsp;14, 2018 by Redmile
Group&nbsp;LLC ("Redmile"). As of December&nbsp;31, 2017, Redmile reported shared voting and investment power of 12,085,770 shares of common stock. The numbers reported in this line include
2,060,000 warrants to purchase common stock, which may be exchanged for ordinary shares at a 1:1 ratio.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided solely in reliance upon information included in a Schedule&nbsp;13G filed with the SEC on January&nbsp;26, 2018 by Prudential
Financial,&nbsp;Inc. ("Prudential"). As of December&nbsp;31, 2017, Prudential reported sole voting power of 52,347 shares of common stock, shared voting power of 10,249,376 shares of common stock,
sole investment power of 52,347 shares of common stock and shared investment power of 10,249,376 shares of common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 1,401,760 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018, 144,312 shares held directly by
Mr.&nbsp;Crowley and 64,895 shares held by a trust f/b/o Mr.&nbsp;Crowley. Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and
unvested restricted stock units as of May&nbsp;30, 2018. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=52,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=757695,FOLIO='49',FILE='DISK109:[18ZAG1.18ZAG13701]DQ13701A.;13',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dq13701_1_50"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 661,729 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 30,837 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 893,816 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 40,483 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 390,997 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018, 8,538 shares held directly by
Dr.&nbsp;Barth and 125 shares held by his daughter. Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock
units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 105,819 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 9,717 shares held directly by
Ms.&nbsp;Rosenberg and 15,000 shares held by her spouse. Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted
stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 120,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018. Excludes shares issuable upon the
exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 85,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 11,933 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 105,634 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018. Excludes shares issuable upon the
exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(15)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 135,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 10,000 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(16)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 100,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 142,000 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(17)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 100,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018. Excludes shares issuable upon the
exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(18)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 14,375 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018. Excludes shares issuable upon the
exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(19)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 4,602,188 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 928,490 total shares held of
record. Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=53,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=596430,FOLIO='50',FILE='DISK109:[18ZAG1.18ZAG13701]DQ13701A.;13',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_ds13701_1_51"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ds13701_policies_and_procedure__ds102278"> </A>
<A NAME="toc_ds13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  POLICIES AND PROCEDURES FOR RELATED PARTY TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board maintains a formal written policy for the review of any transaction, arrangement or relationship in which Amicus is a participant and
one of our executive officers, directors, director nominees, 5% stockholders (or their immediate family members), each of whom we refer to as a "related party," has a direct or indirect interest. If a
related party proposes to enter into such a transaction, arrangement or relationship, which we refer to as a "related party transaction," the related party must report the proposed transaction to our
Chief Financial Officer or Senior Vice President, Finance. The proposed related party transaction must be reviewed and, if deemed appropriate, approved by the Board's Audit and Compliance Committee
prior to entry into such transaction, or ratified as soon as reasonably practicable after discovery that approval is required. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit and Compliance Committee may approve or ratify the transaction only if the Audit and Compliance Committee determines that, under all of the circumstances, the transaction is
not inconsistent with the Company's best interests and does not violate its Code of Business Conduct and Ethics. Any related party transactions that are ongoing in nature will be reviewed annually.
The Audit and Compliance Committee will review and consider such information regarding the related party transaction as it deems appropriate under the circumstances. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ds13701_proposal_no._2_#151;approve_an__pro03198"> </A>
<A NAME="toc_ds13701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 2&#151;APPROVE AND ADOPT<BR>  AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION    <BR>    </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Description of the Amendment  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board has adopted a resolution to amend our Restated Certificate of Incorporation, as amended, to increase the number of shares of common
stock, par value $0.01 per share that we are authorized to issue from 250,000,000 to 500,000,000 shares and has directed that the proposed amendment be submitted to our stockholders for their approval
and adoption. The amendment will not change the number of shares of preferred stock that are authorized (10,000,000 shares), and the total authorized shares will be increased from 260,000,000 to
510,000,000. The amendment will replace the first sentence of Section&nbsp;4 of our current Restated Certificate of Incorporation with the following language: </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOURTH:
The total number of shares of all classes of capital stock which the Corporation shall have authority to issue is Five Hundred Ten Million (510,000,000) shares, consisting solely
of: Five Hundred Million (500,000,000) shares of common stock, par value $0.01 per share ("Common Stock"); and Ten Million (10,000,000) shares of preferred stock, par value $0.01 per share ("Preferred
Stock"). </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation  </I></B></FONT></P>

</UL>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>The Board recommends the vote "FOR" the proposal to approve and adopt an amendment to our Restated Certificate of
Incorporation to increase the authorized shares of common stock to Five Hundred Million shares.</B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Background  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue shares of capital stock to the extent such shares have been authorized under our Restated Certificate of Incorporation. Currently,
we are authorized to issue up to 250,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of March&nbsp;31, 2018, the total shares of common stock issued and outstanding and reserved for issuance pursuant to outstanding warrants, options, and preferred stock equaled
215,825,718 as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 187,972,218 shares of common stock issued and outstanding; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 16,176,047 shares of common stock reserved for issuance pursuant to options to purchase common stock outstanding; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=54,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=985596,FOLIO='51',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;11',USER='WWASSER',CD='12-APR-2018;17:39' -->
<A NAME="page_ds13701_1_52"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 3,110,000 shares of common stock reserved for issuance pursuant to warrants to purchase common stock outstanding; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 3,540,679 shares of common stock reserved for issuance pursuant to unvested RSUs and PRSUs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 25,000 shares of common stock reserved for issuance pursuant to deferred vested RSUs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 5,001,774 shares of common stock available for issuance under our 2007 Equity Incentive and Director Plans. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result, we have only 34,174,282 unreserved shares of common stock available for issuance. There are no shares of preferred stock outstanding. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reason for the Proposal  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have only limited revenue as we are in the initial launch phase of our first marketed product and expect to continue to generate losses over
the next couple of years as we continue to support our geographic expansion, our late stage development of biologics, biologics manufacturing and pre-clinical and early clinical development of our
pipeline. These activities are expected to expand over time and will require further resources if we are to be successful. Because we have not generated significant commercial sales revenue to date
and we expect our losses will continue in the near future, we will need to raise additional capital through a range of activities including equity offerings or other business development
opportunities. Our Board believes that the current amount of unreserved shares of common stock is insufficient for our future financing needs because it is likely that the sale of shares of common
stock will be one of the principal means by which we will raise additional capital until such time as we are able to generate earnings sufficient to finance our operations. For similar reasons, our
Board may also consider using common stock to acquire, or invest in, complementary businesses, technologies, manufacturing, products or assets. Although our Board has no current plan, arrangement or
commitment to issue additional shares of common stock for the purposes described above, the Board believes that it is in the best interest of the Company and our stockholders to have a sufficient
number of authorized but unissued shares of common stock available for issuance in the future for such purposes. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this proposal is approved, all or any of the authorized shares may be issued without further stockholder action (unless such approval is required by applicable law or regulatory
authorities) and without first offering those shares to the stockholders for subscription. The issuance of Common Stock in any manner other than on a pro-rata basis to all stockholders would reduce
the proportionate interest in the Company of each stockholder. Our stockholders have no preemptive rights to subscribe for additional shares of Common Stock when issued. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Possible Anti-Takeover Effects of the Amendment  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The proposed amendment to our Restated Certificate of Incorporation is not being recommended in response to any specific effort of which our
Board is aware to obtain control of the Corporation, and our Board does not intend or view the proposed increase in authorized common stock as an anti-takeover measure. However, the ability of our
Board to authorize the issuance of the additional shares of common stock that would be available if the proposed amendment is approved and adopted could have the effect of discouraging or preventing a
hostile takeover. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=55,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=717031,FOLIO='52',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;11',USER='WWASSER',CD='12-APR-2018;17:39' -->
<A NAME="page_ds13701_1_53"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ds13701_proposal_no._3_#151;approve_th__pro02590"> </A>
<A NAME="toc_ds13701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 3&#151;APPROVE THE AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In this proposal, we are requesting stockholders approve the amendment and restatement of the Amicus Amended and Restated 2007 Equity Incentive
Plan (the "2007 Plan") to increase the number of shares of common stock available for issuance under the 2007 Plan by 5,000,000 shares. The board of directors approved the amendment and restatement of
the 2007 Plan on April&nbsp;11, 2018 subject to and effective upon stockholder approval. The 2007 Plan, as amended and restated if this proposal is approved, is described in more detail below. If
this proposal is not approved by our stockholders, the amendment and restatement of the 2007 Plan will not become effective, but the 2007 Plan will remain in effect in accordance with its present
terms. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation:  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>The Board of Directors recommends the vote "FOR" the approval of the Amended and Restated 2007 Equity Incentive
Plan.</B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are asking our stockholders to approve our Amended and Restated 2007 Equity Incentive Plan (the "2007 Plan"). The Compensation Committee approved the 2007 Plan, subject to approval of
the Board and the stockholders, and the Board approved the 2007 Plan, subject to approval of the stockholders. If our stockholders do not approve the 2007 Plan, the existing version of the Amended and
Restated 2007 Equity Incentive Plan (the "Existing Plan") will remain in effect. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2007 Plan is substantially similar to the Existing Plan. The only change is an increase of 5,000,000 shares of Common Stock available for issuance as equity incentive awards. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Background and Reason for the Proposal  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity compensation has historically been a key element of our compensation program. The ability to grant stock options and restricted stock has
enabled us to attract and retain highly talented employees. Additionally, equity awards have also allowed us to link incentive rewards to Company performance, to encourage employee ownership in our
stock and to align the interests of employees with those of our stockholders. Equity based compensation is a common form of compensation in our industry. Without the ability to grant stock options and
restricted stock, we would be at a disadvantage against our competitors for recruiting and retaining key talent. We expect that we will be required to grow our employee population over the coming
years to meet the requirements of a global commercial enterprise. If we did not expand the pool of shares available, we would also be unable to offer competitive total compensation packages necessary
to attract, retain and motivate individuals critical to our future success. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
purpose of the 2007 Plan is to encourage ownership of our Common Stock by employees and directors of the Company and to provide additional incentive for them to promote the success
of the Company's business through the grant of awards of shares of the Company's Common Stock. As of March&nbsp;31, 2018, there are 4,894,629 shares remaining for issuance under the Existing Plan.
We are therefore seeking approval of the 2007 Plan in order to make an additional 5,000,000 shares of our Common Stock available for issuance as Awards under the 2007 Plan. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board believes that the 2007 Plan will serve a critical role in attracting and retaining officers and employees and in motivating these individuals to strive to meet our goals and
that, without the additional shares which may be offered under the 2007 Plan, we would be at a competitive disadvantage to our peers. The Board further believes that the increased number of shares
that would be available for issuance under the 2007 Plan would provide the Compensation Committee with the flexibility to make the types and amounts of awards it believes are necessary to attract and
retain qualified individuals. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=56,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=42199,FOLIO='53',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;11',USER='WWASSER',CD='12-APR-2018;17:39' -->
<A NAME="page_ds13701_1_54"> </A>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Considerations Relating to the Additional Shares Under the 2007 Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In recommending the 2007 Plan to the board of directors for approval, the Compensation Committee reviewed analyses prepared by Pay Governance,
the committee's independent compensation consultant. Considerations taken into account by the compensation committee included the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Competitiveness</I></FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
market for high caliber, experienced talent in our industry and in our geographic location is extremely competitive. We compete not only with other similar sized and larger
biotechnology companies, but we also compete for talent directly with much larger pharmaceutical companies that have significantly greater resources and generous compensation practices. Our ability to
grant equity awards is critical to our ability to be competitive and to attract, retain and motivate the talent we need to best position our Company for success. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Limited duration of current shares available</I></FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we do not increase the shares available for issuance under the 2007 Plan, we expect the number of available shares under the 2007 Plan to be substantially depleted by the midpoint of
2019 and that we would then be unable to continue to grant broad-based equity awards. If our stockholders approve the amendment and restatement, we estimate that the shares reserved for issuance under
the 2007 Plan, as amended and restated, would be sufficient for up to 18-24&nbsp;months of awards based on projected increase in overall number of employees, projected employee turnover and
historical grant practices. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Employee growth/turnover</I></FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
had a 23% increase in the number of employees in 2017. We are projecting a 40% increase in 2018 and a 30% increase in 2019. In addition, we are projecting employee turnover that is
consistent with the turnover rate of the biotechnology industry generally. In 2017, we had a total of 3 new hires and promotions involving positions at the vice president level or higher. We expect to
increase our hiring at all levels, including senior management, in 2018 and 2019. Accordingly, we anticipate an increase in new hire equity grants in 2018 and 2019, which are traditionally 50% to 100%
greater in value than annual grants, and as the overall number of employees continues to increase, we are planning for a resulting increase in annual equity grants as well. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Broad-based equity programs</I></FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe broad-based equity programs are important to our ability to attract, retain and motivate employees throughout the Company and align employee interests with those of our
stockholders. Historically, less than 30% of the total equity awards granted under the 2007 Plan have gone to our Named Executives. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Eligible Participants/Administration  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2007 Plan provides for the grant of incentive stock options, within the meaning of Section&nbsp;422 of the Code, to employees, and
non-qualified stock options and restricted stock, other stock awards and Performance Awards to our employees and directors. As of April&nbsp;1, 2018, approximately 360 employees and seven directors
are eligible to participate in the 2007 Plan. The 2007
Plan will be administered by the Compensation Committee of our Board, provided that the Board may itself exercise any of the powers and responsibilities assigned to the Committee under the 2007 Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the provisions of the 2007 Plan, the Compensation Committee has been granted the discretion to determine when awards are made, which employees receive awards, the form of an
award, the number of shares subject to each award, and all other relevant terms of the award, including vesting and acceleration of vesting, if any. The Compensation Committee also has been granted
broad discretion to construe and interpret the 2007 Plan and adopt rules and regulations thereunder. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=57,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=490706,FOLIO='54',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;11',USER='WWASSER',CD='12-APR-2018;17:39' -->
<A NAME="page_ds13701_1_55"> </A>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Number of Shares Authorized Under the 2007 Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares of our Common Stock that would be available for issuance after the effective date under the 2007 Plan is 20,058,703 shares,
subject to adjustment to avoid dilution or enlargement of intended benefits in the event of certain significant corporate events. No more than 10,058,703 of the shares of Common Stock available for
issuance under the 2007 Plan after the effective date under the 2007 Plan (upon approval of the requested share increase) as awards of restricted stock, performance restricted stock units, stock
grants and any other similar awards whose intrinsic value is not solely dependent on appreciation in the price of our Common Stock after the date of grant. Each of the above numbers is exclusive of
any grants made under the 2007 Plan prior to the effective date of the approval of the amendment by the Board. If any shares of Common Stock covered by an award granted under the 2007 Plan, or to
which such an award relates, are forfeited, or if an award has expired, terminated or has been canceled for any reason whatsoever (other than by reason of exercise or vesting), then the shares covered
by such award shall again be, or shall become, shares with respect to which awards may be granted under the 2007 Plan. Shares of Common Stock underlying awards under the 2007 Plan that have been used
to satisfy withholding obligations or pay an exercise price will not again be available for a future award. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to such adjustments as provided below, no employee will, in a single calendar year, be granted awards under the 2007 Plan with respect to more than 5,000,000 shares of Common
Stock. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary of the 2007 Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section summarizes certain key features of the 2007 Plan, all of which remain unchanged. The only change is the increase in the number of
authorized shares of common stock, subject to stockholder approval. The summary is qualified in its entirety by reference to the complete text of the 2007 Plan. Stockholders are urged to read the
actual text of the stated 2007 Plan in its entirety which is set forth in </FONT><FONT SIZE=2><B>Exhibit&nbsp;A</B></FONT><FONT SIZE=2> to this proxy statement. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Term of the 2007 Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No award may be granted under the 2007 Plan after April 2026 which is the 10th&nbsp;anniversary of the date on which the 2007 Plan was
approved by the Board. Awards granted prior to the expiration of the 2007 Plan shall not expire solely by reason of the termination of the plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
closing price of a share of our Common Stock on April&nbsp;13, 2018 was $14.16. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms and Conditions of Options  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options granted under the 2007 Plan shall be, as determined by the Compensation Committee, non-qualified or incentive stock options for federal
income tax purposes, and shall be subject to the foregoing and the following terms and conditions and to such other terms and conditions, not inconsistent therewith, as determined by the Compensation
Committee: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Option Exercise Price.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The price at which shares of Common Stock may be acquired under each incentive stock option shall not be less
than 100% of the
fair market value of a share on the date an option is granted; provided, however, that the exercise price of any incentive stock option granted to any participant who, at the time of grant, owns more
than 10% of the total combined voting power of all classes of the Company's stock (a "Ten Percent Holder") shall be at least 110% of the fair market value of the stock on the date of such grant. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercisability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Options granted under the 2007 Plan shall be exercisable at such time and upon such terms and conditions as may be
determined by the
Committee; provided, however, that in no event shall an option be exercisable more than ten years after its grant date or five years after the date it is granted to a Ten Percent Holder. An option may
be exercised by a participant providing written notice specifying the number of shares of Common Stock with respect to which the option is then being exercised. The purchase </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=58,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=286832,FOLIO='55',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;11',USER='WWASSER',CD='12-APR-2018;17:39' -->
<A NAME="page_ds13701_1_56"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>price
for the shares as to which an option is exercised shall be paid to the Company pursuant to one or more of the following methods: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>cash
or check payable to the Company;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>shares
of Common Stock having a fair market value equal to the aggregate option exercise price for the shares being purchased, and only with the Compensation
Committee's approval; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>if
there is a public market for the shares at such time, through and under the terms and conditions of any formal cashless exercise program authorized by the
Company entailing the sale of Common Stock subject to any option in a brokered transaction (other than to the Company). </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
participant shall be deemed for any purpose to be a stockholder of the Company with respect to any shares of Common Stock issuable pursuant to an option until the participant has
given written notice of exercise of the option and has paid in full for such shares. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms and Conditions of Restricted Stock  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of restricted stock may be issued under the 2007 Plan for such consideration, in cash, other property or services, or any combination
thereof, as determined by the Compensation Committee. During the period of time in which the shares of restricted stock are subject to a risk of forfeiture (the "Restriction Period"), such shares
shall be subject to limitations on transferability and a risk of forfeiture arising on the basis of such conditions related to the performance of services, Company performance or otherwise as the
Compensation Committee may determine and set forth in an award agreement. Any such risk of forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Compensation
Committee on such basis as it deems appropriate. Except as otherwise provided in the 2007 Plan or an applicable award agreement, at all times prior to the lapse of the Restriction Period, the
participant shall have all of the rights of a stockholder of the Company, including the right to vote the shares of restricted stock. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms and Conditions of Restricted Stock Units  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each restricted stock unit shall entitle the recipient to a share of Common Stock at the close of a Restriction Period as established by the
Compensation Committee and subject to a risk of forfeiture arising on the basis of such conditions related to the performance of services, Company performance or otherwise as the Compensation
Committee may determine and set forth in an award agreement. Any such risk of forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Compensation Committee on
such basis as it deems appropriate. A participant holding restricted stock units shall not be deemed for any purpose to be a stockholder of the Company with respect to any of the shares of Common
Stock subject to such restricted stock units except to the extent that the Restriction Period with respect to such restricted stock units shall have closed and a certificate shall have been issued for
such shares of Common Stock. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms and Conditions of Stock Grants  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock grants may be issued under the 2007 Plan for such consideration, in cash or other property or services, or any combination thereof, as
determined by the Compensation Committee. Stock grants may be awarded in such circumstances as the Compensation Committee deems appropriate, including in recognition of significant contributions to
the success of the Company or in lieu of compensation otherwise already due. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms and Conditions of Performance Awards</I></B></FONT><FONT SIZE=2><I>.  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee may grant Performance Awards (PRSUs) under the 2007 Plan, which may be denominated as a number of shares of Common
Stock or a specified number of other awards (or a combination of both). Generally, Performance Awards require satisfaction of pre-established Performance Goals (as defined in the following sentence).
The potential performance metrics include: cash flow; </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=59,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=861304,FOLIO='56',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;11',USER='WWASSER',CD='12-APR-2018;17:39' -->
<A NAME="page_ds13701_1_57"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>earnings
(including gross margin, earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation, amortization and charges for stock-based compensation,
earnings before interest, taxes, depreciation and amortization, and net earnings); earnings per share; growth in earnings or earnings per share; stock price; return on equity or average stockholder
equity; total stockholder return or growth in total stockholder return either directly or in relation to a comparative group; return on capital; return on assets or net assets; revenue, growth in
revenue or return on sales; income or net income; operating income, net operating income or net operating income after tax; operating profit or net operating profit; operating margin; return on
operating revenue or return on operating profit; regulatory filings; regulatory approvals, litigation and regulatory resolution goals; other operational, regulatory or departmental objectives; budget
comparisons; growth in stockholder value relative to established indexes, or another peer group or peer group index; development and implementation of strategic plans and/or organizational
restructuring goals; development and implementation of risk and crisis management programs; improvement in workforce diversity; compliance requirements and compliance relief; safety goals;
productivity goals; workforce management and succession planning goals; economic value added (including typical adjustments consistently applied from generally accepted accounting principles required
to determine economic value added performance measures); measures of customer satisfaction, employee satisfaction or staff development; development or marketing collaborations, formations of joint
ventures or partnerships or the completion of other similar transactions intended to enhance the Company's revenue or profitability or enhance its customer base; and/or merger and acquisitions (each,
a "Performance Goal" and collectively the "Performance Goals"). Such Performance Goals may be described in terms of Company-wide objectives or objectives that are related to the performance of the
individual grantee or any subsidiary, division, department or function within the Company and may be measured on an absolute or relative basis. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Committee may provide, at the time a Performance Goal is established, that adjustments will be made to the applicable Performance Goal to take into account, in the manner specified
by the Committee, the impact of one or more of the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> gain or loss from all or certain claims and/or litigation and insurance recoveries, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the impairment of tangible or intangible assets, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> stock-based compensation expense, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> extraordinary, unusual or infrequently occurring events reported in the Company's public filings, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> restructuring activities reported in the Company's public filings, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> investments, dispositions or acquisitions, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> loss from the disposal of certain assets, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> gain or loss from the early extinguishment, redemption, or repurchase of debt, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> cash or non-cash charges related to site closings, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> changes in accounting principles, or any other item, event or circumstance that would not cause an award to fail to constitute "qualified
performance-based compensation" under Section&nbsp;162(m) of the Code, to the extent such exemption is available. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transferability  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise determined by the Compensation Committee, an award (other than a stock award) shall not be transferable or assignable by a
participant otherwise than by will or by the laws of descent and distribution. However, the applicable award agreement or the Compensation Committee may provide that a nonstatutory stock option,
shares of restricted stock or restricted stock units may be transferred by the participant to a family member, so long as such transfer is without payment of any consideration. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=60,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=597057,FOLIO='57',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;11',USER='WWASSER',CD='12-APR-2018;17:39' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_du13701_1_58"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change in Control  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the applicable provisions of the award agreement, in the event of a change of control of the Company after the effective date of the
2007 Plan, the Compensation Committee generally shall have the discretion to provide for any or all of the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the acceleration, in whole or in part, of any or all outstanding options that are not exercisable in full at the time of the change of control; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the lapse or termination of the risk of forfeiture with respect to outstanding awards of restricted stock and restricted stock units; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the assumption of outstanding options or restricted stock units, or the substitution of outstanding options or restricted stock units with
equivalent options or restricted stock units, as the case may be, by the acquiring or succeeding corporation or entity; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the termination of all options and restricted stock units (other than those assumed or substituted for), which termination may or may not be in
exchange for some payment or other consideration, as determined in the sole discretion of the Compensation Committee. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adjustments  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any change in the outstanding shares by reason of merger, consolidation, sale of all or substantially all of the property of the
Company, reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split, or other distribution with respect to such outstanding shares, an appropriate and
proportionate adjustment will be made in (i)&nbsp;the maximum number and kinds of shares that may be issued under the 2007 Plan, (ii)&nbsp;the numbers and kinds of shares or other securities
subject to the then outstanding awards; (iii)&nbsp;the exercise price for each share or other unit of any other securities subject to then outstanding options; and (iv)&nbsp;the repurchase price
of each share of restricted stock then subject to a risk of forfeiture in the form of a Company repurchase right. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Termination of Amendments to the 2007 Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board may at any time terminate or make such amendments or modifications of the 2007 Plan as it shall deem advisable; provided, however,
that no such amendment or modification shall be made without the consent of a participant if such change would:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reduce the number of shares subject to an award, increase the purchase price applicable to shares subject to such award or materially adversely
affect the provisions applicable to such award that relate to the vesting or exercisability of such award or the shares subject thereto; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> result in an incentive stock option no longer being treated as such within the meaning of Section&nbsp;422 of the Code; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> not apply to all other awards outstanding on the date of such amendment or modification. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Federal Income Tax Consequences Relating to Awards Under the 2007 Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The current United States federal income tax treatment of awards under the 2007 Plan is generally described below. This description of tax
consequences is not a complete description. There may be different income tax consequences under certain circumstances, and there may be gift and estate tax consequences. Local, state and other taxing
authorities may also tax awards under the plan. Tax laws are subject to change. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Incentive Stock Options  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There generally are no federal income tax consequences to a participant or to the Company upon the grant of an incentive stock option. A
participant will not recognize income for purposes of the regular federal income tax upon the exercise of an incentive stock option. However, for purposes of the alternative minimum tax, in the year
in which a participant exercises an incentive stock option the amount by which </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=61,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=3231,FOLIO='58',FILE='DISK109:[18ZAG1.18ZAG13701]DU13701A.;12',USER='MKEANE',CD='12-APR-2018;21:29' -->
<A NAME="page_du13701_1_59"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>the
fair market value of the shares acquired upon exercise exceeds the exercise price will be included in a participant's alternative minimum taxable income. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
participant will recognize income when he or she sells stock acquired upon exercise of an incentive stock option. If a participant disposes of the shares acquired upon exercise of an
incentive stock option after two years from the date the option was granted and one year from the date the shares were transferred upon the exercise of the option, a participant will recognize
long-term capital gain or loss in the amount of the difference between the amount realized on the sale and the exercise price. The Company will not be entitled to any corresponding tax deduction. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a participant disposes of shares acquired upon the exercise of an incentive stock option before satisfying both holding period requirements (a "disqualifying disposition"), a
participant's gain recognized on the disposition will be taxed as ordinary income to the extent of the difference between the fair market value of the shares on the date of exercise (or the amount
realized on the disposition, if less) and the exercise price. The Company will generally be entitled to a deduction in that amount. The gain, if any, in excess of the amount recognized as ordinary
income will be long-term or short-term capital gain, depending upon the length of time the participant held the shares before the disposition. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nonqualified Stock Options  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are generally no federal income tax consequences to a participant or to the Company upon the grant of a nonqualified stock option. Upon
the exercise of a nonqualified stock option, a participant will recognize ordinary income in an amount equal to the excess of the fair market value of the shares at the time of exercise over the
aggregate exercise price paid. The Company generally will be entitled to a corresponding federal income tax deduction. The participant will have a tax basis in the shares equal to the exercise price
plus the amount of income recognized at the time of exercise. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
a participant sells shares of stock acquired through the exercise of a nonqualified stock option, the participant will have a capital gain or loss in an amount equal to the
difference between the amount realized on the sale and the tax basis in the shares. The capital gain tax rate will depend on a number of factors, including the length of time the participant held the
shares prior to selling them. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted Stock  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A participant will generally not recognize federal taxable income when he or she receives a grant of restricted stock, and the Company will not
be entitled to a deduction, until the stock is transferable by the participant or is otherwise no longer subject to a substantial risk of forfeiture. When the stock is either transferable or is no
longer subject to a substantial risk of forfeiture, a participant will recognize ordinary income in an amount equal to the fair market value of the shares at that time (less any amounts paid for the
shares), and generally, the Company will be entitled to a deduction in the same amount. Any gain or loss recognized by the participant upon a later disposition of the shares will be capital gain or
loss. A participant's holding period for purposes of determining whether that capital gain or loss is long-term or short-term will be counted from the date the stock became transferable or ceased to
be subject to a substantial risk of forfeiture. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
participant may elect to recognize ordinary income in the year when the share award is granted in an amount equal to the fair market value of the shares subject to the award (less any
amounts paid for such shares) at the time of grant, determined without regard to any restrictions. This election is referred to as a Section&nbsp;83(b) election. In that event, the Company will be
entitled to a corresponding deduction in the same year. Any gain or loss recognized by the participant upon a later disposition of the shares will be capital gain or loss. A participant's holding
period for purposes of determining whether that capital gain or loss is long-term or short-term will be counted from the date of the original transfer to the participant. The participant may not claim
a credit for any tax previously paid on stock that is later forfeited. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=62,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1029650,FOLIO='59',FILE='DISK109:[18ZAG1.18ZAG13701]DU13701A.;12',USER='MKEANE',CD='12-APR-2018;21:29' -->
<A NAME="page_du13701_1_60"> </A>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted Stock Units  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a participant is granted a restricted stock unit, he or she will not be required to recognize any taxable income at the time of grant. Upon
distribution of shares or cash in respect of a restricted stock unit, the fair market value of those shares or the amount of that cash will be taxable to the participant as ordinary income and the
Company will receive a deduction equal to the income recognized by the participant. The subsequent disposition of shares acquired pursuant to a restricted stock unit will result in capital gain or
loss (based on the difference between the price received on disposition and the market value of the shares at the time of their distribution). The capital gain tax
rate will depend on a number of factors, including the length of time the participant held the shares prior to selling them. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Performance Awards  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a Performance Award is settled by the issuance of unrestricted shares of our Common Stock, the participant receiving the shares will
recognize ordinary income equal to the value of the shares at the time of issuance and the Company will be entitled to a congruent deduction. Those shares will then have a tax basis equal to their
fair market value on the date of issuance, and the holding period of those shares will commence on that date for purposes of determining whether a subsequent disposition of the shares will result in
long-term or short-term capital gain or loss. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a Performance Award is settled by the issuance of another type of award under the 2007 Plan, the tax consequences of that other award will be the same as described above with respect
to the relevant type of award. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Section&nbsp;162(m) of the Internal Revenue Code  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;162(m) of the Code limits the federal income tax deductions a publicly held company can claim for compensation in excess of
$1,000,000 paid to certain executive officers (generally, the officers who are "named executive officers" in the summary compensation table in the issuer's proxy statement). With respect to grants
made prior to November&nbsp;2, 2017, "qualified performance-based compensation" was not counted against the $1,000,000 deductibility limit. Under the 2007 Plan, options, granted prior to this date,
with an exercise price at least equal to 100% of the fair market value of the underlying shares at the date of grant may satisfy the requirements for treatment as "qualified performance-based
compensation." In addition, Performance Awards, granted prior to this date, that are conditioned upon achievement of certain Performance Goals may satisfy the requirements for treatment as "qualified
performance-based compensation." Following the enactment of the Tax Cuts and Jobs Act, beginning with the 2018 calendar year, the $1,000,000 annual deduction limitation under Section&nbsp;162(m)
applies to all compensation paid to these executive officers with no exception for qualified performance-based compensation. Accordingly, our ability to actually receive a corresponding deduction for
the equity awards described above, may be limited by this new tax law. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


New Plan Benefits  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the 2007 Plan is approved by stockholders, awards under the 2007 Plan will be determined by the Compensation Committee in its discretion, and
it is, therefore, not possible to predict the number, name or positions of persons who will benefit from the 2007 Plan, if it is approved by stockholders, or the terms of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=3,SEQ=63,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=350278,FOLIO='60',FILE='DISK109:[18ZAG1.18ZAG13701]DU13701A.;12',USER='MKEANE',CD='12-APR-2018;21:29' -->
<A NAME="page_du13701_1_61"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>any
such benefits. However, the following table sets forth information with respect to awards granted under the Existing Plan during the 2017 fiscal year. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Stock<BR>
Units(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>282,485</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>406,504</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84,745</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>121,949</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>103,578</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>149,049</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,169,010</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>967,537</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Non-executive director group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>113,652</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,698</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-executive officer employee group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,779,524</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>459,761</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Includes
RSUs and PRSUs at target level for TSR and 200% for pipeline goal  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
accordance with SEC rules, the following table lists all options granted to the individuals and groups indicated below since the adoption of the 2007 Plan. The option awards listed
below for the covered executives and directors include the option awards listed in the executive and director compensation tables beginning on page&nbsp;36 and&nbsp;45, respectively, of this proxy
statement and are not additional awards. As of April&nbsp;2, 2018, the closing price of a share of our Common Stock on was $14.16 per share. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Persons or Groups of Persons

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>2,787,151</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman Chief Executive Officer</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>972,745</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>1,192,078</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>615,621</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>220,621</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All current executive officers as a group</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>6,747,831</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 All current directors who are not executive officers as a group</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Each nominee for election as a director</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Each associate of any such director, executive officer or nominees</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Each other person who received or is to receive 5% of such options, warrants or rights</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 All employees, including all current officers who are not executive officers as a group</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>11,337,418</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vote Required  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The affirmative vote of a majority of shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter
is required to approve the 2007 Plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=64,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=902745,FOLIO='61',FILE='DISK109:[18ZAG1.18ZAG13701]DU13701A.;12',USER='MKEANE',CD='12-APR-2018;21:29' -->
<A NAME="page_du13701_1_62"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Securities Authorized for Issuance under our Equity Compensation Plans  </I></B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="106pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="107pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Plan category


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
to be issued upon<BR>
exercise of outstanding<BR>
options (a) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-average<BR>
exercise price of<BR>
outstanding options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
remaining available for<BR>
future issuance under<BR>
equity compensation<BR>
plans (excluding<BR>
securities reflected in<BR>
column (a))(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans approved by security holders(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,181,105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,648,405</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans not approved by security holders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,181,105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,648,405 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Includes
awards granted under the Company's 2002 Plan, the Existing Plan and the 2007 Director Option Plan (the "2007 Director Plan"). As of December&nbsp;31,
2015, no shares were reserved for issuance under the 2002 Plan. The number of shares available for issuance under the 2007 Director Plan is increased annually on January&nbsp;1 of each year by
100,000 shares provided that the Board may waive the annual increase in shares available for issuance.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Of
the total presented there are no shares available for issuance as restricted stock, restricted stock units or stock grants.  </FONT></DD></DL>
 </DIV>
 <UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clawback Policy  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As described above, the Board has adopted a Clawback Policy which allows the Board to recoup bonus and equity awards made to executives in the
event of misconduct leading to a restatement and other misconduct. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="du13701_proposal_no._4_#151;independen__pro02256"> </A>
<A NAME="toc_du13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 4&#151;INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit and Compliance Committee has appointed Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, to audit our
financial statements for the fiscal year ending December&nbsp;31, 2018. The Board proposes that the stockholders ratify this appointment. Ernst&nbsp;&amp; Young&nbsp;LLP audited our financial
statements for the fiscal year ended December&nbsp;31, 2017. We expect that representatives of Ernst&nbsp;&amp; Young&nbsp;LLP will be present at the meeting, will be able to make a statement if
they so desire, and will be available to respond to appropriate questions. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>The Board recommends the vote "FOR" to ratify the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent
registered public accounting firm, and proxies solicited by the Board will be voted in favor of such ratification unless a stockholder indicates otherwise on the proxy.</B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fees for Audit Services  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents fees for professional audit services rendered by Ernst&nbsp;&amp; Young&nbsp;LLP for the audit of our annual
financial statements for the years ended December&nbsp;31, 2017 and 2016, and fees billed for other services rendered by Ernst&nbsp;&amp; Young&nbsp;LLP during those periods. All of such fees were
approved by the Audit and Compliance Committee. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,956,979</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,578,983</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-Related Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,658</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78,435</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,060,072</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,597,983 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=65,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=27841,FOLIO='62',FILE='DISK109:[18ZAG1.18ZAG13701]DU13701A.;12',USER='MKEANE',CD='12-APR-2018;21:29' -->
<A NAME="page_du13701_1_63"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fees
for audit services included fees associated with the annual financial statement audit, an audit of our internal controls over financial reporting and reviews of the quarterly
reports on Form&nbsp;10-Q for both 2017 and 2016. In 2017, the audit fees also included costs of $80,000 associated with the review of our Prospectus Supplement for an equity financing and statutory
audits. Fees for tax services in 2017 included fees associated with certain permitted compliance and advisory services. In 2016, audit fees also included fees related to related to audit work for the
financing transactions for the "At the Market" equity offering commenced in February 2016 and the convertible debt financing completed in December 2016 and $16,500 related to consents required for SEC
filings. All other fees in 2017 and 2016 included the subscription fees paid for access to the Ernst&nbsp;&amp; Young&nbsp;LLP on line Accounting&nbsp;&amp; Auditing Research Tool and in 2017, fees
related to a compliance assessment project. There were no audit-related fees in 2017 and 2016. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy on Audit and Compliance Committee Pre-Approval of Audit and Permissible Non-audit Services of
Independent Registered Public Accounting Firm  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent with SEC policies regarding auditor independence, the Audit and Compliance Committee has responsibility for appointing, setting
compensation and overseeing the work of the independent registered public accounting firm. In recognition of this responsibility, the Audit and Compliance Committee has established a policy to
pre-approve all audit and permissible non-audit services provided by the independent registered public accounting firm. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to engagement of the independent registered public accounting firm for the next year's audit, management will submit an aggregate estimate of services expected to be rendered
during that year for each of four categories of services to the Audit and Compliance Committee for approval.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Audit</I></FONT><FONT SIZE=2> services include audit work performed in the preparation of financial statements, as well as work that only the
independent registered public accounting firm can reasonably be expected to provide, including comfort letters, statutory audits, and attest services and consultation regarding financial accounting
and/or reporting standards.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Audit-Related</I></FONT><FONT SIZE=2> services are for assurance and related services that are traditionally performed by the independent
registered public accounting firm, including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Tax</I></FONT><FONT SIZE=2> services include all services performed by the independent registered public accounting firm's tax personnel
except those services specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance, tax planning, and tax advice.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Other Fees</I></FONT><FONT SIZE=2> are those associated with services not captured in the other categories. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to engagement, the Audit and Compliance Committee pre-approves these services by category of service. The fees are budgeted and the Audit and Compliance Committee requires the
independent registered public accounting firm and management to report actual fees versus the budget periodically throughout the year by category of service. During the year, circumstances may arise
when it may become necessary to engage the independent registered public accounting firm for additional services not contemplated in the original pre-approval. In those instances, the Audit and
Compliance Committee requires specific pre-approval before engaging the independent registered public accounting firm. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit and Compliance Committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must report, for informational
purposes only, any pre-approval decisions to the Audit and Compliance Committee at its next scheduled meeting. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event the stockholders do not ratify the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm, the Audit and Compliance Committee
will reconsider its appointment. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
affirmative vote of a majority of the shares voted affirmatively or negatively on the matter at the Annual Meeting is required to ratify the appointment of the independent registered
public accounting firm. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=66,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=304612,FOLIO='63',FILE='DISK109:[18ZAG1.18ZAG13701]DU13701A.;12',USER='MKEANE',CD='12-APR-2018;21:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dw13701_1_64"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw13701_report_of_audit_and_compliance_committee"> </A>
<A NAME="toc_dw13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF AUDIT AND COMPLIANCE COMMITTEE    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit and Compliance Committee of the Board, which currently consists entirely of directors who meet the independence and experience
requirements of the rules and regulations of NASDAQ and the Exchange Act, has furnished the following report. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit and Compliance Committee assists the Board in overseeing and monitoring the integrity of our financial reporting process, compliance with legal and regulatory requirements and
the quality of internal and external audit processes. This Committee reviews and reassesses our charter annually and recommends any changes to the Board for approval. The Audit and Compliance
Committee is responsible for overseeing our financial reporting process on behalf of the Board, and for the appointment, compensation, retention, and oversight of the work of Ernst&nbsp;&amp;
Young&nbsp;LLP. In fulfilling its responsibilities for the financial statements for fiscal year 2017, the Audit and Compliance Committee took the following
actions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Reviewed and discussed the audited financial statements for the fiscal year ended 2017 with management and Ernst&nbsp;&amp; Young&nbsp;LLP, our
independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Discussed with Ernst&nbsp;&amp; Young&nbsp;LLP the matters required to be discussed by PCAOB Auditing Standard No.16, Communications with Audit
and Compliance Committees; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Received written disclosures and the letter from Ernst&nbsp;&amp; Young&nbsp;LLP regarding its communications with the Audit and Compliance
Committee concerning independence as required by Rule&nbsp;3526 of the PCAOB (Communications with Audit and Compliance Committees Concerning Independence). The Audit and Compliance Committee further
discussed Ernst&nbsp;&amp; Young's independence with Ernst&nbsp;&amp; Young&nbsp;LLP. The Audit and Compliance Committee also considered the status of pending litigation, taxation matters and other
areas of oversight relating to the financial reporting and audit process that the Committee determined appropriate. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the Audit and Compliance Committee's review of the audited financial statements, discussions with management and Ernst&nbsp;&amp; Young&nbsp;LLP and written disclosures and the
letter from Ernst&nbsp;&amp; Young&nbsp;LLP regarding its communications with the Audit and Compliance Committee concerning independence as required by applicable requirements of the Public Company
Accounting Oversight Board, the Audit and Compliance Committee recommended to the Board that the audited financial statements be included in our Annual Report on Form&nbsp;10-K for the fiscal year
ended December&nbsp;31, 2017, as amended, for filing with the SEC. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Members
of the Amicus Therapeutics,&nbsp;Inc.<BR>
Audit and Compliance Committee </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Glenn
P. Sblendorio, Chair<BR>
Robert Essner<BR>
Michael G. Raab </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act or the Exchange Act that might incorporate this proxy
statement or future filings with the SEC, in whole or in part, the above report shall not be deemed to be "soliciting material" or "filed" with the SEC and shall not be deemed to be incorporated by
reference into any such filing.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=67,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=395581,FOLIO='64',FILE='DISK109:[18ZAG1.18ZAG13701]DW13701A.;5',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dw13701_1_65"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw13701_proposal_no._5_#151;ad__dw102143"> </A>
<A NAME="toc_dw13701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 5&#151;ADVISORY VOTE ON EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are providing our stockholders the opportunity to vote to approve, on an advisory, non-binding basis, the compensation of our named executive
officers as disclosed in this proxy statement in accordance with the SEC's rules. This proposal, which is commonly referred to as "say-on-pay," is required by the Dodd-Frank Wall Street Reform and
Consumer Protection Act of 2010, which added Section&nbsp;14A to the Exchange Act. Section&nbsp;14A of the Exchange Act also requires that stockholders have the opportunity to cast an advisory
vote with respect to whether future executive compensation advisory votes will be held every one, two or three years. In accordance with the results of this advisory vote at the 2017 Annual Meeting,
the Company's Board determined that the Company will hold an advisory vote on the compensation of the Company's named executive officers every year. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
executive compensation program for our executive officers is designed to attract, motivate, and retain individuals of superior ability and managerial talent who can successfully
perform and succeed in our environment. Our named executive officers are rewarded for the achievement of our near-term and longer-term financial and strategic goals and for driving corporate
performance. This program contains elements of cash and equity-based compensation designed to align the interests of our executives with those of our stockholders as well as have the appropriate
incentive to achieve key strategic and financial performance measures by linking compensation opportunities and actual compensation earned through our pay-for-performance compensation program to the
achievement of corporate goals. We also make equity grants designed to align our named executive officers' compensation to the long-term performance of Amicus in addition to creating an ownership
culture that helps unify the interests of our executives and stockholders. The Company generally targets aggregate total direct compensation for the named executive officers as a group to
approximately the 50th&nbsp;percentile of our peer group at target performance levels in setting our executive compensation programs. Our Board and the Compensation Committee regularly review the
compensation programs for our named executive officers and undertake a comprehensive annual review to ensure that our compensation policies and programs align with current market practices and the
interests of our stockholders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
"Compensation Discussion and Analysis" section of this proxy statement describes in detail our executive compensation program and the decisions made by the Compensation Committee
with respect to the fiscal year ended December&nbsp;31, 2017. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2017, the Company made significant progress towards the goal of becoming a leading orphan and rare disease company with global commercial operations and a diversified product
pipeline. The Company successfully continued its geographic expansion of Galafold (migalastat), exceeding its goal of 300 patients on therapy by end 2017. It also submitted registration packages for
migalastat to US FDA and Japan PDMA. The company also established definitive proof of concept for ATB200/AT2221 for Pompe disease and released a cascade of positive data from the Phase
<SUP>1</SUP>/<SMALL>2</SMALL> clinical trial throughout 2017 and successfully scaled biologics manufacturing from the 250L to 1000L scale, reaching agreement with FDA on comparability between the 250L and 1000L
engineering batches. The company further strengthened the balance sheet with the completion of a $258&nbsp;million follow-on equity offering, while carefully managing expenses. These actions have
provided us with more than 18&nbsp;months of cash runway at the beginning of 2018. We believe that our compensation plan appropriately rewards our executive officers for the exceptional progress
achieved in 2017 and the performance against our corporate goals, and aligns their long term incentives with shareholders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board is therefore asking stockholders to approve, on an advisory basis, the following resolution: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>"RESOLVED,
that the compensation paid to the named executive officers of Amicus Therapeutics, as disclosed pursuant to the compensation disclosure rules of the SEC, including the compensation
discussion and analysis, the compensation tables and any related material disclosed in this proxy statement, is hereby approved." </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=68,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=407251,FOLIO='65',FILE='DISK109:[18ZAG1.18ZAG13701]DW13701A.;5',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dw13701_1_66"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
an advisory vote, this proposal is not binding. The outcome of this advisory vote will not overrule any decision by us or our Board (or any committee thereof), create or imply any
change to our fiduciary duties or those of our Board (or any committee thereof), or create or imply any additional fiduciary duties for us or our Board (or any committee thereof). However, our
Compensation Committee and Board value the opinions expressed by our stockholders in their vote on this proposal and will consider the outcome of the vote when making future compensation decisions for
named executive officers. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw13701_other_matters"> </A>
<A NAME="toc_dw13701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board knows of no other business which will be presented to the 2018 Annual Meeting. If any other business is properly brought before the
2018 Annual Meeting, proxies in the enclosed form will be voted in accordance with the judgment of the individuals named as proxies on the proxy card. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw13701_stockholder_proposals_and_nominations_for_director"> </A>
<A NAME="toc_dw13701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you wish to submit a proposal to be considered for inclusion in next year's proxy materials or nominate a director, your proposal must be in
proper form according to SEC Regulation&nbsp;14A, Rule&nbsp;14a-8 and received by the Secretary of the Company no later than December&nbsp;28, 2018. Proposals received after that date will not
be included in the proxy materials we send out in connection with the 2019 Annual Meeting of Stockholders. If a proposal is received before that date, the proxies that management solicits for the
meeting may still exercise discretionary voting authority on the proposal under circumstances consistent with the proxy rules of the SEC. To be timely in accordance with our Restated By-laws,
stockholder notice of any such proposal must be received by us not earlier than November&nbsp;28, 2018 and not later than December&nbsp;28, 2018; provided, however, that in the event that the date
of the 2019 Annual Meeting of Stockholders is more than 30&nbsp;days before or more than 60&nbsp;days after the anniversary date of the 2018 Annual Meeting of Stockholders, notice by the
stockholder to be timely must be delivered not earlier than the close of business on the 90th&nbsp;day prior to such 2019 Annual Meeting of Stockholders and not later than the close of business on
the later of the 60th&nbsp;day prior to such 2019 Annual Meeting of Stockholders or the 10th&nbsp;day following the day on which we make a public announcement of the date of the 2019 Annual
Meeting of Stockholders. All stockholder proposals should be marked for the attention of General Counsel and Corporate Secretary, c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury,
New&nbsp;Jersey 08512. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2017 (other than the exhibits thereto), filed with the SEC, which provides additional information
about us, is available on the Internet at </FONT><FONT SIZE=2><I>www.amicusrx.com</I></FONT><FONT SIZE=2> and is available in paper form to beneficial owners of our Common Stock without charge upon
written request to Secretary, c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw13701_delivery_of_proxy_materials"> </A>
<A NAME="toc_dw13701_5"> </A>
<BR></FONT><FONT SIZE=2><B>  DELIVERY OF PROXY MATERIALS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some banks, brokers, and other nominee record holders may be participating in the practice of "householding" proxy statements and annual
reports. This means that only one copy of this Proxy Statement, the Notice of 2018 Annual Meeting of Stockholders and our Annual Report to Stockholders may have been sent to multiple stockholders in
your household. Householding is designed to reduce duplicate mailings and save significant printing and postage costs. If you receive a household mailing this year and would like to receive additional
copies of this Proxy Statement, the Notice of 2018 Annual Meeting of Stockholders and our Annual Report to Stockholders, please call us at (609)&nbsp;662-2000 or send a written request to General
Counsel and Corporate Secretary, c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512. If you want to receive separate copies of our Proxy Statement, Notice of our
Annual Meeting of Stockholders and our Annual Report to Stockholders in the future, or if you are receiving multiple copies and would like to receive only one copy for your household, you should
contact your bank, broker, or other nominee record holder, or you may contact us at the above address and phone number. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=69,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=958115,FOLIO='66',FILE='DISK109:[18ZAG1.18ZAG13701]DW13701A.;5',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_la13701_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="la13701_annex_a"> </A>
<A NAME="toc_la13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Annex A    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="la13701_amended_and_restated_amicus_th__ame02604"> </A>
<A NAME="toc_la13701_2"> </A></FONT> <FONT SIZE=2><B>  AMENDED AND RESTATED<BR>  AMICUS THERAPEUTICS,&nbsp;INC.<BR>  2007 EQUITY INCENTIVE PLAN    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purpose  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Plan is intended to encourage ownership of Common Stock by employees, consultants and directors of the Company and its Affiliates and to provide additional
incentive for them to promote the success of the Company's business through the grant of Awards of shares of the Company's Common Stock. The Plan is intended to be an incentive stock option plan
within the meaning of Section&nbsp;422 of the Code but not all Awards granted hereunder are required to be Incentive Options. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As used in the Plan the following terms shall have the respective meanings set out below, unless the context clearly requires otherwise: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Accelerate", "Accelerated",</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>"Acceleration"</I></FONT><FONT SIZE=2> , when used with respect
to an Option, means that as of the time of reference such Option will become exercisable with respect to some or all of the shares of Common Stock for which it was not then otherwise exercisable by
its terms, and, when used with respect to Restricted Stock, Restricted Stock Units or Performance Awards, as the case may be, means that the Risk of Forfeiture and/or Performance Goals otherwise
applicable to such Award, as the case may be, shall expire or be satisfied with respect to some or all of the shares of underlying such Award. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Acquiring Person"</I></FONT><FONT SIZE=2> means, with respect to any Transaction or any acquisition described in clause&nbsp;(ii) of the
definition of Change of Control, the surviving or acquiring person or entity in connection with such Transaction or acquisition, as the case may be, provided that if such surviving or acquiring person
or entity is controlled, directly or indirectly, by any other person or entity (an "Ultimate Parent Entity") that is not itself controlled by any entity or person that is not a natural person, the
term "Acquiring Person" shall mean such Ultimate Parent Entity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Affiliate"</I></FONT><FONT SIZE=2> means, with respect to any person or entity, any other person or entity controlling, controlled by or under
common control with the first person or entity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Applicable Voting Control Percentage"</I></FONT><FONT SIZE=2> means (i)&nbsp;at any time prior to the initial public offering of the Company,
a percentage greater than fifty percent (50%) and (ii)&nbsp;at any time from and after the initial public offering of the Company, twenty percent (20%). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Award"</I></FONT><FONT SIZE=2> means any grant or sale pursuant to the Plan of Options, Restricted Stock, Restricted Stock Units, Stock Grants
or Performance Awards. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Award Agreement"</I></FONT><FONT SIZE=2> means an agreement between the Company and the recipient of an Award, setting forth the terms and
conditions of the Award. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Beneficial Ownership"</I></FONT><FONT SIZE=2> has the meaning ascribed to such term in Rule&nbsp;13d-3, or any successor rule thereto,
promulgated by the Securities and Exchange Commission pursuant to the Exchange Act. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Board"</I></FONT><FONT SIZE=2> means the Company's board of directors. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Change of Control"</I></FONT><FONT SIZE=2> means (i)&nbsp;the closing of any Sale of the Company Transaction or (ii)&nbsp;the direct or
indirect acquisition, in a single transaction or a series of related transactions, by any person or Group (other than the Company or a Controlled Affiliate of the Company) of Beneficial Ownership of
previously outstanding shares of capital stock of the Company if (A)&nbsp;immediately after </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=70,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=194590,FOLIO='A-1',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_2"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>such
acquisition, such person or Group, together with their respective Affiliates, shall own or hold shares of capital stock of the Company possessing at least the Applicable Voting Control Percentage
of the total voting power of the outstanding A-1 capital stock of the Company and (B)&nbsp;immediately prior to such acquisition, such person or Group, together with their respective Affiliates, did
not own or hold shares of capital stock of the Company possessing at least the Applicable Voting Control Percentage of the total voting power of the outstanding capital stock of the Company.
Notwithstanding anything expressed or implied in the foregoing provisions of this definition to the contrary, any direct or indirect acquisition referred to in clause&nbsp;(ii) above in this
definition shall not be treated as a Change of Control if, at any time prior to or after such direct or indirect acquisition, a majority of the members of the board of directors of the Company as
constituted immediately prior to such direct or indirect acquisition consent in writing to exclude such direct or indirect acquisition from the scope of this definition. Notwithstanding the foregoing,
with respect to any Award issued under the Plan, which is subject to Section&nbsp;409A of the Code, no event shall set forth above shall be deemed to be a Change of Control, unless such event would
also be considered a "change in ownership or effective control of a corporation or in the ownership of a substantial portion of the assets of a corporation" under Section&nbsp;409A(a)(2)(A)(v) of
the Code and the regulations thereunder. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10&nbsp;</FONT><FONT
SIZE=2><I>"Code"</I></FONT><FONT SIZE=2> means the Internal Revenue Code of 1986, as amended from time to time, or any successor statute thereto, and any
regulations issued from time to time thereunder. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11&nbsp;</FONT><FONT
SIZE=2><I>"Controlled Affiliate"</I></FONT><FONT SIZE=2> means, with respect to any person or entity, any other person or entity that is controlled by
such person or entity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12&nbsp;</FONT><FONT
SIZE=2><I>"Committee"</I></FONT><FONT SIZE=2> means any committee of the Board delegated responsibility by the Board for the administration of the Plan,
as provided in Section&nbsp;5 of the Plan. For any period during which no such committee is in existence, the term "</FONT><FONT SIZE=2><I>Committee</I></FONT><FONT SIZE=2> "shall mean the Board
and all authority and responsibility assigned the Committee under the Plan shall be exercised, if at all, by the Board. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.13&nbsp;</FONT><FONT
SIZE=2><I>"Common Stock"</I></FONT><FONT SIZE=2> means common stock, par value $0.01 per share, of the Company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.14&nbsp;</FONT><FONT
SIZE=2><I>"Company"</I></FONT><FONT SIZE=2> means Amicus Therapeutics,&nbsp;Inc., a corporation organized under the laws of the State of Delaware. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15&nbsp;</FONT><FONT
SIZE=2><I>"Exchange Act"</I></FONT><FONT SIZE=2> means the Securities Exchange Act of 1934, as amended. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.16&nbsp;</FONT><FONT
SIZE=2><I>"Grant Date"</I></FONT><FONT SIZE=2> means the date as of which an Option is granted, as determined under Section&nbsp;7.1(a). </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.17&nbsp;</FONT><FONT
SIZE=2><I>"Group"</I></FONT><FONT SIZE=2> has the meaning ascribed to such term in Section&nbsp;13(d)(3) of the Exchange Act or any successor section
thereto. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.18&nbsp;</FONT><FONT
SIZE=2><I>"Incentive Option"</I></FONT><FONT SIZE=2> means an Option which by its terms is to be treated as an "incentive stock option" within the meaning
of Section&nbsp;422 of the Code. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.19&nbsp;</FONT><FONT
SIZE=2><I>"Market Value"</I></FONT><FONT SIZE=2> means the value of a share of Common Stock on a particular date determined by such methods or procedures
as may be established by the Committee. Unless otherwise determined by the Committee, the Market Value of Common Stock as of any date is the closing price for the Common Stock as reported on the
NASDAQ Global market (or on any other national securities exchange on which the Common Stock is then listed) for that date or, if no closing price is reported for that date, the closing price on the
next preceding date for which a closing price was reported. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.20&nbsp;</FONT><FONT
SIZE=2><I>"Nonstatutory Option"</I></FONT><FONT SIZE=2> means any Option that is not an Incentive Option. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.21&nbsp;</FONT><FONT
SIZE=2><I>"Option"</I></FONT><FONT SIZE=2> means an option granted under the Plan to purchase shares of Common Stock. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=71,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=357616,FOLIO='A-2',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_3"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.22&nbsp;</FONT><FONT
SIZE=2><I>"Optionee"</I></FONT><FONT SIZE=2> means an employee, consultant or director of the Company to whom an Option shall have been initially granted
under the Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.23&nbsp;</FONT><FONT
SIZE=2><I>"Participant"</I></FONT><FONT SIZE=2> means any holder of an outstanding Award under the Plan. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.24&nbsp;"</FONT><FONT
SIZE=2><I>Performance Award</I></FONT><FONT SIZE=2>" means shares of Common Stock or other Awards that, pursuant to Section&nbsp;7.5 are granted,
vested and/or settled upon the achievement of specified performance conditions </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.25&nbsp;"</FONT><FONT
SIZE=2><I>Performance Goals</I></FONT><FONT SIZE=2>" means any goals established by the Committee in its sole discretion, the attainment of which is
substantially uncertain at the time such goals are established. Performance Goals may be described in terms of Company-wide objectives or objectives that are related to the performance of the
individual Participant or any subsidiary, division, department or function within the Company or any subsidiary in which the Participant is employed. Performance Goals may be measured on an absolute
or relative basis. Relative performance may be measured by a group of peer companies or by a financial market index. Performance Goals may be based upon: cash flow; earnings (including gross margin,
earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation, amortization and charges for stock-based compensation, earnings before interest, taxes,
depreciation and amortization, and net earnings); earnings per share; growth in earnings or earnings per share; stock price; return on equity or average stockholder equity; total stockholder return or
growth in total stockholder return either directly or in relation to a comparative group; return on capital; return on assets or net assets; revenue, growth in revenue or return on sales; income or
net income; operating income, net operating income or net operating income after tax; operating profit or net operating profit; operating margin; return on operating revenue or return on operating
profit; regulatory filings; regulatory approvals, litigation and regulatory resolution goals; other operational, regulatory or departmental objectives; budget comparisons; growth in stockholder value
relative to established indexes, or another peer group or peer group index; development and implementation of strategic plans and/or organizational restructuring goals; development and implementation
of risk and crisis management programs; improvement in workforce diversity; compliance requirements and compliance relief; safety goals; productivity goals; workforce management and succession
planning goals; economic value added (including typical adjustments consistently applied from generally accepted accounting principles required to determine economic value added performance measures);
measures of customer satisfaction, employee satisfaction or staff development; development or marketing collaborations, formations of joint ventures or partnerships or the completion of other similar
transactions intended to enhance the Company's revenue or profitability or enhance its customer base; and merger and acquisitions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.26&nbsp;"Performance
Period" means the period selected by the Committee during which the performance of the Company, any subsidiary, any department or division of the Company
or any subsidiary, or any
individual is measured for the purpose of determining the extent to which a Performance Goal has been achieved. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.27&nbsp;</FONT><FONT
SIZE=2><I>"Plan"</I></FONT><FONT SIZE=2> means this 2007 Amended and Restated Equity Incentive Plan of the Company, as amended and in effect from time to
time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.28&nbsp;</FONT><FONT
SIZE=2><I>"Restricted Stock"</I></FONT><FONT SIZE=2> means a grant or sale pursuant to the Plan of shares of Common Stock to a Participant subject to a
Risk of Forfeiture. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.29&nbsp;</FONT><FONT
SIZE=2><I>"Restricted Stock Units"</I></FONT><FONT SIZE=2> means rights granted pursuant to the Plan to receive shares of Common Stock at the close of a
Restriction Period, subject to a Risk of Forfeiture. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.30&nbsp;</FONT><FONT
SIZE=2><I>"Restriction Period"</I></FONT><FONT SIZE=2> means the period of time, established by the Committee in connection with an Award of Restricted
Stock or Restricted Stock Units, during which the shares of Restricted Stock or Restricted Stock Units are subject to a Risk of Forfeiture described in the applicable Award Agreement. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=72,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=580428,FOLIO='A-3',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_4"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.31&nbsp;</FONT><FONT
SIZE=2><I>"Risk of Forfeiture"</I></FONT><FONT SIZE=2> means a limitation on the right of a Participant to retain an Award of Restricted Stock or
Restricted Stock Units, including subjecting such Award to a Performance Goals and/or a right in the Company to reacquire such Restricted Stock at less than its then Market Value and/or the forfeiture
of Restricted Stock Units held by a Participant, arising because of the occurrence or non-occurrence of specified events or conditions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.32&nbsp;</FONT><FONT
SIZE=2><I>"Sale of the Company Transaction"</I></FONT><FONT SIZE=2> means any Transaction in which the stockholders of the Company immediately prior to
such Transaction, together with any and all of such stockholders' Affiliates, do not own or hold, immediately after consummation of such Transaction, shares of capital stock of the Acquiring Person in
connection with such Transaction possessing at least a majority of the total voting power of the outstanding capital stock of such Acquiring Person. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.33&nbsp;</FONT><FONT
SIZE=2><I>"Securities Act"</I></FONT><FONT SIZE=2> means the Securities Act of 1933, as amended. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.34&nbsp;</FONT><FONT
SIZE=2><I>"Stock Grant"</I></FONT><FONT SIZE=2> means the grant pursuant to the Plan of shares of Common Stock not subject to restrictions or other
forfeiture conditions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.35&nbsp;</FONT><FONT
SIZE=2><I>"Ten Percent Owner"</I></FONT><FONT SIZE=2> means a person who owns, or is deemed within the meaning of Section&nbsp;422(b)(6) of the Code to
own, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company (or any parent or subsidiary corporations of the Company, as defined in
Section&nbsp;424(e) and (f), respectively, of the Code). Whether a person is a Ten Percent Owner shall be determined with respect to each Option based on the facts existing immediately prior to the
Grant Date of such Option. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.36&nbsp;</FONT><FONT
SIZE=2><I>"Transaction"</I></FONT><FONT SIZE=2> means any merger or consolidation of the Company with or into another person or entity or the sale or
transfer of all or substantially all of the assets of the Company, in each case in a single transaction or in a series of related transactions. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term of the Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless the Plan shall have been earlier terminated by the Board, Awards may be granted under this Plan at any time in the period commencing on the Effective Date
of approval of the Amended and restated version of the Plan by the Board and ending immediately prior to the tenth anniversary the Effective Date. Awards granted pursuant to the Plan within such
period shall not expire solely by reason of the termination of the Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Subject to the Plan: Limits  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the provisions of Section&nbsp;8 of the Plan, at no time shall the number of shares of Common Stock issued pursuant to or subject to outstanding
Awards granted under the Plan (including, without limitation, pursuant to Incentive Options), nor the number of shares of Common Stock issued pursuant to Incentive Options, exceed 20,058,703, with
respect to shares of Common Stock. For purposes of applying the foregoing limitation, if any Option expires, terminates, or is cancelled for any reason without having been exercised in full, or if any
Award of Restricted Stock is forfeited, the shares not purchased by the Participant or forfeited by the Participant shall again be available for Awards thereafter to be granted under the Plan. In the
event the exercise price of an Option or a Participant's withholding obligations is paid through the delivery of shares of Common Stock, the number of shares so tendered shall not again be available
for the grant of Awards under the Plan. Shares of Common Stock issued pursuant to the Plan may be either authorized but unissued shares or shares held by the Company in its treasury. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, not more than 10,058,703 of the total number of shares of Common Stock reserved for issuance under the Plan (as adjusted under Section&nbsp;8) may be granted or sold as
Awards of Restricted Stock, Restricted Stock Units, Stock Grants, and any other similar Awards (including, without limitation, Restricted Stock, Restricted Stock Units, Stock Grants, and any other
similar Awards underlying a Performance Award) ("Full-Value Awards") whose intrinsic value is not solely dependent on appreciation </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=73,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=248434,FOLIO='A-4',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_5"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>in
the price of shares of Common Stock after the date of grant. Options and any other similar Awards shall not be subject to, and shall not count against, the limit described in the preceding
sentence. If a Full-Value Award expires, is forfeited, or otherwise lapses as described in this Section&nbsp;4, the shares of Common Stock that were subject to the Award shall be restored to the
total number of shares of Common Stock available for grant or sale as Full-Value Awards. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
maximum number of shares of Common Stock with respect to which Awards may be granted hereunder to any employee of the Company during any fiscal year of the Company shall be five
million (5,000,000) shares of Common Stock. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administration  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Plan shall be administered by the Committee; </FONT><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2> , that at any time and on any one or more
occasions the Board may itself exercise any of the powers and responsibilities assigned the Committee under the Plan and when so acting shall have the benefit of all of the provisions of the Plan
pertaining to the Committee's exercise of its authorities hereunder; </FONT><FONT SIZE=2><I>and provided further</I></FONT><FONT SIZE=2> that the Committee may delegate to an executive officer or
officers the authority to grant Awards hereunder to employees who are not officers, and to consultants, in accordance with such guidelines as the Committee shall set forth at any time or from time to
time. Subject to the provisions of the Plan, the Committee shall have complete authority, in its discretion, to make or to select the manner of making all determinations with respect to each Award to
be granted by the Company under the Plan in addition to any other determination allowed the Committee under the Plan including, without limitation: (a)&nbsp;the employee, consultant or director to
receive the Award; (b)&nbsp;the form of Award; (c)&nbsp;whether an Option (if granted to an employee) will be an Incentive Option or a Nonstatutory Option; (d)&nbsp;the time of granting an
Award; (e)&nbsp;the number of shares subject to an Award; (f)&nbsp;the exercise price of an Option or purchase price, if any, for shares of Restricted Stock or for a Stock Grant and the method of
payment of such exercise price or such purchase price; (g)&nbsp;the term of an Option; (h)&nbsp;the vesting period of shares of Restricted Stock or of Restricted Stock Units and any acceleration
thereof; (i)&nbsp;the exercise date or dates of an Option and any acceleration thereof; (j)&nbsp;the effect of termination of any employment, consulting or Board member relationship with the
Company or any of its Affiliates on the subsequent exercisability of an Option or on the Risk of Forfeiture of Restricted Stock or Restricted Stock Units; (k)&nbsp;whether, and to certify that,
Performance Goals to which an Award is
subject are satisfied; and (l)&nbsp;the terms and conditions of any Award granted under the Plan (including, but not limited to, restrictions as to vesting, transferability or forfeiture,
exercisability or settlement of an Award and waivers or accelerations thereof, and establishment, waivers of or modifications to Performance Goals relating to an Award, based in each case on such
considerations as the Committee shall determine) and all other matters to be determined in connection with an Award. In making such determinations, the Committee may take into account the nature of
the services rendered by the respective employees, consultants and directors, their present and potential contributions to the success of the Company and its Affiliates, and such other factors as the
Committee in its discretion shall deem relevant. Subject to the provisions of the Plan, the Committee shall also have complete authority to interpret the Plan, to prescribe, amend and rescind rules
and regulations relating to it, to determine the terms and provisions of the respective Award Agreements (which need not be identical), and to make all other determinations necessary or advisable for
the administration of the Plan. The Committee's determinations made in good faith on matters referred to in this Plan shall be final, binding and conclusive on all persons having or claiming any
interest under the Plan or an Award made pursuant hereto. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorization and Eligibility  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Committee may grant from time to time and at any time prior to the termination of the Plan one or more Awards, either alone or in combination with any other
Awards, to any employee of or consultant to one or more of the Company and its Affiliates or to any non-employee member of the Board or of any </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=74,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=903068,FOLIO='A-5',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_6"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>board
of directors (or similar governing authority) of any Affiliate. However, only employees of the Company or of any parent or subsidiary corporations of the Company, as defined in
Sections&nbsp;424(e) and (f), respectively, of the Code, shall be eligible for the grant of an Incentive Option. Further, in no event shall the number of shares of Common Stock covered by Options or
other Awards granted to any one person in any one calendar year (or portion of a year) ending after such date exceed fifty percent (50%) of the aggregate number of shares of Common Stock subject to
the Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
grant of an Award shall be subject to all applicable terms and conditions of the Plan (including but not limited to any specific terms and conditions applicable to that type of
Award set out in the following Section), and such other terms and conditions, not inconsistent with the terms of the Plan, as the Committee may prescribe. No prospective Participant shall have any
rights with respect to an Award, unless and until such Participant has executed an agreement evidencing the Award, delivered a fully executed copy thereof to the Company, and otherwise complied with
the applicable terms and conditions of such Award. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specific Terms of Awards  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Date of Grant.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The granting of an Option shall take place at the time specified in the Award Agreement. Only
if expressly so provided in the applicable Award Agreement shall the Grant Date be the date on which the Award Agreement shall have been duly executed and delivered by the Company and the Optionee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exercise Price.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The price at which shares of Common Stock may be acquired under each Incentive Option shall
be not less than 100% of the Market Value of Common Stock on the Grant Date, or not less than 110% of the Market Value of Common Stock on the Grant Date if the Optionee is a Ten Percent Owner. The
price at which shares may be acquired under each Nonstatutory Option shall not be so limited solely by reason of this Section. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Option Period.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No Incentive Option or Nonstatutory Option may be exercised on or after the tenth anniversary
of the Grant Date, or on or after the fifth anniversary of the Grant Date if the Optionee is a Ten Percent Owner. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exercisability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An Option may be immediately exercisable or become exercisable in such installments,
cumulative or non-cumulative, as the Committee may determine. Any Option may be a Performance Award, subject to Section&nbsp;7.5. In the case of an Option not otherwise immediately exercisable in
full, the Committee may Accelerate such Option in whole or in part at any time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Effect of Termination of Employment, Consulting or Board Member Relationship.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless the Committee shall
provide otherwise with respect to any Option, if the applicable Optionee's association with the Company or any of its Affiliates as an employee, director or consultant ends for any reason or no
reason, regardless of whether the end of such association is effected by the Company, any such Affiliate or such Optionee (whether voluntarily or involuntarily, including because an entity with which
such Optionee has any such association ceases to be an Affiliate of the Company), and immediately following the end of any such association, such Optionee is not associated with the Company or any of
its Affiliates as an employee, director or consultant, or if such Optionee dies, then any outstanding Option initially granted to such Optionee, whether then held by such Optionee or any other
Participant, shall cease to be exercisable in any respect not later than ninety (90)&nbsp;days following the end of such association or such death and, for the period it remains exercisable
following the end of such association or such death, shall be exercisable only to the extent exercisable on the date of the end of
such association or such death. Military or sick leave or other bona fide leave shall not be deemed a termination of employment, provided that it does not exceed </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=75,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=797530,FOLIO='A-6',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_7"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>the
longer of ninety (90)&nbsp;days or the period during which the absent Optionee's reemployment rights, if any, are guaranteed by statute or by contract. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Transferability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in this subsection&nbsp;(f), Options shall not be
transferable, and no Option or interest therein may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution
(subject always to the provisions of subsection&nbsp;(e) above). Except as otherwise provided in this subsection&nbsp;(f), all of a Participant's rights in any Option may be exercised during the
life of such Participant only by such Participant or such Participant's legal representative. However, the applicable Award Agreement or the Committee (at or after the grant of a Nonstatutory Option)
may provide that a Nonstatutory Option may be transferred by the applicable Participant to a family member; provided, however, that any such transfer is without payment of any consideration whatsoever
and that no transfer of a Nonstatutory Option shall be valid unless first approved by the Committee, acting in its sole discretion, unless such transfer is permitted under the applicable Award
Agreement. For this purpose, "family member" means any child, stepchild, grandchild, parent, stepparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law,
daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the applicable Participant's household (other than a tenant or employee), a trust in which the
foregoing persons and/or the applicable Participant have more than fifty percent (50%) of the beneficial interests, a foundation in which the foregoing persons and/or the applicable Participant
control the management of assets, and any other entity in which these persons and/or the applicable Participant own more than fifty percent (50%) of the voting interests. The Committee may at any time
or from time to time delegate to one or more officers of the Company the authority to permit transfers of Nonstatutory Options to third parties pursuant to this subsection&nbsp;(f), which
authorization shall be exercised by such officer or officers in accordance with guidelines established by the Committee at any time and from time to time. The restrictions on transferability set forth
in this subsection&nbsp;(f) shall in no way preclude any Participant from effecting "cashless" exercises of an Option pursuant to the terms of the Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Method of Exercise.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An Option may be exercised by a Participant giving written notice, in the manner
provided in Section&nbsp;15, specifying the number of shares of Common Stock with respect to which the Option is then being exercised. The notice shall be accompanied by payment in the form of cash
or check payable to the order of the Company in an amount equal to the exercise price of the shares of Common Stock to be purchased or, subject in each instance to the Committee's approval, acting in
its sole discretion and subject to such conditions, if any, as the Committee may deem necessary to comply with applicable laws, rules and regulations or to avoid adverse accounting effects to the
Company, by
delivery to the Company of shares of Common Stock having a Market Value equal to the exercise price of the shares to be purchased. If the Common Stock is traded on an established market, payment of
any exercise price may also be made through and under the terms and conditions of any formal cashless exercise program authorized by the Company entailing the sale of the Common Stock subject to any
Option in a brokered transaction (other than to the Company). Receipt by the Company of such notice and payment in any authorized or combination of authorized means shall constitute the exercise of
the Option. Within thirty (30)&nbsp;days thereafter but subject to the remaining provisions of the Plan, the Company shall deliver or cause to be delivered to the Participant or his agent a
certificate or certificates for the number of shares then being purchased. Such shares shall be fully paid and nonassessable. Notwithstanding any of the foregoing provisions in this
subsection&nbsp;(g) to the contrary, (A)&nbsp;no Option shall be considered to have been exercised unless and until all of the provisions governing such exercise specified in the Plan and in the
relevant Award Agreement shall have been duly complied with; and (B)&nbsp;the obligation of the Company to issue any shares upon exercise of an Option is subject to the provisions of
Section&nbsp;9.1 hereof and to compliance by the Optionee and the Participant with all of the provisions of the Plan and the relevant Award Agreement. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=76,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=246373,FOLIO='A-7',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_8"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Limit on Incentive Option Characterization.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An Incentive Option shall be considered to be an Incentive
Option only to the extent that the number of shares of Common Stock for which the Option first becomes exercisable in a calendar year does not have an aggregate Market Value (as of the date of the
grant of the Option) in excess of the "current limit". The current limit for any Optionee for any calendar year shall be $100,000 </FONT><FONT SIZE=2><I>minus</I></FONT><FONT SIZE=2> the aggregate
Market Value at the date of grant of the number of shares of Common Stock available for purchase for the first time in the same year under each other Incentive Option previously granted to the
Optionee under the Plan, and under each other incentive stock option previously granted to the Optionee. Any shares of Common Stock which would cause the foregoing limit to be violated shall be deemed
to have been granted under a separate Nonstatutory Option, otherwise identical in its terms to those of the Incentive Option. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Notification of Disposition.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each person exercising any Incentive Option granted under the Plan shall be
deemed to have covenanted with the Company to report to the Company any disposition of such shares prior to the expiration of the holding periods specified by Section&nbsp;422(a)(1) of the Code and,
if and to the extent that the realization of income in such a disposition imposes upon the Company federal, state, local or other withholding tax requirements, or any such withholding is required to
secure for the Company an otherwise available tax deduction, to remit to the Company an amount in cash sufficient to satisfy those requirements. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights Pending Exercise.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No person holding an Option shall be deemed for any purpose to be a stockholder of
the Company with respect to any of the shares of Common Stock issuable pursuant to such Option, except to the extent that such Option shall have been exercised with respect thereto and, in addition, a
certificate shall have been issued therefor and delivered to such person or his agent. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Purchase Price.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Shares of Restricted Stock shall be issued under the Plan for such consideration, in cash,
other property or services, or any combination thereof, as is determined by the Committee. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Certificates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to subsection&nbsp;(c) below, each Participant receiving an Award of
Restricted Stock shall be issued a stock certificate in respect of such shares of Restricted Stock. Such certificate shall be registered in the name of such Participant, and, if applicable, shall bear
an appropriate legend referring to the terms, conditions, and restrictions applicable to such Award substantially in the following form: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
transferability of this certificate and the shares represented by this certificate are subject to the terms and conditions of the Amicus Therapeutics,&nbsp;Inc. Amended and
Restated 2007 Equity Incentive Plan and an Award Agreement entered into by the registered owner and Amicus Therapeutics,&nbsp;Inc. Copies of such Plan and Agreement are on file in the offices of
Amicus Therapeutics,&nbsp;Inc. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Escrow of Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may require that the stock certificates evidencing shares of Restricted
Stock be held in custody by a designated escrow agent (which may but need not be the Company) until the restrictions thereon shall have lapsed, and that the Participant deliver a stock power, endorsed
in blank, relating to the Common Stock covered by such Award. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Restrictions and Restriction Period.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;During the Restriction Period applicable to shares of Restricted Stock,
such shares shall be subject to limitations on transferability and a Risk of Forfeiture arising on the basis of such conditions related to the performance of services, Company or Affiliate performance
or otherwise as the Committee may determine and provide for in the applicable Award Agreement. Any grant of Restricted Stock may be a Performance Award, subject to Section&nbsp;7.5. Any such Risk of
Forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Committee on such basis as it deems appropriate. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=77,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=980748,FOLIO='A-8',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_lc13701_1_9"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights Pending Lapse of Risk of Forfeiture or Forfeiture of Award.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in the Plan
or the applicable Award Agreement, at all times prior to lapse of any Risk of Forfeiture applicable to, or forfeiture of, an Award of Restricted Stock, the Participant shall have all of the rights of
a stockholder of the Company, including the right to vote the shares of Restricted Stock. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Effect of Termination of Employment, Consulting or Board Member Relationship.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise determined by
the Committee at or after grant and subject to the applicable provisions of the Award Agreement, if the applicable original grantee's association with the Company or any of its Affiliates as an
employee, director or consultant ends for any reason or no reason during the Restriction Period, regardless of whether the end of such association is effected by the Company, any such Affiliate or
such original grantee (whether voluntarily or involuntarily, including because an entity with which such original grantee has any such association ceases to be an Affiliate of the Company), and
immediately following the end of any such association, such original grantee is not associated with the Company or any of its Affiliates as an employee, director or consultant, or if such original
grantee dies, then all outstanding shares of Restricted Stock initially granted to such original grantee that are still subject to Risk of Forfeiture, whether then held by such original grantee or any
other Participant, shall be forfeited or otherwise subject to return to or repurchase by the Company if and to the extent so provided by, and subject to and in accordance with, the terms of the
applicable Award Agreement; provided, however, that military or sick leave or other bona fide leave shall not be deemed a termination of employment, if it does not exceed the longer of ninety
(90)&nbsp;days or the period during which the absent original grantee's reemployment rights, if any, are guaranteed by statute or by contract. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Lapse of Restrictions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If and when the Restriction Period expires without a prior forfeiture of the
Restricted Stock, the certificates for such shares shall be delivered to the Participant promptly if not theretofore so delivered. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Transferability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in this subsection&nbsp;(h), shares of Restricted Stock
shall not be transferable, and no share of Restricted Stock or interest therein may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws
of descent and distribution (subject always to the provisions of subsection&nbsp;(f) above). The applicable Award Agreement or the Committee (at or after the grant of a share of Restricted Stock)
may provide that such share of Restricted Stock may be transferred by the applicable Participant to a family member; provided, however, that any such transfer is without payment of any consideration
whatsoever and that no transfer of a share of Restricted Stock shall be valid unless first approved by the Committee, acting in its sole discretion, unless such transfer is permitted under the
applicable Award Agreement. For this purpose, "family member" means any child, stepchild, grandchild, parent, stepparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the applicable Participant's household (other than a tenant or employee), a trust in
which the foregoing persons and/or the applicable Participant have more than fifty percent (50%) of the beneficial interests, a foundation in which the foregoing persons and/or the applicable
Participant control the management of assets, and any other entity in which these persons and/or the applicable Participant own more than fifty percent (50%) of the voting interests. The Committee may
at any time or from time to time delegate to one or more officers of the Company the authority to permit transfers of shares of Restricted Stock to third parties pursuant to this
subsection&nbsp;(h), which authorization shall be exercised by such officer or officers in accordance with guidelines established by the Committee at any time and from time to time. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=78,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=52485,FOLIO='A-9',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_10"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Units.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Character.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each Restricted Stock Unit shall entitle the recipient to a share of Common Stock at a close of
such Restriction Period as the Committee may establish and subject to a Risk of Forfeiture arising on the basis of such conditions relating to the performance of services, Company or Affiliate
performance or otherwise (including any applicable Performance Goal) as the Committee may determine and provide for in the applicable Award Agreement. Any grant of Restricted Stock Units may be a
Performance Award, subject to Section&nbsp;7.5. Any such Risk of Forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Committee on such basis as it deems
appropriate. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Certificates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise determined by the Committee at or after grant and subject to the
applicable provisions of the Award Agreement, at the close of the Restriction Period applicable
to any Restricted Stock Units (including, without limitation, the close of the applicable Restriction Period as a result of (i)&nbsp;any Acceleration of Restricted Stock Units in accordance with the
terms of this Plan or any applicable Award Agreement, (ii)&nbsp;any waiver, lapse or termination of the Risk of Forfeiture applicable to Restricted Stock Units in accordance with the terms of this
Plan or any applicable Award Agreement or (iii)&nbsp;any shortening of the Restriction Period applicable to any Restricted Stock Units in accordance with the terms of this Plan or any applicable
Award Agreement), the Company shall deliver or cause to be delivered to the Participant that is the holder of such Restricted Stock Units a stock certificate in respect of the shares of Common Stock
subject to such Restricted Stock Units. Such certificate shall be registered in the name of such Participant, and, if applicable, shall bear an appropriate legend referring to the terms, conditions,
and restrictions applicable to such shares of Common Stock substantially in the following form: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
transferability of this certificate and the shares represented by this certificate are subject to the terms and conditions of the Amicus Therapeutics,&nbsp;Inc. Amended and
Restated 2007 Equity Incentive Plan and an Award Agreement entered into by the registered owner and Amicus Therapeutics,&nbsp;Inc. Copies of such Plan and Agreement are on file in the offices of
Amicus Therapeutics,&nbsp;Inc. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Dividends.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At the discretion of the Committee, Participants may be entitled to receive payments equivalent
to any dividends declared with respect to Common Stock referenced in grants of Restricted Stock Units but only following the close of the applicable Restriction Period and then only if the underlying
Common Stock shall have been earned. Unless the Committee shall provide otherwise, any such dividend equivalents shall be paid, if at all, without interest or other earnings. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Effect of Termination of Employment, Consulting or Board Member Relationship.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise determined by
the Committee at or after grant and subject to the applicable provisions of the Award Agreement, if the applicable original grantee's association with the Company or any of its Affiliates as an
employee, director or consultant ends for any reason or no reason during the Restriction Period, regardless of whether the end of such association is effected by the Company, any such Affiliate or
such original grantee (whether voluntarily or involuntarily, including because an entity with which such original grantee has any such association ceases to be an Affiliate of the Company), and
immediately following the end of any such association, such original grantee is not associated with the Company or any of its Affiliates as an employee, director or consultant, or if such original
grantee dies, then all outstanding Restricted Stock Units initially granted to such original grantee that are still subject to Risk of Forfeiture, whether then held by such original grantee or any
other Participant, shall be forfeited or otherwise subject to return to the Company in accordance with the terms of the applicable Award Agreement; provided, however, that military or sick leave or
other bona fide leave shall not be deemed a termination of employment, if it does not exceed the longer of ninety (90)&nbsp;days or the period during which the absent original grantee's reemployment
rights, if any, are guaranteed by statute or by contract. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=79,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=932162,FOLIO='A-10',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_11"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Transferability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in this subsection&nbsp;(e), Restricted Stock Units shall
not be transferable, and no Restricted Stock Unit or interest therein may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated. The applicable Award Agreement or the
Committee (at or after the grant of a Restricted Stock Unit) may provide that such Restricted Stock Unit may be transferred by the applicable Participant to a family member; provided, however, that
any such transfer is without payment of any consideration whatsoever and that no transfer of a Restricted Stock Unit shall be valid unless first approved by the Committee, acting in its sole
discretion, unless such transfer is permitted under the applicable Award Agreement. For this purpose, "family member" means any child, stepchild, grandchild, parent, stepparent, spouse, former spouse,
sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the applicable Participant's
household (other than a tenant or employee), a trust in which the foregoing persons and/or the applicable Participant have more than fifty percent (50%) of the beneficial interests, a foundation in
which the foregoing persons and/or the applicable Participant control the management of assets, and any other entity in which these persons and/or the applicable Participant own more than fifty
percent (50%) of the voting interests. The Committee may at any time or from time to time delegate to one or more officers of the Company the authority to permit transfers of Restricted Stock Units to
third parties pursuant to this subsection&nbsp;(e), which authorization shall be exercised by such officer or officers in accordance with guidelines established by the Committee at any time and from
time to time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights Pending Close of Applicable Restriction Period.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No person holding Restricted Stock Units shall be
deemed for any purpose to be a stockholder of the Company with respect to any of the shares of Common Stock subject to such Restricted Stock Units, except to the extent that the Restricted Period with
respect to such Restricted Stock Units shall have closed and, in addition, a certificate shall have been issued for such shares of Common Stock and delivered to such person or his agent. Shares of
Common Stock subject to Restricted Stock Units shall be issued and outstanding only if and to the extent that a stock certificate representing such shares has been issued and delivered in accordance
with the provisions of this Section&nbsp;7.3. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Stock Grants.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;In General.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock Grants shall be issued for such consideration, in cash, other property or services, or any
combination thereof, as is determined by the Committee. Without limiting the generality of the foregoing, Stock Grants may be awarded in such circumstances as the Committee deems appropriate,
including without limitation in recognition of significant contributions to the success of the Company or its Affiliates or in lieu of compensation otherwise already due. Stock Grants shall be made
without forfeiture conditions of any kind. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Certificates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each Participant receiving a Stock Grant shall be issued a stock certificate in
respect of such Stock Grant. Such certificate shall be registered in the name of such Participant, and, if applicable, shall bear an appropriate legend referring to the terms, conditions, and
restrictions applicable to such Award substantially in the following form: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
transferability of this certificate and the shares represented by this certificate are subject to the terms and conditions of the Amicus Therapeutics,&nbsp;Inc. 2007 Equity
Incentive Plan. A copy of such Plan is on file in the offices of Amicus Therapeutics,&nbsp;Inc. </FONT></P>

</UL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Performance Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Performance Awards Generally.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may grant Performance Awards in accordance with this Section.
Performance Awards may be denominated as a number of shares of Common Stock, or specified number of other Awards (or a combination thereof) which may be earned upon achievement or satisfaction of
Performance Goals, as specified by the Committee. In addition, the Committee may specify that any other Award shall constitute a Performance Award by </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=80,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=612664,FOLIO='A-11',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_12"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>conditioning
the vesting or settlement of the Award upon the achievement or satisfaction of such Performance Goals, which the Committee may use in its discretion from time to time. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Qualified Performance-Based Compensation Under Section&nbsp;162(m).</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Performance Awards intended to
constitute "qualified performance-based compensation" under Section&nbsp;162(m) of the Code may be granted by the Committee and will be subject to the terms of this Section. When a Performance Award
is made, the Committee shall establish in writing (i)&nbsp;the objective performance goals that must be met, (ii)&nbsp;the period during which performance will be measured, (iii)&nbsp;the
maximum amounts that may be paid if the performance goals are met, and (iv)&nbsp;any other conditions that the Committee deems appropriate and consistent with the requirements of
section&nbsp;162(m) of the Code for "qualified performance-based compensation." The grant, vesting and/or settlement of a Performance Award subject to this Section will be contingent upon
achievement of one or more Performance Goals. The Committee shall establish the applicable Performance Goals in writing either before the beginning of the Performance Period or during a Performance
Period ending no later than the earlier of (i)&nbsp;90&nbsp;days after the beginning of the Performance Period or (ii)&nbsp;the date on which 25% of the Performance Period has been completed, or
such other date as may be required or permitted under applicable regulations under section&nbsp;162(m) of the Code. The performance goals shall satisfy the requirements for "qualified
performance-based compensation," including the requirement that the achievement of the goals be substantially uncertain at the time they are established and that the performance goals be established
in such a way that a third party with knowledge of the relevant facts could determine whether and to what extent the performance goals have been met. The Committee shall not have discretion to
increase the amount of compensation that is payable, but may reduce the amount of compensation that is payable, pursuant to Awards identified by the Committee as "qualified performance-based
compensation." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to Performance Goals.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may Performance Goals to take into account, in any objective
manner specified by the Committee, the impact of one or more of the following: (A)&nbsp;gain or loss from all or certain claims and/or litigation and insurance recoveries, (B)&nbsp;the impairment
of tangible or intangible assets, (C)&nbsp;stock-based compensation expense, (D)&nbsp;extraordinary, unusual or infrequently occurring events reported in the Company's public filings,
(E)&nbsp;restructuring activities reported in the Company's public filings, (F)&nbsp;investments, dispositions or acquisitions, (G)&nbsp;loss from the disposal of certain assets, (H)&nbsp;gain
or loss from the early extinguishment, redemption, or repurchase of debt, (I)&nbsp;cash or non-cash charges related to site closing expenses, (J)&nbsp;changes in accounting principles, or
(K)&nbsp;any other item, event or circumstance that would not cause an Award to fail to constitute "qualified performance-based compensation" under Section&nbsp;162(m) of the. Such an adjustment
may relate to the Company or to any subsidiary, division or other operational unit of the Company or its Affiliates, as determined by the Committee at the time the Performance Goals are established.
Any adjustment shall be determined in accordance with generally accepted accounting principles and standards, unless such other objective method of measurement is designated by the Committee at the
time Performance Goals are established. In addition, adjustments will be made as necessary to any Performance Goals related to the Company's stock to reflect changes in corporate capitalization,
including a recapitalization, stock split or combination, stock dividend, spin-off, merger, reorganization or other similar event or transaction affecting the Company's stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Other Terms of Performance Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may specify other terms pertinent to a Performance Award in
the applicable Award Agreement, including terms relating to the treatment of that Award in the event of a Change in Control prior to the end of the Performance Period. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Certification of Results.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Committee shall certify the results regarding any Performance Goals for the
Performance Period specified in the Award Agreement after the Performance Period ends. The Committee shall determine the amount, if any, to be paid pursuant to each Award based on </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=4,SEQ=81,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=503765,FOLIO='A-12',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_13"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>the
achievement of the applicable Performance Goals and the satisfaction of all other terms of the Award Agreement. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Awards to Participants Outside the United States.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may modify the terms of any Award under the
Plan granted to a Participant who is, at the time of grant or during the term of the Award, resident or primarily employed outside of the United States in any manner deemed by the Committee to be
necessary or appropriate in order that such Award shall conform to laws, regulations, and customs of the country in which the Participant is then resident or primarily employed, or so that the
value and other benefits of the Award to the Participant, as affected by foreign tax laws and other restrictions applicable as a result of the Participant's residence or employment abroad, shall be
comparable to the value of such an Award to a Participant who is resident or primarily employed in the United States. An Award may be modified under this Section&nbsp;7.4 in a manner that is
inconsistent with the express terms of the Plan, so long as such modifications will not contravene any applicable law or regulation. The Committee may establish supplements to, or amendments,
restatements, or alternative versions of the Plan for the purpose of granting and administrating any such modified Award. No such modification, supplement, amendment, restatement or alternative
version may increase the share limit of Section&nbsp;4. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustment Provisions  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Adjustment for Corporate Actions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the provisions of Section&nbsp;8.2, if subsequent to the
Effective Date, the outstanding shares of Common Stock (or any other securities covered by the Plan by reason of the prior application of this Section) are increased, decreased, or exchanged for a
different number or kind of shares or other securities, or if additional shares or new or different shares or other securities are distributed with respect to such shares of Common Stock or other
securities, through merger, consolidation, sale of all or substantially all the property of the Company, reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock
split, or other distribution with respect to such shares of Common Stock, or other securities, an appropriate and proportionate adjustment will be made in (i)&nbsp;the maximum numbers and kinds of
shares provided in Section&nbsp;4, (ii)&nbsp;the numbers and kinds of shares or other securities subject to the then outstanding Awards, (iii)&nbsp;the exercise price for each share or other
unit of any other securities subject to then outstanding Options (without change in the aggregate purchase price as to which such Options remain exercisable), and (iv)&nbsp;the Performance Goal
applicable to any outstanding Performance Award. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Change of Control.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the applicable provisions of the Award Agreement, in the event of a Change of
Control, the Committee shall have the discretion, exercisable in advance of, at the time of, or (except to the extent otherwise provided below) at any time after, the Change of Control, to provide for
any or all of the following (subject to and upon such terms as the Committee may deem appropriate): (A)&nbsp;the Acceleration, in whole or in part, of any or all outstanding Options (including
Options that are assumed or replaced pursuant to clause&nbsp;(D) below) that are not exercisable in full at the time the Change of Control, such Acceleration to become effective at the time of the
Change of Control, or at such time following the Change of Control that the employment, consulting or Board member relationship of the applicable Optionee or Optionees with the Company and its
Affiliates terminates, or at such other time or times as the Committee shall determine; (B)&nbsp;the lapse or termination of the Risk of Forfeiture (including, without limitation, any or all of the
Company's repurchase rights) with respect to outstanding Awards of Restricted Stock, such lapse or termination to become effective at the time of the Change of Control, or at such time following the
Change of Control that the employment, consulting or Board member relationship with the Company and its Affiliates of the Participant or Participants that hold such Awards of Restricted Stock (or the
person to whom such Awards of Restricted Stock were initially granted) terminates, or at such other time or times as the Committee shall determine; (C)&nbsp;the lapse or termination of the Risk of
Forfeiture with respect to any or all outstanding Awards of Restricted Stock Units (including Restricted Stock Units
that are assumed or replaced pursuant to clause&nbsp;(D) below), such lapse or termination to become effective at the time of the Change of Control, or at such time following the Change of Control </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=82,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=146551,FOLIO='A-13',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_14"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>that
the employment, consulting or Board member relationship with the Company and its Affiliates of the Participant or Participants that hold such Awards of Restricted Stock Units (or the person to
whom such Awards of Restricted Stock Units were initially granted) terminates, or at such other time or times as the Committee shall determine; (D)&nbsp;the assumption of outstanding Options or
Restricted Stock Units, or the substitution of outstanding Options or Restricted Stock Units with equivalent options or equivalent restricted stock units, as the case may be, by the acquiring or
succeeding corporation or entity (or an affiliate thereof); (E)&nbsp;the termination of all Options (other than Options that are assumed or substituted pursuant to clause&nbsp;(D) above) that
remain outstanding at the time of the consummation of the Change of Control, provided that, the Committee shall have made the determination to effect such termination prior to the consummation of the
Change of Control and the Committee shall have given, or caused to be given, to all Participants written notice of such potential termination at least five business days prior to the consummation of
the Change of Control, and provided, further, that, if the Committee shall have determined in its sole and absolute discretion that the Company make payment or provide consideration to the holders of
such terminated Options on account of such termination, which payment or consideration shall be on such terms and conditions as the Committee shall have determined (and which could consist of, in the
Committee's sole and absolute discretion, payment to the applicable Optionee or Optionees of an amount of cash equal to the difference between the Market Value of the shares of Common Stock for which
the Option is then exercisable and the aggregate exercise price for such shares under the Option or cancellation for no payment (or other consideration with respect to Options for which the exercise
price exceeds the Market Value of the shares of Common Stock underlying the Option), then the Company shall be required to make, or cause to be made, such payment or provide, or cause to be provided,
such consideration in accordance with the terms and conditions so determined by the Committee, otherwise the Company shall not be required to make any payment or provide any consideration in
connection with, or as a result of, the termination of Options pursuant to the foregoing provisions of this clause&nbsp;(E); (F)&nbsp;the termination of all Restricted Stock Units (other than
Restricted Stock Units that are assumed or substituted pursuant to clause&nbsp;(D) above) that remain outstanding at the time of the consummation of the Change of Control, provided that, if the
Committee shall have determined in its sole and absolute discretion that the Company make payment or provide consideration to the holders of such terminated Restricted Stock Units on account of such
termination, which payment or consideration shall be on such terms and conditions as the Committee shall have determined (and which could consist of, in the Committee's sole and absolute discretion,
payment to the applicable Participant or Participants of an amount of cash equal to the Market Value of the shares of Common Stock subject to the terminated Restricted Stock Units), then the Company
shall be required to make such payment or provide such consideration in accordance with the terms and conditions so determined by the Committee, otherwise the Company shall not be required to make any
payment or provide any consideration in connection with, or as a result of, the termination of Restricted Stock Units pursuant to the foregoing provisions of this clause&nbsp;(F) and/or
(G)&nbsp;the reduction of any Performance Period applicable to a Performance Award or the satisfaction (or the failure to of such satisfaction) of any applicable Performance Goals with respect to
Performance Awards. The provisions of this Section&nbsp;8.2 shall not be construed as to limit or restrict in any way the Committee's general authority under Sections&nbsp;7.1(d) or 7.2(d) hereof
to Accelerate Options in whole or in part at any time or to waive or terminate at any time any Risk of Forfeiture applicable to shares of Restricted Stock or Restricted Stock Units. Each outstanding
Award that is
assumed in connection with a Change of Control, or is otherwise to continue in effect subsequent to a Change of Control, will be appropriately adjusted, immediately after the Change of Control, as to
the number and class of securities and the price at which it may be exercised in accordance with Section&nbsp;8.1. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Dissolution or Liquidation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon dissolution or liquidation of the Company, each outstanding Option shall
terminate, but the Optionee (if at the time he or she has an employment, consulting or Board member relationship with the Company or any of its Affiliates) shall have the right, immediately prior to
such dissolution or liquidation, to exercise the Option to the extent exercisable on the date of such dissolution or liquidation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=83,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=267584,FOLIO='A-14',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_15"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Related Matters.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any adjustment in Awards made pursuant to this Section&nbsp;8 shall be determined and
made, if at all, by the Committee and shall include any correlative modification of terms, including of Option exercise prices, rates of vesting or exercisability, Risks of Forfeiture, adjustment of
Performance Goals and/or Performance Periods and applicable repurchase prices for Restricted Stock, which the Committee may deem necessary or appropriate so as to ensure that the rights of the
Participants in their respective Awards are not substantially diminished nor enlarged as a result of the adjustment and corporate action other than as expressly contemplated in this Section&nbsp;8.
No fraction of a share shall be purchasable or deliverable upon exercise, but in the event any adjustment hereunder of the number of shares covered by an Award shall cause such number to include a
fraction of a share, such number of shares shall be adjusted to the nearest smaller whole number of shares. No adjustment of an Option exercise price per share pursuant to this Section&nbsp;8 shall
result in an exercise price which is less than the par value of the Common Stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Settlement of Awards  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Violation of Law.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provision of the Plan or the relevant Award Agreement, if, at
any time, in the reasonable opinion of the Company, the issuance of shares of Common Stock covered by an Award may constitute a violation of law, then the Company may delay such issuance and the
delivery of a certificate for such shares until (i)&nbsp;approval shall have been obtained from such governmental agencies, other than the Securities and Exchange Commission, as may be required
under any applicable law, rule, or regulation and (ii)&nbsp;in the case where such issuance would constitute a violation of a law administered by or a regulation of the Securities and Exchange
Commission, one of the following conditions shall have been satisfied: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;the
shares are at the time of the issue of such shares effectively registered under the Securities Act; or </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;the
Company shall have determined, on such basis as it deems appropriate (including an opinion of counsel in form and substance satisfactory to the Company) that the
sale, transfer, assignment, pledge, encumbrance or other disposition of such shares or such beneficial interest, as the case may be, does not require registration under the Securities Act or any
applicable state securities laws. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Corporate Restrictions on Rights in Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any Common Stock to be issued pursuant to Awards granted under
the Plan shall be subject to all restrictions upon the transfer thereof which may be now or hereafter imposed by the Certificate of Incorporation and the By-laws of the Company, each as amended and in
effect from time to time. Whenever Common Stock is to be issued pursuant to an Award, if the Committee so directs at the time of grant (or, if such Award is an Option, at any time prior to the
exercise thereof), the Company shall be under no obligation, notwithstanding any other provision of the Plan or the relevant Award Agreement to the contrary, to issue such shares until such time, if
ever, as the recipient of the Award (and any person who exercises any Option, in whole or in part), shall have become a party to and bound by any agreement that the Committee shall require in its sole
discretion. In addition, any Common Stock to be issued pursuant to Awards granted under the Plan shall be subject to all stop-transfer orders and other restrictions as the Committee may deem advisable
under the rules, regulations and other requirements of any stock exchange upon which the Common Stock is then listed, and any applicable federal or state securities laws, and the Committee may cause a
legend or legends to be put on any such certificates to make appropriate reference to such restrictions. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Investment Representations.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall be under no obligation to issue any shares covered by an Award
unless the shares to be issued pursuant to Awards granted under the Plan have been effectively registered under the Securities Act or the Participant shall have made such written representations to
the Company (upon which the Company believes it may reasonably rely) as the Company may deem necessary or appropriate for purposes of confirming that the issuance of such shares </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=84,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=15351,FOLIO='A-15',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_16"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>will
be exempt from the registration requirements of that Act and any applicable state securities laws and otherwise in compliance with all applicable laws, rules and regulations, including but not
limited to that the Participant is acquiring shares for his or her own account for the purpose of investment and not with a view to, or for sale in connection with, the distribution of any such
shares. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Registration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If the Company shall deem it necessary or desirable to register under the Securities Act or
other applicable statutes any shares of Common Stock issued or to be issued pursuant to Awards granted under the Plan, or to qualify any such shares of Common Stock for exemption from the Securities
Act or other applicable statutes, then the Company shall take such action at its own expense. The Company may require from each recipient of an Award, or each holder of shares of Common Stock acquired
pursuant to the Plan, such information in writing for use in any registration statement, prospectus, preliminary prospectus or offering circular as is reasonably necessary for such purpose and may
require reasonable indemnity to the Company and its officers and directors from such holder against all losses, claims, damage and liabilities arising from such use of the information so furnished and
caused by any untrue statement of any material fact therein or caused by the omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading
in the light of the circumstances under which they were made. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.5</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Lock-Up.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Without the prior written consent of the Company or the managing underwriter in any public offering
of shares of Common Stock, no Participant shall sell, make any short sale of, loan, grant any option for the purchase of, pledge or otherwise encumber, or otherwise dispose of, any shares of Common
Stock during the one hundred-eighty (180)&nbsp;day period commencing on the effective date of the registration statement relating to any underwritten public offering of securities of the Company.
The foregoing restrictions are intended and shall be construed so as to preclude any Participant from engaging in any hedging or other transaction that is designed to or reasonably could be expected
to lead to or result in, a sale or disposition of any shares of Common Stock during such period even if such shares of Common Stock are or would be disposed of by someone other than such Participant.
Such prohibited hedging or other transactions would include, without limitation, any short sale (whether or not against the box) or any purchase, sale or grant of any right (including without
limitation any put or call option) with respect to any shares of Common Stock or with respect to any security that includes, relates to, or derives any significant part of its value from any shares of
Common Stock. Without limiting the generality of the foregoing provisions of this Section&nbsp;9.5, if, in connection with any underwritten public offering of securities of the Company, the managing
underwriter of such offering requires that the Company's directors and officers enter into a lock-up agreement containing provisions that are more restrictive than the provisions set forth in the
preceding sentence, then (a)&nbsp;each Participant (regardless of whether or not such Participant has complied or complies with the provisions of clause&nbsp;(b) below) shall be bound by, and
shall be deemed to have agreed to, the same lock-up terms as those to which the Company's directors and officers are required to adhere; and (b)&nbsp;at the request of the Company or such managing
underwriter, each Participant shall execute and deliver a lock-up agreement in form and substance equivalent to that which is required to be executed by the Company's directors and officers. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Placement of Legends; Stop Orders; Etc.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each share of Common Stock to be issued pursuant to Awards granted
under the Plan may bear a reference to the investment representations made in accordance with Section&nbsp;9.3 in addition to any other applicable restrictions under the Plan, the terms of the Award
and, if applicable, under any agreement between the Company and any Optionee and/or Participant, and to the fact that no registration statement has been filed with the Securities and Exchange
Commission in respect to such shares of Common Stock. All certificates for shares of Common Stock or other securities delivered under the Plan shall be subject to such stock transfer orders and other
restrictions as the Committee may deem advisable under the rules, regulations, and other requirements of any stock exchange upon which the Common Stock is then listed, and any applicable federal or
state securities law, and the Committee may cause a legend or legends to be placed on any such certificates to make appropriate reference to such restrictions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=85,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=278473,FOLIO='A-16',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_17"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.7</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Tax Withholding.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Whenever shares of Common Stock are issued or to be issued pursuant to Awards granted under
the Plan, the Company shall have the right to require the recipient to remit to the Company an amount sufficient to satisfy federal, state, local or other withholding tax requirements if, when, and to
the extent required by law (whether so required to secure for the Company an otherwise available tax deduction or otherwise) prior to the delivery of any certificate or certificates for such shares.
The obligations of the Company under the Plan shall be conditional on satisfaction of all such withholding obligations and the Company shall, to the extent permitted by law, have the right to deduct
any such taxes from any payment of any kind otherwise due to the recipient of an Award. However, in such cases Participants may elect, subject to the approval of the Committee, acting in its sole
discretion, to satisfy an applicable withholding requirements, in whole or in part, by having the Company withhold shares to satisfy their tax obligations. Participants may only elect to have shares
of their Common Stock withheld having a Market Value on the date the tax is to be determined equal to the minimum statutory total tax which could be imposed on the transaction. All elections shall be
irrevocable, made in writing, signed by the Participant, and shall be subject to any restrictions or limitation that the Committee deems appropriate. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>10.&nbsp;&nbsp;&nbsp;Reservation of Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company shall at all times during the term of the Plan and any outstanding Options granted hereunder reserve or otherwise keep available such number of shares
of Common Stock as will be sufficient to satisfy the requirements of the Plan (if then in effect) and such Options and shall pay all fees and expenses necessarily incurred by the Company in connection
therewith. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>11.&nbsp;&nbsp;&nbsp;No Special Service Rights  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained in the Plan or in any Award Agreement shall confer upon any recipient of an Award any right with respect to the continuation of his or her
employment, consulting or Board member relationship or other association with the Company (or any Affiliate), or interfere in any way with the right of the Company (or any Affiliate), subject to the
terms of any separate employment, consulting or Board member agreement or provision of law or corporate articles or by-laws to the contrary, at any time to terminate such employment, consulting or
Board member agreement or to increase or decrease, or otherwise adjust, the other terms and conditions of the recipient's employment, consulting or Board member relationship or other association with
the Company and its Affiliates. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>12.&nbsp;&nbsp;&nbsp;Nonexclusivity of the Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the adoption of the Plan by the Board nor the submission of the Plan to the stockholders of the Company shall be construed as creating any limitations on
the power of the Board to adopt such other incentive arrangements as it may deem desirable, including without limitation, the granting of stock options, restricted stock and restricted stock units
other than under the Plan, and such arrangements may be either applicable generally or only in specific cases. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>13.&nbsp;&nbsp;&nbsp;Termination and Amendment of the Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board may at any time terminate the Plan or make such amendments or modifications of the Plan as it shall deem advisable. In the event of the termination of
the Plan, the terms of the Plan shall survive any such termination with respect to any Award that is outstanding on the date of such termination, unless the holder of such Award agrees in writing to
terminate such Award or to terminate all or any of the provisions of the Plan that apply to such Award. Unless the Board otherwise expressly provides, any amendment or modification of the Plan shall
affect the terms of any Award outstanding on the date of such amendment or modification as well as the terms of any Award made from and after the date of such amendment or modification; </FONT> <FONT SIZE=2><I>provided, however</I></FONT><FONT
SIZE=2> , that, except to the extent otherwise provided in the last sentence of this paragraph, (i)&nbsp;no amendment or modification of the
Plan shall apply to any Award that is outstanding on the date of such amendment or modification if such amendment or modification would </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=86,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=134619,FOLIO='A-17',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_18"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>reduce
the number of shares subject to such Award, increase the purchase price applicable to shares subject to such Award or materially adversely affect the provisions applicable to such Award that
relate to the vesting or exercisability of such Award or of the shares subject to such Award, (ii)&nbsp;no amendment or modification of the Plan shall apply to any Incentive Option that is
outstanding on the date of such amendment or modification if such amendment or modification would result in such Incentive Option no longer being treated as an "incentive stock option" within the
meaning of Section&nbsp;422 of the Code and (iii)&nbsp;no amendment or modification of the Plan shall apply to any Award that is outstanding on the date of such amendment or modification unless
such amendment or modification of the Plan shall also apply to all other Awards outstanding on the date of such amendment or modification. In the event of any amendment or modification of the Plan
that is described in clause&nbsp;(i), (ii)&nbsp;or (iii)&nbsp;of the foregoing proviso, such amendment or modification of the Plan shall apply to any Award outstanding on the date of such
amendment or modification only if the recipient of such Award consents in writing thereto. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Committee may amend or modify, prospectively or retroactively, the terms of any outstanding Award without amending or modifying the terms of the Plan itself, </FONT> <FONT SIZE=2><I>provided that</I></FONT><FONT SIZE=2> as amended or modified such
Award is consistent with the terms of the Plan as in effect at the time of the amendment or modification of
such Award, but no such amendment or modification of such Award shall, without the written consent of the recipient of such Award, reduce the number of shares subject to such Award, increase the
purchase price applicable to shares subject to such Award, adversely affect the provisions applicable to such Award that relate to the vesting or exercisability of such Award or of the shares subject
to such Award, or otherwise materially adversely affect the terms of such Award (except for amendments or modifications to the terms of such Award or of the stock subject to such Award that are
expressly permitted by the terms of the Plan or that result from any amendment or modification of the Plan in accordance with the provisions of the first paragraph of this Section&nbsp;13), or, if
such Award is an Incentive Option, result in such Incentive Option no longer being treated as an "incentive stock option" within the meaning of Section&nbsp;422 of the Code. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
the approval of the Company's stockholders, the Committee will not, directly or indirectly, reduce the exercise price of an outstanding Option (other than in accordance with the
adjustment provisions of Section&nbsp;8.1). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>14.&nbsp;&nbsp;&nbsp;Interpretation of the Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any conflict between the provisions of this Plan and the provisions of any applicable Award Agreement, the provisions of this Plan shall control,
except if and to the extent that the conflicting provision in such Award Agreement was authorized and approved by the Committee at the time of the grant of the Award evidenced by such Award Agreement
or is ratified by the Committee at any time subsequent to the grant of such Award, in which case the conflicting provision in such Award Agreement shall control. Without limiting the generality of the
foregoing provisions of this Section&nbsp;14, insofar as possible the provisions of the Plan and such Award Agreement shall be construed so as to give full force and effect to all such provisions.
In the event of any conflict between the provisions of this Plan and the provisions of any other agreement between the Company and the Optionee and/or Participant, the provisions of such agreement
shall control except as required to fulfill the intention that this Plan constitute an incentive stock option plan within the meaning of Section&nbsp;422 of the Code, but insofar as possible the
provisions of the Plan and any such agreement shall be construed so as to give full force and effect to all such provisions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>15.&nbsp;&nbsp;&nbsp;Notices and Other Communications  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any notice, demand, request or other communication hereunder to any party shall be deemed to be sufficient if contained in a written instrument delivered in
person or duly sent by first class registered, certified or overnight mail, postage prepaid, or telecopied with a confirmation copy by regular, certified or overnight mail, addressed or telecopied, as
the case may be, (i)&nbsp;if to the recipient of an Award, at his or her </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=87,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=776786,FOLIO='A-18',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_19"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>residence
address last filed with the Company and (ii)&nbsp;if to the Company, at its principal place of business, addressed to the attention of its Chief Executive Officer, or to such other address
or telecopier number, as the case may be, as the addressee may have designated by notice to the addressor. All such notices, requests, demands and other communications shall be deemed to have been
received: (i)&nbsp;in the case of personal delivery, on the date of such delivery; (ii)&nbsp;in the case of mailing, when received by the addressee; and (iii)&nbsp;in the case of facsimile
transmission, when confirmed by facsimile machine report. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>16.&nbsp;&nbsp;&nbsp;Governing Law  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Plan and all Award Agreements and actions taken thereunder shall be governed, interpreted and enforced in accordance with the laws of the State of New Jersey,
without regard to the conflict of laws principles thereof. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>17.&nbsp;&nbsp;&nbsp;Effective Date  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amended and Restated 2007 Equity Incentive Plan was approved by the Board on April&nbsp;11, 2018 (the Effective Date") and approved by the stockholders of
the Company effective June&nbsp;7, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=88,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=175883,FOLIO='A-19',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">- 1 AMICUS   THERAPEUTICS, INC. 1 Cedar Brook Drive Cranbury, NJ 08512 THIS PROXY IS   SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned stockholder of   Amicus Therapeutics, Inc. hereby appoints Bradley L. Campbell and Ellen   Rosenberg as proxies, each with full power of substitution, to represent and   vote as designated on the reverse side, all the shares of Common Stock of   Amicus Therapeutics, Inc. held of record by the undersigned on April 16,   2018, and which the undersigned would be entitled to vote if personally   present at the Annual Meeting of Stockholders to be held at the offices of   Amicus Therapeutics, Inc., located at 1 Cedar Brook Drive, Cranbury, New   Jersey, 08512 on June 7, 2018, or any adjournment or postponement thereof.   This proxy is revocable and the undersigned may revoke it at any time prior   to the Annual Meeting by giving written notice of such revocation to the   Secretary of Amicus Therapeutics, Inc. prior to the meeting or by filing with   the Secretary of Amicus Therapeutics, Inc. prior to the meeting a later-dated   proxy. Should the undersigned be present and want to vote in person at the   Annual Meeting, or at any postponement or adjournment thereof, the   undersigned may revoke this proxy by giving written notice of such revocation   to the Secretary of Amicus Therapeutics, Inc. on a form provided at the   Annual Meeting. The undersigned hereby acknowledges receipt of a notice of   Annual Meeting of Stockholders of Amicus Therapeutics, Inc. called for June   7, 2018 and the Proxy Statement for the Annual Meeting, each dated April 24,   2018, prior to the signing of this proxy. (Continued and to be signed on the   reverse side) 14475 1.1 COMMENTS: </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1008" height="1305" src="g28372bgi001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=89,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=623547,FOLIO='',FILE="DISK130:[18ZAG2.18ZAG13702]2837-2-BG_ZAG13702.CHC",USER="VRIVERA",CD='Apr 12 12:14 2018' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">ANNUAL MEETING   OF STOCKHOLDERS OF Amicus Therapeutics, Inc. June 7, 2018 GO GREEN e-Consent   makes it easy to go paperless. With e-Consent, you can quickly access your   proxy material, statements and other eligible documents online, while   reducing costs, clutter and paper waste. Enroll today via   www.astfinancial.com to enjoy online access. NOTICE OF INTERNET AVAILABILITY   OF PROXY MATERIAL: The Notice of Meeting, Proxy Statement, Proxy Card are   available at http://www.astproxyportal.com/ast/15417/ Please sign, date and   mail your proxy card in the envelope provided as soon as possible. Please   detach along perforated line and mail in the envelope provided.   20230030303000000000 1 060718 250,000,000 to 500,000,000 changes to the   registered name(s) on the account may not be submitted via Note: Please sign   exactly as your name or names appear on this Proxy. When shares are held   jointly, each holder should sign. When signing as executor, administrator,   attorney, trustee or guardian, please give full title as such. If the signer   is a corporation, please sign full corporate name by duly authorized officer,   giving full title as such. If signer is a partnership, please sign in   partnership name by authorized person. THE BOARD OF DIRECTORS RECOMMENDS A   VOTE &#147;FOR&#148; THE ELECTION OF DIRECTORS, AND &#147;FOR&#148; PROPOSALS 2, 3, 4 AND 5.   PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK   YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE x 1. Election of Directors:   NOMINEES: FOR ALL NOMINEESO Donald J. Hayden, Jr. O Craig Wheeler WITHHOLD   AUTHORITY FOR ALL NOMINEES FOR ALL EXCEPT (See instructions below)   INSTRUCTIONS: To withhold authority to vote for any individual nominee(s),   mark &#147;FOR ALL EXCEPT&#148; and fill in the circle next to each nominee you wish to   withhold, as shown here: FOR AGAINST ABSTAIN 2. Proposal to approve an   amendment to our Restated Certificate of Incorporation to increase the number   of shares of common stock, par value $0.01 per share, that we are authorized   to issue from 3. Approval of the amendment to the Restated 2007 Equity   Incentive Plan to add 5,000,000 shares to the equity pool 4. Ratify the   appointment of Ernst &amp; Young LLP as the Company&#146;s independent registered   public accounting firm for the fiscal year ending December 31, 2018 5.   Approval, on an advisory basis, the Company&#146;s executive compensation To   change the address on your account, please check the box at right and   indicate your new address in the address space above. Please note that this   method. Signature of Stockholder Date: Signature of StockholderDate: </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1008" height="1208" src="g28372bii001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=90,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=296340,FOLIO='',FILE="DISK130:[18ZAG2.18ZAG13702]2837-2-BI_ZAG13702.CHC",USER="VRIVERA",CD='Apr 12 14:13 2018' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">ANNUAL MEETING   OF STOCKHOLDERS OF Amicus Therapeutics, Inc. June 7, 2018 INTERNET - Access   &#147;www.voteproxy.com&#148; and follow the on-screen instructions or scan the QR code   with your smartphone. Have your proxy card available when you access the web   page, and use the Company Number and Account Number shown on your proxy card.   TELEPHONE - Call toll-free 1-800-PROXIES (1-800-776-9437) in the United   States or 1-718-921-8500 from foreign countries from any touch-tone telephone   and follow the instructions. Have your proxy card available when you call and   use the Company Number and Account Number shown on your proxy card. Vote   online/phone until 11:59 PM EST the day before the meeting. MAIL - Sign, date   and mail your proxy card in the envelope provided as soon as possible. IN   PERSON - You may vote your shares in person by attending the Annual Meeting.   GO GREEN - e-Consent makes it easy to go paperless. With e-Consent, you can   quickly access your proxy material, statements and other eligible documents   online, while reducing costs, clutter and paper waste. Enroll today via   www.astfinancial.com to enjoy online access. Please detach along perforated   line and mail in the envelope provided IF you are not voting via telephone or   the Internet. 20230030303000000000 1 060718 250,000,000 to 500,000,000   changes to the registered name(s) on the account may not be submitted via   Note: Please sign exactly as your name or names appear on this Proxy. When   shares are held jointly, each holder should sign. When signing as executor,   administrator, attorney, trustee or guardian, please give full title as such.   If the signer is a corporation, please sign full corporate name by duly   authorized officer, giving full title as such. If signer is a partnership,   please sign in partnership name by authorized person. THE BOARD OF DIRECTORS   RECOMMENDS A VOTE &#147;FOR&#148; THE ELECTION OF DIRECTORS, AND &#147;FOR&#148; PROPOSALS 2, 3,   4 AND 5. PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.   PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE x 1. Election of   Directors: NOMINEES: FOR ALL NOMINEESO Donald J. Hayden, Jr. O Craig Wheeler   WITHHOLD AUTHORITY FOR ALL NOMINEES FOR ALL EXCEPT (See instructions below)   INSTRUCTIONS: To withhold authority to vote for any individual nominee(s),   mark &#147;FOR ALL EXCEPT&#148; and fill in the circle next to each nominee you wish to   withhold, as shown here: FOR AGAINST ABSTAIN 2. Proposal to approve an   amendment to our Restated Certificate of Incorporation to increase the number   of shares of common stock, par value $0.01 per share, that we are authorized   to issue from 3. Approval of the amendment to the Restated 2007 Equity   Incentive Plan to add 5,000,000 shares to the equity pool 4. Ratify the   appointment of Ernst &amp; Young LLP as the Company&#146;s independent registered   public accounting firm for the fiscal year ending December 31, 2018 5.   Approval, on an advisory basis, the Company&#146;s executive compensation To   change the address on your account, please check the box at right and   indicate your new address in the address space above. Please note that this   method. Signature of Stockholder Date: Signature of StockholderDate: NOTICE   OF INTERNET AVAILABILITY OF PROXY MATERIAL: The Notice of meeting, proxy   statement and proxy card are available at   http://www.astproxyportal.com/ast/15417/ COMPANY NUMBER ACCOUNT NUMBER PROXY   VOTING INSTRUCTIONS </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1038" height="1305" src="g28372bki001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=91,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=735197,FOLIO='',FILE="DISK130:[18ZAG2.18ZAG13702]2837-2-BK_ZAG13702.CHC",USER="VRIVERA",CD='Apr 12 14:18 2018' -->

<BR>
<P><br><A NAME="18ZAG13701_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_be13701_1">NOTICE OF 2018 ANNUAL MEETING OF STOCKHOLDERS</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc13701_1">IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING TO BE HELD ON JUNE 7, 2018.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc13701_2">THE PROXY STATEMENT AND FORM OF PROXY FOR OUR 2018 ANNUAL MEETING OF STOCKHOLDERS AND OUR ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2017 ARE AVAILABLE AT: www.sec.gov , through the Investor
Relations section of our web site at www.amicusrx.com or at http://www.astproxyportal.com/ast/15417/</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc13701_3">PROPOSAL NO. 1&#151;ELECTION OF DIRECTORS</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de13701_1">AMICUS CORPORATE GOVENANCE</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dg13701_1">COMPENSATION DISCUSSION AND ANALYSIS&#151;2017</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dk13701_1">Summary Compensation Table</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq13701_1">COMPENSATION COMMITTEE REPORT</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq13701_2">SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq13701_3">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ds13701_1">POLICIES AND PROCEDURES FOR RELATED PARTY TRANSACTIONS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ds13701_2">PROPOSAL NO. 2&#151;APPROVE AND ADOPT AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ds13701_3">PROPOSAL NO. 3&#151;APPROVE THE AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN</A></FONT><BR>

<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_du13701_1">PROPOSAL NO. 4&#151;INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dw13701_1">REPORT OF AUDIT AND COMPLIANCE COMMITTEE</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dw13701_2">PROPOSAL NO. 5&#151;ADVISORY VOTE ON EXECUTIVE COMPENSATION</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dw13701_3">OTHER MATTERS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dw13701_4">STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dw13701_5">DELIVERY OF PROXY MATERIALS</A></FONT><BR>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_la13701_1">Annex A</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_la13701_2">AMENDED AND RESTATED AMICUS THERAPEUTICS, INC. 2007 EQUITY INCENTIVE PLAN</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=VRIVERA,SEQ=,EFW="2235295",CP="AMICUS THERAPEUTICS, INC.",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g429299.jpg
<DESCRIPTION>G429299.JPG
<TEXT>
begin 644 g429299.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #__@!%35),3%]'4D%02$E#4SI;04U)0U53
M7U1(15)!4$555$E#4UU!34E#55-?5$A%4D%0155424-37U!-4U],3T=/+D50
M4__; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_  !$( &$!(P,!(@ "$0$#$0'_Q  ?  $  @(" P$!
M"0H("P$' @,&!03_Q !'$   !@(! P($ @8&!P8'   ! @,$!08'"  )$1(3
M(0H4%3%!418B(W&!D1<R.4)AL1@9)')WH;<X>+*UMM$S-E)V@I+P_\0 '0$
M 00# 0$               4&!P@" P0) ?_$ #<1  (#  $$ @$#! $" @L
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M,8GT;?LP(LN69B9(_"ER%9*5!Z)=N>WN3V^Q%4:@+L:=@ 9KZLA$.NV?$20
M4Q[+II+R%9$3$",?(<2YC#+5[]2NN-ZKU!-T8)O'_3V:6R.5WB#$P% A6E@L
M;FPD$A2?JE;.TICYI @=O%NY3*( 8!#EYSHA;(2FR?3OPY*V1^:3N.*3S."[
M4^44*HN[6QNHV:59X['P*H+U[C]_47#Q503G<NQ<.3',*H]J375M_M*MS_\
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M7(*?0!#Y8:(Q'K,0XYX'4(F &.8I $Q2 )C 7N8Y@*0H=Q#N8QA I2AW,81
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M'K,_B?Q$^?Q/_E/CY#DRPDPU<N&/)*@QE@QXB?)!$^T1X*/S,>/S'6!_55V
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M3K_5YS'5+DTX)S(*-IV0A9>V)249"O#(Q\K((-V,HNG&K.^]]SK;?V6VWO\
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M6%V!Q&DDW#=U'MI!*\EU46S=STX-TT72"+A,FN&3%RIKID5("[2OK.FJP%4
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M%&,G)E)XG+RDP1^^<*"U$#1D>BFCXI"<TN''CW>YAD<FY#1K<5<Z>)\;PLK
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M-YQO>U8J$O+)79=YXB<@#V$Q0'\A, #_ "[]^1CZ!YUW&G=4\B2>ZF'[+#;
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M&@IK6)7<3LQVZ?P#CKOU.%_KVRY=G2%1"P*JD@0U*$-"9%I(ACF-8!2N7/,
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M^\3_ ,9>0B=)3_M#]7#_ +]LO_Z9'CCB7QW_ ,)]PO\ [9Q__P#I\SI4WO\
MQ/P?_P"MW/\ ]':ZF]XXXXR.GCTXXXX='3CCCAT=....'1TXXXX='3CCCAT=
M....'1TXXXX='3CCCAT=....'1TXXXX='3CCCAT=....'1TXXXX='3CCCAT=
2....'1TXXXX='3CCCAT=?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g650180.jpg
<DESCRIPTION>G650180.JPG
<TEXT>
begin 644 g650180.jpg
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M(T%A@3)QH? 8L29RT?_$ !0! 0                    #_Q  4$0$
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M4J"*JQBJG*BFHJ8B*2BZQBID,<2I(I%.JLH8"_*FDF4RBAQ*0A1,8 'V\\3
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M*360=*UF5HDXZD9^*;FEDZ^T;?/Z<M8*$,!1 P>#_P"CS[?.'ZD\^/F 0$!
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=6FPEK)_I ??W$3>_Y#YA$W@?[AY\?XYY<<<#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g245976.jpg
<DESCRIPTION>G245976.JPG
<TEXT>
begin 644 g245976.jpg
M_]C_X  02D9)1@ ! 0$!K@&N  #__@ ^35),3%]'4D%02$E#4SI;04U)0U53
M7U1(15)!4$555$E#4UU%3$Q%3E]23U-%3D)%4D=?2U]324<N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ 1P#3 P$B  (1 0,1 ?_$ !X  0 " @,! 0$            )"@<( 08+
M! 4"_\0 -A   00#  (! @4# @0' 0  !0,$!@<! @@ "1$*%!(3%2$Q%E%A
M08$7.7&1(B,S0G=XH;;_Q  4 0$                     _\0 %!$!
M                 /_:  P# 0 "$0,1 #\ O\>/'GROGS,:S=D2#MLQ8L6R
M[QZ]>N$FK-HT:I;KN73ITOMHBV;-T$U%G#A;?5)!'3=53;733;; 8GOWH"F^
M7:DFMZW[8,>J^J*]%9,2R92=ULV&CFVRR;5HW12137?$RQ1\NW&! 8IJ],G"
MKIJ,$L7CYPDAMH'ZX_<KQS[0Y/<4.YN7M ?(::;QHV1'6G %X*XE\$F&%4HY
M8\)3V)%=G\2)OFZ[#34M^C2%LK]HY=@T6!)@Z7B!A4=&?44=VR6Y[ W>FO3U
MZ_9VO$:1@KC<JC7W</28I-1S*K5EC-PL.:&JTK]!5FR%,'K!\P* '[$7N[2;
M3&P@VNV'J2WB_3?L*]I7?E7[JK<V[&**X3Y6(AVK87 CD&Y<A2"-GE($-;:X
M9;0;2RGNB4,( 4VD==#7+W=BUT<;.]$ L69SC'\^/*HWOR[OZ"GM^\N^FWUQ
MV3(XGV!T;/HK)[EL"MY*?C$EHFI1BK:2C=B$LBA%H5C6AL0T*S^;)I?G/4ZO
MC&C=1BX;3D>D\L'=?=95%P;R[9G3=]2;["!U'$L$GZZ^Z>AJ7GU,("HS$P3;
M33.'<JG4C78!!#71+".C\E]TZRW'-':Z ;5^/(F/3=?_ 'GU3RF_Z/[PKJ$U
M$7NBQ3M@<^5K&!+P6;BG-QT4$=5ZA-\O2#MR],OU=RA(8_)-QQPA'' PH98,
M5B"#%I+-C.,X^<9QG&?XSC/SC/\ OCP.?'C.<8Q\YSC&,?SG/[8Q_OYQC.-L
M?.,XSC^^,XSC_OCP.?.,YQC'SG^/.?(+_<=T%=<F(4#ZON-YBK#^J.\3C\;-
M+"":NW,AYMX[CVJR=YWY\LD\Z@7KII^9 X*3?O0S@@=>&&\4)-Y.P8O6 8OL
M;LKK'VBW?8O,_J9NF,4)SW0KQW&^D?9(0K9E;S5Y;[?+1PWH7EF)FRHR*S8J
M+8.-'=D6"3SN'%LG*>L=(-]5 3V9_G>BON'J.X[=]D7"G7EJI]%6CZ^N@TZ^
M#]%M:Y"UZK9<+-FYW'6NDF%1=;$>92$66@+UPU9HL]7J0@GAD\+2!45N0UD!
MM"9<@^DGUSGI*#BP6N: Y@KA)K%84&P*&FYW+5=$A\>!IK[:L?ZDLNU)BLVW
M.'GWYI(R:)EI(9<;HMWBZ6B_TX_']ST)R%873?3CTCGI#V*7 ;[!LT$2:(C7
M$58SS5R_AXPD.T9,]F!XP/+/YF:';)MM06TG91O(]BY"O-% L,>/'\_QX\!X
M\>/ >/'F%>C;[KSENA[<Z)M@I^D5U3%?R>Q98Z3W;:O%148&+D-A@I-XX:(.
MSIMPFW" !^7"6Y(V1'CT=\+.=/ S5C.,_P 9QGXS\9^/],_V_P"OCR)'TFSW
MIJ[N$HOT]U<?DCVR.M;'M/I*/PX\JMNPJ6G[%E"FM+5I"4%M]MF,#&UL&C\B
MC;;;75PHA*%7Q#9R3>/7KJ6[P'CSCYQ\_'S^_P#;_O\ 'S_;Y^,_'S_/QGX_
MCSGP'CQX\!X\>/ ?/S\_XS\9\JE?55>U$=QKR+IR%6\I>BNANQ0C\&1<@%OP
MG*[YUV>[!K'EWSJNWV;$)_IJ_K:):;KLMGJ2TU(M'[9:-[;9_0Z'Z,]XGKI[
M%ZT6J/AN1>R?D/HBTHK;M&%0-AEF4HHXK)HW#8')JQ7:-TIF=#1 >3C[5VD&
MQ&1\,#_<O)ZS/LT#,K&L*IW5O)'N(^H"]@_4$O)\W06M[)Y3&0.DIM6ZEK &
M\$J%LV>EGT>K-E8)"1R$%,9YOL6D\SFGZ"^0:I.OU==88!=.!0!P&L/-O4W8
M_L+ZKY%]<_'-J6EQWS6Y;D.;:TK*I)=),:QFF9:W?%[VM&XEHZ^CF;?L.5QI
MC)I_:)PMJ,!JO,.0\0$P^*HM1B?J+4?3O,?JHX:#UU&'>E><W<IU5))(?E$F
M>(N2?Z,#0*S2?SV5/]$FR9&2R0JN:D9;#)HW;KEB/Z<&'-&6H\>C#;Z%_IX8
MCZI]RU]7I*XC<W8<K!KQUJ;BPQXK7U)Q=]LJF8!UJ3D+$>>-2&5ML(H2J=OP
MT:<[BOS(B#$-1.YHE)?X]OTTLOV)=?TQZ.>>I.4CD+E(83?_ ++;)C2KYN\@
M',@TJ-=Q^I_U1NR5092*VG'VBR0W+C\U[^J0A$HWVBQ(]G(=1]$-6F>VK^ZL
M]]?0==.(;..I9.0J[D>+&VHW"=?\KUZ*"PMK)6:N6""ZTCEO],HQ,E*,JM]"
M3*,R-^-UR$EF,^:XS^2-/J._:?'J@@1<Q(O4?ZUSS"6W082RNW@'5/3"9$DB
M'C89PW1;[2*)ZMV*@9D[57<-TH(.G$E&*M&]F19V^[3[_P#V=Z\75M47IN];
M(-D&Z;O2*P>F0X.MDV&NM!5!,]&]>P>!QMKIAQN*LJSV;Q 1%-M=T#41B.[B
M=ZN&I4W$2:LK'+G/?+GT^/JMDS\TLV0#4W %[BZ+GJ;AZN4M^\',?!@BJPM1
MRV47;:RB2-0->5H 19I(#!.0+99)<@H5(O0U?]_WN#DO!T*KSCCC_&Q?V#=8
M9!1JFF@T6(+-JGCLEEK&$LIN\$E,K-'4GDA15[&:H#+C2(W4NR(R0RV6%1M$
M4;FMXMJ>X**Y5HVJ>@KJD70MU0FOQ(RS[BEBB2IB8S'?\Y^;<;N]44'#X:(=
M.]P ,F5_//$P@D>0D+X@9<O7BU,KZ?+B>[/9[VO87OB[Q7+DTV=FF7/,\0(M
M7B<>-3$4U<!QTAC67V^F,5/SX*60A%;M1Z+I G.A;@HZ*_J,+(X-3-_4+^X]
M;USTJ"YZY]T6DW<_5(@E&*=#!U%5BE71PTHM$L7 LS;(.EW<BVDCI*/5,#53
M22/S!%^644<C8<4'/PR5V;U_V#TOV6GZS?6++(M71ZN(^$FG?/9QB.,INUY4
MBTM42<PFLJY E=U8R=Z#G0AL_)-1!X88:AP[IHXV0'9:24_$OG]4'076H[MK
MV:>N_J^]GW42W(9V@YO4%Z'XO!8E-2]?7S$"L@VBTS&U\.#@5'H!9D.V9*8&
MZ/TUG!C5POA@H)'L-J?4WQ.MP/QD $V_(%)1TK:.7E[]E73+C;DW*IY=LN9:
ME9:1EDU//'A$JR@8O"$1'/'K[5EJU!/C.B#9<R0W6C1^G?RXZ8MKVM>TM=AJ
MTCO:O7JL+I[*JV57*]-<ZM2T>BY7;51)55%0FA)1S!_JD1<,MB,><HM&S5!F
MEE8+#G0EZ5_S)1MM]"VH_=#*YI:O)99DS=CVOWY+6/0\.Z,D$!3#*B/WY=ZF
MUPQ$L?S4OO"3EJV_,TPKG;%<OT'3N3=L2/M7WE=--V,',WB>*4%1(TF65:1"
MFN.>?M&I@BR9/7[W9BFU(S?4B\GIYWLF@XE4*DY]D@)9'7S+.G'UE/=96N.?
M*0X#A!W @MTT;VLFX%?S/MM=:DKDXR1B 0BZRXQA$3*+0U1-O=L,ULJMJYW1
MV6T;+.4'/YW-L1E'MHC5+>M+B*56'4OH]XWJ^)5MU/T> #%()*>ZK*%MTW<O
MI^L)(0%CR.87(3;IR8L4B@*"JN]2QX[*VCU(K7(HJ&P=>*'?J1.T@ULR>-'
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M_*OI'U8BZN$^O/D4H@*ZYZL(Q%TA4F0L"#.6@;E7E42IF.#Y$3_1V3(C([2
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M@U!Z_IS:4;2AW8-X6.;3+R&QID-GL:KI)KM")DT#P4.L8E$@(:1M4^$ 6%.
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4A60Y$B,CJ3>.-7CP)F?'CQX'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g677153.jpg
<DESCRIPTION>G677153.JPG
<TEXT>
begin 644 g677153.jpg
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ME$0,H0!#V@)R@(?S 1ZX10/X6^.WT+ZZ^[,?^'CPM\=OH7UU]V8_\/)Z 0,
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M<Z:A3&$1[!#39.QHX2^H;!O3,$UA73!M<;(D4BW4!!4"EDP+W^I2_K" B/=
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M8PB8QC")F$',7WC]D_6U;X)K>;OYA!S%]X_9/UM6^":WA%IYPL]U_4/] ?\
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M6HVM'S<QDW$P=,ZD?;]BM3^75[7Z:L5H5W-O*>@      4I0 I2E  *4H!T
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M[G<$)6!J$P*J(@(>KKGE:X\57;=P13]76.=$$A%(J94_U,N-2$O6;&@Q#O\
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MJWP36\W?S"#F+[Q^R?K:M\$UO"+3SA9[K^H?Z _^(YO+1Y5SA9[K^H?Z _\
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M&0QB)] #T9#&(ET*  4/1E$$^A0  *'=Z%*4I0  * !XQE+))\DGQY/Y>/\
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M*QK/8DFUH]WV9I?C'KAD:0D=K;YV-?-CP]-L_%NGVM9W:;JE9;PSGK'#R4I
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..(Z5ZJF4,7N$$J9"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g144310.jpg
<DESCRIPTION>G144310.JPG
<TEXT>
begin 644 g144310.jpg
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MZ<\X10)X6^.WN7KK[,M_X>/"WQV]R]=?9EO_  \GO&$4">%OCM[EZZ^S+?\
MAX\+?';W+UU]F6_\/)[QA% GA;X[>Y>NOLRW_AX\+?';W+UU]F6_\/)[QA%
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M@KTA<4+LKF8N\08^)U(DR/0-"1&#$(R*[&[(F^K@XD<_FJU;JJF7\YNT/EU
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M)'&$:;8G/8F_0)S:I*G8FMZ*?$K@4$A/"4D[+7E/<U+WU8MY\CH&IY\VQ?\
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M^7LU9K(P!U*D4%X8YXHSEB?EL66=XSM2B7/%7BF/G.,8S.UA2UO[%WVM9O\
M[*7(O_@L<SL-"]>_X[_QSKR]B[[6LW_V4N1?_!8YG8:%Z]_QW_CFI_%K\>;?
M^$XK_6VI_P!#_BIC_P"]Y'_<A7C&,9&ZRE0K:O(2J*65I$-@/KNB6*(S()RI
M31^%S2;G,,!BBE"CDU@2T$,87W<2@C"K<4B9QE<A^3VHL\2@L@Y0) X:2>H'
MR?ITN2RV-C=9<$F"DO)TLG/Z+;.%4#/I@C#?,70@VZ"XD.KU2TE@=FQ2G;T$
MI5KW%8X(F=M3+'A6G0F1YR5KVX+(?VJ-1V(H)+2CS GQCM9I8+1C=/V!89SD
M\! 36CU.G6&R>0MU,JX^)S/E3+"ED>?94ZO(F]0_-C.F6DN\8H^+CRONDM6=
M3<*@4 7S2TWFU96Q75,9(QWA5L_@3M%VJHGJDE^RT;*I2O:N-O[V>$"*)Q!Q
M@R=YJY8<ND1I#?9I[.2:P4=>&-XFGAC$I:MQG<3;:0FE!SA.,7(2>8GA$&"4
M"%R>$I;U!5Q;U@DL3R#,4$TI-%;INPD#CTP*$V"8)39C$81:8C<XI&)A:88K
MG12UX#-QM)$:?#ERUWW*P%M2MCD+$^M9T&6-S=*TDHCLC:F>01!<RN3PSMRE
M#*&MI6&+G5N(3$'^>IQCD3* G<>KHATA:GFCW5' T+G)7<+VVJYU\IGMC&CF
ML?<6!TGKU+(Q8TKNMMDK*"S)/.HF"81>4.5B6)'CAS037!&PQBT 'L&S#-E!
M$ K9@]E &+O# 5L6]E@&+7H$,(.Z$0M>@0M;%KIURMJ36)6D&S \4D;@W,PN
MT,K&#/S1.1.;LSL[DQC&0<PQD+F)NJ&Y#6B>,JL[31R,?JD0E-$XELS3, L
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M8JT89!>7DZ9A[V/92.PJ#97DD =BZ@ <ZP>T49PNX'?<&<4P:\IL(C0)R];
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M)1M&V_1BL'R9"G$3N0T+M0B=W),_(>X($RMO0*5J-.O=A+ -2(]402L=!MY
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M0)>[Y2))S-=Y8HWJ0#"%.2T#/VTSZRBBR"RR20 *** $LLLL(0 ++ '00
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M@EEC'Z-ZT'>_1G'8E8<.G9:\V)/:=Z+;#4I"X2<E83YN8MT9M.$6EB9-L7E
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MRXH)^F5PUV,M)!*9FI3+F!#5[_5">M3WJ+V7'I,B9IK%)*OU;,)VULKE&R'
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8UJU0'0B$90S/**C>IHC!![@-A+ 1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g28372bgi001.gif
<DESCRIPTION>G28372BGI001.GIF
<TEXT>
begin 644 g28372bgi001.gif
M1TE&.#=A\ ,9!7<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
M    \ ,9!8?___\A&2'W__?W___W[^;F__?W_^_>]_?.YO=",3I",4KO[_?O
M[^_FUL7W[]Y*4E+W[\Z]YO?W[_><SN^UE'-SE+W>YO?WYKTQ,4KW_]Z]UN_%
ME&OWUK6<<U)2<YSFQ:7>UMZUM:V48T)*2DK6ULXZ6GNM<U*MWN]K2CK>YMYC
M>Z4Q.FL9(1GOYM9K:VM:2DJMI:76M90Z*3I:6E(Z0F.UG(R4E)Q*8Y24I;VM
MSN\Z0GN,C(Q:.D)SM=[%E%J<>V-"(1G6Q:5[8TI[>X3FUJWFQ93>YN^ESM[%
MUMZ,K=9*<ZTZ4G-SC*4I(1EC(4+.Q<YK&2%*8X1K<X09(3J]Q=8Z,3I[K<YK
M4CISG,XA6GLI,2E"0D)K6FO>K7/WWLYK6B$I,3JEQ=;.]_=K2DJ4Q=[>O8S%
M<VMC.C&MM;T9$#I2E,76O:76UN9CC+TZ,6LI*6M[<VLQ0E+6SGO%M;V,WI2<
MC(3%I7LI(3I*4GN,8U*,O=Z44D)"WMXAG)00WMY",3&]>TK6G'.4I:U:C*W6
MI92UC%K%Q;W%E"$A,4J4I91S6CI*4F,A0G,9G-9S<\YS6DJ4*3IC.B%",2&M
M:S'.K7MK.D(Z&4+6Q;V<O=;WSI0Z8Y00(6M28VN44CHI:[6<M<648RDZ2IQS
M(7.M(;5SWM[WWM9"&6L9<R%*6BDI(2DA8YREWM89:^:M8^80I5(0I1FM(>9*
M<\[>(;7.[QG.Q1E2SI09SI3W*3$9(2F4>WL92B'.I>9[0K5[$+40YE(0YAEK
MG-X90IQ*0C'.0D+68ZW.$$+W*93.0A#.$!!"$-X0$-[WC#'>8^:4WE)"I5)"
MI1F4WAEKWE)KWAG%YIR4(1"4G%+.[TK>(>;6<R'.Q4I[>Z7WC)2E0G-2[Y1[
M0N;60GL9[Y2E$'M[$.;6$'L9$*4I$!E"YE)"YAF4I1EKI5)KI1E:G(R42B&E
M8ZU"0M[WUCH00MY*&:7.YN_FWJU*G-ZEI=X98U+WC.;W*>8A&2GW_\Y*8U(0
M" CW_UH(""$A""$(_P !"!Q(L*#!@P@3*ES(L*'#AQ C2IQ(L:+%BQ@S:MS(
ML:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-FSASZMS)LZ?/GT"#"AU*
MM*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7KV##BAU+MJS9LVC3JEW+
MMJW;MW#CRIU+MZ[=NWCSZMW+MZ_?OX #"QY,N+#APX@3*U[,N+'CQY C2YY,
MN;+ERY@S:][,N;/GSZ!#BQY-NK3ITZA3JU[-NK7KU[!CRYY-N[;MV[ASZ][-
MN[?OW\"#"Q].O+CQX\B3*U_.O+GSY]"C2Y].O;KUZ]BS:]_.O;OW[^##B_\?
M3[Z\^?/HTZM?S[Z]^_?PX\N?3[^^_?OX\^O?S[^___\ !BC@@ 06:."!"":H
MX((,-NC@@Q!&*.&$%%9HX8489JCAAAQVZ.&'((8HXH@DEFCBB2BFJ.**++;H
MXHLPQBCCC#36:..-..:HXXX\]NCCCT &*>201!9IY)%()JGDDDPVZ>234$8I
MY9145FGEE5AFJ>667';IY9=@ABGFF&26:>:9:*:IYIILMNGFFW#&*>><=-9I
MYYUXYJGGGGSVZ>>?@ 8JZ*"$%FKHH8@FJNBBC#;JZ*.01BKII)16:NFEF&:J
MZ::<=NKIIZ"&*NJHI)9JZJFHIJKJJJRVZNJKL,;_*NNLM-9JZZVXYJKKKKSV
MZNNOP 8K[+#$%FOLL<@FJ^RRS#;K[+/01BOMM-16:^VUV&:K[;;<=NOMM^"&
M*^ZXY)9K[KGHIJONNNRVZ^Z[\,8K[[STUFOOO?CFJ^^^_/;K[[\ !RSPP 07
M;/#!"">L\,(,-^SPPQ!'+/'$%%=L\<489ZSQQAQW[/''((<L\L@DEVSRR2BG
MK/+*++?L\LLPQRSSS#37;//-..>L\\X\]^SSST '+?301!=M]-%()ZWTTDPW
M[?334$<M]=145VWUU5AGK?767'?M]==@ARWVV&27;?;9:*>M]MILM^WVVW#'
M+??<=-=M]]UXYZWWWGSW_^WWWX '+OC@A!=N^.&()Z[XXHPW[OCCD$<N^>24
M5V[YY9AGKOGFG'?N^>>@AR[ZZ*27;OKIJ*>N^NJLM^[ZZ[#'+OOLM-=N^^VX
MYZ[[[KSW[OOOP <O_/#$%V_\\<@GK_SRS#?O_//01R_]]-17;_WUV&>O_?;<
M=^_]]^"'+_[XY)=O_OGHIZ_^^NRW[_[[\,<O__STUV___?CGK__^_/?O__\
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MK&A-JUK7RM:VNO6M<(VK7.=*U[K:]:YXS:M>]\K7OOKUKX -K& '2]C"LL<
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M((0L:* N['WPCUT,74-L%@7C#0 CGDP7WYX6ON_U;X@[W(028Q$"%' !'*0
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M#)"F!I ))*A?2W $:9JF .  @$"#B'"7<AFD%0F"N?=;B&"2"&$ =E"6]F4
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M*8\_YZ$.B0ED>:/1-JD!(*V?\ 0A<'=?&G%T_YJ[O4>\YDA^WSE<0EEN2!H
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MW@]F@P>PW?.:QH8*6^KHM3(6!<A9 PC:VAE,@[CP!DQ 62)PB-;Z<W-K@H/
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M \R;$LN#OOU>>NN/FORVL@5<F@_$#^;F;N, LYW6 B^7P+X)$8"8AR>?  '
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MVF\4UZ^=/X<>7?ITZM6M7\>>7?MV[MV]?P<?7OQX\N7-GT>/?6$Y@XBDCH3
M6V(/ H78!U SP  ANEI*<.7 I #B2"B#B RBJ"T"8H C$EP"T.*D.*0XHBT
M"%BC091N"H 3)HPH"@8A"H*P(2D^L= Y SAPL*,2[LIK#Z0"0"2UBSY@R" ,
M@ / @4X LZHW1L0P(! @4H$PE -&*N.K".^H8"\([\#"0A\,HDD)"*!0R:[G
M')"1/:RL>@/&'@F!0R8(.P*#$QP68XRO!SU8<K+*VIM @I$63'/-AIB@HBT'
M:IB!1(G_)JSPHDS^*+$U%?F3"(\( ,A@$HE>W)._!P.@8;"1&OCA"BS9=#,Y
MGV1S-#U55V6U55=?A35666>EM59;PW. !$-V#;0G+W8UY F76GAB5QASG8,*
M-B[*H%A#J$CN5UY![,D 0T* P09!8$""6KP<> );&Q*!(0PD4A0(7&QA$"0$
M*HQ U[EFYWBV5YY^I9<*>9@B@ 1ZGTW.@ 9X!;;@8'MM(5A#YH!3(%T7IB*%
M!O[5MR<'@*4""0,NP;C.UPR0MF J#+;WI6MA2$3;C./M<6%C4S3@X61--1E;
M01)!HUN8+\:67#3>W<F )];XX@XE:+88XW,O),'9I4>*&6.+_WB*.H1Q85@Y
MZ(<SGOI6K[\&.VRQQR:[;+//MI7EZ@PP8&WK#.@:[>T&4-O6ME\U@ #K6$Z+
MRKK/NUMNP0<GO'###T<\<<479[QQQ V(+0 \/'6\<LLOQSQSS3?GO'///S</
M@CVFP(,,T$]'/7755V>]===?1ST3)LR$O7;;;\<]=]UWYYWUP'L'/GCAAR>^
M>../1SYYY9=GOGGGGX<^>NFGI[YZY ?=(='G0*X!#A>D>//OUQQ8H]RXM[L$
M!O6W53]G\;5CH/PPO'V. W+5;Y\*!J"+'P8TD+9>  4X0 (6L%8.H  0TH"%
M\P6M!11 2A/X<94:O8\G0:"+*@"('?\#^* <+&C"!U'BCSA48'_E60\C)A6=
M#1AD@J8IQQ2B<(3G7. 1_F!$<PRX0Q[VT(<_C X#(@<EEB$0"$U Q")F\ *:
M3$$/%M2-251!/^T8H(4'>< ,1O "F2"B!U"LCA= @8NS1,< 76C( U[ Q(]0
MH8$7@< /MH ''0+1CG?$8QZ91X!+_(!$?D,7 305!QR X&(=0-(-7&, !C#@
MC0!H)  ^0!=-> R2+=@@1A@ ,Q\TX3A/  $2^H@D)5@HD@Y<0+P,@$F>+,0W
M*X1.)^^@ B3H"@:*2,4=U("T2/;K"4^3#@,<\$@]%M.8QT0FXR#0 2W<80L3
MP4(F13.1_.C_YA&+8 )75I0+%RQB"/.#6@,(Q04FA. +35"%9()0AVZZX)M3
M"P(<I!"".G"A)53; "X2-)(B1 *=!Q@4')@0 Q>4JD<U< $77,"$(\3- 6A2
MZ#=/*,8 E/$"W-2&!E*$QC0,0B<&F&03-J$! ]A!"C:  1P6@0,2I%0;"$"@
M0!=C@#5P\R$!7<1"&Y9,GO;4IS^]E0T1(0@*0#-><_$-[59IA/U!;@PA[ @&
MK# U#CPB@@'X Y(J"1L4S,@@-'AB!P, ABWP)8=4\Z#?F%4((% ) ! 8(R*
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MKFRDLSRE/<'(!@)+C5S*MX3+.UJE[@'&=_P\FHP. E!&%6BM6/$";H*#00.
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M2!A$$M(EP9$CK1/)P@"B6*83&V0<)@J0HB2 <K.6(!^Z4"$KX@<H82HO9E<
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M9&LT8.(<;?I54)8#V#&R8TX$%-)@ $"6(%7_"SVVAF, H8@!@&[^O&%2=X$
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M S*T+&P!^B-UJI8;16RAC]U<G_5T4\X<&" 3#(J#+P%0!*)IZ#I-V,2&)#(
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M*F4V>X>DS*'Q<Y!'R_S4!# (_U6^E95':M+@ 32@H?%40,QE#*R%8&B5-32
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MU,=2N/\."2E.#OD::\1!Q5T?]31+D4C''3S (,B2#E%"_#0!; 3 (JB 5%Q
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M\$'2];4 RO3(^M2#/I3D+V;AS>7@=GW$ !1.R&1"'$999=0ATE%/@FH: U5
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MM$5LC(;SDMC_6*L>Z5 F<8<9<$((&+A!JRFP!73-( KYVQ&JDP 1(A;; (#
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MX+$ 8078YSK828#6X S:8&!:H#%:2^SJS0/3(A#H*]J>+EW^0 F,H-DP8 ;
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M (K@%C]A+*HQ!W82WPA@ X#@!HIR#=+2 JRI?[CM#-3@1N#('1U )BT!A#@
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MWP '<HB8+@$%JF &N& &S@ 73!8 ],%#:[ %YB)]$$$//+$$IBO 5*"<_N<
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M] *@  S T][N !B^KI*& I,:EQ RREHC@')4H6+(\B;[ZP<D07Y5P-@DJA"
M4B&>)WHP^  $. !200M2 0Q\\X4!-R(,@0)FH'H#H%X!8:022AY,('K;.!5D
M !$^88O-$@#FX1%VD-OV8! :X H\03'X8P/B=W[K5T/"1Q62(P@J88L8H!"L
MDP/^0 U6Q)4@@8+65 / ]P[4MXWO@!'$P((& 2+66'IE0 LP0(6A^.O<H.]
M$ OJ,V5'EQ#"K0JDEY0'R^'_/J!.!VB#],X$WD ,2K8&YV&"7#$Y">NQ2A8R
M5X=0]T!Z:0!B;@3"/.!RCN\/S2ER?J,&A. %W/@.>H!RGK,@3*!_:C(%.F"
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MH .,&+2CN)>'@A!\$7%#8<@_3TPG1$P_X ]B6\1G>U</BBP7Q 2J@!/\G (
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M\51EJ#BP04$$ &)-%3?0A0(\ <)(43'_O* "$DN!9H /B"2!1 R*!* ' 12
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M@4$%\NRU!'.7_^2!AP8F71#)(H+ P"V,@RR0 3NAB"%0)G\H@80#,:!P1P\
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M$+W<5< C\8LE]O[C T9$@ -S+&2R&.>02&! !188XA;V83DR7JL3 :B",ZN
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M9Y DS;8G9$%];1<#V@"#$+<S2C"&+.$%N3 R&_ X^I82!! V3.!HY%$R]>
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M@ ?).?\2'/ (33@/E?!!#A&@6.$"21 (DG '&( ##. #;[ #JC0IWD=@51
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M"A\AH,LQ'UHR8(,W B2 5U8E1*6*$2STJHT% #"MC96H B #,]X($04U%LC
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MX8<_VN".!DQ \/\)),!M$D/96Q6RY*>M&" 0*\#$/("@!O_Y;S0&L(,3T.6
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M7:5H^Z<#/[1T!B[#E+D-(!/T*@M[./$J#@ Q!698@:,PR-93O6!,A&;$ 3B
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M5[*21R#,Z.$4@5LT)C "0N "G1@0%(B#+1#+?"/,S_0@^+N\W)"4JUQ+ &"
M0!"&.(B,$'"!0QG#J*S,\G $/-$N;8O%7&@O 7D[I"#+&;P $8@,!B $C]L)
M%UA*I* $IRP(3I',&H"TQQB/#."&@N,R'O]P@1E02\9TL[3<@LH$FUQ(IA\8
M3Z[)A:O< B;HF/(0&-X( K[< D-QC$#P (ZJFQ>X2@LQB!^X2@^H 4Y@%4K
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M# "[:?.<C1<04 @ ,%B!,.B>)?D#1#@M&E0K!=@"H*3FA\V#*O@#!4CP2<"
MJ:]Z_W +U_R#N&RD%9B_;!D0'OAZ?:D,]8Y*(PS9-7">YQF$[0"$!3SZH3,
M9'0IZ*2H"!&"*JB"F^2,;1&>*A!"]<:.B,4;&A""+:B"ONL != "A". 2Q"!
MKU_\7<& "4E\)2#?C;B^%' ,+Y ']H@$7+A)(VA+!7#GK_:/0@![M0=2:5H
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MLR*\0 T,F <4_RJ N _-""80J-)) ,%&L\E #PS42%U^@(=>$@0">\@"$@Q
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M):=NPP6$$8N8%(<#B=+0UC2ULU[_^DYG S1WV=.;0N A APHDU1=( 1)!.,
M,<#KC AD@URXX#MX#(0;*)>!'Z2T"ZE8@JVE\ @9M,$ 9LCT!X31!B-@J9[;
MV8,.4M !Q\)$ A(P0,@>X )!!"E/JVL=#T!+S4Q4 1C:(GCU?,!VG%JKUK:>
MP1VP,.^H-S8U6/(73+3(.HRN0 /F[KAKS*  _TX3$9R @ZV%<4C$UX<@$O]P
MS]V-=*Q/H)5REJ.X?5Y@!: 4V(3.:P@TMRT/+U!DU0 H P\XDS)+\YT&&N Q
M(J3@;"'\@1'#KPLTM],%,*B0!PJS=SUA#Q.NYB!Q&%@$ZUV BC=@(@/*'O3M
M'L )0;"!86-001 F.Y/+H1GTG9<&<, +(((+6!_V:=]Y(1(#%(+<:9L(0 Y,
M<-U&!!M!E,&P(47_E9P-U$'*%8M2G)!GR(B*U-*.D$4@;1]2+-S_I=61]%B>
MO0!J+-]FP,1=G9E"F0 $^A4>' $(& 37+!I7S$$-8!T*U% 7* !^>8$0L(8E
MX==RX%.G46$56N&0I,0?/(!4N=T W)6B=%],3!/_W #"LF72>F&)ZL'!&L*!
M-@1=4CC &M3!'X!!'%B!I'C)\FD@!R"<_>V ,-13C*26^3S;&@Y!7ET"!5P!
M&/2$D807[[B&864(CH0;3!A6VFA+!M0 &JP*WFU'$3@!,"B%22E%UW'%!E!9
M]V7 ,#!*XF27"7@BB>'5!KS!47# %8R5681 +VW)[7Q;.ZV2!PP:(?# !&@2
M/6P("L0!'-B@6<"BD918AG!5);97 &"$%ECC)4E(YX2'-8&9"01#6ZE,$%S.
MPC 3H"F%7G!%$-3!&4Q!'#@318&$)60(3&5")0#:>UA8)D@"V1DB'#C3U.6C
M"6S!%G#"#B@"W6R &PP:_R"80@100@"LWAI*P1#XB@F@%JRA (M-4RB]EO=D
M 90I%"',QQV,D.#5Q$V8 G[-$W%EPAT06)Z<UH)8CN450@^Q81N&058<P#1-
M8'B%&$QP@")86D.8@1N(WGE]45V8P:/]"R+D)!PT!E?%Y&5526J A!,D 4:F
M5C()Y0M4)0EJR(<Q"M=5T@A0(P8VWY%4@G)Q!<?1!"/\XQ"HF8>!V(PP!V<P
MGP3=$N]D((%EPD>EH;/!P1"TH09\F,:-Y'QD1-"X50P(0^P]49.X%5WDFP9D
M@C#(Y3]6@ -FP5'$5!Y2AZ"YAHI,@ $XV?!E8,@IU :40P!H 38& "(TR6O-
MB/_\E2 ]TL4E[)^$F-!<E)N2P1D*J(*&B%-R#*'M0$5K0-CX9=(=2*95"B,&
M-B, %,$?$)V0O,=:<,(05-MI!H(IZ(@6'1<E/!0*9=H5JN=Z"M,T,8(&,,
M9.; 78U<.$ 81B#<= 3EQ%KT]0< ($ZV($4+G L!< @-',$%9M(?R%HAP$Y9
MF$8@=H(9%A'KY!0#D$!9.  (#  #M,#M9&?#+8&.I(@;! U7L2;#*,)/%EUY
M;0 -X!DAH!*Z9"3?I=4VP9N7T$LPO-R]?<2+XED,B)]P,LP5=%A,7( 3<!Y!
M3%</#  E9H )9 &)4H(I) $&Y> %V  !LL<T3:$!-9#_?^W:H?SEM]R0/#
M QA =U$1W3F/ 0Q#U'&%"7 ;![P(CWW>8-C $23I? ' 7A5+"\@#XC1  O'&
MD)3!SL'$)> C73A@"4Q?C\T% 2#! J $U2T?[41(.FI*(&1:XH1D%\0!)FY)
MI:K="\H*:R2.W$4I'B"!PU&. \# )S  ")P$2HP!(S@B4@R>]9 0! B!N7!
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MF[E&FNA!()<!=A)$#Q,< 6R WX) K:YSXFA)Z9RO=+;&J2$PR?H (@2- 8#
MKJ+0M70HC_47FHBG<"W6"<L# 91._WKF[4(S-)C<CA3L0$]5 6M< !389]2:
M!05L :3LYRISQGN,@!38@!"PA4P00)H<)!S,0$7T*W_V,5H<9"X8B&/)GQEF
MT@LLPA#DP@LDW?,\0D[7P0Q,AQA.DA34@0M$$%W +E*\QW=(U0ML@:4YP']
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M=.-V5RDA2SJAG(_!0;K +@%X0ZOZW7I!#3S;#B@-#@P !-A #NP=(1@34C1
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M@PP\P&<_H_F4>\! J,^[E:ENU*ICP2A9PX":AS+;HQMP_P.,9KM3NU;3H83
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MG :QNY\E.#$4!43!(^LB^!!FH !W0G)ZE#Q"Z&9R'$ P(F[S'HK[]F4 ,\A
M&+9@$1KM!^1NY%!"RTP [^!@"]!(Q5Y@\O"@9^[G#LS-!:K@!BP  DP IDQ'
M(V( Z=I' =!HZV!*&]B&6!3A#C@!#5ZJW-R'!J0D!F;  A5 \$Y)VZS ;DH@
M7:('$4;_3P@L00D49L8>@!.D0!AT@$8<9PB/8P.J8 +6Y0%NHOUB3HVPS(]$
M( KRX$F(A0MR00N,"0#6Q0!G .$N8 SP;@9>('&\@ ,7X031T'\HL/Q<X \R
M< Q_@."DX 6$(0KT!^@4(.]@3P.NIF$XH<<PHN]H  >0H#X*(WVJ8 1.T.J0
M;N3<3OV&@A#O!_^F91%\X@+.  -F8.3<CRYPS]V$X 6B;^J<8,C(S@(EX0XJ
M9V1>X/M([@AH1P:V8 NB0!X"800F+_S6*?0"( J(9ET$T7T0,",R8!CN8 IW
MCQ4= .1$[A'"[Y0"P;=>#]V*HK5J4/ ( *$TH!)Y3A*4B%?0_]!"JB< LH9V
MX*8+_L #Y"P&4.!AHJ>%#@8#R, (1D8!R,!MX@ 3^E$$"$<E&D $HF\  C()
MC& #"<=B+,$*WF(-KL!_8J-VQ,#0_J![.  %EJ#9< \/R!%_<H !@L<29(8#
MQF#O3K(#4B?3M* -2( $?J $-( !+J%T2"N2$$!S\,->*  (Z,8!V($&/H$!
MJB?<K$X!DH B+7(!T+#H+NX,#%(C6(8< R$ XJ!R B%_/H#HY&$!@B?<).8-
M-'+JA"%E.("Q,D $=& 5C(#=TF"W(" 2XJ A&: 0$"$_*($'L*",UF &!L'W
M* 0#!I(!CLZ=+J 3:. (&" %4(H<N_^ BB3 8MP $QS@)35  G;I &* !]I%
MTH1@'J.'FAB@ ?8 $79K)83 %QU@#WB& 1Q@ RPAAS+B\H9L;Y)@QBI SDHI
M^NZ'!O+K8%8 $]Z"$K; "OSBC!!@ 3)!&+[,/-SF* U@ZVA@ BBB*=\"!!_F
M N[R$T!@'L#. A@ !/-C#2H!7!B W4;R8*J@#?IQ S @/RXO/ME3!- H>H+A
M=A0@!\RIA58"[/J"(=]"MPX&")0 "4!@ /P2"^3L$JZ ;L93#5)@SD:@<M*3
M,%$S#X(3$.[ "OJQ$&;QX<: ,/N"=FYR-C> 1(- 0N-*(S9@\RQ&'N7!/,_@
M'B5S15=3)U#_CQPI 0/JSP! (4A3('VX:?8\  G,$P6^*0.@H D!H O H <(
MX05\$S7WP!=CZW-(K7H\H 9&(#\T)PHH00NZQV+^4LY";Q!2P*X>DP'LH-6"
MP$1[*H54(-:&I (,E$1!LP+DH<(B >$TR 8MM+5:2"_#K3<,H B$ 0RVX &8
M8+X4[1&40"S1$"46H 5,@ ;(0-ON$^3VU$FHH! 6(9@:@!U TB$[80D*T0SV
MD0&,X.BZ)PC:R>3V@/OD,@]:M!((\Z%$P - P 12H0U J'<TP0@DX /@X&%B
M@S(G(-;B*40=  0)LQF'50WD;,;<B0,>(?HT]26KB4:CSSS5DMOR_V D9W,O
MI:(07D0J;70>4, J=64#!P0Z>T0#0K'J9FQT<*^%HB<#3TH5?L(!D& !W 8/
MI32RYLB;B@)A%6<^HU $D@1#CJ($XL89&<'KA"'FXI5^CJ,06C44D\+0\./C
M#K,H$E-T8!,#.,<$,."F[L( (DD#'T$3?N0#KN#+($ 1;D!QX"@*.X 1F(.I
M\N!B"2B'!.>NY&)O]$ ?.B$.7J 'CL)V@!1MRD B,X#KT+(>U8"=Z.,#!E0A
M^%4E+H : G0AG$ -',!H4X+;3( 'YV@,V(BI'L%V7">;#F8)8"2,CJ,+$FCK
M4@< ],%S"D$'I$):#/<$!*E[G)";5,(+'O\A:00IT4;6[CZ-M)P$"40@;A-W
M!:0"$)9@3\S)$S!D)<:@=)NQ)Z>.;W0";Q4G$RP!"R# ;C72 'KG8J^H"2_
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MT]# ;B$J(=5"-@<X(#H546HI) #NP(FKH HPH (,8!A2R8KRX ^VDL4,_T!
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MJT6Z"H"Z9R@!!7P:#Y* VPHA ((F $1Z!9) CZPB$UJW6Q-')TJA!C;NL -
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M.V\^YYF=!$P D1L#OG@$ [N%(EK-7W\B \:Q&8=!QZ4%5RU 1@F]V!$]C[K
M% 3XZ:M@$%X^SB=,+QN($GA4RD.Y5C( %!:!8S7S 2*A<:4_AXBX]\"<=K)
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MH\SP?NL!9$'B2LQJCG6J\#TU?2M7(=)'GT)B6*[RLR!>T.,+%C$#J"[)#G_
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MK/=R6?=S;]<7#-  (?!Z/\( DL<4\^=[+H<&\B X!& !7V=S#&!_9]%[0=<
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M90 $@S"K=2 ,[F9J.S"._RM*JJ:*JG_@501G!TVSG38%"+@0K)0A JHZER;
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M,< %B3 &5; %^H45'^R_% PR9K"@OA(_(V#']"/!%(8I/P#$4> 993#"%84
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MQ0VPP?YK!2R'3/T[7TI2/XG[ 2_0NR*Z 0]3*F."$*?RJDH&$5> LU=A.H.
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MCG8 ^G+=YWT%KPT9C" (T!T)[MD"(U4!3S E#23:VDDA,K W=2 )M<5Z>]!
MT"T)H2 /$ !#H8->7$<0L-JV/V<"IF#D2;TAG^#8 .( (_7@6F 5,6!%]-H!
M$0X!4!  'WJ//]*W$]!TPK-EM&P&J8 (4C $"%!%IJU')+$<EC (G?W:>6-$
MV=4<'L6X"54%"&+F:,X$*>"*$T 6\Q,10-$ BO V<P '_**74'ZG];<!0( !
M+C $$;!/P#3:N#0)X2T(+KP""$ A0' 'T/0#<8 %TJ70N;)",0 %8, )+G "
ME( !HA412,VW2T %(L (T;$;Y%H1_PK VA\<"H:0!T#3!0%0GV-;B'>CW6.P
M!$U^1P B'^$M!8F@"-#NY&V" :$]/&"B']B1 8>,GT6L$X*!9#K0%F4PKI.=
M-'I\!FN;:G9L $J"0'/[(U5DX2%QW7ZJ""O $T$0"7<@Y]5@"18N.95@%AE
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M^</][GKV[=V_AQ]?_OR.+2Z%@-$A_0*P_S<Z=S2@"T1<FDB!T@#0S+@N9/
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M\2&;"FJ!!/S@^*,I?:"X 8&K/+6$"1@VAD.8BJ^TQ*H+1/BRH&]7R &[CBZ
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M"NA'ZV"1**""H/S!)(&!XYF C," BJ2 +6B#*\F^I<$572D[J>$-3? )B/"
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M*QB!$=!5"*@#1563$7A: @B$Y[LDCUV$).B,&!""+1@!=C4(94K:E'6!QR
M<GT^%H+7&6 "'3&*EZV#.WTGN3W7$*A;D,#;P-L1#[BZ?<G4<DU;?<L?<$T"
MOQV8%XB".N "#($ =>6$3Z  %9"'MR'9NP@$/-(?3L !T2,$+GB:"T#:%^ $
M7X44>'V!0<"N#X"# PD"+E#;^OHE8%)=8[$#U^W)@?TK"KB!I^E<>#6D*MR"
MB]V7.D G<.7 G>.""5")%B!7<!6$&@#8:^JV^70!RU@#+K"!MN4$D V;&7@
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M,K00C0D&,D72$88$(6$JD&S @,F(PX8&UHRYL3($"@\6,K"3X6$.%88.#6P
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M',D6, ",Y3(""0P 02&D6]F-Q.8"D7B#:2B@J7=M!K9Y4 Q?+*&'%#2@ ZG
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M"LS!=.;>2J[!5]16PK#>LB8,"&2'^!&7NWYJIC80 [A>H#[J9.0K"<@KKP*
M!#@ Z^T4&SX7JQI"RGCDHU;KKJXD2?*JRQ!KQK:&=SG$HR:D<"JJA1K!J_]*
M:ZE6BKHBI;KJ'LI^;)=@A.Z5ZZSV*P/<4RFP 0,@1VI0H;A**[EZ7%@,@O<-
M80L +<TZ@,$B+*Y6*GXZ;5I  )*MQ[D>A,$"JA%H2:..WK@*ZEQ6[+>:+)"
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ME"YQ%2@!J3AF9Z"  K] QY$*!D3Q6ZI%2P1 '*@ L5P!_BJ %*BQ6E1; &!
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MEE-W)^QAI:1'.Y93IQA!8A(9!@@%):0"3SR!E3U+M2D%$K3$AU1?*B@%"%#
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M!FL@&0-CO&@#$8((#RFT<OSP2*I2 X!H1,CZYL0%%#>,0H!R P$ ")4\&:!
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MLPIV[&DU&X' 73]".2>F)3HED=$ !D C3="+$9']JA,SDHI4:(&W 0B $HS
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M"6@S/8"25< H#G@"29(L R7P! L+4+)4+D@&#2[ZKL8VM,ZH8 $%2XF$M09
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MUJS##58,$#  $QB  2CA#-3@DR@A #>I6*S "!Q@#<8 Q:Y# XR N'0 #N)
M#R8P!B(A"W+@260 "]R/ D8 &,Z/<)AB!230 9[CP\8I%;+&_#IAFY1-DDY+
MTDR !HZ  ;R@ ^9O*GIC"8Z  #[GT*(' +J"/!B _P/R@ :DQ"/<A?R\@ *
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M6F3@ 9SS!?3+3A*+N&;L.>=1*$1@/M.E"NPE\DX.<X2 /(WS#F9F:?Z !L+
M!!BA,W2/*BA@/+VS-0>P-&8L7;9 $]3IZ-H.#,@ 15[ !:QF"T8D)D:@/;'#
M3TR&59K0.N'@"NA#Z[#P$1Z "SCA"FIF#<)+U,9D+D84#D"T,!B  E3T"A3
MDCY"N%QBW2J&4^XB?,I374S1ELAH0+^&!YB-(!YS$89 _P@4H *\I@M^JS-B
M D#=DR0ZR34?Q0H6H GG\P6TTZS&[K0P  ^\IX44X#JM)EE*(TZ]QP%$@$FM
M)A7>YD\0<4I^R]P\0B)H  <H@(MN;N88Q2A.QR:D3C:S%"!];@-D@ 8\U#WE
M01\8!7B.3AX<X >L$SNUTSI>9<VN( Z8  DHH$/A0 C8#[?: @,>I"NDXC&
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M!T @!+;SM$I@<SG7<-7V$ACW>JG7EF!@:S^" VR I/PK!-PW:T]7>-$6=3\
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M=.$0PD8LGG1!)'B(I*5J"AH4AH(GT24$(E*4=@D.#!#BA!X#%%?/G)>@ :.
MY"'THF<MKH'#2\7Q9EA0;2[@  5_X"$( A=4<H-N*+KWXQV#S#% (!A\8M81
M8Y:E7IG]C4IJJ::>BFJJI1J@Z0PNN+ %'D<4%,,5B\ QPPA8&"9" (M4<  A
M/,CWP2,CN#!#'%8,\-4+G."*!R9F3AC##(L@J^M\'6A!PQ![3;C&(YQ(,<,+
M6"R002>AB $ 77\ (YRS<+R AP8&;%#% YRXH$ )-?Z5J1-;8#""'LV^.H.L
M1?"@QG,;8) #7=9B:P7_6C]L\>H+'@Q4!KUP"*' #0AXT8$D%R+ P1AM6'"!
M$%N0^X(2)06! L8NO(!!$M.>1$DD:H8QP 7&OKJ%S$D-0+(,(ZAP  <KS2#%
M%1A841($>=@\@Q(#Q29T'(+TV"X#@E+R L*+R > U7%@.X@%\SA1Q195M"'T
M Z^.T,8!7B"V- *)EBV%$!BT@:X)=PB# 2<AH.") 001HH"<[I%X:ZY-K=%!
M  ^T%)L!/JQP0A$JUT3S",\*LP0<+L A#&0 ")M$N[4N$C4-F%!BBK1>@8*'
M/ 84(B^]4HUZ 11*'& 2!)U@ +7@*Z?]0]DN7''#7L5C((P";1 RL0M_A(*
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M! V)P .?^<L%]E O:YJ !A,@P/RPP "LF"2$>%B%->&@ GE,$GD Z$(5>F
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MSMH#_Y\M%H*-1ICH5@>Y,0TIPF@6)(1[X=M4F>F#&D1\@A&^J0,Q_$X!X'4
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M;M@"# !I^@.%E>EN='&+HN0U,*"C/ H C80&>3 (R ,?CD9Y*I "(J *-<$
M#%!A(H (G" (<Y!36T5,<+=_6% $PJ">DK0')N6. U((_A(;2%8"GU&.>YH!
MI-F9X-=0%A&%</<[2Z !A:<)6AH",+"C54H(&,(E** *]X((3)"CEXH&&G !
M5\", " !+9!96%D2"ND!(3 '.DH%C IW/!$'4B (A@ *DFH PR"E2O$P8?!9
MWGD2*FH2\]!:X*&G[9$)8^!+,\ %,R ,/VJ?;41Y22E(4&!Y8@AN6/_H%2"
M.W+R>:$W$$P" ZQ3;L1C/$AW&ZSW;X@E-'TIJYA*$X1F-!G@IIQ@ W+*I(3
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M7XX$ ^N6,J.O.A[4/ZZ)%ZWJK7LO]9DRUE4<+E,NLN(1BE %8]5-<M(R(_
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M#J!(K\B 27BML.  ,_. ,%"QA B$862"7JS&W -!$?P#07RC%<BA>;@"K8&
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MJ&JKKL7_Y(W@(WN!!YB!?;A/!" HM]0,%&C5#KB!$"H$]T(*,\P$#"!D MB
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M$+VB&# 8 ;'F@B@(@^,RW M@;27C! _L[@- K/0&"AO%7[8PK1. Q@,W[45
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M2!)/C$2T:J"+FQ,",YB@"@&*$H0 ,E5ILQ3$60,,'%R"(60%I@O"-.U]PF8
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M$H@_#"\&CZA"<JQ4F]D- H2/P!Z+*-'',(SG#T(,P2/" X 85")D^"K9\"@
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M."T*Y[UH!VB[7!S8A<$.AC M=^WM,Q& $,'=*+VS9E\ )#O/0W"!C48#YS
M0KUUUA<)J,O;(0\D RN.0AU<L% X8.(Q.%+!=&*  E[GP@424K4P[DT0,\AI
M(*[3L+?E08 ?[#G1,Y""_M3_ .R844+ 0_F LD\(/ +'P0,_F/95-L"%.HC7
M!9]]#4P@%K[1 ,[:+%XZF6]J@ -J^-<9.& <A'&IM,R:U[;>&!SJ<2-*D%@]
M^H5X;-ON]K=GYB\@8("50&!F@1# "'3OC 'F3BS@H<4S')2-9PA@=[@+1 *8
M4;Q:&!#XJSA>*E8QO',_PWC0Y+WRFC&\7:02%P3D_9!<,<+=1R]Z NQ]GRS9
M)P- 4"5"#,( KV4  TH_&D)P).^VWXSC=[\9":0> "T@O>"#S_L4&!\SH@?4
MZHFE=\PP8/D^@P&FNG '4#N?[9P9ONB!?YGA>\[QHG> Z_%5^X%PW_F<60T&
M!O5X_\[\1?O$^L&O0]-WXH?&\1#/>^<SH_O/^(7T684#I(#O#83XB4;?+5_O
M>09+:![>K0&47=,+K$D#EM]E,$ *@(8!X)]5T-X#7@9KG,#_#<3E>6#S7<7<
MB5[Z@4;T(=X+PF ,RB#H&, :I!# S& .ZF#H;,GD[&!G.$ -%-P.W@;V_> 1
M(B$03H(.? ()4-.])&$4B@Y1: 7<.4 (P$2N2>$6<J%HP,4;-.$:"($.2$@7
MKE\@F((1FN$:LF$;(EZ[])$&"* ;TJ'GS$I/F2$'&N +LH4:UN$?BLZ-Q<$+
MO  >^"$@<N%JO &FM)T#=$(5*($<(N(D'N$%=  &/, 61/_!L5&BT^ &)8)B
M*/YA SS!@8GB*<H,$J#B"Y)?\JWB*PK?$SP!"8 @+.Z@%UR@VQF 6=2B+?IB
M:#B +-+B'+:A YC$+R)C,BKC,C)C,SKC,T)C-$KC-%)C-5KC-6)C-FKC-G)C
M-WKC-X)C.(KC.))C.9KC.:)C.JKC.K)C.[KC.\)C/,KC/-)C/=KC/>)C/NKC
M/H:C%\" F\W@^?G?'L(6 1#D/A$"#LC?,AHDH)R? 23D07*&%]2!0AXA 30
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M.)<Q@H#S4(&IS4P<),'[<<4O#8*I$0 )@!"@CM]9K 2E$D +@/_0',C#8SC
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M/ 8.U_!P,!T+L[!IP<4WU=KGY<P7RV\<#L6-;=@#" 'Z;%[ S8 "1/_!$0Q
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M/4\*@N@ &"SR-7?A10P?,=CVYF01G&BB0 :P@RFH]KFJ/$&& -A %1NEF0%
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MA$8FN 37A P)';!3?#*@2;<E#P1<LY&<RADB#CBQ"O]2R"/R8IJEP; 22FA
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M!$"E!2B@/Z/3Q'A">\J ;TR# MP22%7(Y52HF!)'!)9- BCA"O  #A2SH C
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M'E[$BVR K#:"("0W9_,+68P7 M#@*?"7M"IV?R=D,2;D$OJ6 )Z :\_6.3@
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M3&@@00:YX% 22W\90!XGI^5U4AE.9)C?&%+4Y<)()GGGED8<#<!!+N"YH,<
M7C"%HTF$A2"$9%24I%AY,1%@AS8-ZIB+'@X4\@<&4F@02 5)L?>6!@9TU)X4
MQJFX(A@9[J7_G4OFF32>33@M9^9Q<'X"'P!JMB0%)@R8N=1V^P@%W9R$%FKH
MH8@FJNBB!FSPQQ92P"',#$W]L$44" !0A@*<V)"+,"M$X( ).I!AT@5CJ##
MH!D (D,5D(;1P0A#U#$##4=H*D,/:>VA@P58*1"C$'$D,0!P.D3@10=XF$H
M)9SN  <&5JP:U50=W.$!&FM$4L4B.PAAR4_ A8KG"YUV@(%G7C4JR0C:U"$$
M'OC- P48<6QAA0&!;-%I'G&T,1,%EF!AT1@>R)-)P16UJD.F4=G[K;0*"'P!
M"IY49  E/'3E51%GX!'N"ZGT $ FE6"Q0!F6F!R7KV+$,$82#$R"_\@,0\!Q
M1@DZ70#P$+F0',5TUVZ  7Y>B#!%5PYTD- >KVZA A(;F(($!<(LHHT1,0@3
M!Q-(1(="4T$K<< \*&# 2;CC6ENT#"-(\:D.^#E  :<V (P%MF!(@88%A/"
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M0QL,X ,,\ <X8#B@]BB5,V'8+BZ=X-X%X,>$'[P 4_J@AOK*$@A$3&!C+_!
M+N"@ "[-B64N,LD'(@(N(6#@)P! &PUV$#3JB1!6(Z#2[[)GB398@(IWB%X=
MKH"'Z=AM"W*$0[$&D($]A*)!FOJ#&E!XAB6 ;1*AR-0%]H !RD5!'@X0 :V"
M%CI#=<&&C:I"@8+_)CRB4&(++M@!P'A%* ?8 9C"M.$!&O6'70JCEP=:X Z6
MR+U%6?.:V,RF-G$G2J(40@:.Y)?C.IG*8Q&O*S'@@8NZH( ?M<L,J5## AC
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MT6%EC5)\^>$$N6E[)M$%/# !9>!P7V%O'6 /.& (;9JE4?$!I+:4,/.09D(
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MF2*]7C4&CLG0,C U:4@@8AG5\IZCKCZBI.C_4)NB981PFE6P!#N@?(]Q!8P
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M2*@R=T!"GG('1IP[ ('$>&<%$4J!.$!>//A"H<9#!V&^81D%$XP3($$_ ,K
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M Q:V\P%%-$$573P. 63Y&E.B%$V9J$(;4G"TQ!F@"'\ !D,(T +MZ-0A"@5
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MC"'"0%;! Q+RR<8@V*L*PE89!$P@V2M@P#],ES0G'H'V?#-\YK@V>T69Q![
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M0"<I+(=%V %!,((BX $/,(0Y2 N'FP<H_]"^@$2!*(@ <V*$@3B(,3&41*J
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MF= &!."/8MV /@. /$$ 4)*W#(A=_]",CK**%?B4D)U:?+53 +@$1[Q311A
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M&-U]!X":%1&P 2,GYE:&$SV0.A9'%LDZ*ZVUVGHKKKGJFFLFPFP&@!T*:+3
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M@L@6>CC\D#">)"92%4\6,48;VT&P1Q0U*"!4%UO0K%A1!LD)W*:LX)3'7 <
MXM-"M<1WA\9E8 ]3 @ E%("%>7DA#]>)4M_*90)$D&AL$R0 )22!%_%A;E4R
M4(-=^B:W"$[((03 R,(,LB\K5,4+';A. TTS+7B=( ;C4DJ*6@, 0%#L [:1
MAP0\]3I2X:<@5V)A8HK5MU>IRB$VG L &! #XO7&/LVJV!;<-Q C2, NU6*B
M4"JD@ E<H!/_2D" !*1&DD (JR 7R(,.*2(US,FM,Q*Q8?$*A(('.J0,55!"
M6=;H&"&(S@%N7%D9PD8J84V+$D 0W6 T4KE.W($LS=K04&@0@;UL00L2N8 0
MDD*:*%"N0OPJA (F)(%Y""$4R#(!'G;"/P28I85V&6$G3(.PWU@D!O";5 >$
MV!U7[:J9SGPF-*-9JTQ@@)DVI $3ZB $&F "8%!XH&[>8*EH,6M$,;K#(K+I
M.@08X%NK,XA(1J "&W0@#N_$5@!$9Y H*>$ %W@$'FR0BQ?(@&8$",06HF"#
M'_Q!!;CY9T#K( Q+X,TAI*&!#6P !V$0TV9QD$(77[.!*D0A#$2D_Y&3ZK*!
MCVI4 8-P(D]0@";[%$);%QC(WGQ @Q- KV(7*Q>\I+ #(4ABIQ"83T9_\()#
M0DYUHJ%(J3QU!RO4Y0?V(!%$%K&#.KR@A!!0D13HB8%WED$&B\!!#4QQ(HMI
M8V4^$$YE\O#1&;S 8'4QP;GJ1@@G:.0UJ2/0?H[UD!<L0J!=!24\"_'1H?X!
M?#AI$Y&N0!!2AE4(55B"7SCP"(S6808T^!I4:,8Q$<2!"3400AR$$B$"E6$,
MBX###(0A20N5#0!>8*0\>A71,7A51=E\A P\$"XO*J \@*&9 RB@ $XL5 ']
MS,!B-E0L;&J3FT]1%W/9=D\#="$ Z)'54?\Q( B-O@!N=2F$/!,A@B6086P3
MX%@RCW IWABD" IPU5='D,UMMI!EJ;C-7O*)FP;J8"8V+*TV1]!"2KR N7 X
M P<!4(I<;,$%<%BJX0!0!F%$] QXR LEQL#<SF;8BTX8TE$1# =A3:0(/%#H
MA=MP7@R$%0X\V-]N$! $%""BLC0PWT.T@ <<#-<Q<MTO-R>2H"J"B *6"&L=
MKE %37Q(CR?UGS# $D\I)&+%!.K.$G!@!""1A0(O"&L]%U9!!//W?!")Z L^
MG)94KNPU@2 F1:*DNPTHLC*/& 25W!BN4F$O#CL8:!4 O1",VD (6PB*;F 6
MH_YE L(DNL 5"@7_)DX(@J'"]3,V:W"%).,$#)P(PWPU99R)/$83>2D"86$K
MC$Y:9,MB[:LAAR3-7?.ZU[WV0AU(YH4:S, %*@C#WBB @Y41H@)HBX$V<&.
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MI6-&R#LYP"70C>M^HL/>"E\P4VX0PB+D@ ,0@C!X@.(1  FL@2#H+$PYP!S
M !I0P;PX4%XXP!/0780PP4O.[_O&K__FQIWV%0-X00C P/\3P,OHKN^*GMNT
M/<$<S"\#D "'HD&^O*X!RV][ ,#Y_<$@/(&6_L 2A #6<$2 ( $)A,"*%K *
M4\&YJ2\;A$3\PH +3\L3Q+!C4 %NJ"_[HL$&TTJP6*I#K $/5,!+XL /UP4
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M>$!G7<$?9%ARP?>J#E GC  7O(#P3LC_=H?Y$.[3'E0!&*@Y;'#W9G\;M,C
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M70,80ZPKW#7=P5Z[Q"+".B<0_W_ @ =L0('11>\_86GXP^6LL3*P&0 H5M,
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MX99@)9LR2#A2*2\!-S,B$Y)17[@'"38 +K72,HY%5S9@8K0'!D*H.0E!&/
M#:#1$&!S5Q1 #Q@ -O#@NUZ%;,;H*HX@!5J 0EKKPDYB-1R )5R-[:I+^^B#
M<-Z",)NG/Q!%-%;"#18&4J"G771@.;U@ ^[@&FN*PSB1@J!@@,2B-HX@,4T
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M*=  >W" GC%-@X $#A $GL17"Z2/S]H9K3$'!OEER0JO\2JO\UJFA#>8U>(
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MXCR&"I77[W^9"/V."%C@,P&P0?*9"DQM>HI.\W4 XIE^ 8K0X@_P )B0['>
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M/5Z8U (O8C)E\>: _QCHE.M"%1X#0"4 IA)7M6# Q$3@P#,^D14B6A<DR=A
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M8/_I%F@ :(!QD>0@R"M^"=LI0GH43P.Q DD+]T-@%90 EN_>89K\0N =3E[
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MP>)H@64,#F0$ &7\#08  1#(E!9X05%4QF@,#FX<CFK<Q8MP@',I#@<  0L
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;(A6K:,4K8C&+6MPB%[OHQ2^",8QBY$I    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g28372bii001.gif
<DESCRIPTION>G28372BII001.GIF
<TEXT>
begin 644 g28372bii001.gif
M1TE&.#=A\ .X!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M<#$5WI$/P"90^Z ""+M#IX9]^WCRXI<A& !M\+3 U+*!"^R,,/=NZ U;'_\
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M O]QD#R"L%"#"(QA "*Q"G 50H&) & <$%@)"B  #&<(XA0QZ(\IL DUF M
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M506>B4$4%3&V%@FN9C8HL)3_0T/I=PMS_Q",!0%L_F %N] Q 7E05&!8Y#<
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M9OH)>OKV!JTP/N3EA O1 ",P 76@D@0*-*N ./Y#DU,F"^B5 1<& =0E!CV
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M'B$;XV\1YWJN>Q#S!M14BWKL7[(#E^@'>O_5]@\1E*&%^'_^"4$9SW;_  %
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M)MSWOP=^\(M7F'=-N1.Q5K *:3WOQ\N=/9D8'[SMR&4%-!2..>#R!SI\&"M
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MM^*)F-&*_S.T@=&'S[J?)*R;0)")?*M('L2(2SJ"$8RJ>1*('1B9!&-%W=H
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M!!*(8[HY%!R%B#%)DV_:>2>>>>JY)Y]]^ODGH(%.:6)?LS2RIJ!W0N##*Q4
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M$O/40SN7HX 9%)$)3XA" *SP#AEP8@'( 4$DA;*'093AB#CJP OTJ!P"I#4
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MR$4'+/\ #F ')(0!"(S"#>1!/92"$-2#=$ (!>Q!(4S!*"2(A(363S7""^:
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M*(3 )ABCG&7!;:S$%I' 86@1"J#I*+#+ @Z #,P%#/* 4"W$3U"& @! ")R
M(EC.!9BH(MBG*3* CWJ "JC+FL9 8.H!)Q1J1PR &YS :@0=)R#!"-Q!PD'J
MB2Z'B6Z&&B+!;:S*#V "$;1$8;# +:B!'X1 6LP!!M2! VS '=RH<QZ$0A2!
M<#S/!] !)?2F Q !!8B$I)H8H[H 6O!H!R !6BQ@&2GJG]JHIZI!(+#0:.S&
M%<Q%"TA!:8C%LY9 C<0IS9&I<'3JHG*"L?Z$>1R(DTX")P"!'ES_JT0\ 15
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M+2>$F?7P0A:7K",T@2>; ($"00>$T3V,P!1XU!J &!R@T;#))03  A4 @W*
M1 ?8 !80 F:MPAQ,%8.*  .,  XH 2>,PB.S 0ILPB&C1*9M BG 00[@@:K-
M  A< ('F01,.0"VLK1=TQP<T@TBOGPRX  .X[ DT,QH3P0V$<V2!DR+30!_(
MP0]D'P(XPB9HP@QTXPXTX0-<P0+L QA'E"-8$"140@GD)[JQA1(P@",T,QR
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M"$P! 1!H*QCQ)-RM=3[ )G3S#O N!YP )GC %15!'M@0:=P "MB! Z5J(\S
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MEE8&6!$-PAYP@9*UU%$!@A9&N:%=$C9#(X1Q.U!G%!3^#1B"$#; F)+6.O
M#0CPG81!!1X#&(T'6OA7 A)ZT,.&-C: *2LSO@2 ,1!<*0M@(HC3&0,,@LC
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M25&:4I6NE*4MY:5)79H3F)Z0AC.-Z4UQFE.=[I2GV!J DW "_PL4V%,F(?!
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MRP@83( :7R'12+BUM_"B!"!4<8,DB(&=^7QC.1@!HSX> ABD!(2[\$:R$GF
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MA#9,0@KH0<,5F<:$?14!!@@84AM((($BL$ /(T">!ZA ) _<8 %MV, C+C
M=8R"<P/X@1 P\&LA/"($DS " * @ U>@ (I'7 #RBMT!%["!$\P^9RU4@H(1
M2" &HR" )27P:!;(#-4D4,170O % '+&#>9^2 BPX -R-TMD_H&#27M8@M](
MC@BW$/ S?^!,/12!"%!1 HE//;M,.9O20(@E*FB@#@3X(,T>4,L-7#"$N&Y
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MD!D<>J &&(JHE>FB%_JAK%"D62(+M@ "0% +7< '*K46LE#_ 4WP"QT*IX&
M!R@P"+-@GF79!:R@2B)$H6& H3FJH6K1HUP: +,@">SI'Z,*HZPP!5)02S?Z
MH5[*(=X6EFL: %Z: :K3 &-0 8#  M33!PV*!\>D V+@"9O1767P!F2 7%60
MHGP  PR5!SJ@#[, 7&"QIW=:!R:@ !T@"W!ZIYCP"U;ZH?H@!I42!5O*IE;
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M0#-,4P5B4/\G-J !^/L;?0NT:(  <S &'5M4!=,%*8JG:1D%*2JLJS0M=AH
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M$ =GD @!8 4E_SAEP 0+, BL4 <CL,D68.#;/O/5B0/ D^=G( K3@WU$+JM
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M(@-#,$ 3=<"*)-GJ0!G(S!ELZ)KFL(UL!6E 6![AB%!LIPGL01(!?%"%,N!
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MOAM^[W=7O-X+D8+!*_[O?/][Y?ENA;]#_NZ0![S@.2_YPB,^\*/G.^/YSO?
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MKW27&WB"1T,XKSS,B5" '2+-J<Q-W2Q!!6B!,0"\1*@ PPL#03BB/E"*VGP
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M A! @ _(%J/;@S5($_9,6IWP:^R]3PYOACMZ<.LV",-M ;(H@S!8V?#V\ Y
M@O_X@#YX&3)*U M0UF^:LSN0&R(V(3 0 V%1K)/03APPDY@9 S]@6A)9*1N@
M TH J5>0!*Q+"-9AA5(HA37_*(0B>826+81&,"8XT.9V(0D,6(Z1*80[J (0
MH(Q2N4\$:*@D8:0QR(V$&( L@(&)NYD)> 3%\0,$.( ]V.5">P"0)AR;(<QO
M:6]+ZP(_,+H&6(,Z<.D ,77#DM50<@32;8 QH&9&[[4;0(*/TA$0,&-$G@%!
M$!8]. %IT8,70.1:"()58$]Z\18@K8.5QE7'BF<3J%<94 +*4  ?&%Z5RX-A
MO6[M?G=X%XE5_@(WE=QS-]E& (-9J(,VV( -" (KZ%R$(Q93]XXWF 1QY8',
MX&N:PH%>FP,A0"J2R80=N":F&^VYX7<2V(!!R($#_90HT!J:H@-,V8%$=7!P
M (&5_UYHE&HJ6@>#%# %X]B 9D@ #0WN4DB"?A^#'$#X9N"7]K1.'4&;@<$
M3 CYFGEP4]:S%,"!C2<!$= $%5" 'E\%!!B9"2CQ@: CNDK9*NB$2? 4/ZT$
M@;YBI<2A01V!0B!B BA8,:U*%SB!7Y#?#YN#1 5N,2@%"?!W^6$#A3:3_:A>
M44+2/6B&>C .$A""*M"%>_@"0N.06L  PEF>3'<Z]TV%)""!-I  $< NN*U5
M!0 &F/8;.# #'I@P-4B$/(4@D_>EVDX:OT;.,8(%*$""$5B!S7@$]YTI,$#M
M#>%P,QBHH(,"%Q@!Q6>%1CCQ=N%O4WB3#5!\#&:1&\@"$O\(]$3@5UO!@1Y
M*>0< .F4^S)SKMD>A==O%CU  20XCO[0A+BE#L72!2F0W"QX@>S0_*]O4>5Q
M@8WWLZNOA95U=X  (' @P8(&#R),J' APX8.'T*,*'$BQ8H6+V+,J'$CQXX>
M*0[X42\3P5M]FJ@ H.#'H$9@Q& JPJ%($1%H")2L]ND"@!!]<+0) L)5E$HF
M!NZ@@X4 '"$\$(0HE&E'(%(4"#Z(8B4F31(BC. 4V.&%T8%@WA!!, ?#TH*W
M7DW!TS1#"S-D'N@$DZ*4")I(1'B@D0<FAYE>@3@2TH@ A!!=5C60Q>.J@EI!
M,-G194&@R2FM%-X"]X;2D M4+AS_4/FARZ.K<R9@N4I SY]*FP' *20F-@ ]
M,T:#"=0J[, !4)3P!  A9 HF1G:P13#65)(8(ZI,*:$ 3A L--2$X4I3!)0H
M.%@ &!#\J (U@-"$&&.**Q(2DWP,FJP2#(9,"A[((@D"Q!6DP >#2 +$!0-0
M 0%."LPP00\ W*)&("RD!L /:_"PF7H!!-)#6 UL@@,;-I2%U0N 4%)0 QNP
M,, "090BP09K)+#*#U()!(8@<CS8PAHD%03!#"O0(0$)+X312 ./I;:C*7T5
M@40,DQ X@"/-8"#!"!N4L8I D$PPB2-F9$"! E"\0%T,&V#'@'F:S"#(A'I$
M,4$I))Q0_P4?'BQ@QF?* 1.(%";5X< :;V RTPE%3$(!<1#\(,0$2HZ@PR=J
M@H$#)01^%*JHHY):JJFGHIJJJJNR2M$M<WPAXD -] &""@>LU-)+I,%R 0J<
M$$*< @U4XP<"*LV0P!E6\'!#'IT,VAX=E*@E!!8(P/'%*G"D(,>Q"K@A B<V
MI$+$!>>VH$1* ^F11P[1JB$(*0A MQ2!M\@"@A0-K&%&&TT80>PG.Z2006E4
M0.'"*.JQ0@DA$/BJQ!")+:7 'MHVT!)E,V# A UO#!K9%$: )DLE-QFTQV,X
MP=',4RIU\(HN S;P @9!U$$* 2N- 0)<QQ8TP QF3#C0@3Q,;/_M WD4/ 05
M(6#7B@(M6"N8%3V<&S$4=C2!WM(YI*3 'U/ )P0.: QPP0TN*-'!(&E26 L&
M<@! JQ\$@$I0"-4("*K0ONRBW Y6Z*S2'&8L1:E\/1^5'G]M6 MT<7+S)M
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M,FF3.FFJL"-TK4 AF()"A=,9L (&V,$9A $..$ ?9&3_C4Z Q5%(;;C; -B
MQ4W-&K0"@/PD;F#'%H7/&_2!@ # #F@ '>48'81"_X!!&?A!2SD"6SS(Y4R
M1E(IC(:$I:CDM.1!%;""RM& #12"1JZ $QK!!X#IH8K *-A  HAI'0"E3S0!
M$>1C,^" ';37[;@,4:1 C5XJ=>681FH7C+J4*62D$$!J:<8@K7K79X"EGBW'
M# 1!J$H!5/"5F#)!2FBJ*01!$&2DC01! HP& 3S )BR;&_C8S4Q 3R%/LJ[
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M]0*L*<&&8"W-W0RO\;KQ&],D.ZZ"ST4!.?7$\^(+'24/*EBC'D0PAJE$+<2
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M-FR$HAB] H'#*)*"?2@##U X%0AX9C6'":-DMNA'_[!8$@)=C.(BLV)&HC1
M%M_KY ^/940^#!$L>QB#&)K0%?GY[C:6<T$1B.F!AF0M(@ 8P U00,QB'M.3
M ]@"$HBIB (M<C90<$ U-8$U&WXE)DJKIA*D@,RSE6"" #A :+) 3#:@@1 /
MD$$WB>*V BVSG8I@@R;^>""-M/,$QJ3! I*G1XN@@)K5A$$_!_* +8S 'JP
M 4,"=("0N+.;R"2+1IIY@F=B,3@$DAHSN=D4UBA F=HLIA&RLTGCA05L0*
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M([ -M(J.:L"@"CRN[,+B%OS+"AJA0:+@B(BO^';@ZK+/!UX@!7C J3Y@$)R
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M(0>] @&N0B%L( AF 1 J3]!F(0Q,(18\0&IXXP]T@ \F 6TX_^$)U-$%HB
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MDB8EK@Q*4Q&K@"4W4PPZLR@^\R+70@%H5 S6+3A.<X#";A9,00(^_W(("&$
MX"!*J<;\&O%-9>$-A\!4B758V1 "_K$,3.'U6O55[<_D'#$2'L&IX#0,2B,B
M/C4Z:94Z7Y(L\(CUB,( )0$-HB\\LZ_4*J >ZL":GD!J!.P1V',&W+-[QH @
M+W58=E"$SL+R( PFS.\2$6< L @P%HX/@""=[HXNBP\K#FD ?*"OK"#!%$ -
MSN!FO^(J& JFKB)K;L$5\N!]P/4!D$P#!T(/9*$0003=;#2S!E;\>)3ZV,(@
M"_$V!B#6CC,B_D ?.D$.QB9#4:!=!R(CC>P!_B  1*V29G:1>"/? @#\LN:K
MRB!-?2X2N#0X6%$,Y/3 .@@G-6DGQ0+6NO\ $&H/4)-"^H!I!]FK]!K@42-U
M '9 !)OU9%$V6 [,R,H"+ ?B!T+A=GSKD'Z !)A@*.CF %?A-K!MM:XG?S8@
M_(+C'\-@:*U01ZUB!I+@[\)L )*5"-R4[9S  ;OGX2*S=-1@%@3QN5ZA##1S
M(+&5*+0U--="#ZA7%URW>QR4>UCQ5SNO^,AL6P&@=1"HO,!@;>GOD![@!)(
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M#,Y #":@#3:@LM\ $Q)M%2YM[O1A%M!6> ;-0J^Z BQLI%?XAF<AK-L@"%+
M%#9@$(!W*B.A$9Q*P.04!%M@#%2P%-K@ADVA@1UV+"R9<@MADZ-O^K)B/7@S
M%>H 5V$3$PP+NT 0%E?9L8FZJ.WR#78!+5 .%[*O*/@JK!)A%NZ@!WV7KL;J
M&]L6"EX!W-R(J?_YM)B@]RX3V>PJ#"A+?3>*N&M'!<. "2KVN33/*8/##6P
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M)(FY$*Q \:C )!J@=RBA&D__:D94]J'&J, >6[ZC'O9:^";@P3/BO0KA!1/
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M=I1A[$4-P(K%K& ]8(<&@(S8$QAG=*(K 'H,/H44%RGP0>)**7 V(!A#$-,
M8.C0R8' ?19 )44[V..F03;=XD/_"L!Q1B2/7$ 8M;,#;[4M?'P.Y P5^'@1
M59%D[I<"/HRQ=]#<=^_]]^"'+_[XY =VB[*I9 (\C)UH[L,K(39(8K4\Q-1
M%;@<Z-?Y"[N-4!2V,$7N *.Z+CBA$5J;B6L:89P&R (_N8. &N0FA=$HH .R
M$,,4M":S2-R! Z\H WHP<HL95&%-?ME!%2XF&!YI[W?3&P$J@$   @P !450
M H(>$,)F.>1%74C$*K0FDPZ\@A530- '7F$PA $&B+IH& #OX#^$5(%X1 1+
M\,:0/(C8PQ:3N@C_K."VX W""EBH8>G4< 9#E>^-<(RC'.=(QSK&L0.-\\-O
M%* &#8P._U$97 53&O *#5I )E;#FOP@4"+B3"]J31B@@T)PM0M-[P^&Q% ?
M;.'#Z<DB '[@&W# $(! J(QE84A YWK@I! <,8PR^8/CFB08%79"-$MQW5\@
M  %84&R3W$+4U3)!IIG(@A6 RTC4[B#)I=S01+SK0QG20L('/D)^@($1'SRA
MO"Y@$2.4M(+Z'@*&%6: "N@< !4( 0LP:( 5M+.C/.=)SWK:\Y[X#$R&RO &
MI3B0>'L4CA6XN10]:&N$5LS?I>:@*;\\H ^QHMP3IR.*=&$D=$X0A$41 E&#
ME,Z!ML "-E>S@^BUXE)YT$$ 6$$WINC!!HYKB&ZJ8 5IF:\6]O_@0Q5W"0L&
MN( #)VB#$ I1@6UUBT<-Q<C*NF"%72QE0%TXV&!NL8.%286'2,/F+6IUS>.-
M(7V0LT<DLE:Z'V1PG "X112JD(A2=(@$27AK**(GARSF\ZYXS:M>]\I7-ZGN
MC(($ !Q2P <T .\'-'7J4VM1!D'H:*98T]HMN.;(KV6U,&9;V$DSDH=9X XB
M$!4I1AI0#2?0Q2Z9$@,K2\>R (C)9C*!PQD?(9.25H)T+<Q#%0!AV(QM03OF
M264"5G#%8,J$DCY"D ):0%.T H]=4VBF4MT S8?H 3D\.*0GR]#5P6B3H#+9
M V]Z(+^9# >M:M6!6>(0*?:J) YO\$W_7^=+W_K:][[U[< ?9N$'!-Q"EHKC
M434JBY&A)853;"%"="# T+9!#CD,*4P!L4'+Z>4AHPT++1$=Z 318@0");7"
M9B$"-K.DK%2N!)0-_:,X A(*$-)%E@G#I 4)L$$30^#AMI0"1.DIM:KU<"ZV
M"'4PV'XX4PP#;21@"!RNVM4NB$N%_RKE/!)50YS D>4;,@ %3C"  9P(LY@K
MC-\RF_G,:$[SSYXIX@8,(A*>,(X"W+"LP(XV"F(XL&ZJH5K)<HV,CXPH9BDI
MBA&3.).<@BB39?* 3WHT(SNP17*1]1DK8$!OC\Z(([KPG _80[5D4VHYMZE<
M6! " @YQY90T_P<DB!K7O)/&B!MD804[#ZH+G\T8UYYCV>R6;@"RL$5W!8,\
MVE;-FV2]R!Z6A58%$$JG3%& FJ=-[6I;^]J646 D,@$''4@"MP\Q8AG\H,;#
MOE)05ANK_)9F"T!CZ&BH&*F#IB,&3Y3[N,<DMY*Q0,0!_"$ WUZ*?ITPA0:Y
M4 P2 T,%R.BDOPYT!T=(66'@L)TT%CB#&3"" DR(S*5\H ^SD-4/2U1HNQC1
M"?J^"..:.!A,F6BCX(D$*HBX5>*ANH6(385B'2(R2Y6U"V%PK@I9@4N,=( 3
M5V@3MI?.]*8[O=JP2P0?HC"+14]E<*S(W0#R<(9:5VT0'9:??LM X/^F_$'0
MA#$O%Z8@2@BP:Z#3"RWE@J<#19:5K2E'R LJ0$6$O,()G:C@4JB2B#O\P0FK
MD#=8"&FPW.5-#'(@@ + L##P]F3&KT:NH:VK<%Y?9 =@9^9@?J+97E,.V,*6
M*%B0UVS2JK:\(1BP<]_7>!*^H@(Z#?73=\_[WOM^CHP<#GM66[H05,&S(U[:
M%9N@W;0*(P#-VP_4].$/*3_XLH3)+!?VIJXYG 8$S4>(Y&RVU3#D0%?J\I-S
M-C6 *' Z\C)![+B5CJQ-LR(1/B:,\@&UQPZ,H0(GMC++(G(]H2P%\SBKD2FQ
M5GP9]$?'=7LL)QA4U06Z@#"$)',TQU5&MA3_U,)2%Z :5A,(K!9_0.=<&[<L
MU*0TM3 \Q?-[+OB",!B#W$-(^@!P9(8LB)4(MJ$(O_ E84!%HP$CJ((#0A47
MI7 :_D,]OI9]IY( 9X$)1: =80 (Q)=HD3 Y=G$Z.H@#(A"%&Y(#9;0#U0("
M? ,[^D!TV'1!K] <DF \AO$ -E %3U@$(U %.I #I* :#S!!K$ 'BN  49@
MIO!_^2%,"U@2[!(F,: (=E (]1 '.N!&@A%\^:>$E--HW*5X2^%**Y4":0%9
M\O40I<%L!18%&I (6E '/#@&*3(ZNB>#L!B+LCB+E $[MC +8U(J ^ &+V 6
M&G C;\ $X(8L67 ?_XF0"%(S"2XP!H*0A!"F>EI$46R0%6&@ ;7Q*TL1<_P6
M;2$0!85@%F9A!9B@"==B'XY#0Y#S0*R#(+"C))GPBG:A!R?@&F$0!V$0!DR
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M== 7/7$ H7,&M<%>5E *:R UK"L3$(!'.B!<0F$6=0"X35$N]V@C$1)A@G$
M"L N4&R-H>&&2M,"H7 &)*Q*$0*I"^8&EW/&<6"23% "QK$TN.8 (KP2*6(%
MD)J]?,RE]E$;XPBV=A ?AA,3<,A4@B@"G. "66$QJS5GLO W/\8Q\?0B]L *
MJ: (#" #CA *98!"^]8@H:,#K& *'L  *& #A<!/\.<0XC4+D=($FD Q@RP&
M'E9$MR>.F@ %\:DW7M&F,><1_Z7@ 3>P!758+'RS-HAL!5N2%))GCK:A"9R0
M!8,< "" 6RLS"!1:.C-P!H! !-@B'#.I&BX4  /)"5;+5N8Q;$/,':B+ @M
M'GSA%UMWAG>@"0R0!2\0([/P!CO%%'NX4N/("5MP J_ 'K 4,N"" SL)MGM7
M:[@J,JQ0!Z<,!9U,.$6' #!".$P@S9U<=TPV$WVP<'4@S?&I 0$P!;B!+8Y
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M_0%P6=0 AY=R]PNY(7!,/[Z)A00"K)VJ1/2;NN"?D\<Q#BH3G*,+2OD7#D.
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M!0HR"3E$Q%$HORJDQ$JT1!B"@# ) ]5(A #(J"+BB8O2_P!/Y,0<D)*O XY
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MY:&+/N*]&_B#C*HH .B /V"%6TI""*@VB@FFO+JEL&3%IA0*5;*2)FL2'0B
M5-!)'[R!B7F;T;"P^$&8M.D$)DBY"8&"*%"1F/S)QX3,R-0.B3B+'Q&,6U@
MC&F+M.$#O-R8'V@#5-C)/)(%^,$67WH@)P@?=G$JDE$(!&"(J" +OW@%*VB$
MDF@ $H@%&("(LX0&FHG%A3@!"5@\7Y(=,2 #5\J#/=H/=GP%,4J+:61$DOB
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MP@_AX@$/PHCJ+)C[-!D#_ IP* ,DBZX@X"T,F  ,P $TF,15U==]/;]!(8H
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M-84-6(,SX +AX$X7<X*DW>)6=F7  R-#)L54\-:S3$LFV2%93@1]2(0/ACU
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M02$$C4>8=!?TN3]X==<YIH-!C5]+EP<V+,\,*NB !3AZ!8#XJ+'!FS%ZHX,
M$MCE;"R":]=7"#@!U7#%,&CQKVB!"4@+L)@"!TB"##A*)/!=3;E"TB]]!;B!
M+,CQQ9L6!R@"17##$QFQ'#\!.IB$HVQ]0DBM2.@C!' H'/< "@Z!'/\W OB
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M5@_V4(E?I"EZ,S #&E@H$^ )KR..4-QDA$5!!<R@&5[H'P# 4(E%O2H63UA
M"FF6B3T( @TA&!0!&G""L\V@$Z+S 1>3T,"'78XX$-C ;P*P JDQLI&.?"0D
M(RG)25(2DE1 I-"><)S=%:()7A"!)OKV@20T8PS X4< 6+$+ +AA!$%(A!A0
M,01'5&$6;Y!#ZA*ACR/P8Q9W:&'*_- 09ZW!E+P,@!6"]06LO&8!*SB#$P2Q
M!F%.9I1RP-X".O<@*-C@E6(  16R.025->06?\" *08Y _]!#.$/GX  ZR;A
M((=0R2FWZ,,D%C &?G#!'\BL@U/T,PD*P"$)GG"(#_J0B>KYCB4+6 ,T!>$
M7YB  &#000"XT,L[*&($JW"(%!?ED ;8@!HT:(H%()$#%=BO&4$H1$9_$P;'
M/:@##SW#+#JW@QS4:@^^>(0C,$$&E#7E6@ 8'!$(  <A8&%F45C%4%P)RTFX
MXGT76%8$K=F2&5$)%RU\ "\F ;L>2>F 0,C#&8[@#WWXXPX]T)T:*G#, ("
M 2?@ZA'OF8$M)&$26S F*L6P4$&\8 H-;<$:Y, RS]T3%?I$Y1&0^5:2["$6
M'HA>"_8C,P6H3$H=2D(K?K &(BS_RP1T9 $8,/'6 <R@"1?X Q>"Y@0F+  3
ME"A(_")($@(@H CZ$%H1*BG<X1*WN,8]+G*3&QT'R!2>QM'*!-[JW(<D00C[
M ,$5GO"$*Q!T DS01 @VP0.A#  *9VI$'MZ@B.P^ 0@4\!LP)$&0#\1B#1@
MP2BVZY@&^*('!]B#&>J@B2&FH!O6*@@0(##*IO*H@"2!Q 1B,(KP@L 5+6C"
M$("Q#,_R0@@X8##_\*"R]S; #&(ER2UR"P"]=HD)HX#"$V2 TBVR+00D."A+
M!C''_A' !YNH Q&@P#T']$\!8#"%(O)[!2#<PPXG.ZH@2E C=8#@ O$SK:(D
MN(+KOGC)_SQT2'B!+.1* .$'VOS !#S@B#8<='\]"\RV$+"'-F"!)5%X!!S>
M ,KP\H &O) (X+(ZJ/*U!@(_0)Y#'F!B"N@!">-5 "0BT8HC*X(!^07"/"$
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M"!+*9$$!=4@%@DU330FJK( %\H 1*( C-(,(TH$(. ()*<] :4T-6N"YG!8
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MI(/4A@MX0'MM'UG.I)0- %VN&!480%(4)@PLG4.P1&%JI4]2)<I,9KI<I28
M@6?JSA4X"'NH!03H@5!T!B>X@EAR)2$<P%Q6Y8K-IET"P$@Z).0,@0'L9D%
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MO4+Z:J\8O$ZZ[$$5[&\%L$(&Y$X(F!+W#K!:I@L<9._V5D J4<+W.D+X/G
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M@/&C%\&4(/"#4$3"%)3(^ !"8(8,V&JJ24 #4*PF%L!BJF)O]BY J(JOAT3
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M%0: !OX@$(A _.Z ")9F:=S(#XP +WSJ O#O%53R MQH"H!@\E[ %!1A :P
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MA@,L(&#_ &R46)N6,6+@!8*Q"5"@"@Z2#$*@$.*@$S#!!KH@$9X6#FS!%)*
M!&( !O@J&'-&#1P40H@##AQE%.:@"^ H>2_ 5FRB'C!A$)AU@][ ,E]!<8F5
M$KSE%FQ@ AJ! ,0U!SY0 U)! B1@ V# 8" U"?!@ 5 !!98D!AQ ":2@(-,)
M*,!.$%3%"C"! T[ FDQ #Z[@ J"@<T%##7B5+_RV%#9@#1* 62%A.><W!C1A
M,D*C'U$7#?QN? 9"48I7 I 7#>@6!T )%K)7 7!V^0# !^P@%3) #5BA%3CJ
M0T5@*1-@>:*@+0%D!U"/=7]@$*:  C('=!U $P #7\I"#5) _P[$AP&BP I
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M #1Z>:  "$388^3V7_F7#^PV###A%ZSI__H"$.0G>R[ F-4I+#E!M)45L"%
M<&AC *) $&)A!*![!*S)+O3 !1B  4HG98U" T[EG@IF3>Q&S$;A E27./1
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M'?1!-& *8(!SJ,!@D@1/5A*6/1P-IGT0 "'038$,%B/=*<#*<_J8%>,5K(0
M-)&#R^ =.OT)C-Q[&F%T;H 0M+1P;H *P-5+&B' 74'#\QD+7 $%7J ).A,\
M93$L4\@3=B#MI=W_$;[@#E!@ YH #R(U /+5GJR0"B+Y7PD@/F$<(A3H!LXZ
M!TB!\I;'!DS!$U!#XO.Z19'=TW<@VL5U]I0B<4U@MM6>"AQA$&R54,A #T:
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M-" %F0.%(API@RQLH0M?N))'10J&-*RA#6]XPQ'24(<X[*$/?_A"'@(14 J
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MGKSE+Y^I!\@B$EK8ZAN(,(!:O $&>2A#'/HS;8-AY]#YD8Y7,G #()B@.9'
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M.2,PCCB (L2S.*I7BM38$R.0%A="!#/T 4(P)@@P Z6A%@>Y4<8D$.^W$0?
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MH-DI-DTMLP<I\'QOU#8(@0 6%@B_!U A.?0FX5Q3$)/G"]L\3R2-,, -Q1R
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ML &\@)_4(<8?W$4A> D-*A00X 1HE$9&@9\Z&,8Q>#K9  $I@(-!<()*H(4
M>$84\(@'0@S)R@0%T$8;>X U2 5<A((K,()]ND=_>CE>JP)=H(5"\ ,C<(,^
MB,$A$80>H#E]$(4/K)"NB+<UL0@WD$@$ !Q7FP%60X$-P $%2X0I&(],V -H
M*X'<HXPH +1Z"8)WA$8@4(H"\9#6BHHY2)F$J8! <#"GR!BA6I,,(8IF2*K_
M&8B$=_C%6J00.V"/7R0$ [2]/$#'19R!;00"*+@>-.B 4)C*7#2/5J."!6 U
M(.B $: #(G %W/"#$$B 7LQ%.UR ,,!%1Q@$'>(<+&2"7S0"2"B("Z@%NT0
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M U@0EMB-UHM=@7IH KWIB!1@7>49A:+1U* J@=3M@T5K7<O: 1W@@Q)  #"
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M=WB/'_B1#WF3/WF43WF5#WB/+_F5SWB7UWB)C_F(IWF6OWB<K_F7GWF5MWF
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M=\!]NX,/;QH"E0N$" !0 .'" 04#S*,_"_\AOGL*7M6CGS\?  0$ZP^D1\4
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M0,:Q/, &0:B#TT@@@A+L01 LH.57;J$.#U!!!G+X)%T4X(8^2"D^#UC#*D5
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MM +^;5\.4F!_?(!)J0B$H. K^8((F #%^%]\0, (!IF;N<LFU$$%RDH3+!P
M)B#T44$(F-03/$%'.<(79  4* %2X>#_"10#XI^OH8(1'"#UO=Q]U&&%P $<
M4IQ85%I;)  4;)<+M(4#@$A9@)JHD5IIG(L73$^%U%$P&?]7\ D"'L !!F3
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M'C#U00ILU0J,K DH +B1 @' 01U00GH@9QOD ,%LGAPX0K@2P"VT0#.0P@X
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M@&2L!-J(+0^= : R6]31+.G< (9%? S(&[$9QIV<Z2Y'CX*%NU3I1+;C)F!
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M[5"C1P/$@F4%C WDXIC-P2 $0$Z7P21I* $4-; E] 6@@(32W2A(6^T"(JH
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M 9N(!1#@1YI2@E)&D(0E>!I@!E2HH$]G8M^T'N"E/KWR5&DR4C"-5"YP!1,
M*@.7)"]9HC,1<B(?,,,DMN 3(UQ DK++D+QD*2Y(QO*7D>S_TS9O6 DC$ *9
MVCSEAF!'LDA"X#5?R ":%%6A4[TF$$8 )9-D!RZM*8 0L'/?,X5Y)+ )\TP'
M5$ '^I!%5"4I0ZG:IZ(TE*%Q<@A,&D*GI-!YIV9"H**AI-4VR^(#7SQ0E)4D
MRRM)Y!(LD$:E^AG 06@Z@9K6U*8V7<$3]$."C.3TID %*@9(H)\G& 2G!YF
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M!/8 %TB!2C"@ A_@!,P #6(OMV0 6TJ"&EPC!"BC 9H!"]@'\WICH5 A#Z:
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M.7G/&G- $SCA28R ??:/BCK" ]!M (73!/A+(BG2+1C0*4CC%F1!#O( !YC
M%?A'M9Z"9.;@Y@A  =R &=Z!,CI$3>8N"#( #OZ3#B8A!,R@#CS@/-FM$J1
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MPE*.*0!'( [D $0'9LB!P "UX #$#I<!T, :D^Q66@MC!,"*'!?L4 <E$;7
M(T3 !!G7 K'X^X :G["GAPU-2$AU*W  T@J)(Z#BR@*"^ L1'#A0$M43-SCR
MAHN0Y$!$!QX ,= )30S1@A4N5DY*NC:@XOE+#VPBM98X2#BV Y/ ]8$9&=
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M!C'(H0,B0@""7 E+,60L,WT<PRP"T8IB'2M9 N.?"N" #0L00'R3<(0$*&'
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MP03:T @( *,3'G" "S2!D.XY@@YL*&S5\*G8#]CA#I1U@0LT^B_)4G8&!/V
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M))QP!7#Q*[X$ 3)P!;25:3#1=SC"'@- *-8'.CUP !!P S+ DD-I!%0T %1
M"%'!"3*P +ZT2;(W"A>P22FYD@@!?"F%"Y>CE% P"DBIC=IH'^6!1A+  6S
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M6V '9G(MCP ,%2 )2L4'0E *I= 'K) !(A8%?$ $3S $5 9O3_ $1*H)(V"
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MT1WD@0 !H "?$P1:H(1K@"ZWP Y^$ 4)D !/<BR;U!MUT 4B^Z16\8Q3*A#
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M&'9I+1O@ 0TNP@(Q %$0 YJ@LXJU&1F@2$%27Q) !"VP+7+8!_"V *$S:6N
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M%I@*,O#,@/F!08B#3I ")'Q+B.O#W?1-,_R-: R 5-J#-4@ QZF'?0"!U:2
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M,=J!@^($_*HW1RB$1\@#4U $2CT>$E$#?P 64.&/?"H0_E"#,N !%"@Q_<$
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MTS;M<GF(-BCMUD9MUZZ'0FB#AU" *WCMVS9MTZ8"S^9M@ICKW@["&R@#3F
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M&V6&]T*6'411!P<CI, #!8?!L@ =43!'@'VQH+ !%D7Y\$4/10TP0QTL_/5
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M2AZ5C'(#"E]0DJA;$'Q@3QAQA#%+*G)0<%03H[CR0R0][$"'!ZX\\0299I@
M00.3#*'F!%@\H$XLKM0"R"A4_) "$?^.-$$) ;>EO9<"%35#B1J2Y'1++4B.
MX,=,#3#3 [D-N!GR7@]$4488"<21 @XF[" O 1\(?<,"*KT6" M[5'(5:D.T
MD$0K'?2127\NP;587>DS-8$+BVG"[%U]+1: 8=OJOS___?O_/P #*,"6%.$S
M0'*;'E:C@O[PKA"F6$$0$I V=JF,=['@A*N*TH!!9()61'&$!"B!EA P(Q.W
M> 464, >!'3@.(5(1 Y4L(<8\D<J>E #\ !P"W P@0$84]E<'L +5"" :!8
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MA3*TH9OIUI*N8 2TS, ,GF(*Q62C"1?$J30SS(G 8C&*[*W$!\,+_P$=T$
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M80%)M$" $"(3A"9PPBA<P '81Q.X B<, ;GT7_]+0( >R, H$$);#( $HL4
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M#[1!I7@8&%"K Z !%-@!!F" &1#!'%B!(CC*"ZB( VS4O7+ &$R!"RR %<0
M#%!FE!8L7A*C.$:!E7*@8\)"!?*?P[K-0$0E!P;B"?[@#/B"IQRH<A;% 02B
MB'FA 5SCQI@!)2RF(WQ!(WB/3%AL5)(+5$+ "7(B!&0L"^3AQ0:.%QK!O04B
M+'1 =84,5>X!#LC!CRB A60 %-2F9@W  B0!*82 #5R'\8C $)#H(U2$&<#
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M "=L;P8P8@C\PA0$DQ]TB+ !J,'^+T3696.$E!1<X)"2@/\(L"< B*H(*,(
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M@AU4E@[)0B%,@<K\:3,006)5=[WSF[(V!A5 [Y>1 1JF= 54G9S= 1[XP!J
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M(/]8;&$#RC+0'G  O<B&5K4$"BQ>D9O< :W@0A,Z8T\.T(!)E" $OY"#*]'
MFQ@ #@4Q@,%8]- "%OS  3$8A6WVXHAF8"*K1'"#"@:@!"IT5Q..6$,='*")
M!9B/ "'(PKQ<&0--C&4 8*@#$] @%P&C( LLL T3AJ .A@#!E2+PP'&5FV$-
M;YAMB^3PA_7H2R?-",,@ME(#-H"&M!;H 2WP+FX'U !U',3$-;8Q@2:@"0I1
M@:IP\ #+LB !15S5$3$X 2H<08(3B "5'5@ $?* B0WP8 $D$/ "-E$'.X!
M$WGH00-BL8 BD$ 1),BR#20@ A+<"PPQV  F2#""&/S_&"MJJ,.1LW "+XB@
M"$B 09*MG 17Z 4)Y57"BF^<:$4O>B1U8_2C(>U44(8V08&D-%9\6>)(;WIN
M99Q0AGPR!R7 US9ML' 4*B*(%]1A S@ FAX< 65*?  $-B!!$6"P!39P  ED
M^-674;$)(E!A")Q41!0PT(H&^,($8* $%!2Q@1$48=1'J<4N&I"$%Y2B#4G
M !(\8 -EFV$3' A"'9*@A"P@08Z<=O>[[>H #,";WO6V][WQ':&OA8VJHJ:
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M#- LR0+TJ*2T=+ AG40N*PTM%7!'#F!' , MCV0O 0DM*0TN-RLLJT0P;8D
MB$LMR]))SE*4^%*UQE('VT:U)-- ;L I(60"&(!!H#)"'" K%<0!>A)"*H N
MO3(DL?% > -R#@1W=. (K: 4W,>K'(E@+$ !YJ *.H$4)%,/" ',.@5N$D40
M/@^0\NA)RJ(X%40!=D W2<4X'*$+*B  IG,6&B&<(,2@X.H'QB ,0("LCN(/
MFJ!.1D* 2O^F2L B8P;D.(B30%RS"$TA%GBS208 %B@@A?Y$T^)J!*I #%)!
M/<$(Q1CF09KR*:.2C, &0O@Q0; R0@* *T_S*.UQ/>>@&<[30!P# \".$Q9@
M!>"B;#8F%HR@ R8!+_J@#F @2=3&,0)O V0';N)J5D#T!X(".7V V23S !Z
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MK+-X0:J20:J<-,=8K>71:R^C%LZ-AY]BD/("%:3@!EI@RL8"Q;Q _"8 %:@
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M'(3\4$E$(TI PG=(D- $BR3]L$$=BCAP@AD9(/!!8V FX<$--O!@P0-Y2$*
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M !,HD+2),('BS6-F3RB7%*A3GPK5J)(DJ4;10PTRJLO#L-0I(T+#31^ A$E
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M^[[^(OFX-8:""Y0 7H=4 @$.NH'_:OQ019/Y?3;F1'8/ (M14+>)*E& #)[
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MOO.?[ZK?%F4/2>#,"/BT!1M$:0]F\/T")H"%&Q!I[HX0! K:?@62CX9(1.B
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M '^P"N>QCTG0"FXR!2+Q 'V0 5 @&I2B  W@"_,R'4JV&WB@!E8@ 5XP BF
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M_Y#&EP  !SC 1-.E"59I.@K[5@L3)8CD"T1@&]31 2-PI.A(FI2@9_I* CQ
M PMPE0:R."*!2!XH73.PCF"0@!+'";;'-I(C FEY$1,7"Z-0'R8  3L0"$I8
M";B15A5(@D; ER1%M;P0F#P@+G 0"8?I$(D'(A9 4E_Q 5KU,(E*F9;)"V\Z
M &EI.IV)!?$A6 _2 +C  B&0E+G1A@>H"T!P 1W@ (OT((FY2!3Z7.8:!3A
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M/@8*#G" !X:  K2"Y,1%RZ\BBN"!41AD92> \<.@D 41:,(($) 34E%P A'
M@+]<.4HS<#"*&VR)PY.(#TA0@"L@W#,K>HA"+,)SBQ_0(3[(P54F*ZD$#GO@
M E^6,X1IG&2=0(S!DW PA"6\VU&Q "8KBRD15O/D&(Q";%<IZY:KJP<9!'D
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M M@#.IB$&QB!>X$% NRRJY@T#R" $KD,GJ,$"/"!-;D 1U"S6^B#1P@!'/"
MH<@ "Q@ %Q@",*@$I5 _.WB-@]@#7&B%_LN I+&)_*+_!%49@19I@;V!@!T(
M!!,  V=A,NGH"!Z< A50 !D@A,V["CW8A$DH*$-QBBG4/Z/+C L109[X 3.8
M!+C; 4!  P2@-E08A5H A%9HC4XP@2-$@:@0EQ=LA0] A5%J.RSXD"6!C!R8
M#$&  633B)7@B"DP 2_$M).Q$T%@)R#)E1"P@S<0@E50"#Z\0\(J,!  C1_
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M>B,+&[,>%0QH(?PO<Y,*] RY  'W#2-H.W0/.:!\Q^_I2RJ(.P0K206PYB.
MP!'D>/TKX]/'GQXN<%43=.:%%-\-A+#7'GAG947%!?7%A2!+WPT!84IQ27'=
M@ONUU%B''^%&!01/W.# 7YP84144?XUR  2R":>)_X;VE78  1W YI%60^C8
M46.N.0#:%4,T)IE]R<%P 2POUAB;:ZM!T5J-,HP"A29!?E3$/C+%QR4 "HA9
MTAZ5H %!F0H8 .)(\4WHT7AN D GF71VEJ>>>_+9IY]_ZA1"$B=L4(<4#RS
M@P^;K#!!$T L\,($A9B""1 [U(/!"F8\@L(&<IQF1P8#+!#$!#C(D=T:"=0S
M02DD-#%$+1A,, $3L8U01RL/S. ' 7J,8&H3:%#6$2Q9;-!,'3%89Y(;FKAR
M10D=9-'#F#-XHN%'B%K;T1QH:#N2'IIDX<"()'7 298PB/2 )N>FI$ 'E(@T
M  I)R('G2P/\T(.^B:'1[_]'S]*G1PNME$1MMRT1K!)V+1 Q\'+ZGJ0 ')X4
MV]$ G&@"A1(S9$H0"Q#\L(&I=9 R *::TF'8?FZLT80)$,#Q1BO[^4 "*B9<
M!T>M&&"0@0LC,#&$(S@0 <$,M+:\Q083K(!!'42L/$$=FB AJ183"-%&$XY4
M8@*='"!UV0>QL$ QH&NSW;;;;\,=]TAPX-!&*%9@T4$44S@2"29YT.$!)R<$
MD4 ='@P!AAB8G# &("?@, D"(?3AAR.%,-$X"$"@L, 8*=3AP"^5K--%$QQL
M\,8D6[S""A8W[$W #BDP,8(9&<S7$0*P=- ')514]02274& U0#&E^:(!)Z$
M,,+_(S<\H48&PA^P^PU 7*"'#9ZT]40ME)R%W1-/$$( +&<-H#0F^XA !/EP
M07_; %10 04#+OS2""$ZGC_F'#%0HCG7HP^;]'.\]0 ! K#(@Q\N0(7RZ$=>
M(P#!;>(G0"!@14&V*9'PBJ<?W%# *RR8W_7T PM7M. $:' #"V!! !>993TN
M.,'()G0^^SPA@2'XA;7L0P7J60]["AR";?2 /2A@<  YQ$I<;', ^P"!"M5S
M@PB,<+T)-4 $)<C8$(57F_+A$(/VN8$-5H$ $W4E!">(P0F8D =6,&X2A/#!
M"]X@@F!M[HV,&\,46-"1!]2B#*;H@0+ $(BT=60/S> !_V2$! 8K2$ $1= $
M&<T@@1=,X0(AJ,+I0M$$)(3"%"(X 1L2M[@1T,X!P:I''8KPBRGD80H\ PD'
MOG29!US!/W+;)2][Z<M? I,F>S"#W69Q!TV\$@RLF 0#V  $ MS"!F:PU@!F
MT D\7$ -=SB!&1HQ.4SFH1,\<X,'>#: 6N"@!^?,010Z@; /O*()+GB%&$RA
MB3Q( @&SRP #', ))'A 0[=X!1D.\ #%P. L>E#"!7Z A0OPQ0,GV <(MA"%
M4FP@!E&XPP9B@09[D2 &T%J )SI  @DT WQ96<H&$">P'^ A#SC8QSY>99@.
M$"HO;OA%#(K@@"RLX0XQ4($"LO\P&07L(&A#B H) CJF+*2I2@X(J0=<$04^
M,(!06N3(3D$P"IQN("\_.(%'D4.")%1Q!R(@02Q<(0.GW$ &)L@.&N8@@HQ^
M="EM( $,4$ $HT(@A8ACZ09(T0)K_4 *>G# !DA !"B<H(=VW4!90!H#&$Q'
M(#% PJ=0  ,7("$&3;T 6*M8EY"B 18H0 4*1A +.1S@%NJPD8\<(9!8. !?
M3W&!5#Q !4>T806K"($2I,"1$-BA%&W P0(Z(40 ^.P1%+C% B9 "6MB3PV
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M#61 %-S,#+P<?MG!'4C !L" L_4?$7B@%W  'NP>$_#?#KP#/8*%%W!?!G2
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M!S@-#K!!5Z:C%GA"?4T"% 0+'62 *^3!+NQ!$*Q "DB7/DY ,Y0"\Q3""B2
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M1-<T3O_'30_%3N=$ <?S4T-U5#\U2$NU3T"'$@@RGXAS"80+A4''_77$ 70
M58R'4C\UV51U6JOU6K-U6VNT67,&+Y_=3*,%7'_BB?]P;!ML0'&T!&^Z]5\#
M=F +=DW,#X1TZ&.IRPUDB)#< +QP- 0\4%&?1 =,1H) @62[!")[!"C#A%B_
MQTO("ZL*!7C$258T"$AP]DFL!U%A!67O!RQ00;=Z1'E 2&'+A&W#A!Y005?#
M! 0P0!&T00(<P0]/0 C>P$IPXF K]W(S=W-W0 MDZ@<(P;TA)76,2'8,L'I
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M__"R_R< "40T2B2WB$O[M%-[VH$46AG!_X24G-N%7B-,.O*!0(K9+[#!  ^
M(Q#!_ZP@(B78"YA"-Q!G#'P=$FP[^H2 5$CC=[=6# A'2!7!1-H@4U1V6R"!
M!# %%'@!4P"!&RC!* S'%M"8>2B &F@G"(I 0K7'K G\8HV 8VD2OF^4!$A
M@1"\P8N *W!A66B<5+!1#!#!&@HD%_+[5/$[:4F%"(S(?,L H6>!)MQ\EQ*!
ME,N5IHKD#V3 !0@6:C %&VR4%\1 SL^!$& "S4NCXHG&BZ!!0\CH'T@"U9:"
M!(@4"MB!RHE 5E$6STW"*-B6MX-$P(L4%<A9#!QF1Z@1"?_$V@_D"E.8O0@,
M01:4 -;?@ NH?0Q05H>LX:&UU 4P517! 5MI LT'1@?D(XF( +(O^V;.\ ^'
MP0IP0DKX=;6#?NB+?B\U0+"YP"8<('O:@+_N>A;H(%K P<Z!@9HA@8S_Y"-
MVRBT&8+X@!?4@1V 0 >\ !DHI9FZ-*+@FJ>"08M*8A:<P,)M@!W4&7LF*L\D
MV 1!01]T _67+@FT 0!182-4>1TX/1$L0*FWW!1P0J*B@(QRX97AV@B\PC&M
M&DT"/Q2\0AO$Y^J? *+9@!  Q"1'/!" >92GCH<%+^HPR;*!$I@I#%[(H0
M0(@BI'SX^I7!511/>3(8<>- !<;_ 9O0J,D!PX8=3">\*$*RX=<45R](702P
M1T*=$QF@V.F!$4(M#X[,,'&PZ9<G,)(N@+FCR88B%&V8N'C5IM$-D7D4G1"A
M,%8KC&OA*,*JR,&"KJ@08 03PX$(&"$V9'#Q8A_(*!XV+6WJ0)TK-3K[]#@
M $ZI25F*:%H @D&?77GN")10E@0I6*,(K,4XA(0&?0%8LU[M.@P'"*9IFW:
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MKCTT(P%-T(0518F)( BV%<!D A1.\#,B?>__$8\1'SC)X(:ZS?:50;,<$X8
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M+@*6!$2@AM9B %"@"(J'"!BX$[Q@ V*  1R !&[8 Z@ !9+@!#: 91\@"TC
M"TA $8S@!D[@A$V(=$JJ$C#D#62XA@8@"Y!8+QRE6(5XADO@ 5R !$Y ",R@
M%?1 B+V@$.0@B8I';:AX$@Z@ Y"8!"@!"H+8"T2 %$Q#BFDB!F" "EI  GJ8
M"?[&#91 "B  "I! $Y" !#"AB-W@:QH("8# $9) 9AT%B)$X!I3@ O2@"$A
M B9A"(+XA*]@"]3X GZ 96\A"Y1@_VVZF&"H0 VL  L08,A")Q9.H).[9 J
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M4-? J!> MVZA#XB 2P"G",SD#M@ "5ZA$7SB S8 "Z!@ 7B  +K9R$U!$3A
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M.&</F&!FY5W1ET99FO;- 2'\Q3T%S+X9B,(&YCYA):';#W\'8@!P;8O_%.:
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M-'+0+8[\7$@&FU&B@!LVM-)QU_5X0M=-$W#!#Q>RTSY[[;C??GL )#F 0:3
M!R_\\,07;_SQR#.J0+[WW6"$2 I 0,4%T.5[V !4$()?5M!!   4HQ@AF3J<
M#N"\]0@=@+Y&O4$PP!#4AZ0'$!?@IT!"A%RI "P7'- ;; > @/,(T!L%9(^
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M01L0AP)?6&4*0X"";WLN@:B;6P0F"($(&.""/C!!!B1H@BMF@&$4-(.4"&E
M#"9!!4?_@. " ))H%)C0\T><;@UH $,GB,!FLVT <2TP QIV\ 8/N& -3%A
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M?P (;( $+X %*C0#[6$#F?  U]@A,\ $J69^@B4F6($P&U!9(; )UL@'2.
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M9CH)'7@++? :/LBABL )?TJD$] #<-<*ES82$\!Z5>5Z(9$2U3FLQ%JLHJ8
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MF(.3'D W B#P"]K*K'1"'?EZB7* BI5@!'"0%F++JOJ".;50:Q(P"32 <F0
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M>XQ>]W8_G3]  D0@I=2^-QW #/7F 3<HJ9I@ S](DV   @/&'(5/@%G0!YX
M!G<@ IP@EDVR ",/!DTP!,,"BT(L?0L ".JQ!A\B!%-F VWPC5C"!Q^BJ:=N
MD3;0" /@R#H[!2>P#YC@ II0 HJ7 S(""&AH!YAP$5.@+AC6?(\P XEU [7P
MWX>Q YVP[)LP>9R@!%MP CS_N .BL'5=S#>4.(!BT0S=X+<_T :^_MEFXPNZ
M:MD2H E4T (O8 K ]_<UJ1])$(8CX/<YNP. VE^B=1@  642%!1?*,&IH^F&
MC"NN'/&@TD%$GB9H!BR(P89$!@0-^O38 8@(#5XBGM@ 80( A!V=6H5HEN')
M@B) H+#AY.A+#SA-2OP0080  %AYI@"YT8>(HR1$+LR00&1!)1-#%<#!,>G"
M A(>;.#0E&50I@, X)1BXD*3@P5^"#1@1FH''4I;,]HX^B,2F1M1/*"H0TG/
MU"&.<I@(R<:%G16EY%"9888% ,J0*NX1X65#(P@=%(W2*8<"9=*E39\^G4 3
M:M:F_ZE48.W 3&O:M6W?QIU;]V[>O7W_!AY<^'#BQ8T?1YY<^7+FIQ7L8"(%
M@((.;1'<BD)$SXDB#M;$8O"K$8$'?4A%R4!!P0Q%#E[<X7"BS:,.)$A@\G!A
MZ( 9E8;\686 ]9B8[($3>+@@#[=NX<6#/#"(@0/[>J#L.?_RP"'"$3 1801/
M !@@.SBF<$!"$D208H 6*C%"#5-$X& #3!SP(H,.7KFCB!B9B(()$Q1H@005
MRGI.$@INJ<4#5UHHHH@1S"!B!TDZ\D4)!)AT;PH.BG@! TF, *"!$TY$D;J/
M*@0C.@#V>(4//ZZ+@I*APMQDDAO:(J^/5ES$9$?I( B!!/\V?OG"DP4R4 D"
M"*!8X$, 'GCED0O,BM"+1A ((1>0IC !@04&*H(' @@8  PC&_!%DPN8' 6%
M)D_8Z8%-O)I$ND>MPXX2](Q0X(>-'*G$ M)Z:@6 '[S Y!4M3]C@D:'$M&\2
M!JR#JP='0  " 3A@/.'2/7#IU*\?ZB#"0!X@F"/8/U[DX)<@0,"#NDV*I4Q6
M)4YHKUM,25 $B4+G%&X"3GRC(A'6BMBG.8479KAAAQ^&.&*))Z:XXN7@8 (-
MHEKXQ:T0R7#$C!DW >\$CZ,@0XT,>*TE!@=^:8(3%T@@HP.9OY)COQ:F^&^5
MT<# 1#H]D&ABB!DD(0 [&!9 RP'_!XJ8;#HI+0"CZ:<YL&&51_L N0X/&&#+
M#"Q4S,$"8 !1[ 0/7!"/AB@ T<2%$2C)(SH%'%&'7I:,5* 6-E#8H X'3IA
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MSP98'6I"X $T5Y%] V ?90!-FP$$FC2.-HVB_!SI/H,(!42 @ ^: 5+2#,
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M@,2PE]WL9T=[6-<3A":\[ XDB $:#A!U6+A@ S& @; [H(0%) $-JY2.BC:
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MUX7=BB,!N(U9?@#=W_4-!!C=Y,6-(%""H(N#IUU.U57>XAC<XBA<GI/=SR,
M?J#=ZQ7=L,U=O=U=U,W*UA7?XO "P"6.S7W;V5W?XZC;\ 6.O)5<5X#:4)Q?
MXE!?X7A=K$U<S_M>^^U?WPB  8!<\[TXIV5.:CQ@X@C>X0A@C"M>^8U@X8"
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M R+XY%;V!/8) 3:XNM:H7$+V#7<<,!!@ +E9&1P:@!#0&MJHX(MK7S:.!0=
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M.I@$^2[P%3J ;1D<19"/Y)D.E[YI_R4P@CEP#"A8QBPX 3EPA!@O@J$J D6
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M< 19"H=Z\. ",XC!0AP'ATH45BE[$($(:+:!#?1$_R_2Q6QY1#*6#MNU7@J
MPRH@L ,YQ 86-R#K3_8@@27]Y696<0,23-"!*$P! 1] A0U8/)4'S" 3<8(
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M;A(TP%"J'7%O+\7"!/L^^*V+70<B5"AC!V'RO8DP\&NAZS?+(I7(\QVT-GB
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M'71#'2C" I1"&V  )OR!&&2 (V! 06; $[1 L1R%C#'!<+R 6^"= Y  W3G
M?"@" RP $QP-'(B 2^P* (0 2"*!)LC$*C@"26Y *)0"$_P%HHVDE]S$!DS+
M <J'$'! #"A"$:B@$." E-C E6S"OU3,MOS%*"Q JGB Z,Q Y&2!$IB(W&W
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MU.6S/L(%U )HVB8'V, 44,!(.D 1_/^"" !EE]*(35:F3$;:OKTGEH*!I8X
M!^@,":PI"'C 7*[!>P8'"B@"$K3!*X  NM 948"E6#*KEK@ $NSKP(1H9.X
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M@1N8@11 @H>80MAF0!!VP FP@$RL0",<X>V1 11$ <'\0A!0 DBZ D&X @J
MP"N8@@040G60P-'YR$2,0!#T +X: 1R\P#OPC)Y&0=5>[19DY";HS8+V2A3T
M  3,06T>9PC80)JHF!]48P8,@2.\0!VP@2,D0<' !9[H"1(L3!ZLP@#P AD0
M@&B0(?E]10;\ #4<Q0"8*HG  0AL0K/6[Z4ZP"O@@! $ >?>PE;R2FK\196N
M @A3PI>1@!",01T +]5NP-6"GA=,0BGEBUN.P 1@+Q/8 0:4PAK4_X'RL*8)
M;V4>]/ :!$%GU$(K@' /'-CV8H()!$T&@$$F $/O2B4*-(?A(J[BAM8/I)\0
MK !F$B\EU *+Z8&A F\4M!:^#L$"C$@12($#KL JI*_G>L "K(40,-T _\0/
M+(B7G  E[!@1I"\!S$!M*@(03!UV[&FVA/!)VH $&*R>YD$/R)GQB@ >3$0)
M*$4$;P 'X$8%2V;]+D ?K, )"H$'## (,^S3M:IO3M[5U +W2D$+(,&%>(*$
MMK(-4,LMK^8-%Z_,28 'S,A)O@ .P+"\01W/Z7'G6;*O -H;AND)*&M%U((N
M/T)=!1;?7F_Z=MLF>@&A("4<^(',WN,;OO]JV7H &'P"KF5 2&1![HT!)IBP
M 2/ #H3".W2RFOR (I! !*8<!W! '<#$F:U"/1J!: !!"Y" !M-N(6 "#Z
M$P3KW#@"" PPKH'K&[N O8E <+KSZ-%M$)@"!@B!&03Q/:O%/I].:MA*^DJS
M(QBG"&R $,# +L\9 LQ U?7-U/7M&JS"!>1!TS6L1H.!'"R B7Y,&&/F!@1!
MH7K*)-@ *J\!!L19+>A=+8 *)X!H%LB!'M2$! 3!(X2'BZ0H&;QL#]3C/>9C
MS2(%A^0  ZQ!%?"LS]Z #72"(P2""5#M/@A!QIP07.T!;0[!!=S /?X!'ZCP
MDA2!;$H H4AO++S_PAW8M O.34/'P/_58R\CP/UB0KC80)@IP!\PI!D0J,\:
M0?^=0"$$ 8O 0HLTQR\,\B9L@)'Y!([E7N0R"7T8RP#80 Q*@1L4@0K<0A[0
M,0@31KOXQ /D@5:F93-48A&0 A1L@@E 0B.\ @9(0&KC#"]<#1A8PRI4SAY,
M][9NZ0E\ 240-?*J@RLX ":\0AW8-))8'2IHPD%P1&RF !DDF1&$P&Q"2\K]
M064+ 25,A!<(P76<0(<]61/# 1L,--VI0U=PR">H&!.8 -MB B5D,7U\3K4A
M31BR7M88\@YPP-UF0%*%@!F0@*B-EALT ^3Y0! TP6M:JLZDWP:LP3YD_\*3
M42/.9 $)Q$ L.'<K9T'*'+';-@!EJS *VUOX'00L&.H(?$%_/^?'X,1QL20"
M1($'V, >M\$:M$$&P"\$0#*UA:P4-,B>K@*@A2L;[$CATK9MB]D/K %1[G%L
MJK>7&X%<MFRQD1B^.IC.(($*/$!X/\(?H,%.7TB6;\ JW[9TS0<JC, )D,(-
M1$$97S(</,(O*((M'\P]1J:<<9U7"'D,; "1D'H>\)PB#,%$(!KGN,$:$.F^
M-($1))F#A0(J7TJD_[AGH;JJ/T(M7/("O$+]WO*%,(%SDS8E]/(%M( BI(U<
MQF8A]$ (( '17 $!2)>.&WBZ!5X>LP4QIR\ (/\V/M:"(FP!09] <8.!FVMS
MP_K&"#3#+D#93@,L!Z!!"ZC#$(2 .=NCI8;"K/ V*I@$ 0SZER$0$C?" !@R
M' @L/SM.:9Y $"P)$Z!XBJH 2\HL/C,!K%O(KXZ $+"!&6P N,[B";R#<P.
MKJO[?PQY#"Q (Y V0]Y?K\= F#T\*2  )(1"3@#6=RN VN;!)!#"#%R*%]B!
M@<.[YU++',@'!RBW]8:""7]NF34W:)0I$Y \6^BY#=0#MCMV#-C!6ER=\D#
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M#B)@<6&2X"9L0!,I0GH !3PZ(.$$&$/@H @2V!@%!0E.>H $$IA &( 'LI
M- 3F(,4'$C9H9I])C+B!DQY=/>&$&$ ;0@8EJ$ A!B1(<*"($T0HX0$7D&YE
M ##\H#@$![PX01&E)2!!#M3VB($(D=PHHHA).M@@A@U@V&+LH7P&:08D,#G:
M P9< $*/+"SXX)$'CH[A*F.#?MP14B@V48I7.4=B S10@.$"&:Z@P148H"#!
M"U18_WYZ$IX!&*"RH_$ PQ0)%%E@GU)$\$"J#8:6(@2Z3T@:!>2GGGL2('S@
MQ(@.+E?@@UA:^8&4"Z!PA(WZGCX\I! H27=J%(1J0&@13D"$W2GA  ]8@!]"
M@ 6*#44/+J $ 08P TH@( 2Z<\,5!+8!$8C $3U00!96-[6J%8%(FL/#]H[6
M/2DH(&A#HT (C%<"K"BO<R3H 1Q(<8,LD$!Q!Q ) N#0 PBT8!07V&$,%.&
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M0K<T0<>00 !E&TC!&H]&@B)X 8 FN^+4D%"$#7QN"Q1)8QO8A  B=D 1AU/
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MO6OL\R''6 >NOC';CWYC*X>XV<G6^MTC.O>Q9Z^C;N!\ D,!V-&%@DYK7K$
M^$,?W.="SWN><WWP_/LDR'['-*"/ *Q?_>Q?__L3$8#VFW_4/V""N2[RCEJ<
MY](50L*U0^(#%$</BH L(N@31N(1B&]"]  (P*YB.L ('O#02JH1'D6S%& /
MBL E\.X&%O#!_QR!!Q9( >;@%4"  R\-#GB ]@KM <QC8W;#B;KL!XH  #%F
M '; #^;D R.0W6[A+>HLMN!@"B!-ECY08WH0-<3N"!_ $1J!8I!"$4Z  Y G
M@BS0"': !QA$T@YM &IA%?0-$J; $4#@ZV*K ]8.LV#! POMN!HAX4A0!,A&
M[%C08C9C%7POZPA!XQIP J<*#)X0L\:KO%@H#1&M ;+ !CM&#]A !!)1WV"!
M"\%L!M[P_*BK MKO_311$S,Q $3 $C<F#K@O_KA 'TC1%.4O%=FO#4:-7 IA
M!;P $V3!"G[A$7XP!58FM7Z@&>J!";9@$%)AVAXM".Y@1GJ 7'H@@O_J 1,X
MX 7J80(>8;T$<%"JX U(00]FL17   /JH0[0@*K6@ Y.J0/ZH!XHPP-&P1'6
MP!22  W H!0*P:8@P!&"  =$8 $P0-2^2PZ>( IZ$7D4( 1>( Q (%UNH07J
ML7*<$0NR10B:X#CJD0A0X!7>X!$@8 >$  =FI!!,@0@<81#J80,R83=P$0A"
M8/&DC;YV )1 0&DZ!0HH\A&D+ H2H G0P( FH F6:"'CH@%LH!N-,00H4@AZ
M8 9^80)PX$A(L HZ@1+ P!-621,<P0273M&LX!%HH!:Z$0U" !^;( _@<6(,
MJ!LY8/%\\052  0NX!5Z\00B<K3 H WB<2G_ZL$4**$HN!$3[. -DG$!@L F
M44,/U$ +<'$3HJ(%.(&.HLX9KTJ"RN(R.$ 1U,$(8&$!7 +Q"N$.B.!OT" P
M-$$66"$4M* 0;!*:FL$N+R N*R$/0B$!PL *YDH@34$..N 53"$(%-!8=G$V
M0V 0$D$#$F$%,L 54" AH< .8#-;-B I6<L-QL 4S$ ;,T =1D&M[( #!D4(
MZD$$=V,",,"P#K(+4H$2=N H9N 5,F !V*"\0D 6 N$7/&$6A;,FFD$S66LW
M:M(!?K(. -('@)$Y/, (6L %I, -7L 4/. /3"$>^PYD *$*PH 'Z"B"$D C
M%X 2'L V,: T4%(._Z0B"E) @>!@.8_$!Y!@,P?!%$[CP?R2#BC!A_9&+E=P
M &P@"#KR!O)@!<J@$UIA!N12)[.@'G,H#X1@"J!@#.I!#M2Q'NB "&Y@ >3@
M'0MA!4%.#_* &YD #%;!"[M1"@;@!\;@#;"@I<8@&*WH+U>G0L8@!RCA(BG!
M%?!Q C:@#;13'U/# W0$ R: (44B+AE4>6PT!J0'!\: %7K $4:@0B6R#V93
M+(2@$AC &9D "9Q1VJA@!AYA!D")/Y'$$;BQ('NM"CH2"GY!3YMD3P_ %0'S
MS3"@$&"D%IQH#XXGM%# &94-#JAL#QID!@I!"_:A50MR /* -&&@ WZ!#O_0
M*@/^( Q>DQ( -2GIZ@4F8 4^ 7&821PO0-&V\P!^8!_H0!%^@32C0M%PT00@
MH0V"P$7]T%@J8!,#(/Y0$17ECQ3I#Q0Q)@S:+Q/U%><VD15'C=(DX*1(H EL
M(!/XXPE.(B[T  4T 3R0 PJ*)>I(@ ADP ',XQ;^@#E$X J>HPT. I\F1 #K
M8P/PT(#" @R:@"] I#9.P"7(91(80 E*A@.( P6L10W\P!7>0B)@( NX(P.N
M;"32TS(X 0BFZ@>(  HV845I$ :,XP3DP%W4@ D\\D-\5@+D8 MLP%/*,,08
M( N*8"FF #;   N> $*J)$\V,"O  !-F1 FR@ /_V, 1Y  %;."&/& ^/"!>
M-($3', 1L  *H@ D2! T. $)"@13R9$,-&)0#$M=;$ MM10!HH!(0N$=D.<!
MY*,(;"!J2DE',D &HJ 1CI,4'$$1KL F2N$19  %DG83F@<$ND<37  )I&HS
M_& ^! 4*3@ )^"(BFL$C*4,$8& !E(!L=L,/%$T('J$#U$$3L*(HLC8AYN0"
M:,,1O$ 1D. N8\$G?D 31D%>/F(JWD4'04!E44!&TI<(U  $OD2I%D!U2BHM
M?A8*_",NAJ,V;$L-)"$/0. 7F" +B*,UMJ0?SP0$%J/@B&(!B  RSF1!S@D)
M-B%[\Z 1MB *>A1F1V 2_WJD[1J!"K34+5Z@$19 $3C02F,E$\  !$: ";*#
M"%I@;4/B!_)V!-; ;=L,*V!A3B"V3N8 -* 4;^P !!A@!!IL0@Y #/-@"A33
M#63$;_-@%< @:NV 2*8%;&$ 4_OQ73#! WRB*YE ,*  L.Z'$\(7"7I$,)5W
M:[T6"13!.!3/#VZA?8M8@VC7=VW@':Y -M9F(8@$B#. ;QQCTUAG!$S%#D+!
M$Y+B"6@#IAIV!$BA%AX!8DN&(L!&720Y! !K,N1'$T[@%?8A.<;,6+1EF5B#
M!'H$ MIW%&JA@5W@,EY@'\R6;U+3;=<"$XB@-5X#!,I#*11% C:"!$9A3H"A
M)?]I T!^@0<4ZA'@@!\+Q!%BH(_:@#7,P 0F(QTS 'F BW07H!$ \0(@Q"<:
MP 7R=@$>80?P$"CPX /.Q@LL> &D. .P69H.P@'( !:>8(E5  Z4"@5$0 KK
MU@X:82C@ !-$:8,*V F'<$:(]@J66:$:80>F@"(::[,.P/W4;U_ECU\SV@OL
M-6/BP%U%^OTRVE\_;0\X *WZZ!T8Y ^LH!ZJ( .DRF<V8 4*00)R31CQL@[8
MP#P@X"VB('^@Z25M0._4)P:TA@,\(7EV  $G(_4:8@P2X!FI Q+6H!0F80$X
MX&T.JQ9@0$M_T -J=#03H!2HS%C&8CM4AL5::@.$H!#_7K26V*!1G+@51F(5
MZB14I, ';( _]V85(B9;D4 (@J .I)*E,X 72($ =L 32@8-ZKK+QH("?H -
MIC &7L$*)J 0,F%[WCHY;  #T":S)R %,L&'3E)E'. 7TM.NHX ,2,((-B>-
M'6$5(  8MK06F.,5ZJ"\UL6#],"V*)L# $@WS$,!=N 1((1E[* .2(&J1L"F
M>V 'WL$.$F T<8 Z!B!B*/<$O !=K81&.B 76@$2&L&Z-_LO>N8%=T "FL !
M%$$H%.!)]>:UQR+UV&!-B(0) -=5?F$#O@ 3TI<4"N)=/@$8,@ !:B&_D6!V
M'"$#HEAHMZ (!.@'7D$+$B %_S# KELY+MR@P9OPG#_!"4= $9"F42P<PU-@
M08"6M1S)2_/@3))#!&+,"S@@C#WA%OJ #+:6 &9 "2#E5;:4,]PB%#+@%^JF
M9QS!#W";%AKA%Q1A!((@ 0HAN[7B! B;3E5&:B!@#H1@0QE$MG/D!([I!G";
M<N'B8B!!$IP0>1H 'W&"07BA!WRECT0 #]Q@!!R M*L KX$V)%":2%9@9GIR
MF0K;)83U/)*;=S>@$&*!#1: OQLA 2\@#UYAJN, !Q3AN.'@JK,:1NQ#/R \
M$QB;1(:B*)P5#/9A%?X@ 2:@&V&@!5)F D@!#D(!!R9!#::Z$'H[>=0Q*3?$
MQ%$O!/^BH T\ 18&=R@<X:38I"#D>W+A &:S@)D2H T>820TY%=D^Q4*(0&\
M?4%6X846+3TY@"M'0#]61 'A($ !H $<H >:L!&V1@A" 00BLP>& P^4%@^6
M=30! 0U<Q1$\ 8BF( 2:8 MB876^= /68 7\H#P/@)]O2A%H-L?YY@^H3&&F
ML ?B;H)"( E*  %T?31-05/T!@RJ-20@H4'^J!0R.P'BP ^^.;5CH7**.@,K
MP<F- !+HB;/@-?[8+_ZX3Z2YH%X_NF+"0!7S]5V7/A%*,0!,&M/LCQGS6TZ4
M%03D)LU9B#86H ]<V %BX<H65F[R)<?[@ AJ00XNX$F] -__[S9D%:<#E#IY
M*/&['N$Z++N%P=8EHLXY\@43>M<$3M)3VB(*] -ZG@,3A&LR+,<!U(&<,+DT
MFF&"D")  V.:Q$*%R>)TI6 /FKM@8F,5L(8#="0&8$Q.6)W.0^47V*!]U,'3
M/F7=.0#)[<"%20 /:H$U-D$10*<AS*#VC6-%3<3Q-^ 7)J&H,58A[GX&.-B>
M&D'D;;%RU?$=)$0!?AL W& 3)JBRBX!-K/0H)@,(A?(=KK%9!J$'YH )/HD-
MBH -YE -QB4*-@ 37& 3/&(!=J$#?,$$]N =HD " ()-$0]&  #0DR>3 C"G
M-@G)8,)@!UZM!OSID>?1A5IL')S _Q.BF80> !3,4.1BC0@''$AUB-(#S"<U
MCX:<1*)(18<%GA(NQ$2"" 4 /S8PR3)"2 \%>8@@*.FFB H]/,$T O/.!I-?
M2J10?<'$@0U2&2\8-.AF0468&6DD7?E+$4^+/:(0N3##@PH #4ZLNJ4FTRU>
MH9@@X=#*X -'[VJMV@$B[H8-BC@4D6(0 IA)+EXDZ5ADT@&H#AS$LI%A2(LB
M14Y4;&'G;RT/3\^>50!IRH)W>P^Z<( DB1U/44C=JD5D@2(\;DYXB(+) 0E2
M8" :#/&+$@H72&(-5= "B8,1J/8^R+-J(:4%',;' .Y)I@*:&\>44G184T(
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MR\*2\ M/P"$)$,N (T10 BW!P&$H,&%U"N*O$TS"=0NHA 5H) $1C(!K 'B
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MPTY$&()\-9$%!NRE ?'T>;2AP  5KSDQ#5#Q$Y8+"QD,(01  ,84_#NS =S
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2EFUI5JZ7E47)5ISHCZL8$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g28372bki001.gif
<DESCRIPTION>G28372BKI001.GIF
<TEXT>
begin 644 g28372bki001.gif
M1TE&.#=A#@09!7<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MMJW;MW#CRIU+MZ[=NWCSZMW+MZ_?OX #"QY,N+#APX@3*U[,N+'CQY C\]T
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M#-Z "]0\00K<:A.7ML"9'QTD'"+DGT"R($$6S&91"Y#"/CIQ,R<*1'MC+*-
MG@ X3 VD!7IB0:>F!2Q]D,I-!/C$N"08+@PYR5QD2M<?N>0$00+@C%?JUM#T
M0;^#A!!ATW+!$XCV)-2<DEE(C"5JLL"E$K11=JS< @!*V*4-D:\$"?F6/CJ!
M'PT\KY5@LI4<8_G 9CIS,=O2!P[2,"H5:0 1!%B5*^3(,@*X#&8-TT<)8 @$
M?Y#J93G;F=!F:+2!V"\,20-F"^ED)X2PC0!O\&*W:E#_0\ )#&OZ& 8,,Z-!
M6S+$@$PL2-TN!,X]L0&&'?@99J2T1VD) 8#J/)H)D1$[@F0!FY"X60M"Z4:$
MP P9#,3"/200M.&@$1M&6L 9RM31@7R4 )# S-3B2,*VV<$[E/,'' 90 VRZ
M8@@#!<"V#,FSY:F+ 1OMF$U!.AOKB:\@'! A!87F16Q<B'Q;-8@&0Z"B:)(5
MJB=<UVYF!ANGH=(W7H0$]D*XS6?:]:Z&D:$C36"&,C'0@G) U9@TR$*Z)L$?
MKF AT99VRHR64$Q?0NL;%  $&*"T@BY,:D+T2@P#%H(S<.P$!W0X,%2Q02%#
M#$))%>H/+M1TEWGJ1!5?)D*X_RDVK=]B*D2(IX]B'(1O!."?KG3+D \T"1GW
MR$,]UV5"/A*$> 20I\BXQ#\=U'&YVG+2)YZ0!BZY#$--8J/R]I$(=8VTMP?I
M:W!WN;A2&@1F!,@H;=_*@3+)ER"I32KY=,FV1.)(LP?)PB3P6<]PD&US$74O
M7A?,8+UD(6LI4( 0KF30YJ2AM_#UE09FM3F\84,6?9 H &KFMU>B*:UMF@4,
MV)A;3")-<@UQ =&(<8@:XF%H!"B&<?]Y)0+(H0@__G$G9M/-L@$YR+BCF3([
M4UE(Y&BTR(B$!(<\XK0:6!]@?$B+#_(!LK%Q6_XPA0,P0 (RAV&U"BBDPXJ@
M! IEYO^E1I(!20W2Y7UDZ<%\6JU D*=%$Y)MF0.AG#ZXYSK729!Y /C6/C#I
MK30"P*H(60)B8=EHIFI/A$&>Q8^KL*CVL> &-Y@ %"30!ZA=* L#), L^$""
M)@!X(/P4IQN#A\P.Z,,5 "1S !G8X%[[.BT;V!(RGMK<#3T 925@ *4X12AO
M:@D&G%J"DY!ZQ9=9UK%G^-F7%H>,*NJ FIWX$M;XA-V"N$"/Q'@"-J_P $3H
M0Q)'(*75NDFV50T+L20:(LE@\*9P%V2)#,03^&8+,VR0@7Q#&,!BO3,R&P*@
M!?!K'05(L%PL..F[!#'NBI4:LUKMB:P)T8$-X$8R%B1H.,W_]9M /L"EL'K+
M89\8 +F(>Y 6.&EU>WI#2Y6Z*X#M25U8V)/+!=(*/<5\E'8SJ:WDRP,]=0N^
M9(NZDZ TL((!:E5=V@.&1(%S$>(*(<-E])X=)D]1Y<U=!*#TK]?.]K"@U=\&
M,+"SFX--WPJ3#=W<W"FG %48<($,Y5P:WG1VXG9J( ET6E3ULKG,%R?Y3H C
M1A[%23R#_TE@#R@"^"I0 2)9@ XD&MO/Z% !XT@ ]/]>,D'JMD@#HW0#7F1B
M1(T&1RQK"^<$<"Z=O7R05JSJ&P-HP?9(, =1D. '1M#S("> @3X$JQ,F@RVT
MC=1EFA,]5;Y*(9]>K2V2$: *41A6_\()(H2&*4$"R.&\"1'=97V('0"^=W_N
M;GU5@BQA%JYP^;=@D((_DHT6I-!YTK$SW80,<F XMK(:L#$/I% X4>=#!T%K
M(0!@P2-K " ,MG("*D!\Q\=K;?>!(&@5PH0-)%""Z4 VQ2(0#R!!P-1?KH #
M5U)8!! U0*(G;T "*-98OH$**"9IN5>")$!-_E!A#) U?1)C:4(, P SA4 *
MD!5O?U=:^@"!")%:#4$TPT9"(P UBQ1"V%!%T,4&@#,FU6<N>L *Z)<)VG80
M=: GTJ4\0L=Q!*!+%+$!=4!-ML=<N:=R-?@DIC0L52)@6O0C"S!02_5]%T!'
MI)5=<U@0\/^E+M!%=07Q+U6"8PJF/$XB7_:C=[:B=@4Q1%#B D'72PJQ , R
M/]$':_XP"U1($$>@)YO37E(5@K18BU3!-H72,!Z74,-1=W-$<G:&,Y?U:&0C
M6'ZC/8D%5RCF9X?"*WZ'/0#U>/84>0AP7J@"3)>W0UDS#'I64,HG$!C(BT+C
M-%XEC(O$!/I0*W946EW"A]/"@[I7$.V6>])R.H@%AK,R5 VQ "-  <3PB=G4
M?^LR#9MB)/,(?1I%-E4$>SBU2$(#!-'"*&138=K3-X&6/.?2,.JB ^Y&@\KH
M"K-E!O07:3GCB=PF1Y+F"IYH)1:(3N#C-SR  K/@<O %:,RE#W+_96Y$DXP7
MR%.V^)- V10U0 4P0 DD$$ !E --0G4K&%T#03Z_XRE?.$?81#9+(V?BA"%<
M G),HC2Z5H)EP'O#H8;<B(3Z0 P(8%W04B5_0C\LLP^GE1!6R!#<%G!U\RI>
M>&K4-#W>,4J8HB)#F7O+)6-.D@)?X@),@%AHR7.1Y!!]-XS^LB>;TQPS!%,D
MM#@$8)A&!%_C-"W2EIE?P@.9  /^!DGBU8M[0H=*972.Z##J,C4-$P*':4!:
MI'B+DW1_&%\8@BI.0")9Y7 &04M$A!H+L )[@D$ ,&$$MBYZU&T'$6S#0@Q!
MHP"7MC1$<XE!F9W:"11RAW&HB9 ,X(O-_U(HG(@,#IE;:S@P>$@+D3 &4+"7
M_'5*5E 06"-B13@_.  %.)"?^UE/]X26."9O ' $]+)#J-()^WD#^JF?+[ H
M67 E++"?":J?6D<0X6B385*.Z 29PI2>1;4G.S !8Z ,$C,][CA5>T(,-S &
MC: _MG(AE/.7#G%_N1<& 3 &'' E4<@S9T":TG)36K2BRN"BX@A57M>>I  W
MXA5-F"1,.RIH^IB1B 8 0*JB+"HK+VI%(F0'$BJA5D,^(:"@.& #2?-6 '!E
M(:"?8JJ?H#%6 R4$(597A$D 2O "-^JB+,!],I5S0EJB9KHE=;6=@CJH.K$!
M\"@M ,!*V6)!;_\(7?KP39MB+WG$ET^Y.NG(*RFX '4D+4-C60F#-3WF)*+J
M"JD(6W#)&5DT)FTY*"K4)/9&-J2B;Z+J<8^@4"(TBRXP M"&EYLR6[!%J0)1
M!U7I)!YW B='&A+$*\-2/F $29+D$'FD)TU2,<@P?NM2!B]I$#Q <O56/BZG
M!WB(=L@DAS'',S,47=X1=B+CFH>4K-XW:%LE+][W)N&%3AL3=;9BK0" -_,J
M=5E",,,Y$"X00FG5.1I#-GQ@DP4!KO56,010!!B'A1Y(J!1;L2S!3]$U:TGS
M0N$Y"[[%,UE4GKY*I5G33@+1 F%),GQ0!3226P)9$&$X $CC<WOB"@[_*; S
MYAU\!G)'4$,&"C YM">D0F\^=Y9)57"OE:C^H*':8YX>5;)&H@%)>BT_L ?E
M-A +P 3NB@QVT"\/ARI1VA ,  7<>@(]H%FY2H\'L0!D>BU=>Q /,+5[T@EA
M,% C):,<(D&/FIQ@RQ[!E@A3*A#ZL;4IX+6+QRLX5ZWC@WN)L+)>.SXT>RC_
M2F$J$BOYRADB5P3)$@*/>Q ,P 'RLR>TP&O5$J@6>[JHFQ4;L  B<$1YH0"M
MRWT* ;L*\(T2 ;L@X$<50;O?N &TFQ*_&Q2K*P([UQ#!F[K(F[S*N[S,V[S.
M^[S0&[W2.[W46[W6>[W8F[W:N[W<V[W>^[W@_QN^XCN^Y%N^YGN^Z)N^ZKN^
M[-N^[ON^\!N_\CN_]%N_]GN_^)N_^KN__-N__ON_ !S  CS !%S !GS ")S
M"KS #-S #OS $$R^"J  _:  "W !K@L3$WS!"Z  LML4'4R[%2S"$]RZ%;P
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M%"9F0)9]1%'E9LV#D V,P#6=6#!K7G(V>X4WE"F!(9L(XD(& IE4:++H77)
M CI$8G?A68 R)! GSP6W02XXWPB5A:A:0O8S7[Y)$CLG$9V:/2%U^($#PA
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M<PI,\1LH&DF6Z-0<*PR$))E4> GB% \I9,^$8#L>44ZXZS O:8&-*IJABLP
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MPAX@RJ<2'*O=Y93YG1ST&YA^RK_F,?V)6;EP_S4C5\Z^Z%#9(JJ97'.=.O9
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MR($)6DTN- ('3TN_@O]L94<(B<.HB;]OQH89P;#PI/@V%]@H%M0LC*Y:KMA
MG2X:E4/.1B>*R#XYHKA9VTG:B3F,RA9K+F39$W]'A!-IW_W [VP0-]L4%RNT
M;J*-&/,WGN<Y0S7+@TV*&Q,,),7YJ>93JY "*5B=G^B-=TD ';S?Q"97HR,V
M]SD !C@ ':3C>9N6WK4*%!SZ"P9,%., IVT4Q$T+*5@ '>Q/>DR #53Z/;P@
MV.2";MF*K)?I=DQ !51 2N6"!9""Q"9/(TBQ ]C!;J5'U+1!;G%CIY?VE^-
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M7G$Y&((!9>@#'V9! )A38 AH<8$-'!!R+RT !Q<XQ,G'M($%A!M\&_@ ,?2
M C*XQ04<,$)6-M""-"###519@ VL   L?$+,:%F 'UB.!2.0>=]M_W=[6380
M!0)D? .I4!8+0&#P3& ##ZO6 16P,0I.BW@)_@C!!4 =Z\*7X *;;L$LN- #
M@Y^! /HH@8>%D(E".,7?6T@\K4F]:2# P VQ/LL#*-"'KG=I S5PPP+H<(%?
MU:$/1@#S]GA #!W\8 IO 4(*['T5()0@ 'F?R@96(.QP$$/V:@EXQ@' ". ;
MZ\K5I['UL7]][6>?^]OWOO5W_';QG\P%8M 'P(&@+*X;?!(L$#H -$ %/B0
M*F;01Q# ;/\0@)@!CB# %0R.Y B "WHO\U9N \3 %:ZN*OQ-V-+"!="@!-"
M#:BLU(ZLU,3,UJ(" ^/"]+""!Y0@ ,J #/\, -1DS017;=1"[]A2$ %<@ 5?
M[01G[--$#?1.L-58S@4$;@M,S *?X@4[#0A_D-8X[2DX\ 0W@,=H4 57<"J.
MT AC$,F*T/2B$ !@;P-(X?VNX@F#T := @@#;MNNP@46X P<\ :?@@&2#P#,
M@ *AD 5#[PMQ$-2";RI<X R@SPR"H 1Q4 J+L$M S0!$S 5XS 7"SQ +\1 5
M,1$94>02\=B:3,2.S04&0! =D<8($1-Y;! 3<?P\<61T<.Y8SOY0P!]8( $.
M+O">0@/Z@ OZ[BDFCAA0P@^.+1P(( 00  $V0 ^H !EZ;P/. !EHP!]*  $R
MKQ &(!2K@"2B(OW_5@\M&. ,K@ <3&'JGD(';$ %4"#VG((!H" '?H 6<,'>
MZH $<F .2L\I=  #<@ %JH#^#.X;56 .(@XK=  '1  *1B$+2* */ P+4.#J
M-H #YB 2;( 69$\(1"$%:JT.?J '^-$?Q2X@68X#> \JZD 4AD#$!A(%?C$7
M1J ,4, .X)$#^H  ^* *CFT=19(.C \+Y^ =1@ %YB#L6(X4YD 94( 6_&
ML@ #4  )P,TI^/$'3DX(2( $0( !;& .7E$ARTW)GL &4.#;< '$L%$DQ5$)
MH> '(D$84. 'F@ D:8 6X'$>4)'IKF(##H$$M)$DG>(#PN ;W;'Y-@ *_T1A
M#N@@"D( *QA  JB $NR@\0XA!^:Q"7B, =)!V":P$,M1!7+ #3SL ^# PQ@
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M :%O^9K/#'!Q:Z&OVB)U2T2 !/;!!WR@>[T7?+UW?,7W>^5  3K3*22  'P
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M2>G8YM-O@UO.J:CK$Z#"W[Y8+!#T<Z'B"!28I9&  GX 'FM %/B@# !"C14
M %QTD(.B#[$$!'GT.8&"CQN"#Z3P$26GR@6"'#MZ]*@#$8$O /]XS.)B@N,&
M,03@ &"0"9FACCK2N)HIY"1# *G\7>D(!$:*CBY(42% X,04CB8)=-J(I<\^
M?7QZ$&1PAD"5H\B,7%TQ4B64HP18["$HA H7/ !DG&1+\ ,!9$L!')D%9P"
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M#U 0"8+DXG;ANJ <H# D#8[-!QTT&X5(D+8O"G*0A"PDM;*PAT!9)U@AJA4
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M) 4)[+"3!5C7 3> 2AHH$88%T*$--J"#"%C1*0:PXEBJ=0 =&'((*KPA# ,
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MXP4P*<,/JJ !5["2Q/:L0Q_H$ D@. $$<=!W)!MZ >@HX07B#L%THQ!L9=B
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M4O]_#R!='^!U@S$42] ).R$,;$ 96$ ,"" $7+ 3(2$/#' +C<=__N<1'\"
M,($S6< %H_  Z3 S>F 5*[$%+Y$) 1@+\D 0](0'SS8$>L$ )+ 48E!_#84
M/( 2!)$%?3 %^8>!56<;.$@1-Z!(-M<I/_@%&W +Q6 9.E &KZ$'9\$$Q7%.
M928,5K$78N 5,K!5!!$.?4=W0. 2'NB#(2B#_V4&*1 HY_0&;RA5@T$ &D,!
M-'!7'Y$%%.!_.D ">,"#2]@'?Z !Z7!D-: &MH$;@O$!2K!+'S!YST8#6S
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M97B&E@F74^!B(<0[SI6$S! H59=.S>B#;2=)C4@=HAFE>Q$%*= ":_FEDL
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M*LCDO,T. N<"(^3NZK'.[NWN[N_./W50!ARG/:WZ198E 0MV6Q?&[W9 "@&
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MZH<)2/CAA+4-X/1:.Z0( =/,#%C @5GNT6^@&\B2 X<H"6!L'^;WD>/."<J
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M)!#>< $&9.('NP0)R<+Q/Q&$L82-,D \," '&R!@.5>:P \(<(()!  '<B"
M86   ^6EQ0$+P $%RG(/*[6E+3@H UH2(8'MI08N5I% ^,:P@7Z0@@+[0 84
MM%.=^855K&,E:UDE$PYDL.X'GD($)1)@@#JH!P#A6"4 A"F0<!1C $WZ3 TH
M0#*"G)!&;Q@6']2S@0ZLT@Q!R E+9ED$P(ZD$X#5P1.!Y4@ B $.?>U$3;+0
MAPI0P JV/ ')'F *N2:E## #0/\C<.&""93JC0"(8X/.$!2! *&NJ%'&K$QU
M1S9TK!R%B$HC*F>&%#@E:NEI;>5("(!6F *P6:" "'>"@#ITHE2W)<@#2@L
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M *DH>C!E2C@  R08 1=T/) L -@%4@C*$93PFIU<8+$#$2PM7T6C^@B$ >E
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M@3!BI4_"C7*ZLH][!( T;^E'W)$'E[9<(!?(V$<BD%K4Q/@#!J+W1YV<>B<
MB. &<I@%"B3OIS[[(ZAE\<M?RGQIW.=>][MWU!(\(]F.+>%8-PC "8\MA2NT
MX 07F/(0VI#H1*O(!6(P@AYH8!*[@__FG8O]#$L0\&2#V%O:01&X&\DE-S4@
MT Q%,'![WN#TQ WD 8A RGYH,X(3T"$23Y@M(X)P;"I8L9)I"8)@ "8X 3MX
M 76"&29(@07 -MI  PJP@ST(  QS"IS8HU%P 0FT@QL0@2BH-W^[F5J;N3>
MOD1S(;R" QX@!J3I 29HHVFC#0QK/A0<@]/@O@'$D0]XOWT**0&4&U<KAUH"
M@%NJ'!HIDQMXAR4PL";$D28I"&3;(A1TB0W0LS+@@\11@#JP@73H+!2C@)IX
M,7)QNB&8PAO\M0\@ABRX-2 P@G#8K&N[AD1[OC$8 !D8P71(.X%0O,]X %<C
M)J'+@SI8H.S_RRU"F$([S(,Q^#6"$ (*$+IWP *HJ!@1P@XJ.[SZH[:,NHPK
M*30?L(&KLA %N <4P %&:1 %Z(>^^ LNF[/%B$6T0 8;" RN\ HY"( - !]9
M7(PZ<0Q6X#UA'$9B+,:-X(S?:P\^,)@H&P@@"#< .((2J">!T*QE>P'V64,T
M**$:8('(2BS:"C<F&2-:8KGVZ"]1LRQ$RHDS"+$$*K+\&H.0@S5$F #,&HA?
MDC(S, *2 "QF@Z,@$#;NP@ZJ*(A/NL3_@)ER< (H:+"8Z8.FLT9["RD\T &(
ME N)= +_\JN+6<</2+F>0<(4NH,8!  TH(45N!BG [**<Q(QB+:D_WB!J-@U
MO/*X@="!>G0D&=,H_=(#7'(*NCN:@NH^GLBOT="!'P !--@M9;F =KS))E
M/2"PI- M .@M@=  5.!#F5DZ&).+6R $",O*%P@8&B"%S5I#*:"9G32<2$@5
M=$R@=,BV#6 $?S-*,WB$SZB#(ABR$U /9C."L2P@;$2(#?(X+! -YG*C*="
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MJEK6GIH% IB%(NB#,W$!JQ !!^@#T10!&XD+J?]:Q?NX /*XC]>T"^0E@'3
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MKNK,UBYNXYZT+/B!CMDC/I:(#RB3%Y"3/ABE]\$B&/^ R4PQ3HEP@<5B;)7
MF]*&6B"@  :5C ^03(- -BYPT0U:/(EX7)5X@%@H;..>8A+P!UA6-?W>;_Z>
M VQ% KC8@ "@Z30#B[B@XC2C *\PLUSH;=*8!SE1M5M5AD8@ 4;;:VP^;@W?
M\).XC:KAD>'8Y6XT">9J/(*P'2'6@#ZXKW*Q(N$X<8% @%\YC[CYE?<=#@[3
MC;?0BX*H7^PP V2PV @;C1J?\=^@YAWO6I'=3P,8X/Q8B" A")> WCLUD=E"
M"!.IQQ"JX!Z'WJK!D?# E.'HB;SJ1" B *YM2;D@D"?/$+EP!*8@8N5HD84P
M<0"0;Y-PX-70\Q9>\X&PBFO_EN&$2'+I..$Z7PT+F?,_+PCS&  [?Q(1P!X4
M& ,(H'1*CP0(P'1-KW0Y\PL*&+2M"(!*K_1(F^([V[-]6)=JY1$N<U9.CSL+
M/PMDN $YYW!;OW6(V!<=VY?/P142&"A8L0%1(($X/8@L\#9:R(.9B 0F^ $2
M^%.5(P%1<(#,-HCZ>147N(%9T0-I)X%]+2 [F(>]<149<(PP4#DZ: 3.65P
M6 !2N!H2N,0'8(5YT!D'()DZB&S:((4I\/$XZ@"D_0#/V!=R<0$L" K(;H,1
MF(,P:&1GGX(!P*(0@()AAV9EF?9+A.Q#^/5.+/<<>!R1@ EN%P4[F!4%X( Y
M((%(_[ARA#@"S\C:HM 9$J!L6.EV';L59Q?M5(GDG4< #0AW>Z^)0T@#;'
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MJ"  _3C@ P%)7."@1 .XL* !!N TQAS[^" A!OTHL &'!#JPCP,*CH$!##Z
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M6D24(0I&AP@94.BDB[*V@4I/P!_W,.Z_ K!9']PC%]D1 2D(@'D?V"$  /]
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M6*;(/E  I3'G*6:F"QAJ $2(#SB VY2!C-B "!07#LB!/W"6:/4EJ"*#!(@
MW_3IJ:)JJ@*.#KP AZKJJ\(J;CD6##@ I K$ALA,6R@26'J27QH2:$G $VR
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M( .U8@WT2N_T1J\<H("A1@(%4"\RK!;TYB*K/0%.,"<%( ,2"", <"H!M)I
MW  *R $%I*_RTB_GSDPC$H3[6=!N]$DH L$<54L<] %ZI-&D=& ;69V"P8%2
ME%$)^8D<X)VLP)M?6&/]6K"J&H"E.0 &<+";@B ';[";8H '<_ ]5$"-#, 3
MF.D(LS (NC ^1@0"J# &L$( \$VG.<#41$0NX$ O9>8% ['=SHQ+T=%>N%V3
ML(^MR->69 $B] $1LQ4 ?$_)G8%:YD1QU<$*;$_WP F7?<#_'51P$(LQGAK
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MR5T$)A<)9DO)3@+U#^# H2C (8@""@Q!04)!LJ,VCG- '_71_D5,K$A['Y'
MLSM)(TA!<9X '<R&"Y ""E0!=M2! IH #Y [AD3!M4L[>DQM.OB#*8>!>R\
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M.2HWKP$- 001GN"  &FMT@=" H'89PN9_2$ !DCZ@#XP9Q57_. >#I"  \)
MD,@1@ (DV(//(M0!)-4,=PB1P0G"T(@5B$L'9\@?#SI1'"3IH SYJQ(73&40
M':3#0UF@P#NBD(X?6($F+#B=28*VA!!(Z"!/@((:5 B &LA!+Q^B0 M7I 8
M 8$/0P"=Z+9612M>$8M9U.(6N<@10%W0*K.@! 8PX( R>@A0 VH6 >9@QKLY
M "?4R@H!_F>GMBPA*W-0 0E(4 8"( ,G4SK94+B#)QB0X0E4V(<DNN(GPA$
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M<ZH6$:0%?: %*^[!BC*P0 %G>(,$;' /$C"GERL8S:FD,%<Y&*(FQ "!'M+
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M81.<&"8[?D# !G1@KT[\_ Q,+N8<QS*EDR,'(0P0@0)$$#6"'$%:!C%+??M
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M">PNYBB@#)"@#"C@>ZQIP_[O_T"&6G(N(<0'XI#")C*%!\(&&22E#[*B8EQ
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MK0@"/87 CZ#6DO0 !TY7 J@ &^A#!Z) 2ZEDH+B@"10 "%PA*Q=%"F3C":*
M?^XB-H 5CU@@+;[Q;9(P/C*A$W C=R$D'.KF="T #WQL"'0@=S?D6-[ #_#H
MF32F'3MB"8(&(PST<W7O<SM7]]#3?!VB!GB)<Q["2*VB>TDB]][*?-,W<.\7
M?].T!<H &RB%!TQ!!!R !.[A,S>@$?B(#AH6<4_F TY-!GI !OC(0W2 #A
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M!MYAIPT%+Y#  4S&#)!@#W(A"F1KSU+B"5: H*%@UA+@4I @SJ+@Z(R%HO-
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M+4Z@,P+-EBC<<!OW5%"AC=Y((-#=51#!O%P@76-:3+( !7"B!B02@:+ ?'A
M>&L@$^P&^#LC#FS@'Y'Y0_I@WDZ6=!2B-PC@;)JQ/*YN%J[+(*9:*V<A^MW_
M"<+QU.KU!I0!>9D=3 ATRD<$4+)B"W@ (/:%  #@"($4 P@JY*&/6"XJV"X
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M-8++!^@1U$$)Z7U"T* #N8#FIFAE(>:B=,5"!IFMN8#= C_-<\:A=JUAI@M
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M(/U@N /"(,M#.=E !T($&PU,8F Y:9%F9( (9,R" "'(W[G2H(]9("-@>"&
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MT;F D8I!*X4"!&S@:GK0!URA YI&&Q<(1)2B+F+@D6[8!XIF!LBK&;7KR_T
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M.$>=RH6 G,7D>(( 6,.P$,> / @%R(5<X WE" !8Y$87@+0%R(, B,<>$H$
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M$MB#_L.:&GB1*SJ!SF@!+D"!'*##G"2!2(""=& 1JZ&!>Y@ *3@H&>B#(9B
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M39D'RS0(FH5:G1H#;C3OKM" _Q$+9; M/:R#"H@$!6@#83_]KE#K-K  B 6
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M=]DBQ, 9UR+SU@.2VTS0!D^TVC1"Y-H,0%X^/>H"$/MP,0KW*&(1**4A:46
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MP,N'&IDFK!@1SZK4068,4 ,G00.=P%6$!UO9*4+ZEY C%/*;J"  -I2B-3Y
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M86(-] &R*/CSGT6Q T,I;1^NV$, VI!H&Z +NA:)DVF121-E,D=EQ%#( XI
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M=KF &#A GOV!/I% &M3*0CQ &1# "?1 .#A!&70@7?E/!1YB-/W2"C@ $N1
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M>2Y$IS*$!K#"B< CL=S;"P0 !]  )/W3+,@!N/(!!52!9WP [2P!1:Z+(=3
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M*@?>$:- #1SXD:@I4\J!(0>H+&R>,<8008&87)BGC3$"X$PE!;Q$; $1XMK
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M"&Q P"9#TXAT$. L0L@$"B)1!RD0H[4IX8$<PI +)LS"KSI Q! "T(81L&
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MO,6J(<2[O,W[O,^;I1M#O1TCO-F;O1O# =!TONF[ONW[OO$[O_5[O^M[ L9
M&<8@$@#\OP-\P %<P+GDP V\P!.<P0D<P1]\P"7@)R!G <I$(N8A .HBPPLC
M  (@4#(<)71 PT'*PTT\ '+AP\>(#O- 1R1"3X1% 2S<#UII/5Q +Q CVN1B
MN;8E%U[ #]9$(N:P2^0P+/3 [L+$OYUO)10@%QKA'12  =X!I"($_Z2\: $F
M( \N8!Y:BP%P7#?,9 /B(2Z>0,E=X,,W($*XG":"\EL4H V48<P89 ZA/$T6
M(![8EQ;G$'8!(!ZRY<TG0,[/O#CFP8LZ8*1I8@&XQ$_FCLCGX2D>G4X /!-;
MZ\:[@]'5527FT-^J? /6O#":4<43G0[]H%?TI#K\9 ,"X%L\7<D[J-/GP=7?
M0PUP(1?L)25<( _J;LEQ9R%(X (X94TR)5+RQ$LXI538Q-@WI=A+A5,N@-F5
MW5V7?0'ZX0(R% $4H*M<-$.U?=NQ7=M+--M%]-K%?=O+?=O!G42M?=PW=$2Q
MO43#G=N!!40&8-ZOQ=X!H-[S/4/R_=[[_?_?%>_?^5W?"3Y# MY;$-[@$5[?
M@67A&SY+3G0C[V:0'H<4PON<P]L!'DN\-5[C!8,$/O[C&T/D.5X&J00V6F!V
MD:0=)2R@>>=]'?A5B/I5-H PM=IV%C8H&$ --G5B\,@!O)=Y*%IT+J*&))XE
M.C)Q:."/C[B)A]CIG]Z/SWB/,4(.]H4!2$BFR4TF%J#.6,<%A*$/G'E6H.\;
ML@2,^H!."T@#?O5E7.CHM\8&X9XFE.%@D.%QH" [^7+ON_(>[( XN](.).#O
M]Y[PN_+P,58Y[V$K)[8K!2;6\\"@K$<'(L'KB0)'7^7(+=]]XF'S%T9Y]L'D
MYQYF%L+H1U\BDO[_]%5_]<'F[5D?:.3^]5.B$319]FW_]G<F<*8.]TF? #3R
M]5,?>7+!Q5-"!_A\)K"<UU=G ]H@(G2@"4#\^'G?>BA']*<_8IR)]QN!XJEG
MYE6B%=*P)OZB)DMGYNO@F%*BS#S_^F\G<$*?_5N&CZ;?8>*'>@ J)49/^8V#
M"*#ZZT?I#@!B ("!!,.%$$@PH<*%#!LZ? @QHL2)%"M:O(@QH\:-'#M61$&
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M0\D"DXI/5&<(!&F%5UBV@0&X0 10"P<QB):)!56'&+@@XGX6   %9(581U.
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M/!O(=,!5=4\7$GN0!LB03H_H!JC@#T$P&7EH0;@P9;D !55(&AW0C$/0!F-
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M-B. RWA='"!@'W Z4/I-X<4 D]@)LG<$(\9$ , !H9=K+H **V@L% <' K&
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M @;?!Y8' (S  L$.!3=_9@80#EQ "Q/0\VX 0L'''Q"Y$/VQ!\KP?(5*"G)
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MA9\ SX@MI!60@W*ZV)K@@3[HS 708HYHJ1Z8D2BX*NHP M(D HY V8*X!9Q
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M& ($]DW,J'$CQXX>/X(,*7(DR9(F3Z),J7(E213^") (\&YF  CO\N1Z%R#
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MQV)6:@LNC>2IFN5+1F+-#A3+5",NKNZ*[DIJ#:?T)CU]T9H>0LV>[.:"#A
M&2200!D"ZP9  A89M*B *&:!C"%T]" :*,,W'2"!-#B6#)!,!3IS0 (4]($
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M 1O<Y<@"YG$!^!+D"'R0J$!XP(6+RO0):AQ(33.JQHXN0 0B4*X"-/[1ERI
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M"MX#%?"!'ZS H:DA$5JA#O3@!BX@   B"H@"'[B!23&$T0$:&L"!#J3#ECV
M*!P:%K"! MC +/#!$$19"$C!#Z2#$E#<:G0:3 P+P< +$CU,P]32Q=S.A G%
M@8%0FP@;BO!0G!35?5W1^S@.@WD,K"E;<3C&%NW7>8Q>[H$%EO"(5:Q:?6!5
MII#CH@S5IT0.5.C20*I0K*G%@8T!M#C?7ND)\KB,!J0!#%@? +2 !%@D#B0
MPA$ O W$P)5 %P) .<P"-DC4(5BD!(0! FP CR&#/MD3-NP! )#6G/B#-X';
M$M3D2\P))&C6$NP#(:#!/A"# IS_ 1?(GT9L  <H@1]LP!-( 2%4EP:D T<6
MA!#T@1MD% <HF@P4P35D%!.\P05D02?@P@;H@"BXP0#\DQM<0%(Z@0F4F1*,
M@@+$@1H8PIP]@A_8V4 (0284EYKQ@14H@! DP:$M 1O@@38!P;GI0)X) 0H
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ME9L^O$&?^ND+[!\!$((.I $R[(&9#6>5:>(/?!="3-^Z*< &'/]!(<C4!B"
M2=6 &E E09A!":P31&+:!S270'SF!90#-C1!$,Y1.(2EXD&D(3  (@#:>QX6
M#[! A@I$"Q3!EFU .&CJ1*W 8>F (AD <A(# N@ %S0"!:BG0'3 1\I4%O!3
M#;BJ32T 2 K$!W0G !R>0NC "JS;!F!JG2U 9AJ "Z JJV)#<LE4(:6!]5WB
M41X$#X0E &3J.B'<IAF$:DI4F1$"A X$#W2"GAD$JAY9%J3#H>F 1#&K=\8"
M;^$B+UJ!"[C !J#!1[J (P":H1D=ABXKPIH X>'"XLT1$!##?KZ4KQ9$"YS
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MX9D)1!DQZ!$:$+A /  .@ "?/5)Z)P1''YZO,@ A#D0NJ.<9=-]ZFX >W,!
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MVJ,%^,$X.H )T1XKPV@2(%;85"0%__DGGGW.2& "O!6QO/.O74ER;;7Z*;\
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M !7&T@D+.$]*%C P]-!@(0=#)P%D%T"".-B<KF.)&@I(, 0.N$%,-LA*0Z*
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M!OA :P @'0' _?BB$P'E UC@(W2 #@:@#II (_[L K(@$^[1(C/A/@VB-O[
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M#;QPN VB#6 ";T_U M(;-B@;0U]C <; F+73-0+L"-X["U([*HP7/_513/)
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M^LM]!5;_!""C#A"! M)!#84C]Y, "3X[%T_ 9H,T)=-45)@ (/H@*6+G @
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M45D:]Y*R317M90'V($]8M:*>[2UV-U$8)7B4OE?*M&,?I@:=,(A& ;"M<J<
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M[CEL&B&H?OJ(D%,+TL!]Z7DD"GS(03H:'.+2AIAKX;A##E" ^4.@  6SL%@
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M$%$R< (*=Y(-!F$W1P10\Y9X4 -)8 6YL@ Z.@!'^&DZ>O\!"M />K &AL
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MH -=.A'RMEEHH(< T+8#,*,'@95P6A8ZT =M>GW2*KHYMX1\0 $AH&*,6Q%
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M'YZ B),^01@MC<JYKI9"[=2!_P^X.*$C4H!-+'0"%^5C@1\6@(59Q*B335!
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M(^J  YQ@ G:2(<8 F+$HFF,N!/"@$ C0@!1((*]9Q60##)5(V>"2!#?\1F\
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M?9 ''9BKU^* %QN!%."<E.H8+, K!H""'B"<EXJI,8" /*BI=^@-8/,+!$2
M<M@/<E2#,, F)N!(+3*%,%-%B5"8%O'+*D@ !?B UTQ'7/"\/I 7(" &$U
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M H83#IR /*"<#9@'$)B'1G@!RE'/#<@#\FG@>9B "!:68\G@Y@4+#$[@[%B
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M/X7DP>8\+B)#U&%_:49<&?O4I %'1N2YY&P&Q,,F$"+=J>=_#$1QVCY8 O!
M0C%:=E1-  B!&0%:%82&/SP"@.)< 7X052=T;2 & 2DL*4(;IJ4 %V,#:&":
M)/^%H],&:[:)9!Z0 M#"+##$2!@!7]6E@4DL-*&  H>DH<](_P ,JX\;.:ZY
M&4%=V2G"/ B1"P!6?BXYCS )$>5"I=CL<8$"N4BQ3Y&6]:&/9BAR(1AQ9\#
M1FXRO*@?086FZF6EM@VA5TP)J360"$MB\6:S\T3$:B$!X,GFG$=BTVP\]+Y(
ME!!4<'$?6S$5$2Q!0NWCWX<]^_PST$$KJ(\(0AO-X#QR'+TTTTT[_9_$JFX
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M(L"<3$C" &!(A2Y\(0P'I(/ I0,&<H.;F&;A"LU)A "NH-E@< 6V'0V@./J
M0X! @@U<+  $"FCB?S0P, ^*:Q;ZJ$H-^H0W (G!1 "P(!],$@($I.0DG!D=
M \T&@@4H8(W_&>&3^,XGF"S,0@Y)6-@%;@6#FC" "E43 ;]$P"VK-"=Q (I+
M"?JHCS 4[TWWF5JN!C(L&!@"*W=+5ZL&@@4",(,ZW3F@\AC&EK-\3P$NT -'
M1,4JM4RR5%8Y%FX( A*@6$6159""/D+PGPV,98P%84 9CBBN-,#@>@$*ASX>
MD9WD?"]>R/M(\]"P#UH6I /[J QQ</F7-SQS,!WPBC"0U,V((2)TD?0),8!
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M])\#<^2@>JD4FK_%A]!HF(>8)$!O8+"=*D1$LPD)"1]N/!"JY;8@?'HS .J
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M#0H09#_8RSN%2*#K.&A"=N#XCC:,A05 !((_Y&:5F(RX-)_Q!U/JPH!)@"=
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MFP3 L>JKL0)* .1K'OC!$[#6#1 LI*KKJ/[J&-R MRH#JT[JK9:K*.)JPMY
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M6LVHQEQ20(,1"KE B,G:JX.*WS98D YE,NMC"/\Z(*"8JC800XG(=(B"(@!
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M"13J30ZK2,I@#B(A )@@J<CHJU""A-"  )CNEISF!0)@ A#!G!B@#XCA!09
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M04E% ;(S/@_E.@WT/+/30ZLS13LE%U6440+ %ULT1F5T1@]%W#2" 8C")#;
M!M*Q,?8C5%9"#-"21D,%VH!4(NJ12)5T295T'_J!21EC.J%T2JG4%GD@#?B
M M0DVART"ML,5,(C0JLT4UP,5%[/'Q9G3-5T38>-1=44V-@T3N74O!0@%_+
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MCJ!JY_9=;W5,:W9XD96 ]$ *+HIR%F"9?F (#B$=N, .\HD#>@ +1 $%G!$
MZB @]X[/'L!B:_]@*9'" 4*H/"*!%6@%:<;Q[O: %)K 9$DA##1")^PWR+87
M,FF%=D0!">9@"!F ">2 !>Q&!UCA'6P !<2Q/21D#[" !N##?VF !/@1)$6F
M*2+3!GC&M_:@/'"!%*;/#71Q'I@@'5" #MJ7%41@!*B/ ZB@$^XA,O0@"MB)
M%N87@QK,9'/!!M(A@&_&!>J !-+A$V^F#FX@ &R@#.P %Q; )G/R.VO@:?3
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M?I1FO@'&."@@&IOEL(0T._32*C*!$&1M:#O"!#;WX"P78X0H#JC >N1EA[-
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M>VV& !H'8 F(00A^5%>((1=.  _*H1!R0;NC+(%P\ (@[:WJ(/EXQ;V1LD@
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M7-8H$%VLI&(@RA$P>S.# LP2H *5Y:("? 12RHXT"GXC2 ?@H ,4\ 0 \YA
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M"_Q:1=$"Z? #]P %+# *&A +IP($.S#&I$ *3;!:JZ$!FZLHL3F;-E9GQ,
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M?BF1#CT@ GJ0#J.E!)5SF5YAL4FW&2S%*6E<!4QM PX"\@@ DE:@:,/X 7>
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MU;8B[[1BW2TK/[8!XETWNQ[9+G8!0-SCH$$?0A1B1YHVB_&2EQ@0>8 _R$N
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MP*UEK1S8,2 *QF8S=%Q0AB??6C"_?DBYA?,!9) AV:VF<*@0C09L^ G'!GB
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M FS0OX>@#<U[ODA\ 'W(&$$$)=$C/=([O?^3#Q28 Q1 @4PHANHSP_9S#1)
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M,C->LO4<%T _X."RQR5< O#6RZ "(G)<B:3:24(",$.P#LW EKS:=56.-'$
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M@P$0AE?,]4P)C%9\Q?"('>\H@W0@ 08,DQ]0G!;(]3=)E@,IQ2JQT(?0@Q%
M 21@EYS(]5*,(1=@@ER_%92(@J98 EWGF >I_X%2''9:*)%R1P$*H 7!R8(?
M&/92; HA$(4R0((J8)$/$(5LY)B)X?830(&!!XP/H'9T][L?B'<5^(31X784
M. &;00ES3X<Y0. #H1O$*$6-&Y9!>?AH#_ESGP(=H)OW2 E)T+=SOQ)C3P>.
M^<,M10&@Q+$HL(.NTP^P,/<RX)%<$7>.(0-SIW9=:Y$>*/<$6( HH/9WT9%T
MH $[$!50FWB.,17$,8(:^('1I,5A'X)_#Q1XEP0-H,4<&$65FW9Q]_GX4#X
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M 0CTH,L!6,L*"P#! O2IX9:)0 ^7\@,J5EB8E,$E1%3@ AGR5)X)( (;-7[
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M65MLS,$3CM!=T((#S!@P?1,"E(GGW5>3A05B'!].I(.U.="MN5&)# 1/Z8C
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MKRY J.+(L\IIG/KJEZ[JJ:9J:-FJM59*L+XJJ9)KN<X./F&KN:KKNCX)&E
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M0F-J_>PG5/"-=,G#$=0)\;HP#-D7+6M,EDDA*M A 1W$.N7"S+CSC533);V
MG*@(,02 J=7%'QF;^K#/#=Q 'ICB+00C"<%& &!%+K!)+J^(=W S2?B@7RQ
M'@S  K2!%/Q;8?:!&.D(QDA!]_G%$1  [K8>6#:9@3BT9!@$0#DD3P"!(F^R
M7US)=DBU0J-UI(YR6K/UHF[20.3 7ES 7>&!I1  %_^T,,/8"D2<C8XL0&$U
M6P<D0I#R )Q<0/M""PNB#8[,8\:MTU2D06I=X7GIB=:-T-+"X@90W9U0=>1P
M@/U BF >2-E RCA?B<W8S_A.@;RTP/EQDXU\  DD />9@ %$ZP9D%8 I%55@
M U#$]9V$0][8]44QS,JZ@#BAS08<PF*"T>;$35M#MZ'B<'13MY]JT[QMC1M(
MEW.L#$5KQ0EL<^*=:>IU0B1IP HD!!'RQ%_Q(PP*<YF5MT-YB>3:B[F ]U[4
MF/4U&U/P07P@PZO4+1+,!@O@@K7@B0[>R:^\+ K0P!#T$#+\@"B<!#+9140@
M P7T 1P$=VDQB!-( ?\: !K__)A?3-YSL%U)^(,D=*]S#(IW&^(V[\,\#Q,Q
MI*$1\/#/5G>.-^E:ZWB/(RD6V$'YZ( #N$$=V$&#.G!?+,'=.H =O$.91B@=
M8"AE+H=#4 P&@"6V5 %A2B\I2+E?Z, ]W!<4.$"2Z4"'D, ](%,-T.^-,  4
MY$!#$.:9B\(<. 0#V !T'D)>ZL'=8L#=UD5/YL <9'!^V("?.\ >U($:%"FK
MU&)V?(!3VP@#2$ J)G'Y:$! UD$5('F02P:3.SF&;H ,,$0/! H'?+F/J[J-
M8.\L%(2K_]2KOSH*'&J$K?JMJZN\N Z5 LFD5"N2C"F4V\03A :.Q(\0%+OL
MZ#JN_S,[ *3##5":",2#M%/[M(L #J0#A?%XLW-[M_.3'G!YCK0!CGM[N9L.
M$HQ!CXP!K4_8=)O[N\-[O,N[G:9#NO/(&%" ME?JO/-[O_O[O[L<NO=((["[
M@R'TD>J !-RM#=!!7R0\ER?\PC<YLE"Z! S/!N2"#0Q$R7[ZH=\MC-X.% R$
M\*0(5-X.FM.!7@J! ]!6%MA!N/\%*7@\'4!\GG=0#4C\W9)!$CN QP=IO^%Y
MH=N%#=@BI6-F3]ZM'=P A:L1*3 Y*Q!RQS/Y'B@ !S#YH0]!3R8GGKN!"T"!
MQSO TML%%%R5"V#!T/;FPEN1 KB S">])\7,(0S$/0BPPO^O!>,TN0E$_*&G
M?-N#?9Y3Y@#-R7+WY9D+O525N9'WI1#8 =J\><\SN93+@*>SRLLC?9/;@)4+
M61WD?'\>@L77Q"'4I'*S!N@#@!"0?*5P?HC@X*&(/ DTO.200E[80>:O4EXX
M@ 1$?0!*P*'7OD-D@0.8NETX !DD_'=*C@U8 9!G_J%CYB'\_!>]?NPG/^TW
M$L+F!>ZGNH[4@034_CW #P! OXD9N0W0?JH+@0VDHMEG1.QK "E\O^W[A1X<
M>E]X/=$;"J4+O0;T_N^'/Q8 !)T+ %Q <=!D    .FR$0:!0A@,R"Z&0($$G
M@<(:!Q4R-,2 E ,;#N[=&*@00 O_B2AEV,FXX1 &$G::+ PITH&#,%EPBJQR
M4B$6.B >.-@SP  #&U90 M @8:0#5@B3DF**<@&'(0D90!D" $O.J$>; L@B
MP:))IU!S2MBCH&E7G/?>$H02)F%9(3J;PI1)!Y="(79& =A0Q\&-APIYDG%!
MBL[#@EOKN QJ=#%+!U<5:B!E$0>(L@#TV"#AX,7#EAD!5 Y\6.9!U0[PV+0S
ML/04+)9;WV[J6K"=B1_$YGQK<*0=' -Y%'= )V_9=&,4ZF&5<0&KP@K'4!C]
M'7QX\>/#*R  EWQZ]>O9DZ_A3PX%"K.<F. !0U+T]_'EWZD-X -_D'$#)1ZH
MX .%) 8$_T , OA(AX)TC(AK!&102(< -A#@P9_\LE@!&0K*(*"3C);0IY"!
M9"# D.]T2"/$^?AHT3 T],&FME;DFX4 ^0P!PD'YTDEAM!-=N2J+(KAH48-,
M4AB !P+B2X( 8H "H 8J8J3RJP8?E&^(!4:@@(H@0P!GEB?-*B(%!<[HD0(J
M2[B @3/TF= %*3J);H,&Y>MC0 W2Z#$=.0$0LT<:Y."C!RS]R7" #<[81PX\
M:IB%/_K>&;,/*2DH(0LY2B@P$V(>0H. "5$*\ H._'ECH"60F0(K*2CH-+X2
M-N@ F8D 0 .9*\KQ5+X=K@22CP@I2 $!(&" P[ .L#'!!29FB?]0CA)_=>6/
MOLR0$@5 \>R  !3*F(6%"RZ-D8(?1OD@2"I-;6I=9948I05_M*UA'TD$[62@
M#<QPY<<@P72SD.@6.C?"63J9J!QDBI"O2A"6,)@"-A0>3>!]D@7TJQ$Z,0$E
M@?U)]H0A$W)!#'T 5F@#)@@X 05TU9V%72<"0RD< @B0Q*Q,_)D7@",$;!1+
M+>53T(@-]$Q@ QM# (J!"EO,\HT$'H!11'0#:V4?0A0J!P9"'E#Z5F2(+% ?
M-1F@(ET&R%4#"4#=R**,^> < EYL(*3@#J V  (22_?II+8:]!$;I2PME)'
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M*$!@R+ "#C.C_Q"6(0.$#SD; 5B   TD@8?#2L$%LJ*/K:!$ U2 E0*R@ B
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M#4$$'E9X66B@P."QJ"QC*(.$N8^2?NRC']T7/P<OA0T2E,%E";C/">.Y#P+
MP!^% ,$&CN"**;3;C,*8!0SVP8*) .%1W._3FD+_" ;%9X8  8((E* %)'("
M+Z )!T#H$)YH-(C'M9"M>U+I1$Z(WEB =CH@  G YTHFAO# JB:$H5) "K@@
M !H) (((9E"AR4 M"?8!_F"@JQCD_01PSMRG".8,W(H!U/J@&!1 #/B/ /0!
M&8;  #:@#!Z!7-Q@! JAC(!$"7*@#^RH^?3!'V! "<.@ X&B9R3A@^[!$>
M#5C !C+M@\SO7'"G:'ZP,T!(8=2) #YA-%H!?60E DL "Y"A6\KB".10IMX/
M"5VA!X:%"_F/:!1"&!YE![\"" K!6HP G?Q@!:?/Z89LHE!B6()@ /#&9PA@
M:A()$OO//LIFIWP'*$QQ_P<]4'&N0:OBH*$&P 7<R@2 Y?\((  93I.H!FZ
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MP62M1I'+&%6@"C*B9[:@32& \SC&#&  "2S"(;1.N;B31_. .8:F$8#$<Q#
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M@#(,';%7P,.JUE8-<LH04E#X]*$8!F!8/.>#"&O4 "\+ #8PZ $;M'0TCF
M-8 .L81-^F1DJ(< ",0%GA! >"1QFT++R& #-L"T]J3 =F=7D.&$- "5\."#
MC,"D_($0PN&6# H!7 #5B&#.SJ9SFX)EV&I@86 5PL&&@HX  /%7K7?F("$0
M&:\'\@T\PBAF%RA%>" 3NLX$3(IQ0&?,&.]]/R"+%J,#],'_$&H@'<8, !8+
M#K+$5W^.=7ZNSAACXIIB6*X@=GB1<<"-#Q8X [EU&DIK@4P614_K<Q_L8F9/
M/>PG4E!"9("6?#D)&?A #?C 81(@"]+!::<S" SJ@(('!O"@07I%#& E2D)D
M;7>GGX2PGR I@P<G5;Z#/6'&GGSE;#S0Y.ZHK"S0+  6*YV.  "%Q)B(*XB(
M5BPRC.^#<;Z#(VN X43(9\K8SN1.4F8IU.("8 <BZ!YA<X#R.\Z&>_,%5)RJ
MJ0J!2&OR)!Z* =)A*#N ?.1 #<@G ;J-@(4 $;9"5@CD8@Q(\L*F3H30J@@@
M86*(*6SDCG9J1"A D0E <V3@;FDO_R9CAJV0\J5.;5M^4TUBYM.RP&< IDFZ
MKC;0R00NY4:"#PU@@$8^P"D["2LC2@,LKD5ZAD;$ S(U@@9H)0LHH-D4+&PW
M2#.O69N72UUEMDIP )PCX3V( 9RAX ;\8*(RK@X.+6H(@!8F@ E*A<V0@0[
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M+FI:L,1W@D^!RUBN6""VTZ (@*9)EA8*8&0*SD;OK"KGRJ*?-++_(\Y@QFY
M-O7N6G]N:#I;<#B2;$)[?MDX2PH!!TC!!@ZM5D/)GO&:5ZH "D8 K+K'2"]<
M86)/"6Y  @X$EUS0?4@Q.E"'$B+<!EXI 8BG$R9;#Y ;!/I!&+*I^0#;OM\)
MHNRIF67V18EG5,*+D]NKN5Y$L)>K"F[\":+ _OJ(#VY@ C*;M^AO%G9 /*=J
MR;=E"A![I8=F(!A@$E2<0?9A7B:1KK[%' N11GHF?Y;0KE_ 70<"N0 FF(D;
M"B9@:@&@:A7B"6)J'K!J:[>9@KXO_ Q=FQ/),:-$#F:!1X@!'/J 1W@$&7!
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M 0E6((G$\6 (,1L!]EI(QSIF1&EVS"-PG+86CE7!)V:X@@QH\H#J9>0!!5N
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M?",%-<D&]$"*/4CX"24)=8@MOA$;F%HCO5$U%(+3@C>S+!-A4/@$1L$[N_*
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MD(U2\ DB$)_S^08K@8%N( +SX&N&,P6!I8RH\F!&I@3"MP1Y90  4$HE, !
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M"#^P,T:5.636 NGPLR?@ $VP%%B@,!I :3/( 3]@M7#HM02S-5G0C7HE,#]
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M<*:6LF:U.6#).#Q'0N"$6YM8'^ U@&,(*SW&,_]X" Y@D92 /4<0! :@ YF
M!$FD GU@=^D3"\<5R\C&B!(Q82_+$8!8$H.X$2+@#THGQU)-*I*U!&_@CQ.!
M=SUXEXF<@\],9PT!!(30U2=W!@FT<6<@03+ !]WJ3HULNL1%@+/7$.C;$$>
M=60C"I**NQQ##"D<SP" O+*(IT%X<F+0.<PL C1 =8P0!.-B '"LAGO0#P/@
MO>4P##&1>_6TUI$  F[- "?0<M;*$,(P5-XV ##A AL@BSG("$80T</,JBR
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M)H, &O &9Y'O\3[O]%P$QB0,>QL%3:;)-.#OJ9=8+?\P=B&C0V5) 7Z1>I_
MS' HA@SAO0$3:21 "Q>@ 50. (R@00(C 5P4NRR0Y;7-$",@;<=( A4@"@5#
MG\+[XESI$%)P DP<!5)O,JS10SY/# NQ!"> ]"3@-0_P"!@EW=TLC4!,"Q4P
M @#&=_%H XM]HVIP-A=)"@XP M7V 4X) (=  _=@\>AC\DB?!C'\9$@PTR?
M.ED@"AIO!&J9 W-$963?P[PC02JU2CXO-!P;\1W\-39Y 36P9V@6PS6@9!)0
M!J2H ^BZ$1 N$EH<8NY7X?#7'!@N$AHN[L!O'/E$1&T0 !#P#EPZ4^-EQ!,A
M FP%7<J07;#X!)$0 ,^E#.?_U1!/0'!GL0'4/P8*P #IZH\Y#7$4-P%^/!'S
M, '<M0 ),&2C,& ,P0-O( +<.5U\*&#9?YE=043-97$ L:!1$Q ,X@%0@ O
M0AT7%CZ<-_ " X6X$#"\"*#AP@VY&N5QN$'AP@4)%KIH,^'"/ 0;YAD X#+C
M/(<(<[UXY]!%@(<+:CZ)E)'DF) I<0UX^'"#GH\9#01HE( !"  N1B9=<!!K
M *0H)QQ]")7@R3%^-(Z)=$&!61<01BT4,68,U9-MROI,NE!!2I!8QRB[.@_I
MPB=C!I0$L, L )95(_9U.2'/AG@A]>1!JF/,A,5Y%RA[L=AE7M( BO LG1H
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MD#$S^(:\4,N/1($'PH(?",JWV$ -<(2J&1;KTI;_"7P+-$NNP(G('+C$#00
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M%\F%2FK:X&#:'/:-+-BY^LD#[)VS6WR.B*4 "[Y@Z$B'G!D. H#>,3H$S "
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M0ZD!*3!/X96^P0@XH1"NFABIV+@Z_XA95/[+P]W*\;C[I71(QS>)N[/9 "C
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M>?2+X;.'&$"WD[X( ?89+X-9#HY:-CNJ;@12D("O:/=W=RP;=PW_-#A.-S,
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MA\RL&9#"LQNA'@N1S[-O[_[]:PJY<*.!(Y;!BC]9U)@'\($8 #*1]L /I)0
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M0A0LF$ A=%"$6V6P#FI(1QAH, WHEJ %B$A'">R2A8K/ ANC,(/%"9 "[!
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M'(@M0L34!330F1V!U)TLW_;MY]W0;6BCWPZN:-PL81)N;\)E;C# $ Z GK#
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M:$"Y LJY-EX+O,$K^1V3*%BGF.$ABB+BY7)"L"O$FBNB?.+ #L6W(40++8#
M^H<Q[TB@O<G#HH#+2-( U$##<K$HGS,Z7_^$U4*F([<S7KDS!5X3":P9X9X5
M0EG? !#2$T"!*!QN:104$O@3?ZD&.=?9H/BNAU;%$J0  _S CJZ&E*2S"BHN
MELE>$XP!1@N,UN"-#6@%LVA/!]B1$%@'=E30/)3!0704+CS![#:*",S#*=9
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MZ[200"1\[0.L@#R0ZQ1 @1UDB-D<@AUT[;34 2O@0/+P@!?WAAU$@H;D@A]
MP7*:=[+NTGO<(I!EF:/1P4Z$BR+6"Z)L "E "Y0]3HWG"0JOV<!TX$5$_Q@
M5@6+NQDE6>:]\(!XW/A%^!@*DSB3-_G%=L VDP:@\?515*]DL  )O-$(V,$$
M0$$Y4LFK8 \=W.[,I00($X@)=(":M,"-."(2X  I?+D+B$$(-(($5#/V30 I
MI'="/ +JK$ 5*(,4=&8'!/1N.[F=43;.U,!#NX8.&-G"U0"DW\88T#.B7SJF
M$VZ"[#%IE$,G\#7O840X$ I@'6Y()\:K !Z5J,%X\\"!2(NK#X D 18%T-Q
M\!&"1%$-*$&W1H6K(\ !=XDAZ,DW9#J.V;"Q)[NR+WL?9U"=M2F5=X!/DHPQ
M8PD4" 8A#$ 6%$(HM%_@X;4K7P 3U DO)T ']/^48_?'$D2%&9P '9A%@GU
M8^" !-@ ,8! .10"$--"!93$&7R=)"PYLXN+H@^\P1\\PE\LW)A72MQCS(C&
MT,2X#-3)$MQ%P)+ #;P#E-0 ,X1".DP'^^'UG#2!*/2'&+Q LSR $ZB[_W5
M"& T1ON!YD3"&+0!)0] "PS#U@U!&T  1I])!Z!*PL\010^]T1\]TDNC#%#
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MV@9:@HTXU$C""C&&2(5##=*8E()1%K!3B#ZF4 "(%)[09T8-SI#D R5,)&:
M#:388J 'BAB!C0%:)6/$0G3_+7/=6PA1H)5._%C!70 Z*.'4/Q0(9Y@8[?T
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M&UO9*N0$(&OI0'@PB](0 @ULP$Z,K, (9*2#"C<52 U.$  J&&*QU3EA039
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M@#:\ ]\(N?Q3NDD3S&/D\QQ1P!-$$ \_4&8CG8=N11(C$<@OTY0BB#Q!(&\
M;C:&,HY,"'IPD?K4^P'F"8D]1XH0C[[_72*SP8@$V*X0$>@#\5!@_/6YHC8#
M,, &/R#!#V*-D(.^MR8,R(&!+4)D%"PT(3*0G0:<8+NF/.!G)>& _!=2RHSH
M80_)&0&C.*(&$.$'4$ 45$ -V"_SH,#>"*(&]F#T#,( A,$(7&\@&( 4O(\&
MP@ S7( )O.\'_VQG 4;@!W(@RPBMY6"HTA3"#+X+!0KP!]2*(GA JP#@$,*O
M(N2@*"X""IA/(79-\%A!F0@ \10/^XQP*F@-#;)L _1%(3Z &*0 _63" '0
M!>0A)]) @1"" 42A!PZH_IHB"W*H)#1 #?#/(%S@GS)B QCA<K@0 #=""&C
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M7& %6  'H" -(,5 _W8 0C^29,)L(%J@#ZY0!\J@"I1A!):P U) &4B! A+
M!83!%+"1!T[@!I1!"A)Q_"+! 'R&-VE 1-C%.6V Q"KB 1 ABARAIP0J!B S
M0+)@1'&R8GXO%?H)NIB %L: %)+ $<OA85Q@!/0)"QS*LJK #]9$(!9@!8;3
M((J [RZ"%#" %)\/%1&B'X:P,(L0,?W4*%B)!W[@!*8 -P\"#8R*0 1" [#K
M:E[GT@+DGQA5@6314%ZG!5@@7_H)"Q3H >Z' 5  #].I_I;@=1@@'=[4(%9
MG\KP"@FFGY: !DT(H! ""CKU4\L =9H+ !!U ([(;,R@;":' 6A@%.8' /\I
MY35]RXA.H"?H+P&^TA,AYM-.%0 1%48<(40'@C612X$^8%D3(AS\\"O)IQ7F
M13(MU2P#+1-@B-).P&HB:B!&H ?FIQ+S0*]&M!$8"?YZ0ERW+QUZ2@A^P-+
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ML)C@R2^  QP)"NS9(,"1!.B@8A9@ 25"!VS "A@@S%M@;6&$%.3<= \HS<-
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M=5**,@+1A; [)'[@ ;#APXF8/5HR^1$3%\6+ !ZP6,HTJM0-=2))!>""U 4
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M$!$"7'R #1N9U4P:4B$E[$$9#\2*%.Q'"OIL  U*B*1! / DL8EOFM0<UI]
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M<5,3!NURCW.)!7W4(PQ "M'2-^ 2@)L#!&:A Q*P298"!20 -_;"FU]8,1Q
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MLU/@ M/* &Q@!K2C #J1 &9 "I\P #J M(BKN% @"DO' (;I B0P O> 8@G
M 3?09"1P"%50!4Q@ P?! ]^PMK';?1DKN[5KN[<[30^J&?O0(RX0N#H0(@O
M 6&0M!8Z 2% +GQ+ C/[N8?@!C5H FA@!6:@M%$P"CS !EA@!"B4 #9 <TU
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M7<H?0 NW"!'8VR,ZD 9;I #SD ?*"@ M,/]B][4 3+( JZ>F;*$!CF %"O
MA7 !\_"I#;$  > 'MCWK >#I+G !FQX 'JKKLU[KLD[K@[(!2L,?P)XQ2\ &
M$Y*(3Q  2C/K(- NO!YH&]#LSTX_2Q "$_(0:HKK&5,'4X@R\V&G"[#I(J
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M-!ED<F#CG@T'/0B/8',!00MD,G64F<*C1- 6TSM(TJE#"@$CC*KA!!N(0<"
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M!FC)/J!I 0#Y$ :ER&$>4R%%3YP" SI)10*",XH"DC(5/D5.CWOD8Q_]^$=
M$HI1.:D!*P*'@2)406\TV1YV&!2@I1E! 0-X0%]0)RI2B2$QG F#*"!3$U=1
M*%8-:X$2PK. H=%$!X@PQ 8Z\H:6!.LD]$) )3^S@7"$(%<C$D((>QBMP;2D
M6@!@5[;40A@SD TXQ7",3 @3  6$\0\GJ</ZV@6:5,B..C.B)2C5<+^R1>$+
MLZ2:8@RQ )8MH YJ.%\JXH?_OS.,1@=4V)%.2AB4#=R"6Y\#V1)A5:5@AG$4
MX^'-7KCPMWO6)!PBRL[+?+*Q(6R DGPP 3HWL  .A+ F15-,_"X)-?[-HWT
M6.4G3V*&NZ1"F=W*VM8$1HN1@2V#GR/$$12T@7\%3# "@6!!\W+,F:"S,H>(
ME5!N,A4<8$!.?W.*#>@HE#SMJ2F!I&I5K7I5K&85<9,32J2"HH Z@/,#;+"7
ME<C@&#=<5$//8B= 3]*=65+@/CE!JP)LAYW]6,8-"EB :MJG S7@ FY1Z 0"
MU5"%"Z0E0))Q P)TT!T&<,QX47"1[4K&TV&.%02AB=_WOO6VZEQ  4@R01C3
M=Q?-_\ZL5@.H03H2TP(2_,T%F9B""!9@6Q$8X#BK.$D+J.2^#AB"!\[:0) X
M @0XL(0F2R"&'\":!BXTUIZZDH$3$N "(9Q )J%=@#!PTXJW:1 R2PA! G3
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M)7@P0 T0 1Z@HD&9UTG+"7*@W9:(8IK.DUD6$%%/_F'A!( >#?U B0H"I)H
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MM-PI(@@R'J>J?OSG7_^-[_W^_?]_F[L^J&@C.>D'[E,*!3"\VD,\ &Q !WQ
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M&(.D; )=K$?K_[Q.[+RY4J0*)V(M.2"!%R %=CH.$H@$#J""A7.)CB2%$M$
M1/B!/6@$#%//,2"%.^"()K&#"="1!SN#(1@#&Y"#Q,B"%1@""(B"T,F"(@!/
M\<0#6E.#YJ.)!U"#.; #,G@?6A@#**  !V6"'S#/='B;VTB X8J$1E@!-UB
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M20GX="QP )WAGQ8(G+NI PQ@R0FH"%PGJ4AP'RB@]5A_@HYI]: P@#;  5P
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MHDRI<B7+EBY?PHPI<R;-FC9OXLRI<R?/GCY_ @TJ="C1GQ1RR=PPCY2#/0H
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M((8DKJTP19?[ <##&P-(85M'73$PPA4:I&/(B#W*EID47Q;_M 0;H4&52H]
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M281 @1.L^"<Z0($\KOFK?]48"X3L"1"NL..3U.&"+0E;'@"0!9')Q"-#@$
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M.N<[J:H,V."'-J2*)-@C P^L]P 2L.('** Q QQ BAR@ %4 >( #;,"'\<G
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MP ,@ A*X6!ET A0J@6J,3C_D $@\  J,@@; &1I\0F@\  N @ %TP!5,&@@
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M0!2<0 Z0)%DR,!K 64F8(VNA0/^W0$4'<*D$S*6'%-Z&FJHPT@ )D'$-) %
MA@0:R.!8;H#A# 834$!L@6A)+$$24$ Z\(')M'#9:0[HXNCY= H/8 /948 1
MP$4+5ZD$K( A>,C.+&!HU, L,+ !K0 2H  ;0*A(U,#SH8 2M(:>)(0.](&8
M<$ =)[)K2('2B6\+H\ /2(#F $$?VR4E%T'Z+( 4G( HG-])J*9UM6-)$,!A
MK@0K&%A)?&"C$7 S%P179:O+,6%! )$)=%O8Y$MU$@3=; "WG02X1ERU71,4
M=#+IW=@V%\17#L;#75/$D@0[P06?;  (;,!)\ FH]0JHG<N%+<$6J#-M"*VR
M!736>%S_09C:(F'!"LMD/0/;T.H:2RR -A<$.*M$C18TIYW%-1D GTR,$\38
M!N ;0Z/$ C#L2-QS/US8 O0ON]6SEWV/.SO;!< T .3O?V47S:T$S9K$/-JF
M,Q.P/M;$P,(H#/W$ [S /[_,MCI0<<024C]3$,$$5D1!6J9,?[TL2L1LHB4S
M22QS/8:@3_]T">($ ]C!DI2*0NO$-,]/_[2H&>D O[F$!I1!_+E,C\7<,),$
MG<;F5LLD/:Z$/8+U .M78"-4,-MTD&U@0=@!7XL$>/4T8?/I>4'V0-5TG.+U
M2.P#3JN$;)J$ OBU2@#V9.,F4!<+Q\VT:#-'$1# :K-V:[?V_RRL-FQ?=DB\
MIFO;MFO#-@$P=D@@V&W[-FS#]E>C-CY*-I;40"3<!@G [G!'1T3?6&4>-'1+
M=S]H=DE<@'37FPAD=W0?=$I<-[=MFZF!]WA'MS<S-W'_*;%\I*T8P#R<]GG#
M=WR/47$+'2C1[F#8!1U@QFWD@0AP !TDP+96 5NX0![, Q3H=V@H0!W8P0UH
M9X$_P038P7TK!2G<PWT;@ [HA8-_71000YN9[F#4@03P!1R]PU(DN'RK^(I7
MSF C9CI<0R.DPXERP F\ !2DP_@\ !^$APVP  G0 1,0*9S\P&!1 %TP ! 0
MPP1( );!R1S0 2G@RX!0P U,@.N4B?\IB(<+74"K%&:?_4%C[, +D,+:^J2&
M1($2P"B+LWF;JPQ]BP2@5-,#T(%$8 L/("T?(#DJ$*(4& (#4,"BQ(X,W"4
M_ B@&]^89D1</L$[ , AB-)T]@5T"HHAX/D2I=##8+.;<WJG'PMIDZN($H0:
M5@0*"*"FIP%%,)"#>D86(,$%F $+Z!(IN!"W8 L/9\&6TD$33$8 3 "MDZBL
MV$KQM.7=F ^L"NIR>_JR,SMGB75+="Q!(,"NJD;:-2<@0F)KG(T;O*UGU( 2
M[ @MC,&XCP$N^"+J:(X"*(,-4,!;+ $*T,$+^$9?T&O8? $C!$%H9 &)WK(P
M*GNS WS FU?_>JL$K S$ ]A!&TPLGCMDQ5PB76P+!7B='NHA\_6 #@\$IP)
M'2A>58H O(H.-G@%(T20V$PD7J805#<&&PM\R[M\<L!Y2!S0/$3( )@!,;S#
M&*R @&@ 'P@$)%)$;3! &CA!$PRQ$Z?!D30"BM@ZVI8)'W2-,.R)&%2!']2!
M%' !1<AN$_19OJQ %03 TLM).0P#RPWCR]^4J17<66"TV@3 !_6:",2#P2W
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M@XPEN!A%2R *N< , B Q80FBCN""#(=ZT("$:Q/20!03%+)ACC"JPV):#JP
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MG,8C43(,9* E8;(3R "VBB =""!4S@ 9OE,23 NUYL_=,$*Y^M$__Q-  U1
M.V(!H  O)*-'DJ,-;. >\H!TV"4A#F$6 PP'$@ S'( .7$,/)*!!(X(!H  A
M%L R#L$&,C0A6F /:N\&/$,/2,$.4O1#76-,&D&)H, !]&8@1O_H 5(4 %[@
M AB %'!A#%;1#]K@.5@1;!P !S2C#32C$>Q@ B84 .;!!L(@%Y1&#VP@$L9
M >J #N;!05U@XC[4#F1G6C;@!13@$&ABP:0( -84.&S #61C VA42[#  2:4
M!^ L2^E BK)@6L@T#PQ@ :0TP*HT /*  0)D \;@.<1 'B1"!W!A 1RT45/'
M 6[@!1 @%UYK2!5":70@4V]@ [)T#QIA Q:@1 .@"= T(G)!()Y :32 %"3
M=P1"#Y2F!HH4 P6B4 ?"1C&R1'^4<P"@3UN%!TA/". L(=H (1H!! P@%TQ
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M#Z3RK$"E'SZ #<(9 8P( 9C !DM !,8[(GA M).R#OA6"*X)"$+@L6G!#^K
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MN$O[[9(A--HR^6(3@-$+==08:27'Y>.A)Q/6X*CA!Y04'2U<.*N0(0/$!@S
M#2E!#@%]!-*G]X<^/04%X^/#I3!&OOW[^//KW\^_O___  8HX( $%FC@@0@F
MJ.""##;HX(,01BAA?@Q(,0045$@"#D<5B3 "'2.P8,+_4R2(X,0&4HSR7$*/
M001 #1,EY((4<,@0A'%=84$+#J((E5 6/^! @AL?&%$#:2_90<H.'&RQP A#
MD$)39-@QX,030=J0P@(D&/( #0DLH01! "RPPA9/H( #!BXEQ$ 459#R PAH
M5#%!&4XQ$><., W  W;21=55'4K@\,,41@V@0U<5;=?#'11%@8<0=^ PPA8
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M/J=<)BXN' V  HU\I -(#$!Q0\\A*7#T!N\ H ,.-WB5AWAZ( 4%2 GIL0<
M>N#P0LTR'H(#UF3[X?(A6U\]M=0 1-U1  ALT 8I.0OM0@ #"#V/"$G/HU/<
MD2#D@MV _QA"S77@<#8 #^#01 #:)M1&6Z>_G!C9/<\#WSQL=S0!U'58T"M<
M.ARM!_](BP/PQ 1Z)Q0 "%(' %_G, N]P00WY *""Z1TN@ 4+Q@-M]QTXVM!
M$SKK-$];<;^0T :$&S &0GXO +C@JH=>-@#Q:#OV'FWIX(=]8U PBWK\2^S
M?_0QF0 '2, "&O" "$R@ A?(P 8Z\$$ZX,X# _2=[$W0/@&@0!'D, OTJ($
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M$4< *$L !QJ0"72  Z10!D8@ Z]K  QP!B@@LOXY$6_Z(F\@GG&" ZS+1&B
M*6.K!X?;$8I;)BO %N.Q.(TPNO+ GZ4XB4= " \ MX&3L=$Z(EF@!";@CW#A
M KF0O8@P"CJ  N;[ PD0&UDJHH;GBQ4K,B>*L3XRIZ53 ]$;.#P0F4 + !Q
M IXSGAH0J"T["I.;$%?! /_I0 <3<,%, P!8@!G8.K(4;,$8["L)O,"&0(UH
M2 (F +,)T0)T*8P:P <W<,$3T!<,H P20 %6,#5U( '_FAEBNZO]L (TG+!P
M\0!*T 9V@  #JRU'  >)"IMX^Y!/\0/W$ F;&K@ 8 !@H8\"3!N,L 4PTA;E
M4 ((@ ;18<:W0;D"28K2:R0A\"LI(,,OL '"0 LW  '0HL,W[*E#$,,3P#TA
MT<4),0!$@1 IR@!\@ ,34#6C<(FT@0 (ZP92@*42[!03"0#E\ 8*( 5V<L&
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MS 6DA<L<'U++ $>90P_- U1, GO0"F0\LIE""Z0@ 64@"0U,$"T;K\)  @Z
M)]@)A3O@AD*0#D-@PIZ=J%!( FYH!CO"PS$A*A)  O6\ 2*8 RV<$#MI!QBP
MG"0 A1;!G!+P [L).JKM ':0 *-XM@B;UT/!!V0B!#_ "JG9.$RP Q)@ \3
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M 03)I=:X 0B@F4A1.B(I(_AXHB +CU&4$-5/C"[PD>-CTR$111GY'\\?. .
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M<KH$F&0C9D@!!/* !18HH ,[:,)!1!6)G"QA"\YZ2E->0A &[(H!9Y!'8LJ
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M_4&$?$ )36@%4C9PE(N$P=Y]V%84>,.6V0ZJMB2Y;:<E/WG*5][RR=S & ;
M #HGALY.OH$?Z+R )LX#"NY-S 1P@ L=_(4!-WCP!&!/DN-J$P<OD(T+VG #
M7 0 );&C2!V(U(;<UP$'V?52=C>0BS\99^-^T$$B=7"#2,SC3W7@/00VWWD
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MJQ (!AB#*&*+.FB^B#@+%QC_ _-S"RNLB#; Q+"("8\"Q4C)B4-9"N-H#+5
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MD ]1<+TH0 ')'0B36 @@\%0-4(,+("KJ\=3$Z#@,XUUY6 )3R/\H&^""YF,
M^K.!1>LPA&B!L6H*GN$JN&H*MCVO+ B>&B#=<SH) $B%YH [U3 ]"Y "!EFO
M/4(Y&IFP+PBM@O!3(&##[_6P4TJWPU+=;5P"&JB"#ZR>@?!3_VHR7!&L&6N.
MG*V!"VT!I#BM6.DK"1A='7@E#1["@BC*''*.BLH%*" %[SQ5+^1'1*Q#,<S;
M)X;B*):=O76!KM(<%0. $2@X/^#5'^ / O9<GL$8!N #(\J>OU" (DX'E&,
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M#$";'$$!-7<T)HAQ6E -(:A>#U\V<7X )3"9%=C8DK!F)HCA/-.#Y+2.!'X
M1&@[$#+6I^#.+W^))> #?N.!$^@+OT"0V.7_-8.*W1^X#SU8@0K- 4.X+!:]
M#P<R%09>(77ZT#1(@3I0@XUA@MBU-="0@J\:SH2( KJBZ$MEW ME"\ E!1P(
M]F$7]F(G]F/'@4;XQ;I][V9W]F>/2M;DC)!H19+P"!?<@ UX)YA@",,DB</L
M=O^)BFH?=];4 Q!@"#1 C'!/"0\!9M8$@&8A=QJR]H6@=EM\B(4@=W5:"*$8
M"/R9H8MTB'!WFPUP@5Z+"'@7RG"/=H23B'GW]ZB(^'I4>(K!1'9,(\[("8AH
M^)&@"<XP@(X(=X,PQXJ B8) 2:6 /ZM@QX-@>-VA ">&]IFG^9JW"FT> X[;
M1MQ1K@GPI9TW)IV+_\3'1KD['*D'MWFQ\.BD9_JFU\V-!PL].#V1)(D-P/BN
MP/>SD/H*Q*T'2"L/F6<]K /4<_JPH !6+?NT5WM';+T&"?/$D(!F0PL7.(\:
M,"FO8  )@,:UY_MB6OJ^!_S '\.[J3E\!ON2%PM! ]^O8#;!=WQBBOG'E_S)
MW[068'7S-8)#N(?L0L7'D  NH8A#8.7]T(//WP@=@ (): P-B )*:((<4@;3
M5S]2H(,_N3\)&(-ZHOS=GYV_Y_W?!_[=>8(R" /S98%(4 9UR]B%RH7]2H@S
MV($Q"!F%&P$W.)T]:(/]^I<0\ ,>0(8P:(,10(P/(($\.(1+04_LB8(3V/_[
MX'=_N8C\]Y?_^9<==?F#Z<IGZ]>R%>"@!:#ZZ0&(+*8N %B2PN %!2V<#/@
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MD $%&1EQ0,8&$EQ0@P,.T($<2:3@ @ #54Q4AU5ZM#@$01K8,(00=$Q4PQ
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MA9$HH X2H ,N)F)1E6R@$1$J3B12LH 74%0/6%Q)'0W*E$;JH&4X> %!3J*
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MF.@&VB!?9>" 0"P+JW7;4-\LK(!'J8F"<&40ACH@PJ]ZX*UM%*!67&Q %*,
M*E_O,(;\DJ8..&C"?CVR@ E,@ F=F<>! ZP,L'+4CM,UR@!YL /4F.$A!JB#
M!5X @AJD(0P(:.@-;*,#]V1DF=YD#Y-EH*")(GD,?M!!'B;_@ /DK)@4*%Z
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M*$!8Z6&!7^@ (DR!"ZR /.C8?JF!._J5!_:9#825&1"" NA!2$2!X"%(PBV
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M-$LMP!C<P)C-&!9=6!/H[W=U%4[V )9/0&%?E(!5]&=G74?!N(:78%.'11L
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MMG-[LX7!S$&! HX$QDM\LM4\"60%OQTA%%!!)-,  G0 7J57'(9")M !*>Q
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MA9$$#V;.RP.E\K, !ZPO*"V,W0#T52<@-$$4UPB 6_;ELS$(XQMPFIJT#,"
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M:K3*< ^G[ $*%(V"$=@8%(X"8*0*:*%50A>K"R:$8CA; !1$43<2A> "P]S
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M'FBBYBP(@PJFRCXHA*9"WT9@#UK(GI+-?\J A49!NQ3@ >Y &>CI#!UMC'1
M*J(E^DR@C.")#1I.;KX"9GS+!7+!O-# %*H"X"IG%/Q,%,A !\X@$JK@ O3
M"0:@T#S%  ZA![+@!WB,%43" !7 -G!N)4)/#-:(#%L ":! EH1 "2" 4ZB'
M#$Y$J-A@!/Y@]0[#*Z@G 43@W<A*1/8D"CGB$,(@!WK.HFK@,#Z _=R %8FF
MX2Y@/RA)8M1@7%[Q FS/FK+ #A"@=B+P,.Z @\RLVO Q'_7Q(-"@R^B) 49
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ML,P@ZC19#T @6D[ZK,BJ<TQ#7(*RL@UB 1K! C9$O)F9LB/A FK L['EJVX
M!,)!0/9@?%L!#A)Q"&81N4D<8X[[!I8Y%P*@NQ?=G$(ANTE+BQ% TYGYJW!@
MD*6\MT6E$4@!>'-AN-& #2@Y +:\#EY[)"R\"9"=PVL@(S";RT5 4:# J=O@
MPZ>G6CX<6TJ\"59%#UX;^Y!=508*N8%W ;Y.NG-A>L@$!R[/(/) 8)[[+7)!
MPTF+LC==RJ$@_P\085OS8-XU?6]X>Q1T  HV'2Y '  P!KM3SY>D7!F2&_DD
M^XZW'=PMN-E]:0-6X)B:8 -&&8U]"<*[^[,+N>5ZX C@X 8V/8Q"FXEU8 Q
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M%"H!8  #S (@@@ZT)+2$$:*$=L2C->QP<W&0C>>"'UD[<<$11B0FZG,Q2 U
MV=DQ<(=('4PM2<YC*&.*'_$$@ 4Q!%FL0(]C-/*G?>F$$<  :7-P'=((/ T
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M'((-@G3#DZ4O=<7)R17F<F'BP,2K*N&;R?17&M'<H+0$4]@Q92:# ?[JKZ3
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M6","8KPZ$S 692I!YI9Q$ ($/,"P)C8" ZRF:S4D(#_;DT0K<).%*G!@"!N
M.]MA<AL$9#\W.J"# O2@=\U700$?* OH$EO,43S@#A?@@1)R00(KVZ?V^1&!
M/.DX!;:#.UN  );"!&Y0@+-Q!PA@07C  ,83,SB!"VUF0[C&&(TT!0S0 83
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M<*  .H "(K ._&-0!B "*R(P/>5U4K=40R5V=TDO.,!U094O6V<NAX>7W_(
MZ6 'E\($5?]0!U[V 3]  H&A$&*! 1P2.8RYD1O0 ;O3 VA) @@& #*P.VXP
M80!0>%_Y68EG!RLB!.E !C;@/4P@#V#X:B+$ XQY#PAP!%< AC^  >=V*0^0
M M=( J)@"$0A:'UC"'H@"KM3=SJ0 P[@ +1 3 "@.R1P*77 F'2P :QY3"=
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@ TW0!6W0!XW0":W0"\W0#>W0/.7/]GPN^[#/<AL0 #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
